TWI328584B - Imidazole derivatives - Google Patents
Imidazole derivatives Download PDFInfo
- Publication number
- TWI328584B TWI328584B TW91101137A TW91101137A TWI328584B TW I328584 B TWI328584 B TW I328584B TW 91101137 A TW91101137 A TW 91101137A TW 91101137 A TW91101137 A TW 91101137A TW I328584 B TWI328584 B TW I328584B
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- methyl
- imidazole
- title compound
- compound
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title claims description 6
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 448
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 363
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 290
- 238000011282 treatment Methods 0.000 claims description 145
- 239000007789 gas Substances 0.000 claims description 142
- 238000000034 method Methods 0.000 claims description 132
- -1 hydroxy-hydroxy Chemical group 0.000 claims description 112
- 238000006243 chemical reaction Methods 0.000 claims description 83
- 239000002253 acid Substances 0.000 claims description 74
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 32
- 238000001704 evaporation Methods 0.000 claims description 30
- 230000008020 evaporation Effects 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 11
- 239000004305 biphenyl Substances 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 230000000626 neurodegenerative effect Effects 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 5
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-O 2-methyl-1h-imidazol-3-ium Chemical compound CC=1NC=C[NH+]=1 LXBGSDVWAMZHDD-UHFFFAOYSA-O 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 388
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 383
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 311
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 242
- 238000004587 chromatography analysis Methods 0.000 description 195
- 229910000104 sodium hydride Inorganic materials 0.000 description 166
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 164
- 238000002844 melting Methods 0.000 description 164
- 230000008018 melting Effects 0.000 description 164
- 239000012312 sodium hydride Substances 0.000 description 164
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 142
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 132
- 239000002178 crystalline material Substances 0.000 description 123
- 239000011541 reaction mixture Substances 0.000 description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 97
- 239000000203 mixture Substances 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 94
- 239000007787 solid Substances 0.000 description 92
- 235000019439 ethyl acetate Nutrition 0.000 description 90
- 238000000605 extraction Methods 0.000 description 81
- 239000012458 free base Substances 0.000 description 81
- 230000007062 hydrolysis Effects 0.000 description 74
- 238000006460 hydrolysis reaction Methods 0.000 description 74
- 229930182558 Sterol Natural products 0.000 description 73
- 235000003702 sterols Nutrition 0.000 description 73
- 150000003432 sterols Chemical class 0.000 description 70
- 229910052742 iron Inorganic materials 0.000 description 64
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 63
- 238000002425 crystallisation Methods 0.000 description 63
- 230000008025 crystallization Effects 0.000 description 63
- 229940093499 ethyl acetate Drugs 0.000 description 63
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 59
- 238000000354 decomposition reaction Methods 0.000 description 56
- 229910000085 borane Inorganic materials 0.000 description 55
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 47
- 230000027455 binding Effects 0.000 description 43
- 239000000243 solution Substances 0.000 description 43
- FTKASJMIPSSXBP-UHFFFAOYSA-N ethyl 2-nitroacetate Chemical compound CCOC(=O)C[N+]([O-])=O FTKASJMIPSSXBP-UHFFFAOYSA-N 0.000 description 39
- PQAMFDRRWURCFQ-UHFFFAOYSA-N 2-ethyl-1h-imidazole Chemical compound CCC1=NC=CN1 PQAMFDRRWURCFQ-UHFFFAOYSA-N 0.000 description 38
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 37
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 33
- 229910052938 sodium sulfate Inorganic materials 0.000 description 30
- 235000011152 sodium sulphate Nutrition 0.000 description 30
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 29
- 239000002585 base Substances 0.000 description 29
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 28
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 25
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 23
- FYUZFGQCEXHZQV-UHFFFAOYSA-N triethoxy(hydroxy)silane Chemical compound CCO[Si](O)(OCC)OCC FYUZFGQCEXHZQV-UHFFFAOYSA-N 0.000 description 20
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 238000007429 general method Methods 0.000 description 18
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 18
- 239000013078 crystal Substances 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 238000001914 filtration Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 210000003296 saliva Anatomy 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 238000010306 acid treatment Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000209094 Oryza Species 0.000 description 9
- 235000007164 Oryza sativa Nutrition 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 239000001307 helium Substances 0.000 description 9
- 229910052734 helium Inorganic materials 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000009566 rice Nutrition 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- 244000294411 Mirabilis expansa Species 0.000 description 8
- 235000015429 Mirabilis expansa Nutrition 0.000 description 8
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 8
- 235000013536 miso Nutrition 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 125000005555 sulfoximide group Chemical group 0.000 description 8
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- RGHXWDVNBYKJQH-UHFFFAOYSA-N nitroacetic acid Chemical compound OC(=O)C[N+]([O-])=O RGHXWDVNBYKJQH-UHFFFAOYSA-N 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 7
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 6
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 6
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- ATBKVKDEMSGMTQ-UHFFFAOYSA-N hydrazine triphenylphosphane Chemical compound NN.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 ATBKVKDEMSGMTQ-UHFFFAOYSA-N 0.000 description 5
- JCZMXVGQBBATMY-UHFFFAOYSA-N nitro acetate Chemical compound CC(=O)O[N+]([O-])=O JCZMXVGQBBATMY-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 125000006001 difluoroethyl group Chemical group 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 4
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 3
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 3
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 101100298048 Mus musculus Pmp22 gene Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 3
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 2
- WFOWWWKKYONWQY-UHFFFAOYSA-N 2-nitroethyl acetate Chemical compound CC(=O)OCC[N+]([O-])=O WFOWWWKKYONWQY-UHFFFAOYSA-N 0.000 description 2
- MKBBSFGKFMQPPC-UHFFFAOYSA-N 2-propyl-1h-imidazole Chemical compound CCCC1=NC=CN1 MKBBSFGKFMQPPC-UHFFFAOYSA-N 0.000 description 2
- KAWYASGZISVRAL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-benzimidazole Chemical compound C1CCCC2=C1N=CN2 KAWYASGZISVRAL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QLUHXYGJFDUZCZ-UHFFFAOYSA-N C(=O)O.C(C)C(C(=O)O)(CC)CC Chemical compound C(=O)O.C(C)C(C(=O)O)(CC)CC QLUHXYGJFDUZCZ-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000010254 Jasminum officinale Nutrition 0.000 description 2
- 240000005385 Jasminum sambac Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical compound OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
- GUNJVIDCYZYFGV-UHFFFAOYSA-K antimony trifluoride Chemical compound F[Sb](F)F GUNJVIDCYZYFGV-UHFFFAOYSA-K 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- MOXXPQWMYMUHHV-UHFFFAOYSA-N diethoxymethanol Chemical compound CCOC(O)OCC MOXXPQWMYMUHHV-UHFFFAOYSA-N 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- SOCAXRLFGRNEPK-IFZYUDKTSA-N (1r,3s,5r)-2-n-[1-carbamoyl-5-(cyanomethoxy)indol-3-yl]-3-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)NC1=CN(C2=CC=C(OCC#N)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F SOCAXRLFGRNEPK-IFZYUDKTSA-N 0.000 description 1
- HGRWHBQLRXWSLV-DEOSSOPVSA-N (4s)-3'-(3,6-dihydro-2h-pyran-5-yl)-1'-fluoro-7'-(3-fluoropyridin-2-yl)spiro[5h-1,3-oxazole-4,5'-chromeno[2,3-c]pyridine]-2-amine Chemical compound C1OC(N)=N[C@]21C1=CC(C=3COCCC=3)=NC(F)=C1OC1=CC=C(C=3C(=CC=CN=3)F)C=C12 HGRWHBQLRXWSLV-DEOSSOPVSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- IGGXVAUUTYVHBN-UHFFFAOYSA-N 1,1,1-trifluorodecane Chemical compound CCCCCCCCCC(F)(F)F IGGXVAUUTYVHBN-UHFFFAOYSA-N 0.000 description 1
- DHBZRQXIRAEMRO-UHFFFAOYSA-N 1,1,2,2-tetramethylhydrazine Chemical compound CN(C)N(C)C DHBZRQXIRAEMRO-UHFFFAOYSA-N 0.000 description 1
- IXADHCVQNVXURI-UHFFFAOYSA-N 1,1-dichlorodecane Chemical compound CCCCCCCCCC(Cl)Cl IXADHCVQNVXURI-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- XZEDOJJUYAVDJB-UHFFFAOYSA-N 1,1-diiododecane Chemical compound CCCCCCCCCC(I)I XZEDOJJUYAVDJB-UHFFFAOYSA-N 0.000 description 1
- FXBUGSFUBWPOML-UHFFFAOYSA-N 1,2,3-trifluoro-1h-indene Chemical compound C1=CC=C2C(F)C(F)=C(F)C2=C1 FXBUGSFUBWPOML-UHFFFAOYSA-N 0.000 description 1
- JCMVPOVHKWWBAU-UHFFFAOYSA-N 1,2-dichlorohydrazine Chemical compound ClNNCl JCMVPOVHKWWBAU-UHFFFAOYSA-N 0.000 description 1
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ACILQFPNTQQMTK-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)imidazole-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CN1C1=CC=C(OCO2)C2=C1 ACILQFPNTQQMTK-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- HWTRGBLMLITTIF-UHFFFAOYSA-N 1-(4-fluoro-3-methylphenyl)imidazole-4-carboxylic acid Chemical compound C1=C(F)C(C)=CC(N2C=C(N=C2)C(O)=O)=C1 HWTRGBLMLITTIF-UHFFFAOYSA-N 0.000 description 1
- UJFWIFJARQEILB-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)imidazole-4-carboxylic acid Chemical compound C1=CC(SC)=CC=C1N1C=C(C(O)=O)N=C1 UJFWIFJARQEILB-UHFFFAOYSA-N 0.000 description 1
- PUCOOPJLAXJKOO-UHFFFAOYSA-N 1-(4-nitrophenyl)imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C=NC=C1 PUCOOPJLAXJKOO-UHFFFAOYSA-N 0.000 description 1
- CZORWHFLOXPOFF-UHFFFAOYSA-N 1-(diethylamino)-3-(2-propylbenzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN(CC)CC)C(CCC)=NC2=C1 CZORWHFLOXPOFF-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- KVGOXGQSTGQXDD-UHFFFAOYSA-N 1-decane-sulfonic-acid Chemical compound CCCCCCCCCCS(O)(=O)=O KVGOXGQSTGQXDD-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- SJXXQENUUQGUAL-UHFFFAOYSA-N 1-phenylindole-4-carboxylic acid Chemical compound C1(=CC=CC=C1)N1C=CC=2C(=CC=CC1=2)C(=O)O SJXXQENUUQGUAL-UHFFFAOYSA-N 0.000 description 1
- GNAFOXREGMBOCM-UHFFFAOYSA-N 10,10,10-trifluorodecylsulfonyl 10,10,10-trifluorodecane-1-sulfonate Chemical compound FC(CCCCCCCCCS(=O)(=O)OS(=O)(=O)CCCCCCCCCC(F)(F)F)(F)F GNAFOXREGMBOCM-UHFFFAOYSA-N 0.000 description 1
- RWPHLPTXMDOTHS-UHFFFAOYSA-N 1H-imidazole-4,5-dithiol Chemical compound SC1=C(N=CN1)S RWPHLPTXMDOTHS-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- CBHXDVOSUKFRBE-UHFFFAOYSA-N 2,2-diethylbutan-1-ol Chemical compound CCC(CC)(CC)CO CBHXDVOSUKFRBE-UHFFFAOYSA-N 0.000 description 1
- CVYQRDKVWVBOFP-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OC(F)(F)OC2=C1 CVYQRDKVWVBOFP-UHFFFAOYSA-N 0.000 description 1
- VINQXBQMPIVBSY-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1H-indol-5-ol Chemical compound N1CCC2CC(=CC=C12)O VINQXBQMPIVBSY-UHFFFAOYSA-N 0.000 description 1
- FZBDFWKLMTWREJ-ZVSIBQGLSA-N 2,4-bis[(E)-hydroxyiminomethyl]-6-methoxyphenol Chemical compound COc1cc(\C=N\O)cc(\C=N\O)c1O FZBDFWKLMTWREJ-ZVSIBQGLSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- MBQKTXUCJWIHQQ-UHFFFAOYSA-N 2-cyclopropyl-1h-imidazole Chemical compound C1CC1C1=NC=CN1 MBQKTXUCJWIHQQ-UHFFFAOYSA-N 0.000 description 1
- FSGHEPDRMHVUCQ-UHFFFAOYSA-N 2-ethoxyprop-1-ene Chemical compound CCOC(C)=C FSGHEPDRMHVUCQ-UHFFFAOYSA-N 0.000 description 1
- SUCDHPJUXCCMDN-UHFFFAOYSA-N 2-ethyl-1,3-oxazole Chemical compound CCC1=NC=CO1 SUCDHPJUXCCMDN-UHFFFAOYSA-N 0.000 description 1
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
- PJLCCHSTNPFKPU-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;ruthenium(3+) Chemical compound [Ru+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJLCCHSTNPFKPU-UHFFFAOYSA-K 0.000 description 1
- FALCXGCLOUKBSP-UHFFFAOYSA-N 2-iodopyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(I)=C1 FALCXGCLOUKBSP-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- JPZKJZJFMLNIMB-UHFFFAOYSA-N 2-nonyl-1h-imidazole Chemical compound CCCCCCCCCC1=NC=CN1 JPZKJZJFMLNIMB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WKZGSVBSQHAHPY-UHFFFAOYSA-N 3,4,5-triethylphthalic acid Chemical compound CCC1=CC(C(O)=O)=C(C(O)=O)C(CC)=C1CC WKZGSVBSQHAHPY-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- SGNQTSWLIUHTQZ-UHFFFAOYSA-N 3,4-diphenylaniline Chemical compound C=1C=CC=CC=1C1=CC(N)=CC=C1C1=CC=CC=C1 SGNQTSWLIUHTQZ-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- RSOFZRXRIPVBBM-UHFFFAOYSA-N 3-(difluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)F)=C1 RSOFZRXRIPVBBM-UHFFFAOYSA-N 0.000 description 1
- IFWSBTBYKXRINT-UHFFFAOYSA-N 3-(difluoromethyl)-4-fluoroaniline Chemical compound NC1=CC=C(F)C(C(F)F)=C1 IFWSBTBYKXRINT-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- ROERXQQNEPTAMA-UHFFFAOYSA-N 3-bromo-5-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CN=CC(Br)=C1 ROERXQQNEPTAMA-UHFFFAOYSA-N 0.000 description 1
- NGZAVSDIXFIWHJ-UHFFFAOYSA-N 3-bromo-5-fluoroaniline Chemical compound NC1=CC(F)=CC(Br)=C1 NGZAVSDIXFIWHJ-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- LGCOAKFQLUXQAB-UHFFFAOYSA-N 3-chloro-5-(trifluoromethoxy)aniline Chemical compound NC1=CC(Cl)=CC(OC(F)(F)F)=C1 LGCOAKFQLUXQAB-UHFFFAOYSA-N 0.000 description 1
- CRRVZRDISHOQQL-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C(F)=C1 CRRVZRDISHOQQL-UHFFFAOYSA-N 0.000 description 1
- WQKQODZOQAFYPR-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)aniline Chemical compound NC1=CC(F)=CC(C(F)(F)F)=C1 WQKQODZOQAFYPR-UHFFFAOYSA-N 0.000 description 1
- FFCSRWGYGMRBGD-UHFFFAOYSA-N 3-iodoaniline Chemical compound NC1=CC=CC(I)=C1 FFCSRWGYGMRBGD-UHFFFAOYSA-N 0.000 description 1
- VTFGJEYZCUWSAM-UHFFFAOYSA-N 3-methoxy-5-(trifluoromethyl)aniline Chemical compound COC1=CC(N)=CC(C(F)(F)F)=C1 VTFGJEYZCUWSAM-UHFFFAOYSA-N 0.000 description 1
- NHVYWXPUSZZRDD-UHFFFAOYSA-N 3-nonoxyaniline Chemical compound CCCCCCCCCOC1=CC=CC(N)=C1 NHVYWXPUSZZRDD-UHFFFAOYSA-N 0.000 description 1
- XCCNRBCNYGWTQX-UHFFFAOYSA-N 3-propan-2-ylaniline Chemical compound CC(C)C1=CC=CC(N)=C1 XCCNRBCNYGWTQX-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DPKTVUKEPNBABS-UHFFFAOYSA-N 3-tert-butylaniline Chemical compound CC(C)(C)C1=CC=CC(N)=C1 DPKTVUKEPNBABS-UHFFFAOYSA-N 0.000 description 1
- YSWBFLWKAIRHEI-UHFFFAOYSA-N 4,5-dimethyl-1h-imidazole Chemical compound CC=1N=CNC=1C YSWBFLWKAIRHEI-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- QJBZPZHMEVSWPU-UHFFFAOYSA-N 4-amino-2-fluorobenzenethiol Chemical compound NC1=CC=C(S)C(F)=C1 QJBZPZHMEVSWPU-UHFFFAOYSA-N 0.000 description 1
- VRSBHZMIJMLFDU-UHFFFAOYSA-N 4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene Chemical compound CC(F)(F)C1=CC(Br)=CC=C1F VRSBHZMIJMLFDU-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- CSFDTBRRIBJILD-UHFFFAOYSA-N 4-chloro-2-fluoroaniline Chemical compound NC1=CC=C(Cl)C=C1F CSFDTBRRIBJILD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- CQJCPOVTPNWVBW-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)aniline Chemical compound COC1=CC=C(N)C=C1C(F)(F)F CQJCPOVTPNWVBW-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- UDWFSJAYXTXMLM-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran Chemical compound BrC1=CC=C2OCCC2=C1 UDWFSJAYXTXMLM-UHFFFAOYSA-N 0.000 description 1
- MMFGGDVQLQQQRX-UHFFFAOYSA-N 5-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C=C1C=O MMFGGDVQLQQQRX-UHFFFAOYSA-N 0.000 description 1
- FQIUCPGDKPXSLL-UHFFFAOYSA-N 5-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Br)=C1 FQIUCPGDKPXSLL-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- APSDTEHUYIJMPZ-UHFFFAOYSA-N 9h-carbazole;hydrochloride Chemical compound Cl.C1=CC=C2C3=CC=CC=C3NC2=C1 APSDTEHUYIJMPZ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- VTNQPKFIQCLBDU-UHFFFAOYSA-N Acetochlor Chemical compound CCOCN(C(=O)CCl)C1=C(C)C=CC=C1CC VTNQPKFIQCLBDU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- GCBLHJXALKFQKI-UHFFFAOYSA-N B(C1=CC(=C(C=C1)Cl)Cl)(OO)OO Chemical compound B(C1=CC(=C(C=C1)Cl)Cl)(OO)OO GCBLHJXALKFQKI-UHFFFAOYSA-N 0.000 description 1
- OQLATMZAFIXINN-UHFFFAOYSA-N B(C1=CC(=C(C=C1)F)Cl)(OO)OO Chemical compound B(C1=CC(=C(C=C1)F)Cl)(OO)OO OQLATMZAFIXINN-UHFFFAOYSA-N 0.000 description 1
- QIGJJAQOYQBNIH-UHFFFAOYSA-N B(C1=CC(=CC=C1)C(F)(F)F)(OO)OO Chemical compound B(C1=CC(=CC=C1)C(F)(F)F)(OO)OO QIGJJAQOYQBNIH-UHFFFAOYSA-N 0.000 description 1
- GOWZDROLAXIQHH-UHFFFAOYSA-N B(C1=CC(=CS1)C)(OO)OO Chemical compound B(C1=CC(=CS1)C)(OO)OO GOWZDROLAXIQHH-UHFFFAOYSA-N 0.000 description 1
- HUXMRLFINGQWLC-UHFFFAOYSA-N B.O1CCOCC1 Chemical compound B.O1CCOCC1 HUXMRLFINGQWLC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- RGSXARUBZRMKCM-UHFFFAOYSA-N C(C)CC([CH2-])=O Chemical compound C(C)CC([CH2-])=O RGSXARUBZRMKCM-UHFFFAOYSA-N 0.000 description 1
- UMLCZYTTXBCRLZ-UHFFFAOYSA-N C1=CC(=CC(=C1)N)CCCCCCCCCC(F)F Chemical compound C1=CC(=CC(=C1)N)CCCCCCCCCC(F)F UMLCZYTTXBCRLZ-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- RAAFRKKFVLEQIL-UHFFFAOYSA-N FC(C1=CC=C(C=C1)B(OO)OO)(F)F Chemical compound FC(C1=CC=C(C=C1)B(OO)OO)(F)F RAAFRKKFVLEQIL-UHFFFAOYSA-N 0.000 description 1
- UMVNZLRMBDJVDH-UHFFFAOYSA-N FC=1C=C(C=CC1F)B(OO)OO Chemical compound FC=1C=C(C=CC1F)B(OO)OO UMVNZLRMBDJVDH-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- FPEFBMRJCQORMZ-UHFFFAOYSA-N NC=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)CC Chemical compound NC=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)CC FPEFBMRJCQORMZ-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- XTSMSHACPMGDEA-UWTATZPHSA-N SN[C@H](CC(=O)O)C(=O)O Chemical compound SN[C@H](CC(=O)O)C(=O)O XTSMSHACPMGDEA-UWTATZPHSA-N 0.000 description 1
- MTTTXYPEAQZYNN-UHFFFAOYSA-L S[Mg]I Chemical compound S[Mg]I MTTTXYPEAQZYNN-UHFFFAOYSA-L 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000266807 Trimium Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- NRDWMRYAVLJHTB-UHFFFAOYSA-N [1-(3-tert-butylphenyl)imidazol-4-yl]methanol Chemical compound CC(C)(C)C1=CC=CC(N2C=C(CO)N=C2)=C1 NRDWMRYAVLJHTB-UHFFFAOYSA-N 0.000 description 1
- GPFWTRKUBIGDCF-UHFFFAOYSA-N [Fe].C#C Chemical group [Fe].C#C GPFWTRKUBIGDCF-UHFFFAOYSA-N 0.000 description 1
- LVMUSZMBRPNEHM-UHFFFAOYSA-N [He].[As] Chemical compound [He].[As] LVMUSZMBRPNEHM-UHFFFAOYSA-N 0.000 description 1
- WFMRQEPYKQVDKS-UHFFFAOYSA-N [IH]1CCCCCCCC1 Chemical compound [IH]1CCCCCCCC1 WFMRQEPYKQVDKS-UHFFFAOYSA-N 0.000 description 1
- GFERWFAWHAQLLF-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C=C(N)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical compound [N]1C2=CC=C1C=C(N1)C=C(N)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 GFERWFAWHAQLLF-UHFFFAOYSA-N 0.000 description 1
- LOMOKCTVHZMXMP-UHFFFAOYSA-N [S].[He] Chemical compound [S].[He] LOMOKCTVHZMXMP-UHFFFAOYSA-N 0.000 description 1
- RWZRMIZNIRCOTB-UHFFFAOYSA-N [hydroxy(phenoxy)boranyl]oxyboronic acid Chemical compound C1(=CC=CC=C1)OB(O)OB(O)O RWZRMIZNIRCOTB-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- CDSUEGXTPYWXAB-UHFFFAOYSA-N acetic acid ethyl acetate Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCOC(C)=O CDSUEGXTPYWXAB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- CWNKMHIETKEBCA-UHFFFAOYSA-N alpha-Ethylaminohexanophenone Chemical compound CCCCC(NCC)C(=O)C1=CC=CC=C1 CWNKMHIETKEBCA-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000001317 arsoryl group Chemical group *[As](*)(*)=O 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 150000008422 chlorobenzenes Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- AJEHNBIPLQJTNU-UHFFFAOYSA-N cyanomethyl acetate Chemical compound CC(=O)OCC#N AJEHNBIPLQJTNU-UHFFFAOYSA-N 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- USKHLWZYZGOYNL-UHFFFAOYSA-N difluoromethylhydrazine Chemical compound [H]C(F)(F)NN USKHLWZYZGOYNL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- ZZHIYQCCIDDTNO-UHFFFAOYSA-N dioxazolidine Chemical compound C1COON1 ZZHIYQCCIDDTNO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- KXSGQVTXLQEQSA-UHFFFAOYSA-N ethene 1-phenylethanone Chemical compound C=C.CC(=O)C1=CC=CC=C1 KXSGQVTXLQEQSA-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- KLWYPRNPRNPORS-UHFFFAOYSA-N ethyl 1h-imidazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CN1 KLWYPRNPRNPORS-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- KAOPWNFACLSZMA-UHFFFAOYSA-N ethyl acetate nitric acid Chemical compound C(C)OC(C)=O.[N+](=O)(O)[O-] KAOPWNFACLSZMA-UHFFFAOYSA-N 0.000 description 1
- WERPATFTSJWQBT-UHFFFAOYSA-N ethyl acetate;2-nitroacetic acid Chemical compound CCOC(C)=O.OC(=O)C[N+]([O-])=O WERPATFTSJWQBT-UHFFFAOYSA-N 0.000 description 1
- LDDOSDVZPSGLFZ-UHFFFAOYSA-N ethyl cyclopropanecarboxylate Chemical compound CCOC(=O)C1CC1 LDDOSDVZPSGLFZ-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003546 flue gas Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VLEGBARSQQYCNB-UHFFFAOYSA-N hydrazine 1H-pyrrole Chemical compound NN.N1C=CC=C1 VLEGBARSQQYCNB-UHFFFAOYSA-N 0.000 description 1
- YQYHEXLCJHNXRW-UHFFFAOYSA-N hydrazine methylhydrazine Chemical compound CNN.NN YQYHEXLCJHNXRW-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- 238000006358 imidation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SGNCOKUHMXLGAH-UHFFFAOYSA-N methyl 6-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Br)=N1 SGNCOKUHMXLGAH-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- GYXXGPBTYFFYRY-UHFFFAOYSA-N n-(diethylaminotrisulfanyl)-n-ethylethanamine Chemical compound CCN(CC)SSSN(CC)CC GYXXGPBTYFFYRY-UHFFFAOYSA-N 0.000 description 1
- VFBILHPIHUPBPZ-UHFFFAOYSA-N n-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NCC1=COC(C=2C=C(OC(C)C)C(OC(F)F)=CC=2)=N1 VFBILHPIHUPBPZ-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- INTJZENRAYCATA-UHFFFAOYSA-N pyrrol-3-one Chemical compound O=C1C=CN=C1 INTJZENRAYCATA-UHFFFAOYSA-N 0.000 description 1
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Chemical compound OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
- 239000009951 qiqi Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- LZOZLBFZGFLFBV-UHFFFAOYSA-N sulfene Chemical compound C=S(=O)=O LZOZLBFZGFLFBV-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- IKRJDNRUEIWOIB-UHFFFAOYSA-N trifluoromethylhydrazine Chemical compound NNC(F)(F)F IKRJDNRUEIWOIB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
1328584 A7 B7 五 發明説明(1 ) 本發明係有關具有如下通式之化合物1328584 A7 B7 V. INSTRUCTION DESCRIPTION OF THE INVENTION (1) The present invention relates to a compound having the following formula
其中 A 為苯基,吡啶-2-基,吡啶-3-基或哌啶-1-基; RVR2 各自分別為氫,鹵原子,低碳烷基,環烷基, 低碳稀基,三氟曱基,-0 -三氟甲基’ -S -三氟曱 基,S-低碳烷基,低碳烷氧基,-CHF2,-C(低 碳烷基)f2,-0CHF2,笨基,硝基,芊氧基,羥 基或胺基或 與其於任何毗鄰位置附接之碳原子共同形成- ch=ch-ch=ch-,-ch=ch-ch=n-,-(ch2)3-,- O-CHrO- ’ _0_CF2_0- ’ -CH2_0-CH2·或· ch2ch2-o-; R3 為氫,低碳烷基,環烷基,苯基,S-低碳烷基 ,胺基,低碳烷基-胺基,-NHC(O)-低碳烷基或 羥-低碳烷基; r4/r5 各自分別為氫或低碳烷基或與其附接之碳原子 共同形成-(ch2)4-; r6/r6' 各自分別為氫或低碳烷基; -5- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐)Wherein A is phenyl, pyridin-2-yl, pyridin-3-yl or piperidin-1-yl; RVR2 are each independently hydrogen, halogen, lower alkyl, cycloalkyl, lower carbon, trifluoro Mercapto,-0-trifluoromethyl'-S-trifluoromethyl, S-lower alkyl, lower alkoxy, -CHF2, -C(lower alkyl)f2, -CHF2, stupid , nitro, decyloxy, hydroxy or amine group or formed together with carbon atoms attached to any adjacent position - ch=ch-ch=ch-, -ch=ch-ch=n-,-(ch2)3 -,- O-CHrO- ' _0_CF2_0- ' -CH2_0-CH2· or · ch2ch2-o-; R3 is hydrogen, lower alkyl, cycloalkyl, phenyl, S-lower alkyl, amine, low Carboalkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl; r4/r5 are each hydrogen or lower alkyl or together with the carbon atom to which they are attached - (ch2) 4-; r6/r6' are each hydrogen or lower alkyl; -5- This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm)
裝 訂Binding
線 1328584 A7 、 B7 五、發明説明(2 ) X 為-N<!-t—; Y 為=N-,-NH-,-N=CH-或-CH=; Z 為-CR = 9 -N= ’ -NR.^- 1 -N—CR^- * =CH- N=C(R7)-或=N-CH=CH-; R7 為氮,.-CH2OH或低碳烧基; * ·· n 為Ο ! 1或2 ; m 為0或1 ;以及 虛線可為鍵結; 及其醫藥可接受性酸加成鹽。 式I之雜環系芳香族基Line 1328584 A7, B7 V. Description of invention (2) X is -N<!-t-; Y is =N-, -NH-, -N=CH- or -CH=; Z is -CR = 9 -N = ' -NR.^- 1 -N-CR^- * =CH- N=C(R7)- or =N-CH=CH-; R7 is nitrogen, .-CH2OH or low carbon alkyl; *·· n is Ο ! 1 or 2 ; m is 0 or 1; and the dotted line can be a bond; and its pharmaceutically acceptable acid addition salt. Heterocyclic aromatic group of formula I
具有如下結構式:Has the following structural formula:
因此,本式I涵蓋下列類型化合物:Therefore, this formula I covers the following types of compounds:
-6- 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明-6- This paper scale applies to China National Standard (CNS) Α4 specification (210 X 297 mm) 1328584 A7 B7 V. Description of invention
lc IdLc Id
各取代基說明如前。 式I化合物及其鹽係有價值的治療性質區別。本發明化合 物為NMDA (N-曱基-D-天冬酸酯)受體亞型選擇性遮斷劑, 此種遮斷劑於神經元活性及成形上扮演關鍵功能,因而於 媒介中樞神經系統潛在發育過程以及學習與記憶形成上扮 演關鍵角色。 於急性及慢性形式神經退化之病理情況下,NMDA受體過 本纸張尺度逋用中S國家標準(CNS) A4规格(210 X 297公釐) 1328584Each substituent is as described above. The compounds of formula I and their salts are valuable therapeutically distinct. The compound of the present invention is a NMDA (N-mercapto-D-aspartate) receptor subtype selective interrupting agent, which acts as a key function in neuronal activity and formation, and thus mediates the central nervous system. Potential developmental processes and play a key role in learning and memory formation. In the pathological condition of acute and chronic forms of neurodegeneration, NMDA receptors have been used in this paper size. The S standard (CNS) A4 specification (210 X 297 mm) 1328584
度活化為促發神經元細胞死亡的關.鍵事件eNMDA受體係 由二亞單位族群成員組成,亦即起源於不同基因的NR-1 (8 種不同割裂變異株及NR-2 (A至D))»此二亞單位族群成員 顯示分佈於腦部不同區域。:^卜丨成員不同NR_2亞單位之非 均質組合結果導致NMDA受體具有不同醫藥性質。NMDA NR-2B受體亞型特異性遮斷劑之可能的治療指標包括例如 由於中風及腦外傷引發的急性神經退化形式,以及慢性神 經退化形式,例如阿滋海默氏病、帕金森氏病、亨丁頓氏 病、ALS(肌萎縮性脊側索硬化),以及細菌性或病毒性感染 引發的神經退化,此外憂鬱症及慢性及急性疼痛。 本發明之目的為式I化合物及其醫藥可接受性酸加成鹽, 式I化合物及其鹽之製備,含有式I化合物或其醫藥可接受性 酸加成鹽之藥物’藥物之製造,以及式I化合物及其醫藥可 接受性鹽用於控制或預防疾病,特別前文引述之各種疾病 及病症,以及個別用於製造對應藥物。 本發明涵蓋外消旋混合物及其對應對映異構物》 後文於此處說明使用的一般術語定義皆適用而與該術語 係單獨或組合出現無關。 用於此處’「低碳烷基J 一詞表示含1至7個碳原子之直 鏈或分支鏈烷基,例如甲基、乙基、丙基、異丙基、丁基 等。較佳低碳烷基含1至4個碳原子》 用於此處,「低碳烯基」一詞表示C2-C7碳基而於鏈中含 有至少一個雙鍵。 「鹵原子」一詞表示氣、破、氟及漠。 -8- 本纸張尺度逋用中國國家標準(CNS) A4規格(210X 297公釐)Activation is a key to the initiation of neuronal cell death. The eNMDA receptor system consists of members of the second subunit group, that is, NR-1 originating from different genes (8 different split variants and NR-2 (A to D) )»The members of this two sub-unit population are shown to be distributed in different areas of the brain. The non-homogeneous combination of different NR 2 subunits of the members of the dichotomy resulted in different medical properties of the NMDA receptor. Possible therapeutic indicators for NMDA NR-2B receptor subtype specific occlusion agents include, for example, acute neurodegenerative forms due to stroke and brain trauma, as well as chronic neurodegenerative forms such as Alzheimer's disease, Parkinson's disease , Huntington's disease, ALS (muscle atrophic lateral sclerosis), and neurodegenerative diseases caused by bacterial or viral infections, in addition to depression and chronic and acute pain. The object of the present invention is the preparation of a compound of the formula I and a pharmaceutically acceptable acid addition salt thereof, a compound of the formula I and a salt thereof, a medicament containing a compound of the formula I or a pharmaceutically acceptable acid addition salt thereof, and The compounds of formula I and their pharmaceutically acceptable salts are useful for the control or prevention of diseases, particularly the various diseases and conditions cited above, as well as for the individual manufacture of corresponding drugs. The present invention encompasses racemic mixtures and their corresponding enantiomers. The general term definitions used hereinafter as used herein are applicable regardless of whether the term appears alone or in combination. The term "lower alkyl J" as used herein denotes a straight or branched alkyl group having 1 to 7 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, etc. Lower alkyl group having 1 to 4 carbon atoms" As used herein, the term "lower alkenyl group" means a C2-C7 carbon group and contains at least one double bond in the chain. The term "halogen atom" means gas, broken, fluorine and desert. -8- The paper size is based on the Chinese National Standard (CNS) A4 specification (210X 297 mm)
裝 訂Binding
1328584 A7 B7 五、發明説明(5 ) — 「低碳烷氧基」一詞表示其中炫.基殘基定義如前以及烷 基透過氧原子連結之基。 環炫基」—詞表示含3至6個碳原子之碳環,較佳為举 丙基。 「醫藥可接受性酸加成鹽」一詞涵蓋與無機及有機酸形 成之鹽’此等酸例如為鹽酸、硝酸、硫酸、碟酸、檸檬酸 '甲酸、反丁烯二酸、順丁烯二酸、乙酸、丁二酸、酒石 酸、曱烷-磺酸、對曱苯磺酸等。 較佳式I化合物為其中A為苯基例如下組化合物:1328584 A7 B7 V. INSTRUCTIONS (5) — The term "lower alkoxy" means a radical in which the radicals are as defined above and the alkyl radicals are bonded through an oxygen atom. "Cyclosyl" - a word means a carbocyclic ring having 3 to 6 carbon atoms, preferably a propyl group. The term "pharmaceutically acceptable acid addition salt" encompasses salts formed with inorganic and organic acids such as hydrochloric acid, nitric acid, sulfuric acid, dish acid, citric acid 'formic acid, fumaric acid, butylene Diacid, acetic acid, succinic acid, tartaric acid, decane-sulfonic acid, p-toluenesulfonic acid, and the like. Preferred compounds of formula I are those wherein A is a phenyl group such as the group consisting of:
其中 rVr2 各自分別為氫’鹵原子’低碳烧基,三氟甲基 ’ S-低碳烷基,低碳烷氧基,_〇CHF2,苯基, 硝基,苄氧基,羥基或胺基或 與其附接之碳原子共同形成為-(CH2)3-,-〇- ch2-〇-,-CH2-0-CH2-或-CH2CH2-0-; R3 為氫’低碳炫基’苯基,S -低碳烧基,胺基, 低碳·院基-胺基,-NHC(〇)-低碳炫基或經-低竣 -9- 本紙張尺度適用中囯國家標準(CNS) A4規格(210X 297公爱) ^28584 五、發明說明( 乙基-, 1H_咪唑,氯-3·曱基苯基)_m 乙基-, 咪唑-4-基]甲基]-2. 基™…(三氣曱基)苯基]—氣_3_曱基苯基)·1Η•咪心基甲基]ιη·咪唾2美_ 1Η“米唆,卜[[1-[3-(1,1-二 甲基-, 乙基)苯基]-1Η-°米嗅-4-基]甲 基 1Η-咪唑,二氟曱基·4_苯基)·1Η•咪唑_4•基 2-甲基-或1Η咪唑,l-[[l-[3-(i,i-甲基]-2-甲基_。 基]- 氟乙基)-4-氟苯基]-1Η-咪唑_4·基] 於本式I範圍進一步較佳為下式化合物Wherein rVr2 is each hydrogen 'halogen atom' low carbon alkyl, trifluoromethyl 'S-lower alkyl, lower alkoxy, _〇CHF2, phenyl, nitro, benzyloxy, hydroxy or amine The base or the carbon atom to which it is attached is formed as -(CH2)3-, -〇-ch2-〇-, -CH2-0-CH2- or -CH2CH2-0-; R3 is hydrogen 'low carbon leuco' Base, S-low carbon alkyl, amine, low carbon, fenyl-amine, -NHC (〇)-low carbon ray or warp-low -9 - This paper scale applies to China National Standard (CNS) A4 Specification (210X 297 public) ^28584 V. Description of the invention (ethyl-, 1H-imidazole, chloro-3-indenylphenyl)_m ethyl-, imidazol-4-yl]methyl]-2. ...(三气曱基)phenyl]-gas_3_mercaptophenyl)·1Η•咪心基methyl]ιη·咪唾2美_ 1Η"米唆,卜[[1-[3-( 1,1-Dimethyl-,ethyl)phenyl]-1Η-°m-ol-4-yl]methyl 1 Η-imidazole, difluoroindolyl 4 phenyl)·1Η•imidazole _4• group 2-methyl- or 1-imidazole, 1-[[l-[3-(i,i-methyl]-2-methyl-.yl]-fluoroethyl)-4-fluorophenyl]-1Η- Imidazole _4·yl] is further preferably a compound of the formula
其中A為苯基,R1及R2為鹵原子,R3為低碳烷基或氫,以及 R4,R5及R0,R6為氫例如為下式化合物: ^(3,4-二氣-苯基)-3-(2-曱基-咪唑-1-基-曱基)-1Η-吡唑。 •11 - 本纸張尺度適用中國S家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 __- ·_____B7 五、發明説明(8 ) 本式I範圍進一步較佳為下式化合物Wherein A is a phenyl group, R1 and R2 are a halogen atom, R3 is a lower alkyl group or hydrogen, and R4, R5 and R0, and R6 is hydrogen, for example, a compound of the formula: ^(3,4-di-phenyl) 3-(2-mercapto-imidazol-1-yl-indenyl)-1Η-pyrazole. •11 - This paper scale applies to China S standard (CNS) Α4 specification (210 X 297 mm) 1328584 A7 __- ·_____B7 V. Description of invention (8) The formula I is further preferably a compound of the formula
其中A為苯基,R1及R2為鹵原子,R3為低碳烷基或氫,以及 R4,R5及R6,R6為氫例如為下式化合物: 1-(3,4-二氣-苯基)-4-咪唑-1·基-甲基]H_吡唑或 卜(3,4-二氣-笨基)-4-〇曱基-咪唑小基-曱基)_m_吡唑。 於本式I範圍進一步較佳為下式化合物Wherein A is a phenyl group, R1 and R2 are a halogen atom, R3 is a lower alkyl group or hydrogen, and R4, R5 and R6 are a hydrogen such as a compound of the formula: 1-(3,4-di-phenyl-phenyl) )-4-imidazolium-1-yl-methyl]H-pyrazole or di(3,4-dioxa-phenyl)-4-mercapto-imidazolyl-indenyl)-m-pyrazole. Further preferred in the scope of Formula I is a compound of the formula
其中A為笨基,R1及R2為鹵原子、氫、CF3或低碳烷基,R3 為低碳烧基或氫,以及R4, R5及V,R6,為氫例如為下式化 合物: 1H-咪唑,2-曱基-1-[[4-[3-(三氟曱基)苯基]_1H咪唑_2基] 曱基]-, 1H-咪唑,l-[[4-(4-氟-3-曱基苯基)_1H_咮唑_2_基]曱基_2•甲 基-, 土 1H-味嗤,1-[[4-(3,4-一氣苯基)-1Η-味唾_2_基]曱基_2_甲基_或 -12- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 A7 B7 五、發明説明(9 ) 1H-咪唑,4-(4-氟-3-曱基苯基)_2-(1Η·咪唑」·基_曱基) 於本式I範圍進一步較佳為下式化合物Wherein A is a stupid group, R1 and R2 are a halogen atom, hydrogen, CF3 or a lower alkyl group, R3 is a lower carbon group or hydrogen, and R4, R5 and V, R6 are hydrogen such as a compound of the formula: 1H- Imidazole, 2-mercapto-1-[[4-[3-(trifluoromethyl)phenyl]_1H imidazolyl-2-yl] fluorenyl]-, 1H-imidazole, 1-[[4-(4-fluoro -3-fluorenylphenyl)_1H_carbazole-2-yl]decyl-2-methyl-, 1H- miso, 1-[[4-(3,4-monophenyl)-1Η- Taste salino_2_yl]decyl-2-methyl- or -12- This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm) 1328584 A7 B7 V. Description of invention (9) 1H-imidazole, 4-(4-Fluoro-3-indolylphenyl)_2-(1Η·imidazole)·yl-fluorenyl) Further preferred in the formula I is a compound of the formula
其中Α為苯基,R1及R2為低碳烷基、鹵原子或,R3為低 碳烷基或氫’以及R4,R5及R6,R6,為氫例如為下式化合物: 3-(3,4-二曱基-苯基)_5·(2_曱基_啼嗅小基_甲基)_吡咬, 3 (4-氟-3-曱基-本基)-5-(2-曱基·味唾_1-基_甲基)比咬, 氣-3-甲基-笨基)-5-(2-曱基-味吨-1-基-曱基)比咬, 3-(3-氣-4-氣-苯基)-5-(2-曱基米唾-1_基-曱基)比咬或 3 (4-氣-3-二氟曱基-苯基)-5-(2-曱基米〇^-1_基_甲基)比咬。 於本式I範圍進一步較佳為下式化合物Wherein Α is phenyl, R 1 and R 2 are lower alkyl, halogen or R 3 is lower alkyl or hydrogen ' and R 4 , R 5 and R 6 , R 6 are hydrogen such as a compound of the formula: 3-(3, 4-dimercapto-phenyl)_5·(2_mercapto-oxime small group_methyl)_pylotidine, 3 (4-fluoro-3-indolyl-yl)-5-(2-oxime Base, taste, salino-1 -yl-methyl) than bite, gas-3-methyl-phenyl)-5-(2-mercapto-yttrium-1-yl-indenyl) than bite, 3-( 3-ox-4-cyclo-phenyl)-5-(2-mercaptoisosyl-1 -yl-indenyl) than bite or 3 (4-a-3-difluoroindolyl-phenyl)-5 -(2-曱基米〇^-1_yl_methyl) than bite. Further preferred in the scope of Formula I is a compound of the formula
其中Α為苯基,R1及R2為鹵原子,R3為低碳烷基以及R4, 及R6,R6·為氫例如為下式化合物:Wherein hydrazine is a phenyl group, R1 and R2 are a halogen atom, R3 is a lower alkyl group and R4, and R6, and R6. is a hydrogen such as a compound of the formula:
線line
五 發明說明(10 (3’4~—氣-笨基)-2-(2-曱基·味嗅小基f基)-峨啶 ;本式1範圍進一步較佳為下式化合物V. DESCRIPTION OF THE INVENTION (10 (3'4~-gas-stupyl)-2-(2-mercapto-smellyl)-acridine; the formula 1 is further preferably a compound of the formula
ig 其中A為苯基’ Ri及R2為鹵原子,R3為低碳烷基以及r4,rS 及R,R0為氫例如為下式化合物: 2-(3,4-二氣-苯基)_4-(2-甲基-畔唑小基曱基)-吡啶。 較佳式I範圍進一步為其中A為吡啶-2-或3-基或A為哌啶-卜 基之化合物。 前述式I化合物可根據本發明製造,該製法係經由 a)—種下式化合物Ig wherein A is phenyl' Ri and R2 is a halogen atom, R3 is a lower alkyl group and r4, rS and R, and R0 is hydrogen, for example, a compound of the formula: 2-(3,4-di-phenyl)_4 -(2-Methyl-ampazole small fluorenyl)-pyridine. Further preferred range of formula I is further a compound wherein A is pyridin-2- or 3-yl or A is piperidinyl-bry. The foregoing compounds of formula I can be made in accordance with the present invention by a) a compound of the formula
裝 訂Binding
[本纸張尺度適用中國留家搮準(CNS) A4规格(210X 297公釐) -14- 1328584 A7 B7[This paper scale applies to China Retained Home (CNS) A4 specification (210X 297 mm) -14- 1328584 A7 B7
裝 訂Binding
線 1328584 五 A7 B7- 、發明說明(12 ) 其中A為苯基或吡啶-2-或3-基’ RJ-R7定義如前以及hal為 溴或氣,或 b)由下式化合物割裂去除N保護基Line 1328584 V A7 B7-, invention description (12) wherein A is phenyl or pyridin-2- or 3-yl' RJ-R7 is as defined above and hal is bromine or gas, or b) is cleaved by a compound of the formula Protective base
獲得下式化合物Obtaining a compound of the formula
裝 訂 其中A及RLR6定義如前以及PgN保護基如2-(三曱基矽烷 基)-乙氧曱基,或 c)一種下式化合物Binding wherein A and RLR6 are as defined above and PgN protecting groups such as 2-(tridecyldecane)-ethoxylated, or c) a compound of the formula
VIII 或VIII or
IX -16· 本纸張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 B7IX -16· This paper scale applies to Chinese National Standard (CNS) A4 specification (210X 297 mm) 1328584 A7 B7
1328584 A7 ____;_ B7 五、發明説明(14 ) 其中A為苯基或吡啶-2-或3-基以及rLr6定義如前以及hal 為氣或漠,以及 若有所需將所得式I化合物轉成醫藥可接受性鹽》 後文將說明製備式I化合物之進一步細節。 根據前述變化法以及使用下式反應圖1_1〇,式I化合物可 藉已知程序製備,製備程序舉例說明如後: 根據方法步驟a)’氫化鈉添加至式V咪唑化合物如2-丙基 咪唑、2-甲基咪唑、咪唑、4-甲基咪唑或4,5,6,7-四氫笨并 咪唑於DMF之溶液。3 0分鐘後於室溫,混合物於冰浴冷卻 ,以及加入式II、III或IV化合物例如4-氣曱基-1-(3,4-二氣-苯基)-1Η-喷唑,4-氣曱基-1-(3,4-二氣-苯基)-1Η-吡唑或4-氣曱基-1-(3,4-二氯-苯基)-3-曱基-1H-咪唑。结果所得混合 物於室溫攪拌30分鐘’蒸發去除溶劑後,以習知方式獲得 式la、lb及Ic化合物。 式Id化合物可根據變化法b)製備。式VI化合物例如1H-咪 唑,2-[(2-曱基-1H-咪唑-1-基)甲基]-4-[3-(三氟曱基)苯基]-1-[[2-(三甲基矽烷基)乙氧]曱基]或丄^咪唑,4-(4-氟-3-曱基 苯基)-[(2-甲基-1H-咪唑-1-基)甲基]-l-[[2-(三甲基矽烷基)乙 氧]甲基]溶解於乙醇及以鹽酸處理《然後反應混合物回流隔 夜,冷卻至室溫,濃缩及純化。 式If、Ig或Ih化合物係根據變化法C)製備如後:於氫化鈉 於礦油及DMF之懸浮液内加入式V化合物如2-丙基咪唑、2-甲基咪唑、咪唑或4-曱基咪唑。混合物於室溫攪拌1 5小時 。然後加入式VIII、IX或X化合物,混合物加熱至約1〇〇充4 -18- 本纸银尺度通用t固固家標準(CNS) A4規格(2l〇x297公著)1328584 A7 ____; _ B7 V. Description of the invention (14) wherein A is phenyl or pyridin-2- or 3-yl and rLr6 is as defined above and hal is gas or desert, and if desired, the resulting compound of formula I is converted Further details of the preparation of the compound of formula I will be described hereinafter. According to the foregoing variants and using the reaction of the following formula, Figure 1_1, the compound of formula I can be prepared by a known procedure, the preparation procedure being exemplified as follows: According to method step a) 'Sodium hydride is added to the imidazole compound of formula V such as 2-propylimidazole , 2-methylimidazole, imidazole, 4-methylimidazole or a solution of 4,5,6,7-tetrahydrobenzimidazole in DMF. After 30 minutes at room temperature, the mixture is cooled in an ice bath, and a compound of formula II, III or IV such as 4- gas decyl-1-(3,4-di-phenyl)-1 hydrazine-azole is added, 4 - gassulfonyl-1-(3,4-dioxa-phenyl)-1Η-pyrazole or 4-mercapto-1-(3,4-dichloro-phenyl)-3-indolyl-1H - Imidazole. As a result, the resulting mixture was stirred at room temperature for 30 minutes. After evaporation of the solvent, the compound of formula la, lb and Ic was obtained in a conventional manner. Compounds of formula Id can be prepared according to variant b). Compounds of formula VI, for example 1H-imidazole, 2-[(2-indolyl-1H-imidazol-1-yl)methyl]-4-[3-(trifluoromethyl)phenyl]-1-[[2- (trimethyldecyl)ethoxy]indolyl] or oxime imidazole, 4-(4-fluoro-3-indolylphenyl)-[(2-methyl-1H-imidazol-1-yl)methyl ]-l-[[2-(Trimethyldecyl)ethoxy]methyl] was dissolved in ethanol and treated with hydrochloric acid. The reaction mixture was refluxed overnight, cooled to room temperature, concentrated and purified. The compound of the formula If, Ig or Ih is prepared according to the modification method C) as follows: a compound of the formula V such as 2-propylimidazole, 2-methylimidazole, imidazole or 4- is added to a suspension of sodium hydride in mineral oil and DMF. Mercaptoimidazole. The mixture was stirred at room temperature for 15 hours. Then add the compound of formula VIII, IX or X, and heat the mixture to about 1 〇〇 4 -18 - the paper silver scale universal t solid standard (CNS) A4 specification (2l 〇 x 297 public)
裝 訂Binding
線 1328584 A7 • B7 五 、發明說明(16 ) 其中R1及R2說明如前以及DIBAH為二異丁基氫化鋁及LAH 為鋁氫化鋰。 反應圖2Line 1328584 A7 • B7 V. Inventive Note (16) wherein R1 and R2 are as previously described and DIBAH is diisobutylaluminum hydride and LAH is lithium aluminum hydride. Reaction diagram 2
取代基R1至R5及R7說明如前及LAH為鋁氫化鋰。 式XV化合物中,苯基可由吡啶-2-或3-基置換獲得對應式 la化合物。 -20- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584The substituents R1 to R5 and R7 are as previously described and LAH is lithium aluminum hydride. In the compound of the formula XV, the phenyl group may be substituted with a pyridine-2- or 3-yl group to give a corresponding compound of the formula la. -20- This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1328584
0〆 R2 XX0〆 R2 XX
A7 B7 五、發明説明(17 ) 反應圖3A7 B7 V. Description of invention (17) Reaction diagram 3
NBS,NBS,
A旧NA old N
R3 3XCR3 3XC
NaH, R v R Ib1 取代基R1及R5說明如前及NBS為N-溴丁二醯亞胺及AIBN為 偶氮-貳-異丁腈。 式XX化合物中,苯基可藉吡啶-2-或3-基置換獲得對應式 lb化合物。 反應圖4The substituents R1 and R5 of NaH, R v R Ib1 are as previously described, and NBS is N-bromobutadienimide and AIBN is azo-hydrazine-isobutyronitrile. In the compound of the formula XX, the phenyl group may be substituted with a pyridine-2- or 3-yl group to give a corresponding compound of the formula lb. Reaction Figure 4
-21 - 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公爱)-21 - This paper size applies to Chinese National Standard (CNS) A4 specification (210X297 public)
1328584 A7 B7 五、發明説明(18 ) 取代基R1至R5說明如前及THF為四氫呋喃。 式XXIII化合物中,笨基可由吡啶-2-或3-基替代獲得對應式 Ic化合物。 反應圖51328584 A7 B7 V. INSTRUCTION DESCRIPTION (18) Substituents R1 to R5 are as previously described and THF is tetrahydrofuran. In the compound of the formula XXIII, the strepyl group may be substituted with a pyridin-2- or 3-yl group to obtain a corresponding compound of the formula Ic. Reaction Figure 5
1. NaHNaH
XXIV 2. 2·(三甲基矽烷基) 乙氣甲基氣XXIV 2. 2·(trimethyldecyl) ethylene methyl gas
取代基R1至R5說明如前及DMF為N,N-二甲基甲醯胺。The substituents R1 to R5 are as previously described and DMF is N,N-dimethylformamide.
裝 訂Binding
式XV化合物中,苯基可由吡啶-2-或3-基替代獲得對應式Id 化合物。 -22- 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7 五 發明說明(19 ) 反應圖6In the compound of the formula XV, the phenyl group may be substituted with a pyridin-2- or 3-yl group to obtain a compound of the corresponding formula Id. -22- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 B7 V Invention description (19 ) Reaction diagram 6
装 取代基R1至R5及R7說明如前及LAH為鋁氫化鋰。另外式XV 化合物可由化合物 訂The substituents R1 to R5 and R7 are as described above and LAH is lithium aluminum hydride. Additional compounds of formula XV may be formulated by the compound
線 替代。 式XV化合物中,苯基可由p比咬-2-或3-基替代獲得對應式Ie 化合物。 -23- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7Line replacement. In the compound of formula XV, the phenyl group can be replaced by a p-but-2- or 3-yl group to give a corresponding compound of formula Ie. -23- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 B7
1328584 A7 B7 五、發明説明(21 ) 反應圖81328584 A7 B7 V. INSTRUCTIONS (21) Reaction Figure 8
裝 取代基R1至R5說明如前及LAH為鋁氫化鋰。 訂 式XV化合物中,苯基可由吡啶-2-或3-基替代獲得對應式Ig 化合物。The substituents R1 to R5 are as described above and LAH is lithium aluminum hydride. In the formula XV compound, the phenyl group can be substituted with a pyridine-2- or 3-yl group to give a corresponding compound of the formula Ig.
反應圖9Reaction Figure 9
-25- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(22 ) 取代基係如前述以及BINAP為2,2,-貳(二苯基膦基)-1,Γ-聯 奈。 反應圖10-25- This paper size applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 B7 V. Description of invention (22) The substituents are as described above and BINAP is 2,2,-贰 (diphenyl) Phosphyl)-1, Γ-Linkai. Reaction diagram 10
式XV或其它化合物中,苯基可由吡啶-2-或3-基替代。 如前文說明’式I化合物及其醫藥有用之酸加成鹽具有有 價值之藥力學性質。其為NMD Α受體亞型2Β選擇性遮斷劑 ’其於神經元活性及成形之調控上具有關鍵功能,因此於 媒介潛在中樞神經系統發育過程以及學習及記憶形成扮演 關鍵角色。 化合物係根據後文研究。 試驗方法 !E-Ro 25-6981 結合(Ro 25-698 1 為[R-(R*,s*)]_ a -(4-羥-苯基 )-冷·曱基-4-(苯基-甲基)-1·喊啶丙醇) 使用體重150-200克重之雄福林朵夫白化大鼠。經由將全腦 扣除小腦以及延腦於25倍容積冷Tris-Hc丨5〇 mM、EDTA 10 mM ’ pH 7.1緩衝液使用寶麗沖(p〇lytr〇n)(1〇〇〇〇 Γριη,30 秒 )均化製備膜。均化物於48,000 g於4eC離心10分鐘。丸粒使 用寶麗沖於相等容積緩衝液内再度懸浮,均化‘於37«C培In formula XV or other compounds, the phenyl group may be replaced by a pyridin-2- or 3-yl group. As described above, the compound of the formula I and its pharmaceutically useful acid addition salt have valuable pharmacodynamic properties. It is a NMD Α receptor subtype 2 Β selective occluder ’ which plays a key role in the regulation of neuronal activity and formation, and therefore plays a key role in the development of the underlying central nervous system and learning and memory formation. The compounds are based on the following studies. Test method! E-Ro 25-6981 Binding (Ro 25-698 1 is [R-(R*,s*)]_ a-(4-hydroxy-phenyl)-cold·indolyl-4-(phenyl) -Methyl)-1 - pyridine propyl alcohol) A male Flintoff albino rat weighing 150-200 g. Use the whole brain to deduct the cerebellum and ventilate the brain in 25 times volume cold Tris-Hc丨5〇mM, EDTA 10 mM 'pH 7.1 buffer using 宝丽冲(p〇lytr〇n) (1〇〇〇〇Γριη, 30 Second) homogenization to prepare the film. The homogenate was centrifuged at 48,000 g for 10 minutes at 4eC. The pellets were resuspended in a volumetric buffer using Polaroid and homogenized at 37 «C
裝 訂Binding
線 -26-Line -26-
1328584 A7 B71328584 A7 B7
育10分鐘。離心後,丸粒於相同緩衝液均化,於_8〇。匚冷凍 至少16小時但不超過1〇日。用於結合檢定分析,均化:於 37eC解凍,離心,丸粒如前述於Tris_HC1 5 mM , pH 7 4冷 緩衝液洗三次。最終丸粒再度懸浮於相同緩衝液且於終濃 度200毫克蛋白質/毫升使用。 、' 3H-Ro結合實驗係使用Tris_HCl 50 mM,PH 7.4緩衝液進行 。至於置換貫驗’使用5 nM 3H-Ro 25-6981,使用1 〇 mM四 氫異。奎B林測量非特異性結合,通常占總量之丨。培育時間 於4C為2小時’於瓦特曼(whatmann) GF/B玻璃纖維過渡膜 (優尼非特(Unifilter)-96 ’派克(Packard)公司,瑞士蘇黎克) 過濾中止檢定分析。過濾膜以冷緩衝液洗5次。過滤膜之放 射性係於添加40毫升微閃爍劑(microscint) 40(坎巴拉派克 (Canberra Packard)公司’瑞士蘇黎克)後於派克桌面計數微 平板閃爍計數器計數。 化合物效果係使用至少8種濃度測量且至少重複一次《匯集 之常規化值使用非線性迴歸計算程式分析,獲得IC5(),帶有 其相對95%可信度上限及下限。Breed for 10 minutes. After centrifugation, the pellets were homogenized in the same buffer at _8 Torr.匚 Freeze for at least 16 hours but no more than 1 day. For binding assay analysis, homogenization: Thaw at 37 eC, centrifugation, and pellets washed three times in Tris_HC1 5 mM, pH 7 4 cold buffer. The pellet was finally resuspended in the same buffer and used at a final concentration of 200 mg protein/ml. The '3H-Ro binding assay was performed using Tris_HCl 50 mM, pH 7.4 buffer. As for the replacement test, '5 nM 3H-Ro 25-6981 was used, and 1 mM mM tetrahydroiso was used. Quin B forest measures non-specific binding, usually accounting for the total amount. Incubation time was 2 hours at 4C' Filtering abort assay analysis on whatmann GF/B glass fiber transition membrane (Unifilter-96' Packard, Inc., Zurich, Switzerland). The filter membrane was washed 5 times with cold buffer. The radioactivity of the filter membrane was counted on a Parker table count microplate scintillation counter after the addition of 40 ml of microscint 40 (Canberra Packard, Inc., Zurich, Switzerland). Compound effects were measured using at least 8 concentrations and repeated at least once. The pooled normalized values were analyzed using a non-linear regression calculation program to obtain IC5() with its relative 95% confidence upper and lower limits.
装 订 f 根據前述方法試驗之較佳式I化合物之Ι(:5()(μΜ)係小於〇. 1 μΜ °下表顯示若干結合活性資料: 實例編號 IC5〇(mM) 貫例編號 ICsn(uM) 1 0.007 151 0.014 2 0.01 152 0.01 3 0.012 153 0.02 4 0.017 154 0.048 -27- 本纸張尺度逋用中國g家標準(CNs) A4規格(210X297公釐) 1328584 A7 B7 五、發明說明(24 6 0.045 155 0.01 10 0.004 156 0.014 11 0.005 157 0.014 12 0.008 158 0.041 13 0.095 159 0.014 16 0.009 160 0.016 17 0.012 161 0.05 21 0.043 162 0.016 24 0.016 163 0.017 27 0.027 164 0.03 39 0.043 165 0.046 48 0.061 166 0.02 52 0.078 168 0.038 58 0.093 170 0.039 87 0.017 172 0.024 89 0.048 173 0.028 93 0.02 174 0.063 94 0.021 176 0.032 103 0.043 177 0.0375 105 0.001 178 0.074 109 0.085 180 0.05 111 0.011 181 0.053 119 0.046 183 0.052 130 0.065 186 0.052 -28-Binding f The compound of the preferred formula I tested according to the above method (: 5 () (μΜ) is less than 〇. 1 μΜ ° The following table shows several binding activity data: Example number IC5〇 (mM) Example number ICsn (uM ) 1 0.007 151 0.014 2 0.01 152 0.01 3 0.012 153 0.02 4 0.017 154 0.048 -27- This paper scale adopts Chinese g standard (CNs) A4 specification (210X297 mm) 1328584 A7 B7 V. Invention description (24 6 0.045 155 0.01 10 0.004 156 0.014 11 0.005 157 0.014 12 0.008 158 0.041 13 0.095 159 0.014 16 0.009 160 0.016 17 0.012 161 0.05 21 0.043 162 0.016 24 0.016 163 0.017 27 0.027 164 0.03 39 0.043 165 0.046 48 0.061 166 0.02 52 0.078 168 0.038 58 0.093 170 0.039 87 0.017 172 0.024 89 0.048 173 0.028 93 0.02 174 0.063 94 0.021 176 0.032 103 0.043 177 0.0375 105 0.001 178 0.074 109 0.085 180 0.05 111 0.011 181 0.053 119 0.046 183 0.052 130 0.065 186 0.052 -28-
裝 訂Binding
線 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 • B7 五、發明·説明(25 ) 136 0.08 189 0.053 139 0.065 192 0.055 140 0.04 194 0.079 141 0.039 199 0.098 143 0.0073 224 0.01 144 0.038 225 0.01 145 0.054 226 0.02 146 0.008 227 0.03 147 0.0092 229 0.012 149 0.0082 230 0.084 150 0.0135 232 0.04 如此處所述,式I化合物及其鹽可攙混於標準醫藥劑型例 如用於與尋常醫藥佐劑材料進行經口或腸外投藥,佐劑材 料例如為有機或無機惰性載劑物料如水、明膠、乳糖、澱 粉、硬脂酸鎂、滑石、植物油類、樹膠類、聚烷二醇類等 。醫藥製劑可以固體劑型如錠劑、栓劑、膠囊劑使用,或 呈液體劑型如溶液劑、懸浮液劑或乳液劑使用。可添加醫 藥佐劑物料,包括保藏劑、安定劑、濕潤或乳化劑、變更 滲透壓或作為緩衝劑之鹽類。醫藥製劑也含有其它治療活 性物質。 劑量可於寬廣限度之内改變,當然須配合個別特定案例 需求。口服投藥案例,劑量係於每劑約〇. 1毫克至每曰約 1000毫克通式I化合物之範圍,但若適用時也可超過此上限。 下列實例舉例說明本發明之進一步細節。但此等實例絕 -29- 本紙張尺度逋用中國國家標準(CNS) A4規格(210X 297公釐) 五、發明·説明(26 ) 非囿限本發明之範圍。全部溫度皆係以攝氏度數表示。 實例1 jH-丰喷,】-|·|·1·(3,4-二氣苯基)-ιη·哞咬·4-甚)甲某ι·2_丙 基-鹽酸肄Π 氫化鈉(0·44克55%於礦油分散液,10毫莫耳)緩慢添加至2· 丙基咪嗤(0.55克,5毫莫耳)於DMF之溶液。於2〇°c經30分 鐘後,混合物於冰浴冷卻,一次加入4_氣甲基^(3 4•二氣_ 苯基)-1Η-咪唑(1.0克,4毫莫耳)。所得混合物於2〇乞授拌 30分鐘。蒸發去除溶劑後,殘餘物溶解於乙酸乙酯,以水 洗滌,脫水(硫酸鈉)及層析[矽膠,以二氣甲烷至5〇%(二氣 甲烷,甲醇/水性氫氧化銨=90:1〇:1)梯度洗提]。獲得標題化 合物之自由態驗呈褐色油.(1.12克’ 84%)。使用鹽酸於曱醇 溶劑處理接著加入乙醚後,標題化合物分離呈白色結晶性 物質。溶點 241-243°C (甲醇/乙越),MS: m/e=334(M+). 實例2至9係根據實例1所述概略程序製備。 實例2 上技二味嗅’ Wn-(3,4-二氣茉基咏-4-某)甲某1-2·甲 基-,鹽酸鹽Π:2) 2-甲基咪唑與氫化鈉反應,接著以4_氣曱基二氣_苯 基)-1Η-咪唑後續處理,經萃取後續處理以及層析術後獲得 標題化合物自由態驗,其被轉成其白色鹽酸鹽。熔點>25〇 °C (曱醇/乙醚),MS: m/e=306(M+)。 實例3 1H-咪吐’ 1-[[1-(3,4-二氣苯基)-ih-咪唑_4_基)甲基]-2-乙 -30- 本纸張尺度適用中S國家標竿(CNS) A4規格(210X 297公Line paper size applies to China National Standard (CNS) A4 size (210X 297 mm) 1328584 A7 • B7 V. Inventions and descriptions (25) 136 0.08 189 0.053 139 0.065 192 0.055 140 0.04 194 0.079 141 0.039 199 0.098 143 0.0073 224 0.01 144 0.038 225 0.01 145 0.054 226 0.02 146 0.008 227 0.03 147 0.0092 229 0.012 149 0.0082 230 0.084 150 0.0135 232 0.04 As described herein, the compounds of the formula I and their salts can be admixed in standard pharmaceutical dosage forms, for example with conventional medicines The agent material is administered orally or parenterally, and the adjuvant material is, for example, an organic or inorganic inert carrier material such as water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oil, gum, polyalkylene glycol and the like. The pharmaceutical preparations can be used in solid dosage forms such as tablets, suppositories, capsules, or in liquid dosage forms such as solutions, suspensions or emulsions. Medical adjuvant materials may be added, including preservatives, stabilizers, wetting or emulsifying agents, varying osmotic pressure or salts as buffering agents. Medicinal preparations also contain other therapeutically active substances. Dosages can vary within wide limits, and of course must be tailored to individual case requirements. For oral administration, the dosage is in the range of about 1 mg to about 1000 mg of the compound of formula I per dose, but may be exceeded if applicable. The following examples illustrate further details of the invention. However, these examples are not limited to the scope of the present invention. The paper is based on the Chinese National Standard (CNS) A4 specification (210X 297 mm). 5. Inventions and Descriptions (26) Not limited to the scope of the present invention. All temperatures are expressed in degrees Celsius. Example 1 jH-Feng spray,]-|·|·1·(3,4-diphenyl)-ιη·哞 bit·4-very) A certain ι·2_propyl-hydrochloric acid 肄Π sodium hydride ( 0. 44 grams of 55% in mineral oil dispersion, 10 millimoles) was slowly added to a solution of 2·propylidene (0.55 grams, 5 millimoles) in DMF. After 30 minutes at 2 ° C, the mixture was cooled in an ice bath, and 4_methanol (3 4 • 2 gas phenyl)-1 Η-imidazole (1.0 g, 4 mmol) was added in one portion. The resulting mixture was mixed for 30 minutes at 2 Torr. After evaporation of the solvent, the residue was dissolved in ethyl acetate, washed with water, washed with water, sodium sulfate, and chromatographs, hexanes, methane to 5% (methane, methanol/aqueous ammonium hydroxide = 90: 1〇: 1) Gradient elution]. The free state of the title compound was obtained as a brown oil. (1.12 g ' 84%). After the treatment with hydrochloric acid in methanol solvent followed by diethyl ether, the title compound was isolated as white crystalline material. Melting point 241-243 ° C (methanol / hexane), MS: m / e = 334 (M + ). Examples 2 to 9 were prepared according to the procedure outlined in Example 1. Example 2 Shangji Erwei sniffing 'Wn-(3,4-digas jasmonium-4-) A certain 1-2 methyl-, hydrochloride Π: 2) 2-methylimidazole and sodium hydride The reaction is followed by subsequent treatment with 4_g-mercaptodiuret-phenyl)-indole-imidazole, followed by extraction and subsequent chromatography to give the title compound freeness which is converted to white salt. Melting point > 25 ° C (melanol / diethyl ether), MS: m / e = 306 (M +). Example 3 1H-mimi' 1-[[1-(3,4-diphenyl)-ih-imidazole_4_yl)methyl]-2-ethyl-30- This paper scale applies to S countries Standard (CNS) A4 specification (210X 297 public)
基-,鹽酸鹽(1:2) 2乙基米嗤與氫化鈉反應,接著以4-氣甲基小(a二氣-苯 基)-1Η-咪唑後續處理,經萃取後續處理以及層析術後獲得 ,題化。物自由態鹼,其被轉成其白色鹽酸鹽。熔點>25〇 C (曱醇/乙謎),MS: m/e=320(M+)。 實例4 1H米嗅,i_[[i_(3’4-二氣苯基)_1H咪唾_4基)甲基]•曱 基乙基)-,鹽酸鹽(1:2) 2-異丙基咪唑與氫化鈉反應,接著以4_氣甲基+(3 +二氣_ 苯基)-1Η-咪唑後續處理,經萃取後續處理以及層析術後獲 得標題化合物自由態鹼,其被轉成其白色鹽酸鹽。熔點 236-238°C (分解)(甲醇/乙醚),Ms: m/e=335(M+H+)。 實例5 1H-咪唑,ι_(3,4-二氣苯基)-4-(ι_Η-咪唑-1-基-曱基)-,鹽酸 鹽(1:2) 米嗤與氫化納反應,接著以4_氣曱基_1·(3,4_二氣-苯基)·ΐΗ· 味吐後續處理’經萃取後續處理以及層析術後獲得標題化 合物自由態鹼,其被轉成其白色鹽酸鹽。熔點>25(rc (甲醇/ 乙醚),MS: m/e=292(M+)。 實例6 jjl-味唾,1-(3,4-二氣笨某)·4·「(4-甲某-1H-咪唑-1-某、甲其 ;L_,鹽酸鹽(I:2)以及1Η-喷唑,ΐ-η,4-二窗.笑篡)-4-Γ(5-甲其-1Η-咪啥-1-基)甲基μ,鹽酸鹽(1:2吖比例3:2) 4-甲基咪唑與氫化鈉反應,接著以4_氣曱基4-(3,4-二氣-笨 -31 - 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 __'__B7 __ 五、發明·説明(28 ) 基)-1Η-畔唾後續處理’經萃取後續處理以及層析術後獲得 標題化合物自由態鹼,其被轉成其白色鹽酸鹽。MS: m/e=306(M+)。 實例7 Ιτί 一 氣-笑基)-1Η-味啥-4·基甲某 1-4.5,6.7-四氣-1Η- 苯并咪唑,鹽酸凿 4,5,6,7-四氫笨并咪唑與氫化鈉反應,接著以4_氣曱基-卜 (3,4-二氯-苯基)-iH-咪唾後續處理,經萃取後續處理以及層 析術後獲得標題化合物自由態鹼,其被轉成其白色鹽酸鹽 。炫點>250 C (甲醇/ 乙趟),MS: m/e=346(M+)。 實例8 1.技-_嗤’1-『『卜(3,4-二氮芄基丫-1只-咄地-4-某)甲基卜4.5-二 曱基-,鹽酸鹱<Ί ·9Λ 4,5-二甲基咪唑與氫化鈉反應,接著以4_氣曱基-丨气夂扣二 氣-苯基)-1Η-咪唑後續處理,經萃取後續處理以及層析術後 獲得標題化合物自由態鹼,其被轉成其白色鹽酸鹽,熔點 >250°C (曱醇/乙醚),MS: m/e=320(M+)。 實例9 1H-味唾’ 1-ΓΓΐ_ρ,4·二氪茉基)_1H-咪衅_4_基)甲基μ2_^ 基-,鹽酸镑Π·9) 2-苯基咪唑與氫化鈉反應,接著以4-氣甲基-1-(3,4-二氣-苯 基)-1Η-咪唑後續處理,經萃取後續處理以及層析術後獲得 標題化合物自由態鹼,其被轉成其白色鹽酸鹽。熔點197-198°C (甲醇/乙醚),MS: m/e=369(M+H+). •32- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公爱) 1328584 A7 B7 五、發明說明(29 ) 實例10 1H-球+,1-ΓΓ1-(4-氧甲基丰基)-1Η-啼某1甲某1-上· Λ篡-,鲤酸鹽(1:21 Π-(4-氣-3-甲基-苯基)-1Η·咪唑-4-基]-曱醇使用亞磺醯氯處 理,所得4-氯甲基氣-3-曱基-笨基)_ιη·味嗅呈其鹽酸 鹽直接用於進一步反應。 如實例1所述’ 2-乙基咪唑與氫化鈉反應,接著以4-氯甲基-1-(4·氣-3-甲基-本基)-1Η-味唾鹽酸鹽後續處理,經萃取後 續處理以及層析術後獲得標題化合物自由態驗,其被轉成 其白色鹽酸鹽。熔點186-187 °C (甲醇/乙醚),MS: m/e=300(M+)。 實例11至103係根據實例1〇所述概略程序製備。 實例11 ,1-ΓΓ1-(4 -乳-3-甲基笨基 -基]甲某 Ί 2 甲某·,镑酸鹽(1:2) [1-(4-氣-3-曱基-苯基)-1Η-咪嗅-4-基]-甲醇首先使用亞續醯 氣處理,然後使用氫化納及2-甲基-咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。稼點218-220°C (甲醇 /乙鍵),MS: m/e=286(M+)。 實例12 1H-味啥,1-(4-氣-3-曱基笨基)-4-ΠΗ-咕唾-1-暮-甲甚,瞄 酸鹽(1:2) [1-(4-氯-3-甲基-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞續酶 本纸張尺度適用中國國家標準(CNS〉Α4規格(210X 297公釐) -33- 1328584 A7 B7Base-, hydrochloride (1:2) 2 ethyl rice bran reacted with sodium hydride, followed by 4-methylmethyl small (a di-phenyl)-1 Η-imidazole followed by extraction followed by treatment and layer After the analysis, the problem was obtained. A free base which is converted to its white hydrochloride. Melting point > 25 〇 C (sterol/J puzzle), MS: m/e = 320 (M+). Example 4 1H rice sniffing, i_[[i_(3'4-diphenyl)-1H imino-4-yl)methyl]•mercaptoethyl)-, hydrochloride (1:2) 2-isopropyl The imidazole is reacted with sodium hydride, followed by 4 - gas methyl + (3 + di- phenyl) 1-indole - imidazole, followed by extraction and subsequent chromatography to obtain the title compound free base, which is transferred Into its white hydrochloride. Melting point 236-238 ° C (decomposition) (methanol / diethyl ether), Ms: m/e = 335 (M+H+). Example 5 1H-imidazole, i-(3,4-diphenyl)-4-(ι_Η-imidazol-1-yl-indenyl)-, hydrochloride (1:2) rice bran reacted with sodium hydride, then Follow-up treatment with 4_gas thiol_1·(3,4_di-phenyl-phenyl)· ΐΗ· 味 吐 'after extraction and after chromatography, the title compound free base was obtained, which was converted into white Hydrochloride. Melting point > 25 (rc (methanol / diethyl ether), MS: m / e = 292 (M +). Example 6 jjl - taste saliva, 1- (3, 4- two gas stupid) · 4 · "(4-A a-1H-imidazole-1-, A; L_, hydrochloride (I:2) and 1Η-spazole, ΐ-η,4-二窗.笑篡)-4-Γ(5-甲其-1Η-imidol-1-yl)methyl μ, hydrochloride (1:2吖 ratio 3:2) 4-methylimidazole is reacted with sodium hydride, followed by 4-methane 4-(3,4 -Second gas - stupid -31 - This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 __'__B7 __ V. Inventions and explanations (28) Base) -1Η-Salt follow-up Treatment - After extraction and subsequent chromatography, the title compound free base was obtained, which was converted to its white hydrochloride. MS: m/e = 306 (M+). Example 7 Ιτί 一气-笑基)-1Η Miso-4·基甲一1-4.5,6.7-tetraki-1Η-benzimidazole, hydrochloric acid chisel 4,5,6,7-tetrahydrobenzimidazole is reacted with sodium hydride, followed by 4 曱 曱-Bu (3,4-dichloro-phenyl)-iH-imidation, subsequent treatment with extraction and chromatography to obtain the title compound free base, which was converted to its white hydrochloride. ;250 C (methanol / 乙趟), MS: m/e=346(M+). Example 8 1. Technique-_嗤'1-『『Bu (3,4-diazepine-based 丫-1 only-咄地-4- Methyl bromide 4.5-dimercapto-, guanidine hydrochloride < Ί · 9 Λ 4,5-dimethylimidazole and sodium hydride, followed by 4 曱 曱 丨 丨 丨 丨 二 二 苯基Subsequent treatment with 1 Η-imidazole, after extraction and subsequent chromatography, obtained the title compound as a free base, which was converted to white salt, m.p. <250 ° C (decyl alcohol / diethyl ether), MS: m/e =320(M+). Example 9 1H-flavored saliva '1-ΓΓΐ_ρ,4·dimercapto)_1H-imiphate_4_yl)methyl μ2_^ base-, sterol hydrochloride 9) 2-phenyl The imidazole is reacted with sodium hydride, followed by 4-sulfomethyl-1-(3,4-di-phenyl)-1 hydrazine-imidazole, followed by extraction and subsequent chromatography to obtain the title compound free base. It is converted to its white hydrochloride. Melting point 197-198 ° C (methanol / diethyl ether), MS: m / e = 369 (M + H +). • 32 - This paper scale applies to China National Standard (CNS) A4 specifications (210X 297 public) 1328584 A7 B7 V. Description of invention (29) Example 10 1H-ball+, 1-ΓΓ1-(4-oxomethyl-fundy)-1Η-啼一一甲1-Up·Λ篡-, citrate (1:21 Π-(4-gas-3-methyl-phenyl)-1Η·imidazol-4-yl]-nonanol was treated with sulfinium chloride 4-Chloromethyl-3-n-yl-styl)_ιη·smell is directly used in the reaction. '2-Ethyl imidazole was reacted with sodium hydride as described in Example 1, followed by subsequent treatment with 4-chloromethyl-1-(4· gas-3-methyl-benyl)-1Η-flavored salic acid hydrochloride. The title compound free assay was obtained after extraction and subsequent chromatography and was converted to its white hydrochloride. Melting point 186-187 ° C (methanol / diethyl ether), MS: m / e = 300 (M+). Examples 11 to 103 were prepared according to the schematic procedure described in Example 1〇. Example 11, 1-ΓΓ1-(4-lact-3-methylphenyl-yl)methyl Ί 2 甲 、, pound acid salt (1:2) [1-(4- gas-3-fluorenyl- Phenyl)-1Η-imidol-4-yl]-methanol was first treated with a helium gas, then treated with a reaction mixture of sodium hydride and 2-methyl-imidazole. After extraction followed by chromatography and chromatography, The title compound is in a free state. The free state is converted to its white hydrochloride salt. 218-220 ° C (methanol / ethyl bond), MS: m / e = 286 (M +). Example 12 1H-flavor啥, 1-(4-气-3-曱基笨基)-4-ΠΗ-咕 暮-1-暮-甲甚,焦酸盐(1:2) [1-(4-chloro-3-甲) Base-phenyl)-1Η-imidazol-4-yl]-methanol First use the sub-enzymes This paper scale applies to Chinese national standards (CNS>Α4 specifications (210X 297 mm) -33- 1328584 A7 B7
氣處理’然後使用氫化鈉及咪唑之.反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態检。該 自由態鹼被轉成其白色鹽酸鹽。熔點206-207。(:(曱醇/乙越) MS: m/e=272(M+)。 實例13 1H-味峻’ 1-丨丨1-(4-氣-3-甲基笨基)-1H-喃啤-4-某1甲某卜4 i、 二甲基-,鹽酸鹽Π:2) [1-(4-氣-3-曱基-苯基)-1 Η-咪唑-4-基]-甲醇首先使用亞續醯 氣處理’然後使用氫化鈉及4,5-二曱基咪唑之反應混合物處 理。於萃取後續處理及層析術後,獲得標題化合物呈自由 態驗。該自由態驗被轉成其白色鹽酸鹽。炫點>25〇 (甲醇/ 乙醚),MS: m/e=300(M+)。 實例14 1-『1-(4-亂-3 -曱基笨基)-1Η -口米峻-4 -基1-4.5^(^7 -四窗.-1H-苹 并咪唑-,鹽酸鹽(1:2) [卜⑷氣-3 -曱基-苯基)-lH-c米吐-4-基]-曱醇首先使用亞績酿 氣處理,然後使用氮化納及4,5,6,7 -四氣苯并味唾之反庚混 合物處理。於萃取後續處理及層析術後,獲得標題化合物 呈自由態驗。該自由態驗被轉成其白色鹽酸鹽。溶點>250 °C (曱醇/乙醚),MS: m/e=326(M+)。 實例15 1H-味啥,氯-3-甲基笨基)-1Η-喃-4-某1甲某l-2-f 曱硫篡V,鹽酸鹽(1:2) Π-(4-氣-3-甲基-苯基)-1Η-啼吐-4-基]-曱醇首先使用亞續醯 -34- 本纸張尺度適用中國國家標準(CNS) Α4規格(210X 297公釐) 1328584 A7 B7 ,然後使用氫化鈉及咪唑之反應芩.合物處理。於萃取後續 處理及層析術後,獲得標題化合物呈自由態鹼。該自由態 鹼被轉成其白色鹽酸鹽。熔點214-216¾ (曱醇/乙醚),MS: m/e=264(M+)。 實例19 1Η-_ 嗅 ’ 1-[Π_(3,4-—甲基笨基)-lH-°米峰·4-11 甲某 1-2·乙 甚-,鹽酸鹽0:2) [1-(3,4-二甲基-苯基)-1Η·咪唑-4-基]·甲醇首先使用亞磺醯 氣處理’然後使用氫化納及2-乙基咪唾之反應混合物處理 。於萃取後續處理及層析術後’獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。溶點>250 °c (曱醇/乙 謎),MS: m/e=280(M+)。 實例20 1H-味唆’ 1-ΓΠ-(3,4-二甲基笨基崎·4-基1甲某甲 某-,鹽酸鹽(1:2) [1-(3,4-二曱基-苯基)·1Η-咪唑-4-基]-曱醇首先使用亞項酿 氯處理’然後使用氫化鈉及2-曱基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由库 檢。該自由態驗被轉成其白色鹽酸鹽。溶點249-25 (甲醇 /乙謎),MS: m/e=266(M+)。 實例21 1H-P/H 吐·,1-(3,4-二甲基笨基 ~)-4-(1Η-^Η 吐-1-基-甲某 y,骑— S愛鹽(1:2) [1-(3,4-二曱基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞項酿 36-The gas treatment was then treated with a reaction mixture of sodium hydride and imidazole. After the subsequent treatment and chromatography, the title compound was obtained as a free state test. This free base is converted to its white hydrochloride. Melting point 206-207. (: (sterol/Byco) MS: m/e = 272 (M+). Example 13 1H-味峻' 1-丨丨1-(4-Ga-3-methylphenyl)-1H-alcohol -4-A 1 A, 4 i, dimethyl-, hydrochloride Π: 2) [1-(4-Ga-3-indolyl-phenyl)-1 Η-imidazol-4-yl]- Methanol was first treated with a helium-neutral treatment and then treated with a reaction mixture of sodium hydride and 4,5-dimercaptoimidazole. After the extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Hyun spot > 25 〇 (methanol / diethyl ether), MS: m / e = 300 (M +). Example 14 1-"1-(4-乱-3 -曱基笨基)-1Η - Mimi-4 -yl 1-4.5^(^7 - four-window.-1H-Pentimidazole-, hydrochloric acid Salt (1:2) [Bu (4) gas-3 -mercapto-phenyl)-lH-c-m--4-yl]-nonanol is first treated with agglomerated gas, then sodium nitride and 4,5 , 6,7 - four gas benzene and saliva anti-heptane mixture treatment. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Melting point > 250 ° C (nonanol/diethyl ether), MS: m/e = 326 (M+). Example 15 1H-Miso, chloro-3-methylindolyl)-1Η-am-4-one 1 A certain l-2-f thiopurine V, hydrochloride (1:2) Π-(4- Gas-3-methyl-phenyl)-1Η-啼吐-4-yl]-sterol First use 亚-醯-34- This paper scale applies to Chinese National Standard (CNS) Α4 specification (210X 297 mm) 1328584 A7 B7, then treated with sodium hydride and imidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point 214-2163⁄4 (furfuryl alcohol / diethyl ether), MS: m/e = 264 (M+). Example 19 1Η-_ sniffing ' 1-[Π_(3,4-methylphenyl)-lH-°米峰·4-11 A certain 1-2·Bis-, hydrochloride 0:2) [ 1-(3,4-Dimethyl-phenyl)-1Η-imidazol-4-yl]·methanol was first treated with sulfoximine gas and then treated with a reaction mixture of sodium hydride and 2-ethyl hydrazine. The title compound was obtained in a free state after extraction and subsequent chromatography. This free state was converted to its white hydrochloride. Melting point > 250 °c (sterol/accuracy), MS: m/e = 280 (M+). Example 20 1H-Miso '1-ΓΠ-(3,4-dimethyl phenyl ketone 4-yl 1 甲甲甲-, hydrochloride (1:2) [1-(3,4-di) Mercapto-phenyl)·1Η-imidazol-4-yl]-nonanol was first treated with sub-grinding chlorine' and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. The title compound was obtained as a free library. The free state was converted to its white hydrochloride. Melting point 249-25 (methanol / sigma), MS: m/e = 266 (M+). Example 21 1H-P /H 吐·, 1-(3,4-dimethyl stupid~)-4-(1Η-^Η 吐-1-基-甲某y, riding - S love salt (1:2) [1- (3,4-Dimercapto-phenyl)-1Η-imidazol-4-yl]-nonanol
本纸張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 B7This paper scale applies to the Chinese National Standard (CNS) A4 specification (210X 297 mm) 1328584 A7 B7
五、發明说明(33 ) ----- 氣處理’然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點218_219eC (甲醇/乙醚) MS: m/e=252(M+)。 , 實例22 lEr咪嘘’ ;?·甲基-1-ΓΓ1-(4-甲甚笨某)_1H_唑唑_4·其1甲芊1 ,鹽酸鹽(1:2) m/e=252(M+) » (1-對甲苯基-1H-咪唑-4-基)-曱醇首先使用亞磺醯氯處理, 然後使用氫化鈉及2-曱基咪唑之反應混合物處理。於萃取 後續處理及層析術後,獲得標題化合物呈自由態鹼。該自 由態鹼被轉成其白色鹽酸鹽。熔點>25(rc (曱醇/乙醚),Ms: 實例23V. INSTRUCTIONS (33) ----- Gas treatment' is then treated with a reaction mixture of sodium hydride and imidazole. After the subsequent treatment and chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point 218_219eC (methanol / diethyl ether) MS: m / e = 252 (M+). Example 22 lEr 嘘 嘘 ; 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 甲基 _1 _1 _1 _1 _1 _1 , , , , , , , , , , , , , , , , , , , , 252(M+)»(1-p-Tolyl-1H-imidazol-4-yl)-nonanol was first treated with sulfinium chloride and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point > 25 (rc (sterol/diethyl ether), Ms: Example 23
(1-對曱苯基·1Η·^_4·基)_甲醇首先使用亞續醯氣處理 然後使用氫化鈉及咪唑之反應混合物處理。於(1-P-Phenylphenyl) 1Η·^_4·yl)-Methanol was first treated with a helium gas and then treated with a reaction mixture of sodium hydride and imidazole. to
m/e=238(M+)。 實例24m/e = 238 (M+). Example 24
唑-4-某 1 甲基 1-2 甲某-,鹽酸鹽(1:2)Azole-4-one 1 methyl 1-2 methyl--, hydrochloride (1:2)
-37- _本纸银尺度適用中囷國家標準(CNS) A4規格(2i〇X297公爱j ' —----- 1328584 A7 B7 五、發明‘説明(34 ) 氯處理,然後使用氫化鈉及2-甲基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其白色鹽酸鹽。熔點210-212^(甲醇 /乙謎),MS: m/e=270(M+)。 實例25 1H-咪唑,2-乙基-1-丨丨1-(4-氟-3-甲基茉某V1H-咪唑-4-某1 基1-,鹽酸鹽(1:2) [1-(4-氟-3 -曱基-苯基)-1Η-味吐-4-基]-曱醇首先使用亞項酿 氯處理,然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 絵:。該自由態驗被轉成其白色鹽酸鹽》、熔點210-212°C (甲醇 /乙醚),MS: m/e=284(M+)。 實例26 1H-咪唑,1-(4-氟-3-甲基装某)-4-ΠΗ-嵘唑-1-基-甲基)·,發 酸鹽Π:2) [1-(4-氟-3 -曱基-苯基)-1Η-哺唆-4-基]-甲醇首先使用亞續酿 氣處理’然後使用氫化鈉及味咕之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點242-243 °C (曱醇/乙域), MS: m/e=256(M+)。 實例27 1—H-咪唑’ 2-甲基-1-丨丨1-(4-(甲硫某)笑某1-1H-哚岫-4-其1甲 基)-,鹽酸鹽(1:2) [1-(4-曱基硫烧基-苯基)-iH-咪峻-4-基]-曱醇首先使用亞項 •38· 本紙银尺度逋用中S固家椟準(CNS) A4規格(21〇χ297公釐)-37- _ This paper silver scale is applicable to China National Standard (CNS) A4 specification (2i〇X297 public love j '.----- 1328584 A7 B7 V. Invention 'Note (34) Chlorine treatment, then use sodium hydride And the reaction mixture of 2-methylimidazole is treated. After the subsequent treatment of the extraction and chromatography, the title compound is obtained as a free base. The free base is converted to white hydrochloride. m.p. 210-212. B.) MS: m/e = 270 (M+). Example 25 1H-imidazole, 2-ethyl-1-indole 1-(4-fluoro-3-methyl-methyl-V1H-imidazole-4- 1 base 1, hydrochloride (1:2) [1-(4-fluoro-3-indolyl-phenyl)-1 oxime-sodium-4-yl]-sterol is first treated with sub-branched chlorine. Then, it is treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After the subsequent treatment of extraction and chromatography, the title compound is obtained as a free state: the free state is converted to its white hydrochloride, melting point 210 -212 ° C (methanol / diethyl ether), MS: m / e = 284 (M + ). Example 26 1H-imidazole, 1-(4-fluoro-3-methyl-m-)-4-indole-carbazole-1 -yl-methyl)·, hair acid hydrazine: 2) [1-(4-fluoro-3-indolyl-phenyl)-1 fluorene-naphtho-4-yl]-methanol Stuffed gas treatment 'and then the reaction mixture is treated using sodium hydride and flavor of cushions. After the subsequent treatment and chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Mp 242-243 ° C (sterol/B domain), MS: m/e = 256 (M+). Example 27 1-H-Imidazole '2-Methyl-1-indole 1-(4-(methylthio), 1-1H-哚岫-4-, 1 methyl)-, hydrochloride (1 :2) [1-(4-Mercaptothio-phenyl)-iH-mio-4-yl]-sterol First use sub-items • 38· This paper is used in silver scales. CNS) A4 size (21〇χ297 mm)
裝 訂Binding
線 1328584 A7 B7 五、發明·説明(35 ) ;-- 酿氣處理’然後使用氮化納及2-甲基咪唑之反應混合物處 理。於萃取後續處理及層析術後’獲得標題化合物呈自由 態鹼。該自由態鹼被轉成其白色鹽酸鹽。炫點242_243,c (甲 醇/乙醚),MS: m/e=284(M+)。 實例28 1H-咪嗅’ 2-乙碁士『f (甲硫基_)^基ι_Ί 呻 < 冰基1甲 基V,鹽酸鹽(1:2) [1-(4·曱基硫烧基-苯基)-m-味嗤-4·基]_甲醇首先使用亞磺 醯氣處理’然後使用氩化納及2-乙基咪唑之反應混合物處 理。於萃取後續處理及層析術後,獲得標題化合物呈自由 態驗。該自由態驗被轉成其淺黃色鹽酸鹽。溶點i 6丨_丨62( 曱醇/乙醚),MS: m/e=298(M+)。 實例29 1H-哞唆’ 4-(1,ϋ-·生-卜棊-甲甲硫某)笑某^,镑 酸鹽Π:2) [1-(4(-氟-3 -甲基-笨基)-1Η-β米唾-4-基)·曱醇首先使用亞績醯 氯處理’然後使用風化納及味峻之反應混合物處理β於萃 取後續處理及層析術後’獲得標題化合物呈自由態驗。該 自由態驗被轉成其淺黃色鹽酸鹽》炼點233-234°C (甲醇/乙 醚),MS: m/e=270(M+)。 實例30 1H-咪唑,2·甲棊_-ΗΠ·(3-(毛基)笑某ι·1Η_啐地其1 甲某V,镑酸鹽(1:2) [1-(3-三氟甲基-笨基)-1Η-咪唑-4-基]·甲醇首先使用亞磺醯 -39-Line 1328584 A7 B7 V. Invention · Description (35) ;-- Brewing treatment' is then treated with a reaction mixture of sodium nitride and 2-methylimidazole. The title compound was obtained as a free base after extraction and subsequent chromatography. This free base is converted to its white hydrochloride. Hyun spot 242_243, c (methanol/diethyl ether), MS: m/e = 284 (M+). Example 28 1H-Mim sniff '2-B's gentleman's f (Methylthio-)^-based ι_Ί 呻< Ice-based 1 methyl V, hydrochloride (1:2) [1-(4·曱-sulfur The alkyl-phenyl)-m-miso-4·yl]-methanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After the extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its pale yellow hydrochloride. Melting point i 6 丨 丨 62 (sterol/ethyl ether), MS: m/e = 298 (M+). Example 29 1H-哞唆' 4-(1,ϋ-·生-卜棊-甲甲硫) Xiaomou^, Phenolate Π: 2) [1-(4(-fluoro-3-methyl-) Stupid)-1Η-β-sodium-4-yl)·sterol is first treated with chlorinated chlorinated chlorinated solution and then treated with a mixture of weathered and sulphur-like reaction mixture for subsequent treatment and chromatography. A free test. The free state was converted to its pale yellow hydrochloride salt 233-234 ° C (methanol / diethyl ether), MS: m / e = 270 (M +). Example 30 1H-imidazole, 2·甲棊_-ΗΠ·(3-(毛基)笑某ι·1Η_啐地其1 A certain V, pound acid salt (1:2) [1-(3-three Fluoromethyl-phenyl)-1Η-imidazol-4-yl]·methanol first using sulfinium-39-
本紙張尺度適用中囷國家標竿(CNS) A4規格(210X297公爱YThis paper scale applies to the China National Standard (CNS) A4 specification (210X297 public Y
裝 訂Binding
線 1328584Line 1328584
氣處理’然後使用氫化鈉及2-曱基咪唑之反應混合物處理 。於萃取後續處理及層析術後’獲得標題化合物呈自由態 驗。該自由態檢被轉成其白色鹽酸鹽。溶點218-220(甲醇 /乙醚),MS: m/e=306(M+)。 實例3 1 迅咪吐’圣乙基-1-丨丨1-(3_(三氟其卜m-咪岫1 曱基V,镑酸鹽(1:2) [1-(3-主氟甲基-苯基)-1Η-咪唑-4-基]·甲醇首先使用亞磺醯 氣處理’然後使用氫化納及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由ill驗被轉成其白色鹽酸鹽。熔點216-218。〇(甲醇 / 乙醚),MS: m/e=320(M+)。 實例32 迎_°米吐’ 4-(1士哞唾-1-基-甲基三氟甲某、芄篡八, 鹽酸鹽(1:2) [1-(3-三氟甲基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氣處理’然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及·層析術後’獲得標題化合物呈自由雜驗。該 自由態驗被轉成其白色鹽酸鹽》炼點224-226°C (甲醇/乙謎) MS: m/e=292(M+)。 實例33 2.H-咪唾’ 2-乙氟-3-(三氟甲某)竿某卜1H味吔_ 4-基1甲基1-,鹽酸鹽(1:2) [1-(4-氟-3-三氟曱基-苯基)-1Η-味唾-4-基]-曱醇首先使用亞 -40-Gas treatment was then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. The title compound was obtained in a free state after extraction and subsequent chromatography. This free state test was converted to its white hydrochloride. Melting point 218-220 (methanol / diethyl ether), MS: m/e = 306 (M+). Example 3 1 Xun Mi Tu's St. Ethyl-1-丨丨1-(3_(Trifluoromethane m-imiphate 1 fluorenyl V, pound acid salt (1:2) [1-(3- main fluorocarbon Base-phenyl)-1Η-imidazol-4-yl]·methanol was first treated with sulfoximine gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction followed by chromatography and chromatography, The title compound is in a free state. The free ill is converted to its white hydrochloride salt. mp 216-218. 〇 (methanol / ether), MS: m/e = 320 (M+). ' 4-(1 哞 哞 -1--1-yl-methyl trifluoromethyl, octagonal, hydrochloride (1:2) [1-(3-trifluoromethyl-phenyl)-1 Η-imidazole -4-yl]-sterol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and imidazole. After the subsequent treatment and chromatography, the title compound was freely tested. It was converted to its white hydrochloride. Refining point 224-226 ° C (methanol / sigma) MS: m / e = 292 (M +). Example 33 2.H-imida' 2-ethylfluoro-3- ( Trifluoromethyl) 竿 卜 1H miso _ 4-yl 1 methyl 1-, hydrochloride (1:2) [1-(4-fluoro-3-trifluoromethyl-phenyl)-1 Η- taste 4-yl] - ol Yue first used ethylene -40-
1328584 A7 _ B7 五、發明説明(37 ) 磺醯氣處理,然後使用氫化鈉及2-.乙基咪唑之反應混合物 處理。於萃取後續處理及層析術後’獲得標題化合物呈自 由態驗。該自由態驗被轉成其淺黃色鹽酸鹽。炫點>238°c ( 分解)(甲醇/乙醚),MS: m/e=338(M+)。 實例34 1H-咪唑,氟·3_(三氟甲基)茉某咄岫_4·其1甲 基1-2-甲某-,鹽酸鹽(1:2) [1_(4-氟-3-三氟曱基-苯基)-1Η-哺唾-4-基]-甲醇首先使用亞 磺醯氣處理,然後使用氫化鈉及2-曱基咪唑之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由態驗。該自由態驗被轉成其淺黃色鹽酸鹽。溶點>23 1 °c 分解(曱醇/ 乙醚),MS: m/e=324(M+)。 實例35 1Η-°米唾,1-『4-氟-3-(三氣甲基)苯基1-4-Π.Η-0来峰-1-基-甲某 )-,鹽酸驗η :2、 [1-(4-乱-3-三氟甲基-苯基)-1Η-味唾-4-基]-甲醇首先使用亞 磺醯氣處理,然後使用氫化鈉及咪唑之反應混合物處理。 於萃取後續處理及層析術後’獲得標題化合物呈自由態驗 。該自由態驗被轉成其淺黃色鹽酸鹽《溶點>246°C分解(曱 醇 / 乙醚),MS: m/e=310(M+)。 實例36 1H-咪唑,1-Γ3-氟-4-〔三氟甲基)笨基卜4-ΠΗ-咄唑-1-某·甲某 )-,鹽酸鹽Π:2) [1-(3-氟-4-三氟曱基-苯基)-1 Η-蜂喷-4-基]-曱醇首先使用亞 •41 - 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐)1328584 A7 _ B7 V. INSTRUCTIONS (37) Sulfur helium treatment, followed by treatment with a reaction mixture of sodium hydride and 2-ethylimidazole. The title compound was obtained as a free test after extraction and subsequent chromatography. This free state was converted to its pale yellow hydrochloride. Hyun spot > 238 ° C (decomposition) (methanol / diethyl ether), MS: m / e = 338 (M +). Example 34 1H-imidazole, fluoro.3_(trifluoromethyl)mosa 咄岫4. Its 1 methyl 1-2-methyl--hydrochloride (1:2) [1_(4-fluoro-3) -Trifluorodecyl-phenyl)-1Η-ylide-4-yl]-methanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After the subsequent treatment of extraction and chromatography, the title compound was obtained as a free test. This free state was converted to its pale yellow hydrochloride. Melting point > 23 1 °c decomposition (sterol/ethyl ether), MS: m/e = 324 (M+). Example 35 1Η-° rice saliva, 1-“4-fluoro-3-(trimethylmethyl)phenyl1-4-Π.Η-0 to peak-1-yl-methyl)-, hydrochloric acid test η: 2, [1-(4-ran-3-trifluoromethyl-phenyl)-1Η-sodium-4-yl]-methanol is first treated with sulfinium gas, then treated with a reaction mixture of sodium hydride and imidazole . The title compound was obtained in a free state after extraction and subsequent chromatography. This free state was converted to its pale yellow hydrochloride "melting point" > 246 ° C decomposition (sterol / diethyl ether), MS: m / e = 310 (M +). Example 36 1H-imidazole, 1-anthracene 3-fluoro-4-[trifluoromethyl)phenylidene 4-indole-carbazole-1-some·methyl)-, hydrochloride salt: 2) [1-( 3-Fluoro-4-trifluoromethyl-phenyl)-1 Η-bee pent-4-yl]-sterol First use of the Asian 41 - This paper scale applies to the Chinese National Standard (CNS) Α 4 specifications (210 X 297 mm)
磺醯氯處理,然後使用氫化鈉及咪.喷之反應混合物處理β 於萃取後續處理及層析術後’獲得標題化合物呈自由態驗 。該自由態检被轉成其淺黃色鹽酸鹽。溶點232-234°C (甲醇 /乙醚),MS: m/e=311(M+H+)。 實例37 1H-咪唑’ 1-『Γ1-Π-氟_4-(三氟甲某)茉某i_m·崃唑_4-亭]甲 基1-2-甲甚-,鹽酸鹽Π:2) Π-(3-氟-4-三氟曱基-苯基)-1 Η-味唾-4-基]-曱醇首先使用亞 磺醯氣處理,然後使用氫化鈉及2-甲基咪唑之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由癌驗。該自由癌驗被轉成其淺黃色鹽酸鹽。溶點238_239 °C (甲醇/乙醚),MS: m/e=325(M+H+)。 實例38 味嗅,2-乙基氟-4-(三氟曱基)笑其衅_ 4-基1甲基1-,鹽酸鹽(1:2) [1-(3-氟-4-三氟曱基-苯基)-1Η·咪唑-4-基]•曱醇首先使用亞 磺醯氣處理,然後使用氫化鈉及2-乙基咪唑之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由ill驗。該自由癌驗被轉成其白色鹽酸鹽。炫點222-224 °C 分解(曱醇/乙醚),MS: m/e=339(M+H+) » 實例39 1ϋ-咪唑,2-甲基甲碁-3-(三,氟笨某uH-咕 嗦-4-基1甲基1·,鹽酸鹽(1:2) [1-(4-甲基-3-三氣甲基-苯基)-1Η-味嗤-4-基卜甲醇首先使用 -42- 1328584 A7 B7 發明説明 亞磺醯氣處理,然後使用氫化鈉及.2-曱基咪唾之反應混合 物處理。於萃取後續處理及層析術後,獲得標題化合物呈 自由態鹼。該自由態鹼被轉成其灰白色鹽酸鹽。·溶點>235 °C 分解(曱醇/乙醚),MS: m/e=320(M+)。 實例40 米峻,2·乙基ri-「『i-『U基_3_(三荦甲篡)竿芊卜1H-咪 唑-4-基1甲基1-,鹽酸鹽(1:2) [1-(4-肀基-3-三氟甲基-苯基)-1Η-°米唾-4-基]-甲醇首先使用 亞磺醯氣處理,然後使用氫化鈉及2-乙基啼唾之反應混合 物處理。於萃取後續處理及層析術後,獲得標題化合物呈 自由態驗。該自由態驗被轉成其灰白色鹽酸鹽。溶點>25〇 °C (甲醇/乙醚),MS: m/e=334(M+)。 實例41 jjj-咪唾,4-(1Η·.涉吨-1-基甲基)-ΐ·『4·甲爷(一竹甲某)芏 基1-,鹽酸轉Π:2) [1-(4-曱基-3-三氟甲基-苯基)-1Η-咪唑-4-基]·曱醇首先使用 亞績酿氯處理’然後使用氫化鈉及咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其灰白色鹽酸鹽。熔點>25(rc (曱醇/ 乙醚),MS: m/e=306(M+) » 實例42 JJL-咪啥’ 1-『丨1-_(4-甲棊-3-甲氧笨甲幕」^ 2-乙基-,羧酸鹽(1:2) [1-(4-氯-3-曱氧-笨基)-1H·咪唑_4_基曱醇首先使用亞磺醯 本紙張尺度適用中國国家標準(CNS) A4規格(210X297公茇)Treatment with sulfonium chloride, followed by treatment with β sodium hydride and a reaction mixture of sodium methoxide, followed by extraction and subsequent chromatography to obtain the title compound in a free state. This free state test was converted to its pale yellow hydrochloride. Melting point 232-234 ° C (methanol / diethyl ether), MS: m / e = 311 (M+H+). Example 37 1H-Imidazole ' 1- Γ 1-Π-Fluorine_4-(Trifluoromethyl) Molybdenum i_m·carbazole _4-Ting] Methyl 1-2-methyl--, hydrochloride Π: 2 Π-(3-Fluoro-4-trifluoromethyl-phenyl)-1 oxime-salt-4-yl]-nonanol was first treated with sulfinium, followed by sodium hydride and 2-methylimidazole The reaction mixture is treated. After extraction and subsequent chromatography, the title compound was obtained as a free cancer test. The free cancer test was converted to its pale yellow hydrochloride. The melting point was 238-239 ° C (methanol / diethyl ether), MS: m/e = 325 (M+H+). Example 38 Taste, 2-ethylfluoro-4-(trifluoromethyl) acetonide _ 4-yl 1 methyl 1-, hydrochloride (1:2) [1-(3-fluoro-4- Trifluoromethyl-phenyl)-1Η-imidazol-4-yl]• decyl alcohol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction and subsequent chromatography, the title compound was obtained as a free ill test. The free cancer test was converted to its white hydrochloride. Hyun point 222-224 °C decomposition (sterol / ether), MS: m / e = 339 (M + H +) » Example 39 1 ϋ - imidazole, 2-methylformamidine-3- (three, fluorine stupid uH -咕嗦-4-yl 1 methyl 1·, hydrochloride (1:2) [1-(4-methyl-3-tris-methyl-phenyl)-1Η- miso-4-yl Methanol was first treated with -42- 1328584 A7 B7. The invention was treated with sulfinium gas, and then treated with a reaction mixture of sodium hydride and .2-mercaptopurine. After the subsequent treatment and chromatography, the title compound was obtained as a free state. The base is converted to its off-white hydrochloride. ·Soluble point > 235 ° C decomposition (sterol / ether), MS: m / e = 320 (M +). Example 40 m, 2 · B Base ri-""i-"U-based_3_(三荦甲篡)竿芊 1H-imidazol-4-yl 1methyl 1-, hydrochloride (1:2) [1-(4-fluorenyl) -3-Trifluoromethyl-phenyl)-1Η-°m-7-yl]-methanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethyl hydrazine. After the subsequent treatment and chromatography, the title compound was obtained in a free state. The free state was converted to its off-white hydrochloride. Melting point > 25 ° ° C (methanol / B) ), MS: m/e = 334 (M+). Example 41 jjj-mi saliva, 4-(1Η·. 吨-1-ylmethyl)-ΐ·“4·甲爷(一竹甲)芏Base 1-, Hydrochloric acid conversion: 2) [1-(4-Mercapto-3-trifluoromethyl-phenyl)-1Η-imidazol-4-yl]·nonanol was first treated with agitated chlorine. Treated with a reaction mixture of sodium hydride and imidazole. After the subsequent treatment of the extraction and chromatography, the title compound is obtained as a free base. The free base is converted to its pale white hydrochloride. Melting point > 25 (rc (sterol) / Ether), MS: m/e = 306 (M+) » Example 42 JJL-Mi啥' 1- "丨1-_(4-甲棊-3-甲氧甲甲幕)^ 2-Ethyl-, Carboxylate (1:2) [1-(4-Chloro-3-indole-stupyl)-1H.imidazole_4_yl sterol First use sulfinic acid paper scale applicable Chinese National Standard (CNS) A4 Specifications (210X297 public)
裝 訂·Binding·
k -43- 1328584k -43- 1328584
氣處理,然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其灰白色鹽酸鹽。溶點244-246°C分 解(甲醇/乙醚),MS: m/e=316(M+) » 實例43 十喷—’ 1-『[.1-(4·-甲基_3·曱氣策基)-IHd卡唾_4_基1甲基ι_ 2-甲基-,鹽酸鹽(1:2) [1-(4-氣-3-甲氧-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯 氣處理,然後使用氫化鈉及2-曱基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其灰白色鹽酸鹽。熔點>25〇它(曱醇/ 乙醚),MS: m/e=302(M+)。 實例44 1H二咪喷’ 1-(4-氧.-3-甲氧苯基)-4-(1Η-咄咄-1竿-甲篡、,醆 酸鹽(1:2) [1-(4-氣-3-曱氧-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氯處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態驗。該 自由態鹼被轉成其白色鹽酸鹽。熔點22 1-2221 (甲醇/乙鍵) MS: m/e=288(M+)。 實例45 唑-4-革1甲 1H-咪唑,2-乙基-W『l-(4-翁.-3-篡1-,鹽酸鹽(1:2) [1-(4-氧-3-曱氧-笨基)-1Η-味唾-4-基]_曱醇首先使用亞磺醯 -44- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 A7 B7 五、發明説明(41 ) 氣處理,然後使用氫化納及2-乙基味唾之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態絵被轉成其灰白色鹽酸鹽。溶點>250 ec分解( 曱醇/乙醚),MS: m/e=300(M+) » 實例46 _11~1-°米吐,1-『『1-(4-氟-3-甲氣装某)-1幵-,唾-4-某1甲基1-2-甲基-,鹽酸鹽Π:2)Gas treatment followed by treatment with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its off-white hydrochloride. Melting point 244-246 ° C decomposition (methanol / ether), MS: m / e = 316 (M +) » Example 43 ten spray - ' 1- 『 [. 1- (4 · - methyl _3 · 曱 策 策))-IHd card s___ yl 1 methyl ι_ 2-methyl-, hydrochloride (1:2) [1-(4- gas-3-methoxy-phenyl)-1 Η-imidazole-4 The -methanol--methanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. The free base is converted to its off-white hydrochloride. Melting point > 25 〇 (methanol / diethyl ether), MS: m / e = 302 (M +). Example 44 1H Dimime' 1-(4-oxo-3-methoxyphenyl)-4-(1Η-咄咄-1竿-formamidine, decanoate (1:2) [1-(4 - gas-3-oxo-phenyl)-1Η-imidazol-4-yl]-nonanol is first treated with sulfinium chloride, then treated with a reaction mixture of sodium hydride and imidazole. Subsequent extraction and chromatography After that, the title compound was obtained in a free state. The free base was converted to white salt. m.p. 22 1-2221 (methanol / hexane) MS: m/e = 288 (M+). - leather 1 methyl 1H-imidazole, 2-ethyl-W "l-(4-翁.-3-篡1-, hydrochloride (1:2) [1-(4-oxo-3-oxo-) Stupid base)-1Η-味唾-4-yl]_sterol first use sulfinium-44- This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1328584 A7 B7 V. Description of invention ( 41) Gas treatment, and then treatment with a reaction mixture of sodium hydride and 2-ethyl flavonoids. After the subsequent treatment of extraction and chromatography, the title compound is obtained in a free state. The free state ruthenium is converted into its grayish white hydrochloric acid. Salt. Melting point >250 ec decomposition (sterol/diethyl ether), MS: m/e=300 (M+) » Example 46 _11~1-° rice spit, 1-『『1- (4-Fluoro-3-methyl-charged)-1幵-, sal-4-a 1-methyl1-2-methyl-, hydrochloride Π: 2)
裝 [1-(4-氟-3-甲氧-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氣處理’然後使用氫化鈉及2-甲基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其灰白色鹽酸鹽。熔點>22〇»c分解( 曱醇/乙醚),MS: m/e=286(M+)。 實例47 1H-喃唾,1-(4-氟-3 -曱氧笨基)-4-ΠΗ-喃岭-1_基_甲基)_,镑 酸鹽(1:2) 訂[1-(4-Fluoro-3-methoxy-phenyl)-1Η-imidazol-4-yl]-nonanol was first treated with sulfoximine gas and then a reaction mixture of sodium hydride and 2-methylimidazole was used. deal with. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. The free base is converted to its off-white hydrochloride. Melting point >22〇»c decomposition (sterol/diethyl ether), MS: m/e = 286 (M+). Example 47 1H-pyrazine, 1-(4-fluoro-3-oxooxyphenyl)-4-indolyl-pyranyl-1-yl-methyl)-, pound acid salt (1:2)
[1-(4-氟-3-曱氧-苯基)-1Η-咪唾-4-基]-曱醇首先使用亞續醯 氣處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態驗。該 自由態鹼被轉成其灰白色鹽酸鹽。熔點174-178X:(甲醇/乙 醚),MS: m/e=272(M+) » 實例48 】H-味吐,1-丨丨1-(4-氣笨基)-1Η-咪唾-4-篡1甲某甲早. 鹽酸 [1·(4-氣-笨基)-1Η-咪唑-4-基]·曱醇首先使用亞磺醯氯處理 45 1328584 A7B7 五、發明説明( ,然後使用氫化鈉及2-曱基咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼β該 自由態驗被轉成其淺黃色鹽酸鹽。炫點243-244 °C (甲酵/乙 醚),MS: m/e=272(M+)。 實例49 _lH-_ 唑,l-ffl.-(4-氣苯基甲暮卜9·己基·, 轉酸鹽(1:2) [1-(4-氣-苯基)-1Η-咪唑-4-基]·甲醇首先使用亞磺醯氯處理 ’然後使用氫化鈉及2-乙基咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點200-20 1。(:(曱醇/乙謎), MS: m/e=286(M+)。 實例50 1H-咪吐,1-(4-氣笨基)-4-ΠΗ-咪唾-1-某-甲某v,鹽酸鹽 Π:2) [1-(4-氣-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯氣處理 ,然後使用氬化鈉及咪唑之反應混合物處理。於萃取後續 處理及層析術後,獲得標題化合物呈自由態鹼。該自由態 鹼被轉成其白色鹽酸鹽。熔點228-229°C (甲醇/乙越),MS: m/e=258(M+)。 實例51 1H-喷啥,1-ΓΓ1-Π.3-笑#二氩伍囿-5-基)-1 H-味峰·4·其1甲 基1-2-乙基-,鹽酸鹽(1:2) (1-笨并[1,3]二氧伍園-5-基-1Η-味嗤-4-基)-曱醇首先使用亞 -46- 本紙張尺度適用中國國家標準(CNS)A4規格(210X297公釐)[1-(4-Fluoro-3-indolyl-phenyl)-1Η-imidazo-4-yl]-nonanol was first treated with a helium-neutral treatment and then treated with a reaction mixture of sodium hydride and imidazole. After the subsequent treatment and chromatography, the title compound was obtained as a free assay. The free base is converted to its off-white hydrochloride. Melting point 174-178X: (methanol / diethyl ether), MS: m / e = 272 (M +) » Example 48 】 H-sweet, 1-丨丨 1-(4-气笨基)-1Η-imipen-4 -篡1甲甲甲早. Hydrochloric acid [1·(4-gas-stupyl)-1Η-imidazol-4-yl]·sterol first treated with sulfinium chloride 45 1328584 A7B7 V. Description of invention (and then used The reaction mixture of sodium hydride and 2-mercaptoimidazole is treated. After the subsequent treatment of extraction and chromatography, the title compound is obtained as a free base. The free state is converted into its pale yellow hydrochloride. Hyun Point 243-244 °C (methyl leaven / diethyl ether), MS: m/e = 272 (M+). Example 49 _lH-- azole, l-ffl.-(4-carbophenylmethylpyrazine 9·hexyl·, 1:2) [1-(4-Ga-phenyl)-1Η-imidazol-4-yl]·Methanol was first treated with sulfinium chloride. Then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. The free base was converted to white salt. m.p. 200-20 1. (: (sterol/s), MS: m/ e = 286 (M+). Example 50 1H-mip, 1-(4-gas-based)-4-ΠΗ-imida-1-one-methyl v, hydrochloric acid Salt Π: 2) [1-(4-Ga-phenyl)-1Η-imidazol-4-yl]-methanol is first treated with sulfinium gas, then treated with a reaction mixture of sodium hydride and imidazole. After treatment and chromatography, the title compound was obtained as a free base. The free base was converted to white salt. mp 228-229 ° C (methanol / EtOAc), MS: m/e = 258 (M+ Example 51 1H-Sneeze, 1-ΓΓ1-Π.3-笑#Diargon-5-yl)-1 H-味峰·4·1 methyl1-2-ethyl-, salt Acid salt (1:2) (1-Bute and [1,3] Dioxin-5-yl-1Η-Miso-4-yl)-sterol first use sub-46- This paper scale applies to China Standard (CNS) A4 specification (210X297 mm)
裝 訂Binding
k. 1328584 五 、發明説明( A7 B7k. 1328584 V. Description of invention (A7 B7
磺醯氣處理,然後使用氫化鈉及2·乙基咪唑之反應混合物 處理。於萃取後續處理及層析術後’獲得標題化合物呈自 由態驗。該自由態驗被轉成其白色鹽酸鹽。炫點>25〇«>c (甲 醇/乙越),MS: m/e=296(M+)。 實例52 1Η-°米嗅,1-Γ『1-Π,3-苯并二氣伍囿-5-棊)沛咬-4-某1甲 基1-2-甲某-,镑酸鹽Π:2) (1-苯并[1,3]二氧伍園-5-1H-咪唾-4-基)·曱醇首先使用亞確 醯氣處理’然後使用氫化納及2-甲基咪唑之反應混合物處 理。於萃取後續處理及層析術後’獲得標題化合物呈自由 態鹼。該自由態鹼被轉成其白色鹽酸鹽。溶點>25 〇〇C (甲醇/ 乙醚),MS: m/e=282(M+)。 實例53 1Η-°米唾’ 1-(1,3-笨并二氧伍圜-5-某味吨-1_某_甲某 )-,鹽酸鹽(1:2) (1-本并[1,3] —氧伍圜-5-1Η-°米唆-4-基)_曱醇首先使用亞項 酿氣處理,然後使用氫化納及咪唑之反應混合物處理。於 萃取後續處理及層析術後,獲得標題化合物呈自由態驗。 該自由態驗被轉成其白色鹽酸鹽。炫點197_198。〇(甲醇/乙 醚),MS: m/e=268(M+)。 實例54 _ljj-咪吐,1-|~[1-(3-氟-4-H 苯基卡地-4-基 1 甲其卜:>_ 甲基-,鹽酸鹽(1:2) [1-(3-氟-4-曱基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 -47- 本纸張尺度適用中囯國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 _B7 五、發明説明(44~' 一 ' 氣處理’然後使用氫化鈉及2-曱基味咬之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼》該自由態鹼被轉成其白色鹽酸鹽。熔點>250°C (曱醇/乙 醚),MS: m/e=270(M+)。 實例55 j_H-咪.吐,2_乙基-l-f『l-(3-氟_4·甲盖苹早viH-咪唑-4-基·[甲 基1-,鹽酸鹽(1:2) [1-(3-氟-4-甲基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氣處理’然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。溶點>25〇。匚(甲醇/乙 醚),MS: m/e=284(M+)。 實例56 j_H-咪。坐’ 1-(3-氟-4-甲基笨基)-4-(1只-°米啥-1-基-甲某v,睡 • 酸鹽(1:2) [1-(3-氟-4-曱基-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯 氣處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態驗被轉成其白色鹽酸鹽。溶點223-224 °C (曱醇/乙越) MS: m/e=256(M+)。 實例57 1H -味啥’ 1-『|~1-(3-氣-4-曱氡笨某味峡-4-基1甲基ι·2· 甲基-,鹽酸鹽(1:2) [1-(3-氣-4-曱氧-笨基)-1Η-咪唑-4-基]-曱醇首先使用亞磺睡 •48- 本纸乐尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1328584The mixture is treated with sulfonium and then treated with a reaction mixture of sodium hydride and 2·ethylimidazole. The title compound was obtained as a free test after extraction and subsequent chromatography. This free state was converted to its white hydrochloride. Hyun Point >25〇«>c (Methanol/Byco), MS: m/e=296 (M+). Example 52 1Η-°米 sniffing, 1-Γ『1-Π,3-Benzo 2 gas 囿-5-棊) Pei -4- a certain methyl 1-2-A--, pound salt Π :2) (1-Benzo[1,3]dioxoindol-5-1H-imidin-4-yl)·sterol is first treated with arsenic helium and then using sodium hydride and 2-methylimidazole The reaction mixture is treated. The title compound was obtained as a free base after extraction and subsequent chromatography. This free base is converted to its white hydrochloride. Melting point > 25 〇〇C (methanol / diethyl ether), MS: m/e = 282 (M+). Example 53 1Η-°米唾' 1-(1,3-Anodic dioxin-5-something ton-1_some_甲)-, hydrochloride (1:2) (1-this [1,3]-oxosulfonium-5-1Η-°m唆-4-yl)-sterol was first treated with a sub-grinding gas and then treated with a reaction mixture of sodium hydride and imidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Hyun point 197_198. 〇 (methanol / diethyl ether), MS: m/e = 268 (M+). Example 54 _ljj-mimi, 1-|~[1-(3-fluoro-4-H phenyl carbazide-4-yl 1 ketyl: > _ methyl-, hydrochloride (1:2) [1-(3-Fluoro-4-indolyl-phenyl)-1Η-imidazol-4-yl]-nonanol First use sulfinium-47- This paper scale applies to China National Standard (CNS) Α4 specification ( 210 X 297 mm) 1328584 A7 _B7 V. Description of the invention (44~'-a gas treatment' and then treated with a reaction mixture of sodium hydride and 2-mercapto-bite. After the extraction and chromatography, the title was obtained. The compound is in the form of a free base. The free base is converted to its white hydrochloride. Melting point > 250 ° C (decyl alcohol / diethyl ether), MS: m/e = 270 (M+). Example 55 j_H-M. , 2_ethyl-lf "l-(3-fluoro_4·甲盖苹早viH-imidazol-4-yl·[methyl 1-, hydrochloride (1:2) [1-(3-fluoro -4-Methyl-phenyl)-1Η-imidazol-4-yl]-nonanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After the analysis, the title compound was obtained in a free state. The free state was converted to its white hydrochloride. The melting point > 25 〇. 匚 (methanol / diethyl ether), MS : m/e = 284 (M+). Example 56 j_H-Mimi. Sit ' 1-(3-Fluoro-4-methylphenyl)-4-(1 -°米啥-1-yl-甲某v , sleep • acid salt (1:2) [1-(3-fluoro-4-mercapto-phenyl)-1Η-imidazol-4-yl]-methanol was first treated with sulfinium, then sodium hydride and The reaction mixture of imidazole is treated. After the subsequent treatment and chromatography, the title compound is obtained as a free base. The free state is converted to its white hydrochloride. The melting point is 223-224 ° C (sterol / acetyl MS: m/e = 256 (M+). Example 57 1H - miso' 1-"|~1-(3-gas-4-曱氡 某某味峡-4 yl 1 methyl ι·2· Methyl-, hydrochloride (1:2) [1-(3- gas-4-oxo-phenyl)-1Η-imidazol-4-yl]-sterol First use sulfinamide sleep 48-paper The music scale applies to the Chinese National Standard (CNS) Α4 specification (210 X 297 mm) 1328584
氣處理’然後使用氫化納及2-甲基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。溶點240-241 eC (曱醇 /乙鍵),MS: m/e=302(M+)。 實例58 1好·咪唾’ 1-『『1-(3-氣-4-曱氧茉基)唾-4-某1甲某1-2_ 乙基-,鹽酸鹽(1:2) [1-(3-氣-4-曱氧-苯基)-1Η-咪唑-4-基]·曱醇首先使用亞磺醯 氣處理’然後使用氫化納及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後’獲得標題化合物呈自由態 驗。該自由態驗被轉成其淺黃色鹽酸鹽。熔點220-22leC (甲 醇/乙醚),MS: m/e=316(M+)。 實例59 ΙΗ-喃吐’ l-(j-氣-4-曱氧笨基唾-1-基-甲基,鹽 酸鹽(1:2) [1-(3-氣-4-甲氧-笨基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氯處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點245-246°C (曱醇/乙醚), MS: m/e=288(M+)。 實·例60 1H-咪唑,1-ΓΠ-(4-氣-2-氟笨基Viff-呻唑-4-基甲基卜2-甲 其-,镑酸鹽(1:2) [1-(4-氣-2-氟-苯基)-1Η-咪唑-4·基]-曱醇首先使用亞磺醯氣 -49· 本紙張尺度適用中國國家標竿(CNS) A4規格(210x 297公釐)The gas treatment was then treated with a reaction mixture of sodium hydride and 2-methylimidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Melting point 240-241 eC (sterol/ethyl bond), MS: m/e = 302 (M+). Example 58 1 good · Mimi saliva ' 1- 『 1- (3- gas 4-曱 oxy methoxy) saliva-4- a 1 A certain 1-2_ ethyl-, hydrochloride (1:2) [ 1-(3-Ga-4-oxo-phenyl)-1Η-imidazol-4-yl]·nonanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. The title compound was obtained in a free state after extraction and subsequent chromatography. This free state was converted to its pale yellow hydrochloride. Melting point 220-22 leC (methanol/diethyl ether), MS: m/e = 316 (M+). Example 59 ΙΗ- 吐 吐 ' l-(j-Ga-4-indoxy phenyl-1-yl-methyl, hydrochloride (1:2) [1-(3- gas-4-methoxy- Styrene)-1Η-imidazol-4-yl]-nonanol is first treated with sulfinium chloride and then treated with a reaction mixture of sodium hydride and imidazole. After extraction followed by chromatography and chromatography, the title compound is obtained as free state. The free base is converted to its white hydrochloride salt. mp 245-246 ° C (decanol/diethyl ether), MS: m/e = 288 (M+). Example 60 1H-imidazole, 1-indole -(4-Ga-2-fluoroindolyl Viff-oxazol-4-ylmethylbu- 2-methyl--, pound acid salt (1:2) [1-(4-Ga-2-fluoro-phenyl) )-1Η-imidazole-4·yl]-sterol first use sulfinamide-49. This paper scale applies to China National Standard (CNS) A4 specification (210x 297 mm)
裝 訂Binding
k 1328584 五 發明説明( 46 A7 B7k 1328584 Five invention description ( 46 A7 B7
處理,然後使用氫化鈉及2-甲基味.唑之反應混合物處理。 於萃取後續處理及層析術後,獲得標題化合物呈自由態鹼 。該自由態鹼被轉成其白色鹽酸鹽。熔點235_236充(曱醇/ 乙趟),MS: m/e=290(M+)。 實例61 i_H-蛛喷,1-ΓΠ-(4-氯-2-氟茉某申 _4-基 1 甲基 1-2-Λ 基-,鹽酸鹽Π:2) [1-(4-氣-2-氟-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯氣 處理,然後使用氫化鈉及2-乙基咪唑之反應混合物處理。 於萃取後續處理及層析術後,獲得標題化合物呈自由態驗 。該自由態鹼被轉成其白色鹽酸鹽。熔點248_249»c (甲醇/ 乙喊),MS: m/e=304(M+)。 實例62 1H-咪唑,1-(4-氣-2-氟笨基V4-(1H-咣唑-1-某·甲基)·,睡舱 鹽(1:2) [1-(4-氣-2-氟-苯基)-1Η-味唾-4-基]-曱醇首先使用亞績酿氣 處理,然後使用氫化納及_啥之反應混合物處理。於萃取 後續處理及層析術後,獲得標題化合物呈自由態驗。該自 由態鹼被轉成其白色鹽酸鹽。熔點>212°C分解(甲醇/乙_ ), MS: m/e=276(M+)。 實例63 1H-咪唑,1-ΓΓ1-Μ-溴茉某V1H-咄咄-4-基1甲篡1-2- 7. + _ 鹽酸鹽(1:2) [1-(4-溴-笨基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯氯處理 -50- 本纸張尺度適用中S國家標準(CNS> A4規格(210X297公爱) 1328584 A7 B7Treated and then treated with a reaction mixture of sodium hydride and 2-methyl oxazole. After extraction and subsequent chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point 235_236 charged (sterol/acetamidine), MS: m/e = 290 (M+). Example 61 i_H-spider spray, 1-ΓΠ-(4-chloro-2-fluoromethane _4-yl 1 methyl 1-2-fluorenyl-, hydrochloride hydrazine: 2) [1-(4- Gas-2-fluoro-phenyl)-1Η-imidazol-4-yl]-nonanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free base is converted to its white hydrochloride. Melting point 248_249»c (methanol / y), MS: m/e = 304 (M+). Example 62 1H-imidazole, 1-(4-Ga-2-fluorophenyl V4-(1H-carbazole-1-m-methyl)·, sleeping cabin salt (1:2) [1-(4-gas -2-Fluoro-phenyl)-1 oxime-salt-4-yl]-nonanol was first treated with agglomerated gas, then treated with a mixture of sodium hydride and hydrazine. After extraction followed by chromatography and chromatography The title compound is obtained in a free state. The free base is converted to its white hydrochloride salt. Melting point > 212 ° C decomposition (methanol / B), MS: m/e = 276 (M+). Example 63 1H -Imidazole, 1-ΓΓ1-Μ-bromo-V1H-咄咄-4-yl 1 formazan 1-2- 7. + _ hydrochloride (1:2) [1-(4-bromo-phenyl)- 1Η-imidazol-4-yl]-nonanol is first treated with sulfinium chloride -50 - This paper scale applies to the S national standard (CNS> A4 specification (210X297 public) 1328584 A7 B7
五、發明説明(47 ,然後使用氫化鈉及2-乙基咪唑之.反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點>250 °C (甲醇/乙酵), MS: m/e=330(M+)。 實例64 1H-咪吐,1-ΓΠ·(4-溴笨基)-1Η-缔啥-4-某1甲基1-2-甲某-, 鹽酸鹽(1:2) [1-(4-漠-苯基)-1Η-味嗓-4-基]-甲醇首先使用亞續醒氣處理 ’然後使用氫化納及2-甲基0米唾之反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態鹼。該 自由態鹼被轉成其白色鹽酸鹽。熔點>25 0。(:(曱醇/乙趟), MS: m/e=316(M+)。 實例65 111-味。坐’ 臭苯基)-4-(lH-g来吨-1-基-甲基)-,鹽酸续 (1:2) [1-(4-溴-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯氣處理 ,然後使用氫化鈉及2-乙基咪唑之反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態驗《該 自由態鹼被轉成其白色鹽酸鹽。熔點23 7-23 9。(:(曱醇/乙醚), MS: m/e=302(M+)。 實例66 1H-咪唑’ 1-『『1-(4-二氟曱氧)茉基μ1Η-咄唑-4-基1甲基1-2- Λ&-,鹽酸鹽(1:2) [1-(4-二氟曱氧-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醒 -51 - 本紙張尺度適用中®固家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 B75. Description of the invention (47, then treated with sodium hydride and 2-ethylimidazole. The reaction mixture was subjected to subsequent treatment and chromatography to obtain the title compound as a free base. The free base was converted to white. Hydrochloride. Melting point > 250 ° C (methanol / ethyl acetate), MS: m/e = 330 (M+). Example 64 1H-mpy, 1-ΓΠ·(4-bromophenyl)-1Η-啥-4- certain 1 methyl 1-2-methyl-, hydrochloride (1:2) [1-(4-di-phenyl)-1Η-miso-4-yl]-methanol first used sub Continued aeration treatment and then treated with a reaction mixture of sodium hydride and 2-methyl 0 m saliva. After the extraction and subsequent chromatography, the title compound was obtained as a free base. The free base was converted to its white salt. Acid salt. Melting point > 25 0. (: (sterol / acetamidine), MS: m / e = 316 (M +). Example 65 111-flavor. Sit 'odor phenyl) -4- (lH-g Tons-1-yl-methyl)-, hydrochloride continued (1:2) [1-(4-bromo-phenyl)-1Η-imidazol-4-yl]-methanol was first treated with sulfoximine gas and then used Treatment of the reaction mixture of sodium hydride and 2-ethylimidazole. After the extraction and subsequent chromatography, the title compound was obtained. In a free state, the free base is converted to its white hydrochloride salt. Melting point 23 7-23 9. (: (decyl alcohol / diethyl ether), MS: m/e = 302 (M+). Example 66 1H-imidazole ' 1-『『1-(4-Difluorodecyloxy) mosyl μ1Η-carbazol-4-yl 1methyl1-2- Λ&-, hydrochloride (1:2) [1-(4- Difluoroanthracene-phenyl)-1Η-imidazol-4-yl]-nonanol was first used with sulfinamide-51 - This paper size is applicable to the Medium Standard (CNS) Α4 specification (210 X 297 mm) 1328584 A7 B7
醒氯處理’然後使用氫化納及2-曱基咪唑之反應混合物處 理。於萃取後續處理及層析術後,獲得標題化合物呈自由 •癌驗。該自由態檢被轉成其白色鹽酸鹽。炫^點232-235(甲 醇/乙鍵),MS: m/e=282(M+)。 實例73 1H-咪唑,4-(1Η-咪唑-1-基-甲棊):h(3-甲氢_4_甲某茇甚)… 鹽酸鹽Π:2) [1-(3-曱氧-4-甲基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺 醒氣處理’然後使用氫化鈉及咪唑之反應混合物處理。於 萃取後續處理及層析術後,獲得標題化合物呈自由態驗。 該自由態驗被轉成其淺黃色鹽酸鹽。炫點249-251°C (甲醇/ 乙謎),MS: m/e=268(M+)。 實例74 ]JH-咪唑’ 2_-乙基-1-丨丨1-丨4-(三氟甲某)茉篡〗·丨η-咪唑_4_甚1 曱基1-,鹽酸鹽(1:2) [1-(4-三氟曱基-苯基)-1Η-咪唾-4-基]-甲醇首先使用亞續酿 氣處理’然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。炫點240-242°C (甲醇 /乙醚),MS: m/e=320(M+)。 實例75 1M-咪唑,2-曱基-l-[『l-『4-三氟甲基笑某1-1H-咪唑-4-篡1 曱基ί-,续酸鹽(1:2) [1-(4·三氟曱基-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯 -54-The chlorine treatment was awake' and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction and subsequent chromatography, the title compound was obtained as a free cancer test. This free state test was converted to its white hydrochloride. Hyun ^ point 232-235 (methanol / B bond), MS: m / e = 282 (M +). Example 73 1H-Imidazole, 4-(1Η-imidazol-1-yl-methylhydrazine): h(3-methylhydro_4_甲茇茇)... Hydrochloride Π: 2) [1-(3-曱Oxy-4-methyl-phenyl)-1Η-imidazol-4-yl]-nonanol was first treated with a sulfene aerated treatment and then treated with a reaction mixture of sodium hydride and imidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its pale yellow hydrochloride. Hyun point 249-251 ° C (methanol / puzzle), MS: m / e = 268 (M +). Example 74] JH-imidazole' 2_-ethyl-1-indole 1-indole 4-(trifluoromethyl)methane 丨·丨η-imidazole _4_ 11 曱yl 1-, hydrochloride (1 :2) [1-(4-Trifluoromethyl-phenyl)-1Η-imidazo-4-yl]-methanol was first treated with a sub-continuous gas stream' followed by a reaction mixture of sodium hydride and 2-ethylimidazole deal with. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Hyun spot 240-242 ° C (methanol / diethyl ether), MS: m / e = 320 (M +). Example 75 1M-imidazole, 2-mercapto-l-["l-"4-trifluoromethyl methoxyl 1-1H-imidazol-4-indole 1 fluorenyl, </ RTI> (1:2) [ 1-(4·Trifluoromethyl-phenyl)-1Η-imidazol-4-yl]-methanol first using sulfinium-54-
1328584 五、發明説明(51 氣處理,然後使用氫化鈉及2-曱基哺唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其白色鹽酸鹽。熔點246_248t (甲醇 / 乙謎),MS: m/e=306(M+)。 實例76 UL-嘯一唾’ 味唾-1-棊-甲華)-144_(三氟甲某、笑其^ 鹽酸鹽(1:2) [1-(4-三氟曱基-苯基)-ih-咪唑-4-基]-曱醇首先使用亞磺醯 氣處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後’獲得標題化合物呈自由態鹼。該 自由態驗被轉成其白色鹽酸鹽。炫點220-222 °C (甲醇/乙鍵) MS: m/e=292(M+)。 實例77 .1_Η-咪嗤’ 1-[丨1-(1,3-二氫-5-異笨共咭嚙篡uH_哚崦_4_其】 曱基1-2-乙基-’鹽酸鹽:2) [1-(1,3-一 異苯并吱0^-5-基)-1Η-0米啥-4-基]-曱醇首先使 用亞磺醯氣處理’然後使用氫化鈉及2·乙基咪唑之反應混 合物處理。於萃取後續處理及層析術後’獲得標題化合物 呈自由態驗。該自由態驗被轉成其灰白色鹽酸鹽。溶點 >I〇8°C 分解(曱醇/乙醚),MS: m/e=294(M+)。 實例78 jg-味嗅’ 1·「[·1_Π·3-二異笨并咭喃某咪唑-4-基1 f基1-2-甲基-,鹽酸鹽π:2) [1-(1,3- 一風-異苯并咬畴-5-基)-1Η -咪啥-4-基]-甲醇首先使 -55- 1328584 A7 ___B7_ 五、發明説明(52 ) 用亞磺醯氣處理,然後使用氫化納及2-甲基咪唑之反應混 合物處理。於萃取後續處理及層析術後,獲得標題化合物 呈自由態驗。該自由態鹼被轉成其灰白色鹽酸鹽。溶點 >250°C (甲醇/乙醚),MS: m/e=280(M+)。 實例79 1H-咪唑,1-ΓΠ-Π-氟-4-甲氣茉基)-1Η-咪吔-4-基1甲某1-2-甲某-,鹱酸鹱(1:2) [1-(3-氟-4-甲氧-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯 氣處理,然後使用氫化鈉及2-曱基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其白色鹽酸鹽。熔點23 8-240°C (曱醇 / 乙醚),MS: m/e=286(M+)。 實例80 1H-味咬,2-乙基-1-ΓΠ-(3-氟-4-甲氧笨甚)-1Η-°米嗤-4-某1甲 某1-,镑酸鹽(1:2) [1-(3 -氟-4-曱氧-苯基)-1Η-°米嗤-4-基]-甲醇首先使用亞續酿 氣處理,然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 鹼。該自由態鹼被轉成其白色鹽酸鹽。熔點218-220°C (曱醇 /乙 _),MS: m/e=300(M+)。 實例81 1H-哇唑,ΐ4Π-(4-曱氧茉基V1H-咪唑-4·其1甲基1-2·甲$ -,鹽酸鹽(1:2) [1-(4-曱氧-笨基)-1Η·咪唑-4-基]-曱醇首先使用亞磺醯氯處 -56- 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 ___B7 五、發明説明(53) 理’然後使用氫化鈉及2-曱基咪唑之反應混合物處理。於 萃取後續處理及層析術後,獲得標題化合物呈自由態驗。 該自由態驗被轉成其白色鹽酸鹽。溶點>250。〇(曱醇/乙謎), MS: m/e=268(M+)。 實例82 1H-咪嗤’ 2-3碁二(?:甲笔^基)_1H•咄衅基·!甲某μ ,鹽酸鹽(1:2) [1-(3·甲氧-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯氣處 理’然後使用氫化納及2-乙基咪唑之反應混合物處理。於 萃取後續處理及層析術後’獲得標題化合物呈自由態驗。 該自由悲絵被轉成其白色鹽酸鹽。溶點246-248 °C (甲醇/乙 醚),MS: m/e=282(M+)。 實例83 1Η-_吐,l-LH-(3-甲—氧_苯基)-1Η·哔吃_4-某1曱其I-2-甲基· ,鹽酸鹽(1:2) [1-(3-曱氧-苯基)-1Η-咪唑-4-基]•曱醇首先使用亞磺醯氯處 理’然後使用氫化納及2-曱基。米嗅之反應混合物處理。於 萃取後續處理及層析術後’獲得標題化合物呈自由態驗。 該自由態驗被轉成其白色鹽酸鹽。炫sj 242-243°C (甲醇/已 醚),MS: m/e=268(M+)。 實例84 1H-咪唑’ 4-(ljj-咪唑-1-基-甲某甲氧赛,鹽 (1:2) [1-(3-甲氧-本基)-1Η-味啥-4-基]-甲酵首先使用亞續酿氯處 -57· 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 _ B7 五、發明説明(54~) " 理,然後使用氫化鈉及咪唑之反應.混合物處理。於萃取後 續處理及層析術後,獲得標題化合物呈自由態鹼》該自由 態鹼被轉成其白色鹽酸鹽。熔點219-220°C (曱醇/乙醚),MS: m/e=254(M+)。 實例85 1H-咪唑,1-ΓΓ1-Γ4-甲氳-3-(三氟甲某)茉基MH-咄岫-4-篡1 甲基1-2-甲基-,镑酸鹽(1:2) [1-(4-曱氧-3-三氟曱基-苯基)-1Η-咪唑-4-基]-曱醇首先使用 亞磺醯氣處理,然後使用氫化鈉及2-曱基咪唑之反應混合 物處理。於萃取後續處理及層析術後,獲得標題化合物呈 自由態鹼。該自由態鹼被轉成其淺褐色鹽酸鹽。熔點>222 °C 分解(甲醇/乙醚),MS: m/e=337(M+H+)。 實例86 _1H-味唾,2·乙基-l-ffl-f4·曱氧-3-(三氣甲基)苯基~|·ΐΗ-ρ米 唑-4-基1甲基1-,鹽酸鹽(1:2) [1-(4-甲氧-3-三氟曱基-苯基)-1Η-°米嗅-4-基]-甲醇首先使用 亞磺醯氣處理,然後使用氫化鈉及2-乙基咪唑之反應混合 物處理。於萃取後續處理及層析術後,獲得標題化合物呈 自由態驗。該自由態驗被轉成其淺褐色鹽酸鹽。溶點>226 °C 分解(曱醇/ 乙醚),MS: m/e=351(M+H+)。 實例87 唑,1-[Γ1-(3-氪-4-甲基笨基 基 1 甲 I基-,鲤酸鹽(1:2) [1·(3-氣-4-曱基-苯基)-1Η-咪唑-4-基卜甲醇首先使用亞磺醯 -58- 本紙張尺度適用中囷囷家標準(CNS) A4規格(210X297公釐) A7 B71328584 V. Description of the invention (51 gas treatment, followed by treatment with a reaction mixture of sodium hydride and 2-mercaptocarazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. It is white hydrochloride. Melting point 246_248t (methanol / sigma), MS: m/e = 306 (M+). Example 76 UL- 一一唾 '味味素棊-棊-甲华)-144_(Trifluoro A, Xiaoxiao^ Hydrochloride (1:2) [1-(4-Trifluoromethyl-phenyl)-ih-imidazol-4-yl]-sterol is first treated with sulfinium gas and then used The reaction mixture of sodium hydride and imidazole is treated. After the extraction and subsequent chromatography, the title compound is obtained as a free base. The free state is converted to its white hydrochloride. Hyun point 220-222 ° C (methanol / B key) MS: m/e=292(M+). Example 77 .1_Η-咪嗤' 1-[丨1-(1,3-dihydro-5-iso-stuppy 咭uH_哚崦_4 _ its] thiol 1-2-ethyl-'hydrochloride: 2) [1-(1,3-isobenzopyrene 0^-5-yl)-1Η-0m啥-4-yl] - decyl alcohol is first treated with sulfoximine gas and then treated with a reaction mixture of sodium hydride and 2 · ethyl imidazole. After treatment and chromatography, the title compound was obtained in a free state. The free state was converted to its off-white hydrochloride. The melting point > I 〇 8 ° C decomposition (sterol / ether), MS: m / e =294(M+). Example 78 jg-flavoring '1·"[·1_Π·3-diiso-p- and pyridyl 4-imidazolyl-4-yl 1 f-based 1-2-methyl-, hydrochloride π: 2) [1-(1,3-Igly-isobenzo-bito-5-yl)-1Η-imidol-4-yl]-methanol first makes -55- 1328584 A7 ___B7_ V. Description of invention (52) Treated with sulfinium helium, then treated with a reaction mixture of sodium hydride and 2-methylimidazole. After extraction and subsequent chromatography, the title compound is obtained in a free state. The free base is converted to its off-white salt. Acid salt. Melting point > 250 ° C (methanol / diethyl ether), MS: m / e = 280 (M + ). Example 79 1H-imidazole, 1-indole-fluorene-fluoro-4-methyl-l-yl)-1Η -Mimi-4-yl 1A 1-2-A-, bismuth citrate (1:2) [1-(3-Fluoro-4-methoxy-phenyl)-1 Η-imidazol-4-yl ]-Methanol was first treated with sulfinium gas, then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction followed by chromatography and chromatography, the title was obtained. The free-form base is converted to its white hydrochloride salt, m.p. 23-240 ° C (decanol/ethyl ether), MS: m/e = 286 (M+). Example 80 1H-flavor Bite, 2-ethyl-1-indole-(3-fluoro-4-methoxy bromide)-1Η-°米嗤-4-一一甲一1-, pound acid salt (1:2) [1- (3-Fluoro-4-indolyl-phenyl)-1 Η-°m嗤-4-yl]-methanol was first treated with a sub-continuous gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point 218-220 ° C (sterol / B _), MS: m / e = 300 (M +). Example 81 1H-wortazole, ΐ4Π-(4-oxime-oxymethyl V1H-imidazole-4·1 methyl1-2·A$-, hydrochloride (1:2) [1-(4-oxo) - Stupid base -1Η·imidazol-4-yl]-sterol first use sulfinium chloride -56- This paper scale applies to China National Standard (CNS) Α4 specification (210 X 297 mm) 1328584 A7 ___B7 Description of the invention (53) </ RTI> then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained in a free state. The free state was converted to white. Hydrochloride. Melting point > 250. 〇 (sterol / sigma), MS: m / e = 268 (M +). Example 82 1H - 嗤 ' 2-3 碁 two (?: A pen base) _1H•咄衅基·!甲μμ, hydrochloride (1:2) [1-(3·methoxy-phenyl)-1Η-imidazol-4-yl]-sterol was first treated with sulfinium 'There was then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After the extraction and subsequent chromatography, the title compound was obtained in a free state. The free sorrow was converted to its white hydrochloride. -248 ° C (methanol / diethyl ether), MS: m / e = 282 (M +). Example 83 1 Η - _ spit, l-LH- (3-(3-oxo-phenyl)-1Η·哔 eat_4-一一曱I-2-methyl·, hydrochloride (1:2) [1-(3-曱-oxy-phenyl) -1Η-imidazol-4-yl]•sterol was first treated with sulfinium chloride. Then it was treated with sodium hydride and 2-mercapto. The reaction mixture was extracted. After extraction and subsequent chromatography, the title compound was obtained. The free state was converted to its white hydrochloride. H.S. 242-243 ° C (methanol / ether), MS: m/e = 268 (M+). Example 84 1H-imidazole 4 -(ljj-imidazol-1-yl-methyl methoxy race, salt (1:2) [1-(3-methoxy-benyl)-1Η-miso-4-yl]-formaldehyde first used Continued Brewing Chlorine-57· This paper scale applies Chinese National Standard (CNS) A4 Specification (210 X 297 mm) 1328584 A7 _ B7 V. Invention Description (54~) " Rational, then use sodium hydride and imidazole The mixture is treated. After the subsequent treatment of the extraction and the chromatography, the title compound is obtained as a free base. The free base is converted to the white salt. mp 219-220 ° C (decyl alcohol / diethyl ether), MS: m/e = 254 (M+). Example 85 1H-imidazole, 1-ΓΓ1-Γ4-methylindole-3-(trifluoromethyl)methyl MH-咄-4-篡1 methyl1-2-methyl-, pound acid salt (1:2) [1-(4-oxo-3-trifluoromethyl-phenyl)-1Η-imidazol-4-yl The sterol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. The free base is converted to its light brown hydrochloride. Melting point > 222 ° C Decomposition (methanol / diethyl ether), MS: m / e = 337 (M + H +). Example 86 _1H-flavored saliva, 2·ethyl-l-ffl-f4·decyloxy-3-(trimethylmethyl)phenyl~|·ΐΗ-ρ-myzol-4-yl 1methyl 1-, salt Acid salt (1:2) [1-(4-Methoxy-3-trifluoromethyl-phenyl)-1Η-°m-ol-4-yl]-methanol was first treated with sulfinium gas and then hydrogenated. The reaction mixture of sodium and 2-ethylimidazole is treated. After extraction and subsequent chromatography, the title compound was obtained as a free test. This free state was converted to its light brown hydrochloride. Melting point > 226 ° C decomposition (sterol / diethyl ether), MS: m / e = 351 (M + H +). Example 87 azole, 1-[Γ1-(3-氪-4-methylphenyl)-methyl-1,- decanoate (1:2) [1·(3- gas-4-mercapto-phenyl )-1Η-imidazole-4-ylbupropanethanol First use sulfinium-58- This paper scale applies to the Chinese Standard (CNS) A4 specification (210X297 mm) A7 B7
1328584 五、發明説明(55 氯處理’然後使用氫化納及2-曱基咪唑之反應混合物處理 。於萃取後續處理及層析術後,獲得標題化合物呈自由態 驗。該自由態驗被轉成其白色鹽酸鹽。溶點242-243 °C (甲醇 /乙謎),MS: m/e=286(M+)。 實例88 1H-味峻,氣-4-曱某笨基)·ιη·ρ朵-4-基1甲某ι·9 _ 乙基-,鹽酸鹽(1:2) [1-(3-氯-4-曱基-苯基)-1Η-咪唑-4-基]-曱醇首先使用亞磺醯 氯處理’然後使用氫化鈉及2-乙基咪唑之反應混合物處理 。於萃取後續處理及層析術後’獲得標題化合物呈自由態 驗。該自由態檢被轉成其白色鹽酸鹽。溶點178-179°C(甲醇 /乙醚),MS: m/e=300(M+)。 實例89 1H-畔啥’ 1-(~Γ1-(3 -氣-4-甲基笨基)-4-(1!^-°米唾-1-某-甲某)· ,鹽酸鹽(1:2) [1-(3-氯-4-曱基-苯基)-1Η-咪峻-4-基]-甲醇首先使用亞項醯 氣處理’然後使用氫化鈉及咪唑之反應混合物處理。於萃 取後續處理及層析術後,獲得標題化合物呈自由態鹼。該 自由態驗被轉成其白色鹽酸鹽。熔點218-220°C (曱醇/乙醚), MS: m/e=272(M+)。 實例90 1H-咪唑,卜『『1-Γ4-氣-3-(三氟曱某)笑某1-1H-咪唑-4-某1甲 基1-2-甲基-,鹽酸鹽(1:2) [1-(4-氯-3-三氟甲基-苯基)-1Η·咪唑-4·基]-曱醇首先使用亞 -59- 本纸張尺度適用中國國家標準(CNS) A4規格(210X 297公爱)1328584 V. Description of the invention (55 chlorine treatment 'then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After the subsequent treatment of extraction and chromatography, the title compound was obtained in a free state. The free state was converted into Its white hydrochloride. melting point 242-243 ° C (methanol / sigma), MS: m / e = 286 (M +). Example 88 1H-weijun, gas-4-曱 a stupid base)·ιη· ρ朵-4-yl 1 A certain ι·9 _ ethyl-, hydrochloride (1:2) [1-(3-chloro-4-indolyl-phenyl)-1Η-imidazol-4-yl] - The sterol is first treated with sulfinium chloride and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. The title compound was obtained in a free state after extraction and subsequent chromatography. This free state test was converted to its white hydrochloride. Melting point 178-179 ° C (methanol / diethyl ether), MS: m / e = 300 (M+). Example 89 1H-啥啥' 1-(~Γ1-(3 -Ga-4-methylphenyl)-4-(1!^-°米唾-1-某-甲)·, hydrochloride ( 1:2) [1-(3-Chloro-4-indolyl-phenyl)-1Η-imisin-4-yl]-methanol was first treated with a sub-neuterium gas and then treated with a reaction mixture of sodium hydride and imidazole After the extraction and subsequent chromatography, the title compound was obtained as a free base. The free state was converted to white hydrochloride. mp 218-220 ° C (decanol/diethyl ether), MS: m/e =272(M+). Example 90 1H-imidazole, 『『1-Γ4-gas-3-(trifluoromethane) 笑一1-1H-imidazole-4-one 1 methyl1-2-methyl- , hydrochloride (1:2) [1-(4-chloro-3-trifluoromethyl-phenyl)-1Η·imidazol-4-yl]-sterol first used in sub-59- paper scale China National Standard (CNS) A4 specification (210X 297 public)
裝 訂Binding
1328584 A7 _____B7 五、發明説明(56 ) 績醒氯處理,然後使用氫化鈉及2-.乙基味唾之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由態鹼。該自由態驗被轉成其白色鹽酸鹽。熔點179-180。〇( 曱醇/乙域),MS: m/e=354(M+)。 實例91 I_H-咪唑,1-ΓΓ1-Γ4-氣-3-(三氟甲某、笼某ΐ·1Η-咄咄-4-甚1甲 基卜2-甲篡-,轉酸鹽Π:2) [1-(4-氯-3-三氟曱基-苯基)-1 Η-味吐-4-基]-曱醇首先使用亞 石黃醯氯處理,然後使用氫化納及2 -甲基味唾之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由態驗。該自由態驗被轉成其白色鹽酸鹽。溶點>250°C (甲 醇/乙醚),MS: m/e=340(M+)。 實例92 LH-咪唑,1-丨4-氣-3-(三氟曱基)菜某1-4-ΠΗ-咪唑-1-美甲其 )·,镑酸鞔Π.-2) -氣-3-三氟曱基-苯基)-1Η-咪唾-4-基]-曱醇首先使用亞 磺醯氣處理,然後使用氫化鈉及咪唑之反應混合物處理。 於萃取後續處理及層析術後,獲得標題化合物呈自由態鹼 。該自由態鹼被轉成其白色鹽酸鹽。熔點>250°C (甲醇/乙謎 ),MS: m/e=326(M+)。 實例93 1H-咪唑,1-ΓΓΜ3·氣-4-氟茉某V1H-哚唑-4-基甲篡1·:>·甲 基-,鹽酸肄Π:2) [1-(3-氣-4-氟-苯基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯氣 -60· 本紙張尺度適用中國國家標準(CNS) Α4規格(210X 297公釐) !3285841328584 A7 _____B7 V. INSTRUCTIONS (56) Treatment with chlorine, followed by treatment with a mixture of sodium hydride and 2-ethyl sulphate. After extraction followed by chromatography and chromatography, the title compound was obtained as a free base. This free state was converted to its white hydrochloride. Melting point 179-180. 〇 (sterol/B domain), MS: m/e = 354 (M+). Example 91 I_H-imidazole, 1-ΓΓ1-Γ4-gas-3-(trifluoromethyl, cage ΐ·1Η-咄咄-4-fur 1 methyl b-2-carboindole-, trans-acid salt Π: 2) [1-(4-Chloro-3-trifluoromethyl-phenyl)-1 oxime-sodium-4-yl]-sterol is first treated with sulphate, then sodium hydride and 2-methyl The saliva reaction mixture is treated. After the subsequent treatment of extraction and chromatography, the title compound was obtained as a free test. This free state was converted to its white hydrochloride. Melting point > 250 ° C (methanol/diethyl ether), MS: m/e = 340 (M+). Example 92 LH-imidazole, 1-indole 4-gas-3-(trifluoromethyl) dish 1-4-anthracene-imidazole-1-methanone··, pound bismuth.-2)-gas-3 -Trifluoromethyl-phenyl)-1 oxime-imidazo-4-yl]-nonanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and imidazole. After extraction and subsequent chromatography, the title compound was obtained as a free base. This free base is converted to its white hydrochloride. Melting point > 250 ° C (methanol / sigma), MS: m/e = 326 (M+). Example 93 1H-imidazole, 1-ΓΓΜ3·gas-4-fluoromethane V1H-carbazole-4-ylformamidine1·:>·methyl-, guanidine hydrochloride: 2) [1-(3-gas -4-Fluoro-phenyl)-1Η-imidazol-4-yl]-methanol First use sulfinamide-60· This paper scale applies to China National Standard (CNS) Α4 specification (210X 297 mm) !328584
五、發明説明(57 A7 B7V. Description of the invention (57 A7 B7
處理,然後使用氫化納及2-曱基咪唑之反應混合物處理。 於萃取後續處理及層析術後,獲得標題化合物呈自由態岭 。該自由態驗被轉成其白色鹽酸鹽。炫點224-225 (甲醇/ 乙醚),MS: m/e=290(M+)。 實例94 JH-球咬,1-ΓΓ1-Π-氯-4-氟茉基)-ιη·味砂_4_基甲 裏-,m m 鹽(1:2) [1-(3-氣-4-氟-苯基)-1Η-咪唑-4-基]-甲醇首先使用 亞續酿氣 處理,然後使用氫化鈉及2-乙基咪唑之反應混合物處理。 於萃取後續處理及層析術後,獲得標題化合物呈自由態驗 。該自由態驗被轉成其白色鹽酸鹽。炫點248-250¾ (甲醇/ 乙越),MS: m/e=304(M+)。 實例95 1H-咪唑 鹽 Π:2) 1-(3-氣-4-氟笨基)-4-Π Η-蛛吨-丨-其 [1-(3-氣-4-氟-笨基)-1Η-咪唑-4-基]-甲醇首先使用亞磺醯氣 處理,然後使用氫化鈉及咪唑之反應混合物處理。於萃取 後續處理及層析術後,獲得標題化合物呈自由態驗。該自 由態鹼被轉成其白色鹽酸鹽。熔點2 10-212 °C (曱醇/乙越) MS: m/e=276(M+)。 實例96 1H-味吐’ 1-『(1-『1,1’-聯笨1-4-基)-1Η-味峻-4-竿1甲^ γ 基-,鹽酸鹽(1:2) (1-聯苯-4-基-1Η-咪唑-4-基)-曱醇首先使用亞磺醯氣處理, -61 -Treated and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. After extraction and subsequent chromatography, the title compound was obtained as a free state. This free state was converted to its white hydrochloride. Hyun Point 224-225 (methanol / diethyl ether), MS: m/e = 290 (M+). Example 94 JH-Ball biting, 1-ΓΓ1-Π-chloro-4-fluoromethyl)-ιη·味味_4_基甲里-,mm salt (1:2) [1-(3-气-4 -Fluoro-phenyl)-1Η-imidazol-4-yl]-methanol was first treated with a sub-continuous gas and then treated with a reaction mixture of sodium hydride and 2-ethylimidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free state was converted to its white hydrochloride. Hyun point 248-2503⁄4 (methanol / ethyl), MS: m / e = 304 (M +). Example 95 1H-Imidazoline Salt: 2) 1-(3-Ga-4-fluorophenyl)-4-indole-Arachnene-丨-[1-(3-Ga-4-fluoro-stupyl) -1Η-imidazol-4-yl]-methanol was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and imidazole. After extraction and subsequent chromatography, the title compound was obtained in a free state. This free base is converted to its white hydrochloride. Melting point 2 10-212 ° C (furfuryl alcohol / ethyl ester) MS: m/e = 276 (M+). Example 96 1H-味吐' 1-"(1-『1,1'-联笨1-4-yl)-1Η-味峻-4-竿1甲^ γ-based, hydrochloride (1:2 ) (1-Biphenyl-4-yl-1Η-imidazol-4-yl)-nonanol was first treated with sulfinium, -61 -
装 訂Binding
1328584 A7 ____B7 五、發明説明(58~) :-- 然後使用氫化鈉及2·乙基咪唑之反.應混合物處理。於萃取 後續處理及層析術後’獲得標題化合物呈自由態驗。該自 由態鹼被轉成其白色鹽酸鹽。熔點248-253 eC (曱醇/乙越) MS: m/e=328(M+)。 實例97 jjj-咪唑,卜ΓΠ-Γ1.1’-聯笨1-4-基-1H-唑崠-4·芊)甲其I。甲 基-,鹽酸鹽Π:2) (1-聯苯-4-基-1Η-咪唑-4-基)-曱醇首先使用亞磺醯氯處理, 然後使用氫化鈉及2-甲基咪唑之反應混合物處理。於萃取 後續處理及層析術後’獲得標題化合物呈自由態驗^該自 由態驗被轉成其淺黃色鹽酸鹽。熔點169-175。(:(甲醇/乙鍵) MS: m/e=314(M+) » 實例98 jjj-咪吐’ 2-乙基-1-ΓΓ1-Π-甲基-4-n-f基乙其、y某啼— 唑-4-基1甲基1-,鹽酸鹽(1:2) [1-(4-異丙基-3-甲基-苯基)-111-°糸唾-4-基]-甲醇首先使用亞 磺醯氯處理,然後使用氩化鈉及2-乙基咪唑之反應忠合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由態驗。該自由態驗被轉成其白色鹽酸鹽。炼點> 1 8 〇分 解(甲醇/乙醚),MS: m/e=308(M+)。 實例99 1H-咪唾,2-甲基-1-ΓΓ1-Γ3-甲基-4-(1-甲甚 '某、笑基ι_1Η_味 唑-4-某1甲篡,轉Sf镑Π:2) [1-(4-異丙基-3 -甲基-苯基)-1 Η-味唾-4-基]-甲醇首先使用亞 -62- 本紙張尺度適用中國國家標竿(CNS) Α4规格(210χ297公釐) 1328584 A7 ____ B7 五、發明説明(59) 續醯氣處理,然後使用氫化鈉及2-.甲基咪唑之反應混合物 處理。於萃取後續處理及層析術後,獲得標題化合物呈自 由態驗。該自由態驗被轉成其白色鹽酸鹽。溶點>25〇°c (曱 醇/乙鱗),MS: m/e=294(M+)。 實例100 1_Η-咪唾’ 2-甲皋_-1-『『ΐ·(4·硝基茉基ViH-咣咄-4-基1甲基1- ,鹽酸轉Π:2Ί 1-(4-硝基苯基)-1Η-咪唑-4-曱醇(根據ι· Antonini等人,合成 ,l%3,L 47_49製備)首先使用亞績醯氣處理,然後使用氫 化納及2_甲基咪唑之反應混合物處理。於萃取後續處理及 層析術後,獲得標題化合物呈自由態鹼,該自由態鹼被轉 成其黃色鹽酸鹽。熔點>250。(:(甲醇/乙醚),MS: m/e=283(M+)。 實例101 j_H-°米唾’ 2-乙革二1•『以硝基苯咪唑_4基]曱基^ ,鹽酸鹽(1:2) 1-(4-硝基苯基)-1Η-咪唑-4-曱醇(根據L Ant〇nini等人,合成 ,1983,L 47-49製備)首先使用亞磺醯氣處理,然後使用氫 化納及2_乙基味唾之反應混合物處理。於萃取後續處理及 層析術後,獲得標題化合物呈自由態鹼。該自由態鹼被轉 成其黃色鹽酸鹽。熔點⑺6」97 »c (甲醇/乙醚MS: m/e=297(M+)。 實例102 lg.-°米嗤,4-(1Η二基-甲基)峭某笑基)_,鹽酸肄 -63 · 本纸張尺度適财g S家料(CNS)^^格(21GX297公爱)--- 1328584 A7 B7 五、發明説明(60 ) am 1-(4-硝基苯基)_1H-咪唑·4-甲醇(根據I. Antonini等人’合成 ’ 1983,L 47-49製備)首先使用亞磺醯氣處理,然後使用氫 化納及咪唑之反應混合物處理。於萃取後續處理及層析術 後’獲得標題化合物呈自由態鹼《該自由態鹼被轉成其黃 色鹽酸鹽。熔點245-246°C (曱醇/乙醚),MS: m/e=269(M+)。 實例103 咪01 ’ 1-(3.4-二氣苯基)-5-甲基·4-ΙΥ2-甲某-1H-咪唑-1-基)曱基1-,鹽酸瞜η-?) [1-(3,4-二氣-苯基)_5_曱基-1Η-咪。坐-4-基]-甲醇首先使用亞 績酿氣處理,然後使用氫化鈉及2_曱基咪唑之反應混合物 處理。於萃取後續處理及層析術後’獲得標題化合物呈自 由態驗。該自由態驗被轉成其白色鹽酸鹽。溶點>24〇 »〇分 解(曱醇/乙醚),MS: m/e=320(M+)。 實例104 i-fl-(3,4-二氣-苯皋)-ih-咪唑_4_基-甲基ι·1Η·啐唑·2·基胺-,鹽酸镑Π·?.) 1Η-咪唑,W1-(3,4_二氣_苯基)_1Η_咪唑_4•基曱基]·2硝 基_(2_1克,6.2毫莫耳)溶解於乙酸(50毫升),加入鐵粉(3 5 克,62毫莫耳),結果所得混合物於6〇〇c攪拌2小時。添加 乙酸乙酯(200毫升)後,熱混合物再度調整至回流及過濾。 真空去除全部揮發分,殘餘酸與曱笨共同蒸餾去除。所得 半固體藉層析術純化[矽膠,以梯度二氣曱烷至1〇〇%(二氯 曱烷/甲醇/水性氫氧化銨=90:10:1)洗提]純化,獲得標題化 •64-1328584 A7 ____B7 V. INSTRUCTIONS (58~) :-- Then treated with a mixture of sodium hydride and 2·ethylimidazole. The title compound was subjected to a free assay after extraction and subsequent chromatography. This free base is converted to its white hydrochloride. Melting point 248-253 eC (nonanol/ethylidene) MS: m/e = 328 (M+). Example 97 jjj-imidazole, dip-oxime 1.1'- phenylidene 1-4-yl-1H-oxazol-4. Methyl-, hydrochloride Π: 2) (1-biphenyl-4-yl-1Η-imidazol-4-yl)-nonanol was first treated with sulfinium chloride, then sodium hydride and 2-methylimidazole were used. The reaction mixture is treated. After the extraction and subsequent chromatography, the title compound was obtained as a free state. The free state was converted to its pale yellow hydrochloride. Melting point 169-175. (:(methanol/ethyl bond) MS: m/e=314(M+) » Example 98 jjj-mimi' 2-ethyl-1-ΓΓ1-Π-methyl-4-nf-based y, y 啼— oxazol-4-yl 1 methyl 1-, hydrochloride (1:2) [1-(4-isopropyl-3-methyl-phenyl)-111-°糸--4-yl]- Methanol was first treated with sulfinium chloride and then treated with sodium hydride and 2-ethylimidazole. After the subsequent treatment and chromatography, the title compound was tested in a free state. Conversion to its white hydrochloride. Refining point > 1 8 〇 decomposition (methanol / diethyl ether), MS: m / e = 308 (M +). Example 99 1H - sodium saliva, 2-methyl-1-ΓΓ 1-Γ3 -Methyl-4-(1-methyl-[, 笑 ιιι Η 味 -4- -4- 1 某 某 某 某 某 某 转 转 转 转 2 2 2 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- Phenyl)-1 oxime-sodium-4-yl]-methanol first used sub-62- This paper scale applies China National Standard (CNS) Α4 specification (210χ297 mm) 1328584 A7 ____ B7 V. Invention description (59 The helium gas treatment is continued, and then treated with a reaction mixture of sodium hydride and 2-methylimidazole. After the subsequent treatment of extraction and chromatography, the title compound is obtained in a free state. The test was converted to its white hydrochloride. Melting point > 25 〇 °c (sterol/ethyl scale), MS: m/e = 294 (M+). Example 100 1_Η-咪唾' 2-甲皋_- 1-『『ΐ·(4·Nitromethyl ViH-咣咄-4-yl 1methyl 1-, Hydrochloric acid conversion: 2Ί 1-(4-nitrophenyl)-1Η-imidazole-4-曱Alcohol (prepared according to ι· Antonini et al., synthesis, 1% 3, L 47_49) was first treated with a sulphur gas and then treated with a reaction mixture of sodium hydride and 2-methylimidazole. After the title compound was obtained as a free base, the free base was converted to its yellow hydrochloride. mp. < 250. (: (methanol / ethyl ether), MS: m/e = 283 (M+). Example 101 j_H -°米唾' 2-乙革二1•“Nitrobenzimidazole_4yl]indenyl^, hydrochloride (1:2) 1-(4-nitrophenyl)-1Η-imidazole-4 - sterol (prepared according to L Ant〇nini et al., Synthesis, 1983, L 47-49) was first treated with sulfinium gas and then treated with a mixture of sodium hydride and 2-ethyl saponin. After chromatography, the title compound was obtained as a free base. The free base was converted to yellow. The salt of the salt. (M).肄-63 hydrochloride · This paper scale is suitable for g S material (CNS) ^ ^ grid (21GX297 public) --- 1328584 A7 B7 V. Description of invention (60 ) am 1-(4-nitrophenyl) _1H-Imidazole·4-methanol (prepared according to I. Antonini et al. 'Synthesis' 1983, L 47-49) was first treated with sulfinium gas and then treated with a reaction mixture of sodium hydride and imidazole. After the extraction subsequent treatment and chromatography, the title compound was obtained as a free base. The free base was converted to its yellow hydrochloride. Mp 245-246 ° C (decyl alcohol / diethyl ether), MS: m / e = 269 (M+). Example 103 M. 01 ' 1-(3.4-diphenyl)-5-methyl·4-indol-2-methyl-1H-imidazol-1-yl)indolyl 1-, hydrochloride 瞜η-?) [1- (3,4-diqi-phenyl)_5_mercapto-1Η-mi. Sodium-4-yl]-methanol was first treated with a prior art brewing gas and then treated with a reaction mixture of sodium hydride and 2-mercaptoimidazole. The title compound was obtained as a free test after extraction and subsequent chromatography. This free state was converted to its white hydrochloride. Melting point > 24 〇 » 〇 解 solution (sterol / diethyl ether), MS: m / e = 320 (M +). Example 104 i-fl-(3,4-dioxa-benzoquinone)-ih-imidazole_4_yl-methyl ι·1Η·carbazole·2·ylamine-, sterol hydrochloride·?.) 1Η- Imidazole, W1-(3,4_digas_phenyl)_1Η_imidazole_4•ylindenyl]·2nitro-(2_1 g, 6.2 mmol) dissolved in acetic acid (50 ml), iron powder added (3 5 g, 62 mmol), and the resulting mixture was stirred at 6 ° C for 2 hours. After the addition of ethyl acetate (200 mL), the hot mixture was adjusted again to reflux and filtered. The entire volatiles were removed in vacuo and the residual acid was removed by distillation. The obtained semi-solid was purified by chromatography (purine, eluted with gradient dioxane to 1% by weight (dichlorodecane/methanol/aqueous ammonium hydroxide = 90:10:1) to obtain the title. 64-
13285841328584
合物之自由態鹼(1.9克,ι〇0%), J至次·白色固體分離》使用 鹽酸於曱醇溶液處理,捿著加 有加入乙醚後’標題化合物分離 呈白色結晶固體。熔點164_165。 C (甲醇/乙醚),MS. m/e=308(M+H+)。 實例105至107係根據實例1〇4所述概略程序製備。 實例105 氧_3_甲碁-苯碁-甲某-呻啤_2·某· 胺-,鹽酸镑Π:2) 1Η-咪唑,1-[1-(4-氣-3-甲基笨咪唑_4•基曱基]·2硝 基與鐵於乙酸反應。過濾後,藉蒸發及層析術分離標題化 合物之自由態鹼。自由態鹼轉成其白色鹽酸鹽。熔點23〇_ 233°C (曱醇/乙鍵),MS: m/e=288(M+H+)。 實例106 1-(1-對甲苯基-1H-咪唑-4-基-甲基)-^-咪唑-2-其-胺…瞄 酸鹽(1:2) 1H-咪唑’ l-[[l-(4-曱基苯基)-1Η-咪唑-4-基-甲基]_2-硝基與 鐵於乙酸反應。過濾後’藉蒸發及層析術分離標題化合物 之自由態鹼。自由態鹼轉成其白色鹽酸鹽。熔點232-2331 (; 曱醇/乙醚),MS: m/e=253(M+) » 實例107 1-Π-茉某-1H-咄唑-4-基-曱基V1H-哚唑-2-基-胺-,豳啊瞄 _ ―― (1:2) 1H-味喷,2-硝基笨基米嗅-4-基)-甲基]_與鐵於 乙酸反應。過濾後’藉蒸發及層析術分離標題化合物之自 -65 - 本纸張尺度適用中國圉家標準(CNS) A4规格(210 X 297公釐)The free base of the compound (1.9 g, ι 〇 0%), J-sub-white solid separation was treated with hydrochloric acid in decyl alcohol solution, and the title compound was isolated as a white crystalline solid. Melting point 164_165. C (methanol / diethyl ether), MS. m / e = 308 (M+H+). Examples 105 through 107 were prepared according to the general procedure described in Example 1-4. Example 105 Oxygen _3_ formazan-benzoquinone-methyl 呻-呻 beer_2·an amine-, sterol hydrochloride: 2) 1 Η-imidazole, 1-[1-(4-gas-3-methyl stupid The imidazole is reacted with iron in acetic acid. After filtration, the free base of the title compound is isolated by evaporation and chromatography. The free base is converted to white salt. 233 ° C (sterol / ethyl bond), MS: m / e = 288 (M + H +). Example 106 1-(1-p-tolyl-1H-imidazol-4-yl-methyl)-^-imidazole -2- its-amine ... (1:2) 1H-imidazole ' l-[[l-(4-mercaptophenyl)-1Η-imidazol-4-yl-methyl]_2-nitro and The iron is reacted with acetic acid. After filtration, the free base of the title compound is isolated by evaporation and chromatography. The free base is converted to white salt. mp 232-2331 (; decyl alcohol / diethyl ether), MS: m/e =253(M+) » Example 107 1-Π-茉-1H-indazol-4-yl-indenyl V1H-carbazol-2-yl-amine-, 豳 瞄 _ —— (1:2) 1H - Flavor spray, 2-nitro stupidyl ol-4-yl)-methyl]_ is reacted with iron in acetic acid. After filtration, the title compound is separated by evaporation and chromatography -65 - This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm)
裝 訂Binding
1328584 A7 B7 五、發明説明(62 ) 由態驗。自由態鹼轉成其白色鹽酸鹽。熔點153_155°C (曱醇 /乙醚),MS: m/e=239(M+) » 實例108 jiiA^__Ll_-『Π-(3,4-二氣笨基VlH-咭咄-d其-甲某l-2.5-二 甲基,鹽酸睡 Ν-[1-(3,4·二氯-苯基)-ιη·咪唑-4-基·曱基]•硫乙醯胺(0.60克 ’ 2.0毫莫耳)於丙酮(1〇毫升)之懸浮液以碳酸鉀(〇 28克, 2,0毫莫耳)及碘曱烷(0_26克,1.8毫莫耳)處理。混合物回流 1小時’蒸發及懸浮於乙醇(3毫升)。加入丙炔胺(1」克,2〇 毫莫耳)後回流9小時。過濾及蒸發後,殘餘物藉層析術純 化[石夕耀’以梯度二氣甲烷至30〇/〇(二氣甲烷/甲醇/水性氩氧 化銨=90:10:1)洗提],分離標題化合物之自由態鹼(〇 2〇克, 28%)呈淺褐色油。使用鹽酸於曱醇溶液處理接著加入乙醚 後’標題化合物分離呈白色結晶物質,炫點>25〇〇C (甲醇/乙 醚),MS: m/e=321(M+H+) » 實例109 11-11-(3,4-二氣-苯基、1仏咪唑-4-基-甲某1-1只-咪唑-2-甚1- 曱醇 1-[1-(3,4-二氣-苯基)_11^咪唑_4-基-曱基]-111-咪唑-2-甲醛 (0.52克,1.6毫莫耳)於曱醇(16毫升)之溶液使用硼氫化鈉 (0.12克,3.2毫莫耳)處理。混合物於室溫攪拌2小時。然後 洛發去除全部揮發分,殘餘物分溶(乙酸乙酯/水)。有機相 經脫水(硫酸鈉)及濃縮至約3〇毫升。獲得標題化合物呈白色 結晶物質(0.21克’ 41%)。熔點202-203。(:(乙酸乙酯),MS: *66-1328584 A7 B7 V. Description of invention (62) From the test. The free base is converted to its white hydrochloride. Melting point 153_155 ° C (sterol / diethyl ether), MS: m / e = 239 (M +) » Example 108 jiiA ^ __Ll_- "Π - (3, 4- two gas stupid VlH-咭咄-d its - A L-2.5-Dimethyl, hydrochloric acid sleep-[1-(3,4·dichloro-phenyl)-ιη·imidazol-4-yl·indenyl]•thioethylamine (0.60 g '2.0 mmol The suspension of acetone (1 ml) was treated with potassium carbonate (28 g, 2,0 mmol) and iodonane (0-26 g, 1.8 mmol). The mixture was refluxed for 1 hour to evaporate and suspend. In ethanol (3 ml), add propargylamine (1 g, 2 mmol) and reflux for 9 hours. After filtration and evaporation, the residue was purified by chromatography [Shi Xi Yao] with gradient dimethane to 30 〇 / 〇 (di-gas methane / methanol / aqueous argon arsenide = 90:10:1) elution], the free base of the title compound (2 g, 28%) was isolated as a light brown oil. Treatment with decyl alcohol solution followed by the addition of diethyl ether. The title compound was isolated as a white crystalline material, spurred <25 〇〇C (methanol/diethyl ether), MS: m/e = 321 (M+H+). (3,4-di-phenyl-phenyl, 1-imidazol-4-yl-methyl-1-1-1-imidazol-2-even 1-nonanol 1-[1-( 3,4-Dioxo-phenyl)_11^imidazole-4-yl-indenyl]-111-imidazol-2-carbaldehyde (0.52 g, 1.6 mmol) in decyl alcohol (16 mL) Treated with sodium (0.12 g, 3.2 mmol). The mixture was stirred at room temperature for 2 hr. then the residue was evaporated and the residue was partitioned (ethyl acetate/water). The title compound was obtained as a white crystalline material (0.21 g, 41%). mp.
1328584 A7 ______ B7 五、發明説明(63 ) m/e=322(M+)。 實例110 N - {1 -1~ 1 — 乱-名基)-1Η-ρ朵咬-4-基-甲某某 }-乙醯胺 1-[1-(3,4-二氯-苯基)_出-咪唑-4-基-甲基]-111-咪唑-2-基胺 (1.0克,3.2毫莫耳)於THF (32毫升)之溶液於室溫使用三乙 基胺(〇·33克’ 3·2毫莫耳)及乙醯氯(〇·25克,3·2毫莫耳)處理 。混合物於室溫授拌2小時,過遽,有機相蒸發至乾《層析 術[矽膠,以梯度二氣曱烷至50〇/〇(二氣曱烷/甲醇/水性氫氧 化銨=90:10:1)洗提]後,分離標題化合物(019克,17%)呈淺 褐色固體。熔點>236 °C分解(乙酸乙酯),MS: m/e=350 (M+H+)。 實例111 _{l-『l-(3,4-二氣笨基ViH-咪唑-4-基-甲某1-1士咪唑-2-某1-乙基-胺,鹽酸鹽(1:2) 1^-{1-[1-(3,4-二氣-苯基)_1士咪唑-4-基-甲基]-1!1-咪唑-2-基 }-乙醯胺(0.30克,0.86毫莫耳)使用1M BH3 THF錯合物(1.6 毫升)處理及回流2小時。混合物冷卻至5。〇,緩慢加入曱醇 (5毫升)。蒸發去除全部揮發分後,殘餘物攝取於2N鹽酸溶 液(3毫升)及回流20分鐘。混合物經冷卻及加入2N氫氧化鈉 溶液(3毫升)^以乙酸乙酯(50毫升)萃取後,有機相經脫水( 硫酸鈉)及蒸發至乾。藉層析術純化[矽膠,以梯度二氯曱烷 至500/〇(二氣甲烷/甲醇/水性氫氧化銨=9〇:1〇:1)洗提]獲得標 題化合物自由態鹼。以鹽酸於曱醇溶液處理接著加入乙醚 -67- 本紙張尺度適用中國圉家標準(CNS) A4規格(210X297公釐) 13285841328584 A7 ______ B7 V. Description of invention (63) m/e = 322 (M+). Example 110 N - {1 -1~ 1 - chaotic-name base) -1 Η-ρ 咬-4-基-甲 某 - - - - - - 1-[1-(3,4-dichloro-phenyl) a solution of 1-exidazolyl-4-yl-methyl]-111-imidazol-2-ylamine (1.0 g, 3.2 mmol) in THF (32 mL) using triethylamine at room temperature 33 g '3.2 mils) and acetochlor chloride (〇·25 g, 3.2 mM). The mixture was stirred at room temperature for 2 hours, and the organic phase was evaporated to dryness "chromatography [gelatin, with gradient dioxane to 50 〇 / 〇 (dioxane / methanol / aqueous ammonium hydroxide = 90: After 10:1) elution, the title compound (019 g, 17%) Melting point > 236 ° C decomposition (ethyl acetate), MS: m/e = 350 (M+H+). Example 111 _{l-"l-(3,4-dioxa-based ViH-imidazol-4-yl-methyl 1-1 imidazole-2-one 1-ethyl-amine, hydrochloride (1: 2) 1^-{1-[1-(3,4-Di-(phenyl)phenyl)-1-imidazol-4-yl-methyl]-1!1-imidazol-2-yl}-acetamide (0.30 The mixture was treated with 1 M BH3 THF (1.6 mL) and refluxed for 2 hr. The mixture was cooled to 5. 〇, decyl alcohol (5 mL The mixture was extracted with EtOAc (3 mL) EtOAc. The title compound was obtained as a free base by chromatography. Treated with hydrochloric acid in decyl alcohol solution followed by diethyl ether-67- This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1328584
後,分離標題化合物呈灰白色結晶物質(〇 〇62克,22%)。 溶點 >250°C (甲醇/乙醚),ms: m/e=336(M+H+)。 實例112 二氧-苯棊)-1-(2-甲某-咄咄_^基-甲某岫,路 酸鹽Π:Π 1-(3,4-二氣-苯基)·3·曱基·1Η_吡唑(1 4克,6」毫莫耳)於四 氣化碳之溶液以Ν-溴丁二醯亞胺(1 2克,6 8毫莫耳)及催化 量2,2’-偶氮貳·(異丁腈)處理。混合物回流2小時,冷卻,過 渡及蒸發。油性殘餘物溶解於DMF (10毫升),添加至以氮 化納(0.32克,7.3毫莫耳,參考實例1)去質子化之2_甲基味 吐(0.60克’ 7.3毫莫耳)於DMF (10毫升)之溶液内。於室溫 攪拌12小時後,真空去除全部揮發分,所得殘餘物溶解於 乙酸乙酯。有機相以水洗滌(3次),脫水(硫酸鈉)及濃縮。 藉層析術純化[矽膠’以梯度二氣曱烷至60〇/〇(二氣曱院/曱 酵/水性氫氧化銨=90:10:1)洗提]獲得標題化合物自由態驗 (0.98克’ 52%)呈淺褐色油。以鹽酸於曱醇溶液處理接著加 入乙醚後,分離標題化合物呈白色結晶物質。熔點2〇4 2〇5 °C (曱醇/乙醚),MS: m/e=306(M+)。 實例113 1-(3.4-二氣-笨基)-4-咪唑-1-基-甲基-111-吡唑 氫化鈉(〇_24克55%於礦油分散液,5.5毫莫耳)緩慢添加至味 唑(0.19克,2_8毫莫耳)於DMF (15毫升)之溶液。於的力授 掉30分鐘後’混合物於冰浴冷卻及一次加入4-氣甲基.ΙΟ〆-二氣-笨基)-1Η-ρ 比吐(0.50克, 1.9毫莫耳結果所得混 -68-Thereafter, the title compound was isolated as an off-white crystalline material (yield: 62 g, 22%). Melting point > 250 ° C (methanol / diethyl ether), ms: m / e = 336 (M + H +). Example 112 Dioxo-benzoquinone)-1-(2-methyl- 咄咄-^-yl-methyl oxime, oxalate Π: Π 1-(3,4-di-phenyl)·3·fluorenyl · 1 Η _ pyrazole (14 g, 6 "mole) in a solution of four gasified carbon with bismuth-bromobutaneimide (12 g, 6 8 mmol) and catalytic amount 2, 2' -Azo oxime (isobutyronitrile) treatment. The mixture was refluxed for 2 hours, cooled, transferred and evaporated. The oily residue was dissolved in DMF (10 mL) and added to sodium nitrite (0.32 g, 7.3 m. Example 1) Deprotonated 2_methyl-flavored (0.60 g '7.3 mmol) in DMF (10 ml). After stirring at room temperature for 12 hours, all volatiles were removed in vacuo and the residue was dissolved. Ethyl acetate. The organic phase was washed with water (3 times), dehydrated (sodium sulfate) and concentrated. Purified by chromatography [矽 ' 以 梯度 梯度 梯度 梯度 梯度 至 至 至 至 至 至 至 至 二 二 二 二 二/Aqueous ammonium hydroxide = 90:10:1) elution] The title compound was obtained as a light brown oil (0.98 g of '52%) as a light brown oil. Crystalline substance. Melting point 2〇 4 2 〇 5 ° C (melanol / diethyl ether), MS: m / e = 306 (M +). Example 113 1-(3.4-di- s- yl)-4-imidazol-1-yl-methyl-111 - Pyrazole sodium hydride (〇_24 g 55% in mineral oil dispersion, 5.5 mmol) was slowly added to a solution of the oxazole (0.19 g, 2-8 mmol) in DMF (15 mL). After 30 minutes of drop, the mixture was cooled in an ice bath and added with 4-methyl-methyl hydrazine-dialdehyde-stupyl one-time Η-ρ ratio (0.50 g, 1.9 mmol) resulting in a mixture of -68-
裝 訂Binding
線 本紙張尺度適用中國國家標準(CNS> Α4規格(210 X 297公釐) 1328584 A7 B7Line This paper scale applies to Chinese national standards (CNS> Α4 specifications (210 X 297 mm) 1328584 A7 B7
合物於20°c攪拌1小時。蒸發去除溶劑後’殘餘物溶解於乙 酸乙酯,以水洗滌,脫水(硫酸鈉)及層析[矽膠,以梯度二 氣甲烷至30%(二氣甲烷/甲醇/水性氫氧化銨=9〇:1〇:1)洗提] 獲得0.23克(41%)標題化合物。熔點i〇3-i〇4°c (二異丙基謎) ,MS: m/e=293(M+H+)。 實例114係根據實例113所述概略程序製備。 實例114 1- (3,4-二氣笨基)-4-(2-甲基-°米嗅-1 -基-甲基)-iH-nth 2- 曱基咪唑使用氫化鈉脫去質子化,然後以4-氣曱基_i-(3,4-二氣-苯基)-1Η-ρ比唑處理。萃取及層析後續處理獲得標 題化合物呈白色結晶固體。熔點176-177°C (乙酸乙酯),MS: m/e=307(M+H+)。 實例115 1只-咪唑,1-(3.4-二氯笨基)-4-丨1-(1小咪唑-1-某八厂其1-, 以及1H-咪唑,1-(3,4-二氣茉某V3-氪-4-Π-ΠΗ-咮崠-i-其V 乙基1- 1-[1-(3,4-二氣-苯基)-1Η-咪唑-4-基]-乙醇(0.2克,0.78毫莫 耳)及亞磺醯氯(3毫升,過量)之混合物於室溫攪拌1.5小時 。藉溫和氣流去除溶劑。然後咪唑(3·5克’過量)添加至殘 餘物,混合物於90°C攪拌30分鐘。加水(1〇毫升)後’混合物 以二氣甲烷萃取。有機相經脫水(硫酸納)’溶劑經蒸發。殘 餘物藉層析術純化[矽膠’以二氣甲炫·/曱醇/水性氫氧化敍 = 140:10:1 洗提)獲得1H-蜂咬,1-(3,4-二氣苯基)-4-[1-(1Η·喃 唑-卜基)-乙基]-(82毫克,34%)呈淺褐色固體[MS: -69- 本纸張尺度適用中國國家標準(CNS) A4规格(210 X 297公釐) 1328584 A7 B7 五、發明説明(66 ) m/e=306.1 (M+)]以及副產物1H-咪唑,1-(3,4-二氯苯基)-3-氯-4·[1-(1Η-咪唑-1-基)-乙基]-(102毫克,38%)呈淺黃色油 。MS: m/e=341.1 (Μ+Η+)。 實例116係根據實例115所述概略程序製備。 實例116 _1H-咪唑,1-Π-Π-(3,4-二氣笨基)-1Η-哚唑-4-某1乙基1-2-甲 卜[1·(〗,4-二氣-苯基)-1Η-味0^-4-基]-乙醇與亞續醢氣反應, 接著以2-甲基咪唑處理,於萃取後續處理及層析術後結果 導致獲得標題化合物呈淺褐色固體。MS: m/e=320.1 (M+)。 實例117 1^-咪唑’1彳3.4-二氣笨基)-4-丨1-(1只-唑唑-1-某)-1-甲基乙 基1- 2-[1-(3,4-二氣-苯基)-1Η-咪唑-4-基]-丙-2-醇(150毫克,0.55 毫莫耳)及三溴化硼(1M於二氣甲烷,3毫升)之混合物於室 溫搜拌2小時。於氣流下去除溶劑後,殘餘物經脫水隔夜。 加入咪唑(226毫克,33.2毫莫耳),混合物於i〇(TC攪拌45分 鐘。加水後,混合物以二氣曱烷萃取。有機相經脫水(硫酸 納)’蒸發,殘餘物藉層析術純化(石夕膠’首先以乙酸乙酯然 後以二氣甲烷/曱醇=95:5洗提)獲得標題化合物(15毫克, 8%)呈淺黃色固體。MS: m/e=320.0 (M+)。 實例118 迅-味咬,?-甲華-1-Κ4-Γ3-(三氟甲基)裟某ΜΗ-唑吔-2-某1 ’鹽酸镑(1:2) -70- 1328584The mixture was stirred at 20 ° C for 1 hour. After evaporating to remove the solvent, the residue was dissolved in ethyl acetate, washed with water, dried (sodium sulfate) and chromatographed [yield, with a gradient of methane to 30% (di-methane/methanol/aqueous ammonium hydroxide = 9 〇) :1〇:1) elution] 0.23 g (41%) of title compound was obtained. M.p. Example 114 was prepared according to the general procedure described in Example 113. Example 114 1-(3,4-Dioxaphenyl)-4-(2-methyl-°m-ol-1 -yl-methyl)-iH-nth 2-mercaptoimidazole was deprotonated using sodium hydride And then treated with 4-carbolyl _i-(3,4-dioxa-phenyl)-1 Η-ρ-butyrazole. Subsequent extraction and subsequent chromatography gave the title compound as a white crystalline solid. Melting point 176-177 ° C (ethyl acetate), MS: m / e = 307 (M+H+). Example 115 1 -imidazole, 1-(3.4-dichlorophenyl)-4-indole 1-(1 small imidazole-1- 8 plant, 1-, and 1H-imidazole, 1-(3,4-di V-V-氪-4-Π-ΠΗ-咮崠-i-V-ethyl 1- 1-[1-(3,4-di-phenyl)-1Η-imidazol-4-yl]- A mixture of ethanol (0.2 g, 0.78 mmol) and sulfinium chloride (3 mL, excess) was stirred at room temperature for 1.5 hours. The solvent was removed by a warm air stream. Then imidazole (3.5 gram 'excess) was added to the residue. The mixture was stirred at 90 ° C for 30 minutes. After adding water (1 mL), the mixture was extracted with di-methane. The organic phase was dehydrated (sodium sulphate). The solvent was evaporated. The residue was purified by chromatography.甲甲炫·/曱醇/aqueous hydroxide ==140:10:1 elution) to obtain 1H-bee bite, 1-(3,4-diphenyl)-4-[1-(1Η· azole) -Buji)-Ethyl]-(82 mg, 34%) was a light brown solid [MS: -69- This paper scale applies to Chinese National Standard (CNS) A4 size (210 X 297 mm) 1328584 A7 B7 V , invention instructions (66) m / e = 306.1 (M +)] and by-product 1H-imidazole, 1-(3,4-dichlorophenyl)-3-chloro-4·[1-(1Η-imidazole-1 -yl)-ethyl]-(10 2 mg, 38%) was a pale yellow oil. MS: m / e = 341.1 ( Μ + Η + ). Example 116 was prepared according to the procedure outlined in Example 115. Example 116 _1H-imidazole, 1-Π-Π-( 3,4-diqi stupid)-1Η-carbazole-4-one 1 ethyl 1-2-methyl b[1·(〗, 4-di-phenyl-phenyl)-1Η-味0^-4- The reaction of the ethanol with the subtropical helium, followed by the treatment with 2-methylimidazole, the subsequent work up of the extracts and chromatography gave the title compound as a light brown solid. MS: m/e=320.1 (M+). Example 117 1^-imidazole '1彳3.4-diqi stupyl)-4-丨1-(1-oxazol-1-one)-1-methylethyl 1- 2-[1-(3, a mixture of 4-dioxo-phenyl)-1Η-imidazol-4-yl]-propan-2-ol (150 mg, 0.55 mmol) and boron tribromide (1M in di-methane, 3 mL) Mix for 2 hours at room temperature. After removing the solvent under a stream of air, the residue was dehydrated overnight. Imidazole (226 mg, 33.2 mmol) was added and the mixture was stirred for 4 minutes on EtOAc. After water was added, the mixture was extracted with dioxane. The organic phase was evaporated (sodium sulfate) and evaporated. The title compound (15 mg, 8%) was obtained as a pale-yellow solid, m.p. Example 118 迅-味咬,?-甲华-1-Κ4-Γ3-(trifluoromethyl)裟裟ΜΗ-oxazol-2-one 1 'hydrochloric acid pound (1:2) -70- 1328584
1H-咪唑,2·[(2-曱基-1H-咪唑-1-基)甲基]_4-[3-(三氟曱基) 苯基]-卜[[2·(三曱基矽烷基)乙氧]曱基]-(0.034克,〇〇78毫 莫耳)溶解於乙醇(0.8毫升)及以2N鹽酸(0.86毫升)處理。反 應混合物回流隔夜’冷卻至室溫及濃縮。粗製殘餘物攝取 於乙酸乙酯及於室溫攪拌30分鐘。過濾獲得1H-咪唑,2-曱 基-1-[[4-[3-(三氟甲基)苯基]-1H·咪唑-2-基]曱基-,鹽酸鹽 (24毫克 ’ 81%)呈淺黃色固體,MS: m/e=307.2 (M+H+)。 實例119至122係根據實例118所述概略程序製備。 實例119 j_H-咪唑,ΐ-【『4-(4-氟-3-曱基笨基)-1Η-"来唑-2-基1甲某-2-甲 基-,鹽酸镑Π:2) 標題化合物’ MS: m/e=270.1 (Μ+)係由1Η-°米嗤,4-(4-氣-3- 曱基苯基)-2-[(2-甲基-1H-咪唑-1-基)曱基]_i-[[2-(三甲基矽 烷基)乙氧]曱基]製備。 實例120 1K-咪唑’ l-f『4-(3,4-二氟笨基)-1Η-咪唑-2-基1甲某-2-甲其. ,鹽醅睡(1 -?Λ 標題化合物,MS: m/e=275.2 (Μ+Η+)係由 1Η-°米唾,4-(3,4-二氟苯基)-2-[(2 -曱基-1Η-σ米嗤-1-基)曱基]· 1-[[2-(三甲基石夕 院基)乙氧]甲基]製備。 實例121 111-味啥’ 2-曱基- l-f[~4-(4-甲硫基)策基~|·ΐΗ-η米岐-2-某1甲 基-2-甲某-,鹽酸鹽(1:2) 標題化合物,MS: m/e=285.2 (Μ+Η+)係由 1Η-°米也,2-[(2- -71 -1H-imidazole, 2·[(2-mercapto-1H-imidazol-1-yl)methyl]_4-[3-(trifluoromethyl)phenyl]-bu[[2·(tridecylfluorenyl) Ethoxy]hydrazino]-(0.034 g, 〇〇78 mmol) was dissolved in ethanol (0.8 mL) and treated with 2N hydrochloric acid (0.86 mL). The reaction mixture was refluxed overnight and cooled to room temperature and concentrated. The crude residue was taken in ethyl acetate and stirred at room temperature for 30 min. Filtration of 1H-imidazole, 2-mercapto-1-[[4-[3-(trifluoromethyl)phenyl]-1H.imidazol-2-yl]indolyl-, hydrochloride (24 mg' 81) %) is a pale yellow solid, MS: m/e = 307.2 (M+H+). Examples 119 through 122 were prepared according to the general procedure described in Example 118. Example 119 j_H-imidazole, hydrazine-["4-(4-fluoro-3-indolyl)-anthracene-" oxazol-2-yl 1 methyl-2-methyl-, hydrochloric acid pound Π: 2 The title compound 'MS: m/e=270.1 (Μ+) is from 1Η-° rice, 4-(4-carb-3-phenylphenyl)-2-[(2-methyl-1H-imidazole) Preparation of -1-yl)fluorenyl]_i-[[2-(trimethyldecyl)ethoxy]indolyl]. Example 120 1K-Imidazole ' lf "4-(3,4-Difluorophenyl)-1 oxime-imidazol-2-yl 1 A-methyl-2-yl., salt sputum (1 -? Λ title compound, MS : m/e=275.2 (Μ+Η+) is from 1Η-°米唾, 4-(3,4-difluorophenyl)-2-[(2-indolyl-1Η-σ米嗤-1- Preparation of 1-[[2-(trimethylglycine)ethoxy]methyl]. Example 121 111-Miso '2-mercapto-l[~4-(4-methylthio) )基基~|·ΐΗ-η米岐-2-一1methyl-2-methyl-, hydrochloride (1:2) title compound, MS: m/e=285.2 (Μ+Η+) By 1Η-°m also, 2-[(2-71-
裝Loading
訂 線 本纸張尺度適用中國國家標準(Cns) Α4規格(210Χ 297公爱) 1328584Ordering This paper scale applies to Chinese National Standard (Cns) Α4 Specifications (210Χ 297 公爱) 1328584
甲基-1H_咪唑基)甲基]-4_[4-(曱硫基)苯基]-l-[[2-(三甲基 矽烧基)乙氧]甲基]製備。 實例122 —-味啥’ 氟-3-甲基茉某V2.HH-咄唑-1-某-甲某、-,鹽 酸鹽(1:2)Preparation of methyl-1H-imidazolyl)methyl]-4_[4-(indolylthio)phenyl]-l-[[2-(trimethylsulfonyl)ethoxy]methyl]. Example 122 - miso' fluoro-3-methyl jasmine V2.HH-carbazole-1-some-methyl,-,hydrochloride (1:2)
裝 標題化合物,MS: m/e=257.1 (M+H+)係由 1H-咪唑,4-(4-氟-3-曱基苯基)_2-(1Η-咪唑-1-基·甲基三曱基矽烷 基)乙氧]甲基]製備。 實例123. 二氧-苯基曱基-咪唑-i_基-甲基>吡啶,鹽酸鹽 π:η 訂Heading compound, MS: m/e = 257.1 (M+H+) from 1H-imidazole, 4-(4-fluoro-3-indolylphenyl)_2-(1Η-imidazol-1-yl·methyltri Preparation of fluorenylalkyl)ethoxy]methyl]. Example 123. Dioxy-phenylindenyl-imidazolium-i-yl-methyl>pyridine, hydrochloride π:η
於氫化鈉(17毫克55%於礦物油分散液,〇 39毫莫耳)於DMF (5毫升)之懸浮液内加入2-曱基D米嗤(3 2毫克,0.39毫莫耳)。 混合物於20°C攪拌1.5小時《隨後加入3·氣甲基·5-(3,4-二氣-笨基)-晚啶鹽酸鹽(1:1)(100毫克’ 〇·32毫莫耳)及三乙基胺 (78毫克,0.78毫莫耳),混合物加熱至i〇〇°c歷4小時。冷卻 後DMF經蒸發’殘餘物直接層析[矽膠,以二氣曱烷/(21^氨 於甲醇)= 85:15洗提]獲得標題化合物自由態驗呈黃色油。此 物料溶解於曱醇’以攪拌冷卻至4°C及以鹽酸/乙醇(1.46 Μ ,1.1當量)攪拌及處理15分鐘。於50°C於高度真空蒸發去除 溶劑及脫水2小時獲得標題化合物(71毫克,62%)呈淺黃色 固體。MS: m/e=317.1 (M+)。 實例124至127係根據實例123所述概略程序製備。 實例124 -72- 本紙張尺度適用中國国家標竿(CNS) A4規格(210X 297公釐)To a suspension of sodium hydride (17 mg of 55% in mineral oil dispersion, 〇 39 mmol) in DMF (5 mL) was added 2-mercapto D-methane (3 2 mg, 0.39 mmol). The mixture was stirred at 20 ° C for 1.5 hours. Then 3·gasmethyl·5-(3,4-dioxa-phenyl)-acridinium hydrochloride (1:1) was added (100 mg' 〇·32 mmol Ear) and triethylamine (78 mg, 0.78 mmol), and the mixture was heated to i 〇〇 °c for 4 hours. After cooling, the title compound was obtained as a yellow oil. This material was dissolved in decyl alcohol, cooled to 4 ° C with stirring, and stirred and treated with hydrochloric acid/ethanol (1.46 Torr, 1.1 eq.) for 15 minutes. The solvent was removed in vacuo <RTI ID=0.0></RTI> to <RTI ID=0.0> MS: m/e = 317.1 (M+). Examples 124 through 127 were prepared according to the general procedure described in Example 123. Example 124 -72- This paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm)
標題3化合物’ MS: m/e=317.〇 (M+)係呈淺褐色固體(60〇/〇產率 )獲仟,其獲得方式係經由2-氣曱基-3-(3,4-二氣-苯基)_吡啶 ’鹽酸鹽(1:1)與2·甲基味啥使用氫化納及三乙基胺作為驗 反應’接著形成鹽酸鹽。 實例125Title 3 Compound 'MS: m/e = 317. 〇(M+) is obtained as a light brown solid (60 〇 / 〇 yield) obtained by 2-pyringyl-3-(3,4- Dioxo-phenyl)-pyridine's hydrochloride (1:1) and 2-methyl miso were treated with sodium hydride and triethylamine as the 'reaction' followed by the formation of the hydrochloride. Example 125
(1:2) 標題化合物,MS: m/e=317.0 (M+)係呈嗶嘰色固體(51%產率 )獲得,其獲得方式係經由仁氣甲基-2-(3,4-二氣-苯基)·吡啶 ’鹽酸鹽(1:1)與2-甲基咪唑使用氫化鈉及三乙基胺作為鹼 反應,接著形成鹽酸鹽。 實例126 苯基)-5-咪唑-1-某-甲基··吡啶,鹽酸鹽π:Π 標題化合物’ MS: m/e=304.1 (Μ+Η+)係呈固體(56%產率)獲 得’其獲得方式係經由3-氣曱基-5-(3,4-二氣-苯基)-吡啶, 鹽酸鹽(1:1)與咪唑使用氫化鈉及三乙基胺作為鹼反應,接 著形成鹽酸鹽。 實例127 j_-(3,4-一亂-笨基)-5-(2-甲基-咕嗅-l-基-曱基比咬,鹽酸鹽 π:η 標題化合物,MS: m/e=332.2 (Μ+Η+)係呈橙色固體(49%產 率)獲得,其獲得方式係經由3-氣甲基-5-(3,4-二氣-苯基)-吡 -73- 本紙張尺度適用中國國家標竿(CNS) A4規格(210 X 297公釐) 1328584(1:2) The title compound, MS: m/e = 317.0 (M+) was obtained as a color solid (yield: 51% yield). -Phenyl)·pyridine's hydrochloride (1:1) is reacted with 2-methylimidazole using sodium hydride and triethylamine as a base, followed by the formation of the hydrochloride salt. Example 126 phenyl)-5-imidazol-1-y-methyl·pyridine, hydrochloride π: Π title compound ' MS: m/e=304.1 (Μ+Η+) as solid (56% yield Obtained 'by obtaining 3-sulfonyl-5-(3,4-di-phenyl)-pyridine, hydrochloride (1:1) and imidazole using sodium hydride and triethylamine as the base The reaction is followed by the formation of the hydrochloride salt. Example 127 j_-(3,4-disorgano-styl)-5-(2-methyl-oxime-l-yl-indenylpyramine, hydrochloride π:η title compound, MS: m/e =332.2 (Μ+Η+) is obtained as an orange solid (49% yield) obtained from 3-methylmethyl-5-(3,4-di-phenyl)-py-73- Paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1328584
咬’鹽酸鹽(1:1)與2-曱基咪唑使用.氫化鈉及三乙基胺作為 鹼反應,接著形成鹽酸鹽。 實例128 1τ(.3,4 - 一氣-苯基)-2-甲基-3-(2-甲基-喷吐-1-基-甲基比咬 ,鹽酸鹽Π:Π 標題化合物,MS: m/e=292.2 (Μ+Η+)係呈嗶嘰色固體(77% 產率)獲得,其獲得方式係經由3-氣曱基-5-(3,4-二氣-苯基)- 2- 曱基-吡啶’鹽酸鹽(1:1)與2-曱基咪唑(5當量),使用氫化 鈉(3當量)作為鹼反應,接著形成鹽酸鹽。 實例129 3_-(4-氣-苯基)-5-(2-曱基-咪唑-1-基-甲基吡啶鞔酸鹽ο: 1) 3- 溴-5-(2-甲基-味吐-1-基曱基)-P比咬(120毫克,0.48毫莫耳) ,貳(三苯基膦)氣化鈀(Π)(1〇毫克,〇·〇1毫莫耳)及乙酸鉀 (140¾克,0.14毫莫耳)之混合物於二!》号烧(1〇毫升)於2〇。〇授 拌1小時。然後加入4-氣苯基二羥硼酸(78毫克,〇.〇5毫莫耳 )及2N碳酸鈉溶液(1.2毫升),混合物於1〇〇。(:於氬氣氣氛下 加熱7-24小時。冷卻後,蒸發去除溶劑及加入2N氫氧化鈉 (5毫升)及乙酸乙酯。混合物經振搖,水相經分離,進一步 以乙酸乙酯萃取。合併有機萃取物以鹽水洗滌然後以硫酸 鈉脫水,過濾及蒸發。殘餘物經層析[矽膠,以二氯曱烷 /(2M氨於曱醇=97:3)洗提]。產物溶解於曱醇,以攪拌冷卻 至4t,以鹽酸/乙醇(1.46 Μ,1.1當量)處理45分鐘。於50°C 於高皮真空蒸發去除溶劑及脫水2小時獲得標題化合物(98 毫克,64%)呈淺褐色固體。MS: m/e=284.2 (M+H+)。 -74- 本纸張尺度逋用中国國家標準(CNS) A4规格(210X297公釐) 1328584 A7 B7 實例130至142係根據實例129所述概略程序製備。 實例130 一甲基-本基)-5-(2 -甲基-p米啥-1-基-甲基)-|7出咬鹽酸鹽 π:η 標題化合物,MS: m/e=277 (Μ+)係經由3-溴-5-(2-曱基-咪 唑-1-基甲基)-吡啶與3,4-二甲基苯基二羥硼酸反應獲得,呈 淺黃色發泡體(54%產率)。 實例131 1:丄4-氣-3二甲基苯基)-5-(2-甲基米嗤-1·某·甲基卜比啶镑酴 鹽(1:1、 標題化合物,MS: m/e=281.1 (M+)係經由3-溴-5-(2-曱基-咪 唑-1-基曱基)-吡啶與4-氟-3-甲基-笨基二羥硼酸反應獲得, 呈淺褐色發泡體(63%產率)。 實例132 1ι(3,4-二氟-笨基)-5-(2-甲某-咪唑-1-基-甲基吡啶鹽酸鹽 (1:1) 標題化合物’ MS: m/e=286.2 (M+H+)係經由3-溴-5-(2-曱基-味喷-1-基甲基)-吡啶與3,4_二氟·苯基二羥硼酸反應獲得, 呈淺黃色發泡體(85%產率)。 實例133 1^4-1-苯基)-5-(2-曱基-畔崎·ι_基·甲某驗酸镑π:1) 標題化合物,MS: m/e=268.3 (Μ+Η+)係經由3-溴-5-(2-甲基-味唾-1-基甲基)-吡啶與4·氟苯基二羥硼酸反應獲得,呈淺 黃色發泡體(90%產率)。 -75- 本紙張尺度通財目@家標竿(CNS)域格(2lGX297公爱)The bite 'hydrochloride (1:1) was used with 2-mercaptoimidazole. Sodium hydride and triethylamine were reacted as a base, followed by the formation of the hydrochloride salt. Example 128 1τ(.3,4 -mono-phenyl)-2-methyl-3-(2-methyl- sulty-1-yl-methyl-bito, hydrochloride Π: Π title compound, MS: m/e = 292.2 (Μ + Η +) was obtained as a ochre solid (77% yield) obtained from 3-carbazin-5-(3,4-di-phenyl)- 2 - mercapto-pyridine' hydrochloride (1:1) and 2-mercaptoimidazole (5 equivalents) using sodium hydride (3 equivalents) as a base, followed by the formation of the hydrochloride salt. Example 129 3_-(4- gas -phenyl)-5-(2-indolyl-imidazol-1-yl-methylpyridinium ο: 1) 3-bromo-5-(2-methyl-sodium-1-ylindenyl) -P ratio bite (120 mg, 0.48 mmol), hydrazine (triphenylphosphine) gasified palladium (Π) (1 〇 mg, 〇·〇 1 mmol) and potassium acetate (1403⁄4 g, 0.14 mmol) The mixture of the ears) was simmered in 2 liters (1 liters) at 2 Torr. The mixture was stirred for 1 hour, then 4-cyclophenyldihydroxyboric acid (78 mg, 〇.〇5 mmol) and 2N carbonic acid were added. Sodium solution (1.2 ml), the mixture was stirred at 1 Torr. (: argon atmosphere was heated for 7-24 hours. After cooling, solvent was evaporated and 2N sodium hydroxide (5 mL) and ethyl acetate were added. The mixture was shaken, the aqueous phase was separated, and then extracted with ethyl acetate. The organic extracts were washed with brine and dried over sodium sulfate, filtered and evaporated. The residue was chromatographed 2M ammonia in decyl alcohol = 97:3) elution]. The product was dissolved in decyl alcohol, cooled to 4 t with stirring, treated with hydrochloric acid/ethanol (1.46 Μ, 1.1 eq.) for 45 minutes, and evaporated at 50 ° C in high skin vacuum. The solvent was removed and dehydrated for 2 hours to give the title compound (98 mg, 64%) as a pale brown solid. MS: m/e=284.2 (M+H+). -74- The paper size was measured using Chinese National Standard (CNS) A4 Specifications (210 X 297 mm) 1328584 A7 B7 Examples 130 through 142 were prepared according to the general procedure described in Example 129. Example 130 Monomethyl-bens)-5-(2-methyl-p-m-indol-1-yl-- Base)-|7 out of the salt hydrochloride π:η title compound, MS: m/e=277 (Μ+) via 3-bromo-5-(2-indolyl-imidazol-1-ylmethyl)- Pyridine was obtained by reaction with 3,4-dimethylphenyldihydroxyboronic acid as a pale yellow foam (54% yield). Example 131: 丄4-y-3 dimethylphenyl)-5- ( 2-Methyl rice bran-1 · a certain methyl buppyridinium salt (1:1 , title compound, MS: m/e = 281.1 (M+) via 3-bromo-5-(2-indolyl-imidazol-1-ylindenyl)-pyridine and 4-fluoro-3-methyl-phenyl Obtained by the reaction of diboric acid, it was a light brown foam (63% yield). Example 132 1 1 (3,4-Difluoro-phenyl)-5-(2-methyl-imidazol-1-yl-methylpyridine hydrochloride (1:1) title compound < MS: m/e=286.2 (M+H+) is obtained by reacting 3-bromo-5-(2-mercapto-ylidene-1-ylmethyl)-pyridine with 3,4-difluoro-phenyldihydroxyboronic acid, which is light yellow Bubbles (85% yield). Example 133 1^4-1-phenyl)-5-(2-indolyl-Nasaki·ι_基·甲一酸酸磅 π:1) Title compound, MS: m/e=268.3 (Μ+Η+) is obtained by reacting 3-bromo-5-(2-methyl--salt-1-ylmethyl)-pyridine with 4·fluorophenyldihydroxyboronic acid. Yellow foam (90% yield). -75- This paper scales through the currency @家标竿(CNS) domain (2lGX297 public)
裝 訂Binding
13285841328584
實例134 . 甲基基-甲幕»(3_三氟甲篡苯篡、·吡鹽酸鹽 π:η 標題化合物,MS: m/e=318.3 (Μ+Η+)係經由3-溴-5-(2-甲基- 味唾-1-基甲基)-,比咬與3_三氟甲基苯基二羥硼酸反應獲得 ’呈嗶嘰色發泡體(74%產率)。 實例135 甲基-味唾-1-基-甲基)_%(4_三氟甲某-笨基)·吡啶鹽酸 鹽 標題化合物,MS: m/e=318.3 (Μ+Η+)係經由3_溴_5_(2·甲基· 咪唑-1-基甲基)_吡啶與4_三氟甲基苯基二羥硼酸反應獲得 ’呈嗶嘰色發泡體(77%產率)。 實例136 氣-4-甲基-苯基)·5-(2-甲甚-咪唑-1-某-甲基)_毗咛驂醅 Μ π:η 標題化合物,MS·· m/e=298.3 (Μ+Η+)係經由3-溴-5-(2-甲基_ 咪唑-1-基曱基)-吡啶與2-(3-氣·4-曱基-笨基)·4,4,5,5-四曱基 [1,3,2]-二氧雜伍圓硼烷反應獲得’呈嗶嘰色固體(78%產率) 〇 實例137 1_-(4·氯-3-甲基-苯基)-5-(2·甲基-咪唑-1·某-甲其)^睡 鹽(1:1、 標題化合物,MS: m/e=298.3 (Μ+Η+)係經由3-漠_5_(2_甲基· 咪唑-1-基曱基)-吡啶與2-(4-氣-3-曱基-苯基)_4,4,5,5-四甲基Example 134. Methyl-A-Curtain»(3_Trifluoromethyl hydrazine, ·pyridine π:η title compound, MS: m/e=318.3 (Μ+Η+) via 3-bromo- 5-(2-Methyl-sodium-1-ylmethyl)-, which was reacted with 3-trifluoromethylphenyldihydroxyboronic acid to give a 'yellow foam (74% yield). 135 Methyl-salt-1-yl-methyl)_% (4-trifluoromethyl-phenyl)-pyridine hydrochloride title compound, MS: m/e = 318.3 (Μ+Η+) 3-Bromo-5-(2-methylimidazol-1-ylmethyl)-pyridine was reacted with 4-trifluoromethylphenyldihydroxyboronic acid to give a 'yellow foam (77% yield). Example 136 gas-4-methyl-phenyl)·5-(2-methyl-imidazol-1-y-methyl)-pyridinium π:η title compound, MS·· m/e=298.3 (Μ+Η+) via 3-bromo-5-(2-methyl-imidazol-1-ylindenyl)-pyridine and 2-(3- gas·4-mercapto-phenyl)·4,4 ,5,5-tetradecyl[1,3,2]-dioxaindole borane reaction to give 'black solid (78% yield) 〇 Example 137 1_-(4·chloro-3-methyl -Phenyl)-5-(2.methyl-imidazole-1·a-methyl-)-sleeping salt (1:1, title compound, MS: m/e=298.3 (Μ+Η+) via 3- _5_(2_Methyl-imidazol-1-ylindenyl)-pyridine and 2-(4-carb-3-indolyl-phenyl)_4,4,5,5-tetramethyl
裝Loading
-76--76-
13285841328584
[1,3,2]_二氧雜伍園硼烷反應獲得,呈.白色固體(73%產率)。 實例138 基)-5-(2-甲某-唑岫-u某-甲基 V吡 咬鹽酸ϋ ρ · 1丨 標題化合物’ MS: m/e=292.2 (Μ+Η+)係經由3-溴-5-(2-曱基- 咪唑·1-基曱基)-吡啶與5-(4,4,5,5-四甲基[1,3,2]-二氧雜伍園 硼烷-2-基)·2,3-二氫·苯并呋喃反應獲得,呈淺黃色發泡體 (1 8%產率)。 實例139 -四乳^-5-基-(2·甲某-p米吐-1·基-甲基)比咬鹽酸鹽 標題化合物,MS: m/e=289.1 (M+)係經由3-溴-5-(2-曱基-咪 。坐-1-基曱基)·吡啶與2_四氫茚基_5_基_4 4 5 5四曱基 [1,3,2]-二氧雜伍園硼烧反應獲得,呈白色固體(91〇/〇產率)。 實例140 3(3__4 -氣-本基)-5-(2-曱基-喷唾-1-基-甲基比咬镑酸鹽 π:η 標題化合物,MS: m/e=301.1 (Μ+)係經由3-溴-5-(2-曱基-咪 嚷-l-基甲基)-吡啶與3-氯-4-氟-苯基二羥硼酸反應獲得,呈 黃色固體(53%產率)。 實 $ 141 3-(4-氣-3-三氟甲基-苯基甲基朵吨-1-基-甲基)卜咭 ,鹽酸鹽(1:1) 標題也合物,MS: m/e=352.3 (M+H+)係經由3-演-5-(2-甲基-咪唑-1-基甲基)-吡啶與2-(4-氣-3-三氟曱基-苯基)-4,4,5,5-四 -77- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)[1,3,2]_Dioxaborane borane was obtained as a white solid (yield: 73%). Example 138: </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; Bromo-5-(2-indolyl-imidazolyl-1-ylindenyl)-pyridine and 5-(4,4,5,5-tetramethyl[1,3,2]-dioxaborane borane -2-yl)·2,3-dihydrobenzoyl furan reaction, obtained as a pale yellow foam (18% yield). Example 139 - tetra-milk-5-yl-(2·甲某- P.m.-1 -yl-methyl) than the salt of the title compound, MS: m/e = 289.1 (M+) via 3-bromo-5-(2-indolyl-m. The fluorenyl group was obtained as a white solid (91 〇 / 与) with 2 - tetrahydroindenyl _5_yl _4 4 5 5 tetradecyl [1,3,2]-dioxaboron. Yield). Example 140 3(3__4 - gas-benyl)-5-(2-mercapto-salt-1-yl-methyl-p-picolinate π:η title compound, MS: m/e = 301.1 (Μ+) is obtained by the reaction of 3-bromo-5-(2-indolyl-methane-l-ylmethyl)-pyridine with 3-chloro-4-fluoro-phenyldihydroxyboronic acid as a yellow solid. (53% yield). Real $ 141 3-(4-Gas-3-trifluoromethyl-phenylmethyltolo-l-yl-methyl) dip, hydrochloride (1:1) Also, MS: m/ e=352.3 (M+H+) via 3-act-5-(2-methyl-imidazol-1-ylmethyl)-pyridine and 2-(4- gas-3-trifluoromethyl-phenyl) -4,4,5,5-four-77- This paper size applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm)
裝 訂Binding
線 1328584 A7 — B7 五、發明説明(74 ) 甲基[1,3,2]-二氧雜伍園硼烷反應獲得,呈嗶嘰色固體(49% 產率)。 實例142 1-(4-氟-3-三窗.甲基-菜基)-5-(2-甲基-咪唑-1-某-甲其 ,鹽酸镑(1:1) 標題化合物,MS: m/e=336.3 (Μ+Η+)係經由3-溴-5-(2-甲基-咪嗤-1-基甲基)-ι»比咬與2-(4-氟-3-三氟甲基-苯基)-4,4,5,5-四 甲基[1,3,2]-二氧雜伍圜硼烷反應獲得,呈白色固體(6〇0/〇產 率)。 實例143 _1_H-咪唑,2-乙某-1-ΓΓΐ-「3-(三氟甲基硫)茉甚γ 1甲基1-,鞔酸驗Γ1:2) 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用[1-(3 -三氟曱基硫燒基_ 笨基)-1Η-咪唑-4-基]-甲醇與亞磺醯氣反應,然後與2_乙基 咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。炫點 234-236°C (曱醇/乙趟)’ MS: m/e=353 (M+H+)。 實例144 1H-咪唑,2-曱基-1-Γ『1·『3·(三氟甲基硫)茉基 1甲基1-,鹽酸鹽(1:2) 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[1-(3-三氟曱基碳炫基· 苯基)-1Η-味吐-4-基]-曱醇與亞確酿氣反應,然後與2_甲基 咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。炫點 -78- 本紙張尺度適用中國圉家標準(CNS) A4規格(21〇X 297公爱) 1328584Line 1328584 A7 - B7 V. INSTRUCTIONS (74) Methyl [1,3,2]-dioxaborane borane was obtained as a ochre solid (49% yield). Example 142 1-(4-Fluoro-3-tris.methyl-carotyl)-5-(2-methyl-imidazol-1-yl-methyl,pound hydrochloride (1:1) title compound, MS: m/e=336.3 (Μ+Η+) via 3-bromo-5-(2-methyl-imidon-1-ylmethyl)-ι» bite with 2-(4-fluoro-3-III The reaction was carried out by the reaction of fluoromethyl-phenyl)-4,4,5,5-tetramethyl[1,3,2]-dioxaindole borane as a white solid (6 〇0 / 〇 yield). Example 143 _1_H-imidazole, 2-ethyl-1-pyrene-"3-(trifluoromethylsulfanyl) gamma gamma 1 methyl 1-, decanoic acid test 1:2) Follow the general procedure described in Example 10, title The compound is obtained as a white crystalline material, which is obtained by first reacting [1-(3-trifluoromethylsulfanyl-phenyl)-p-imidazol-4-yl]-methanol with sulfoximine gas. It is then reacted with 2_ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Happiness 234-236 ° C (sterol / acetamidine) ' MS: m / e = 353 (M + H + Example 144 1H-imidazole, 2-mercapto-1-yron "1·"3 (trifluoromethylsulfanyl)methyl 1 methyl 1-, hydrochloride (1:2) as described in Example 10. A summary procedure in which the title compound is obtained as a white crystalline material. By first reacting [1-(3-trifluorodecylcarbophenyl)-1Η-miso-4-yl]-nonanol with argon, then with 2-methylimidazole and sodium hydride Reaction, followed by chromatography and crystallization of hydrochloride. Hyun-78- This paper scale applies to China National Standard (CNS) A4 specification (21〇X 297 public) 1328584
>200°C 分解(甲醇/乙越),MS: m/e=3〇3 (M+H+)。 實例148 1ι[3-(1τ1-二氟乙棊)-苯基卜4·咪唑-i-基甲基-1Η·η兔唑鹽酸鹽 (1:2、> 200 ° C decomposition (methanol / ethylene), MS: m / e = 3 〇 3 (M + H +). Example 148 1ι[3-(1τ1-difluoroacetamidine)-phenylpyr-4.imidazole-i-ylmethyl-1Η·η-rhamazole hydrochloride (1:2)
裝 遵照實例10所述概略程序標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用{1-[3-(1,1_二氟_乙基)_ 苯基]-1Η-咪唑-4-基卜曱醇與亞磺醯氣反應,然後與味啥及 氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>2〇〇<t 分解(曱醇/乙醚),MS: m/e=303 (M+H+). 實例149 JJj-°米。坐 ’ 1-ΓΠ-Γ3-Π.1-二氟乙基唑岫-4-芊] _曱基1-2-甲基-,鹽酸鹽Π:2) 訂The title compound was obtained as an off-white crystalline material according to the procedure outlined in Example 10, which was obtained by first using {1-[3-(1,1-difluoro-ethyl)-phenyl]-1Η-imidazole- 4-Gipoxime is reacted with sulfinium gas and then reacted with miso and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point > 2 〇〇 < t decomposition (sterol / diethyl ether), MS: m / e = 303 (M + H +). Example 149 JJj-° m. Sit ’ 1-ΓΠ-Γ3-Π.1-difluoroethyloxazole-4-芊] _mercapto 1-2-methyl-, hydrochloride Π: 2)
k 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用{1-[3-(ι,ι_二氟_乙基)_ 4-氟-苯基]-1Η-咪唑-4-基}-曱醇與亞磺醯氣反應,然後與2_ 甲基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。 ’溶點 >200°C 分解(曱醇/ 乙謎),MS: m/e=321 (Μ+Η+)。 實例150 1-【3-(1,1-二氟-乙基)-4-氟-苯某1-4-°米吐-1-某甲某_1只-〇半地 鹽酸鹽Π:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用{1-[3-(1,卜二氟-乙基)_ 4-氟-苯基]-1Η-咪唑-4-基卜甲醇與亞磺醯氣反應,然後與咪 唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點 -80- 本故張尺度適用中國國家標準(CNS)A4規格(210X297公爱) 1328584 A7 __B7 五、發明説明(77 ) >200°C 分解(甲醇/乙醚),MS: m/e=307 (M+H+). 實例151 .1H -味吐》1-丨丨1-丨3-(~1,1·二氣乙基)-4 -氣笨基〗-1{^-°米唾-4 -基1 甲基1-2-乙基-,鹽酸鹽Π:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用{卜[3-(1,1-二氟-乙基)· 4-氟-苯基]-1H-咪唑-4-基}-甲醇與亞磺醯氣反應,然後與2_ 乙基味咬及氫化納反應,接著為層析術及鹽酸鹽之結晶。 熔點 >200°C 分解(曱醇 / 乙醚),MS: m/e=335 (M+H+)。 實例152 _1Η-°米啥’ 異丙基笨基米吐-4-基甲某1-2-甲 基-,鹽酸鹽(1:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用[1-[3-(異丙基_笨基)_ 1H-咪咬-4-基]-曱醇與亞績醯氣反應’然後與2·曱基σ米嗅及 氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>2〇〇<>c 分解(曱醇/乙醚),MS: m/e=281 (M+H+)。 實例153 * jjj-咪唑’ 2-乙基-1_丨丨1-Π-異丙基茉某•咪唑·4其]甲芊 ,鹽酸鹽(1:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用[1-[3-(異丙基_苯基)_ 1Η-咪唑-4-基]-甲醇與亞磺醯氣反應,然後與2_乙基咪唑及 氫化鈉反應’接著為層析術及鹽酸鹽之結晶。炫點>2〇〇β(:k Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material obtained by first using {1-[3-(ι,ι-difluoro-ethyl)-4-fluoro-phenyl] -1Η-imidazol-4-yl}-nonanol is reacted with sulfinium gas and then reacted with 2-methylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. 'Solution point > 200 ° C decomposition (sterol / B puzzle), MS: m / e = 321 (Μ + Η +). Example 150 1-[3-(1,1-Difluoro-ethyl)-4-fluoro-benzene 1-4-°m 吐-1-A certain 1-1 only 〇 〇 地 盐 盐 Π: 2) Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material, which was obtained by first using {1-[3-(1,difluoro-ethyl)-4-fluoro-phenyl] -1Η-imidazole-4-ylbupropanol is reacted with sulfinium gas, then with imidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride salt. Melting point -80- The standard of Zhang is applicable to China National Standard (CNS) A4 specification (210X297 public) 1328584 A7 __B7 V. Invention description (77) >200°C decomposition (methanol/diethyl ether), MS: m/e= 307 (M+H+). Example 151.1H - taste spit" 1-丨丨1-丨3-(~1,1·digasethyl)-4 - gas stupidity -1{^-°m saliva -4 -yl 1 methyl 1-2-ethyl-, hydrochloride Π: 2) Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material obtained by first using -(1,1-Difluoro-ethyl)·4-fluoro-phenyl]-1H-imidazol-4-yl}-methanol is reacted with sulfinium gas, and then reacted with 2_ethyl bite and sodium hydride, This is followed by chromatography of the chromatogram and the hydrochloride. Melting point > 200 ° C decomposition (sterol / diethyl ether), MS: m / e = 335 (M + H +). Example 152 _1 Η ° ° 异 异 异 笨 笨 基 基 吐 基 基 基 基 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 1-2 Sexual Substance Acquired 'The method of obtaining it by first using [1-[3-(isopropyl-phenyl)- 1H-methylene-4-yl]-sterol to react with the sub-gas” and then with 2·曱The base sigma scent and sodium hydride reaction, followed by chromatography and crystallization of the hydrochloride. Melting point > 2 〇〇 <> c decomposition (sterol / diethyl ether), MS: m / e = 281 (M + H +). Example 153 * jjj-imidazole '2-ethyl-1_丨丨1-Π-isopropyl 莫 • imidazole · 4 ] 芊 芊, hydrochloride (1:2) according to the general procedure described in Example 10, The title compound is obtained as an off-white crystalline material, which is obtained by first reacting [1-[3-(isopropyl-phenyl)- 1 Η-imidazol-4-yl]-methanol with sulfinium gas, and then 2_ethylimidazole and sodium hydride reaction' followed by chromatography and crystallization of the hydrochloride. Hyun Point >2〇〇β(:
1328584 發明説明 分解(曱醇/乙謎),MS: m/e=295 (M+H+)。 實例15 4 4-味吐-1-基甲基-1-(3-(異丙基-笼基)_ih-p米咕镑g定鹽(1:2) 遵照實例10所述概略程序’標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用異丙基-苯基)· 1H·咪唑-4-基]•曱醇與亞磺醯氣反應,然後與咪唑及氫化鈉 反應,接著為層析術及鹽酸鹽之結晶。炫點2〇〇_2〇6°C (曱醇 /乙謎),MS: m/e=267 (M+H+)。 實例155 jH-°米吐,2-曱基-Ι-fri-(莫-2-某)唾-4-某1甲基1-,鹽 酸鹽(1:2) 遵照實例10所述概略程序’標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用(1 _茬_2_基_ 1H-咪唑-4-基 )-甲醇與亞磺醯氣反應,然後與2-甲基咪唑及氫化鈉反應, 接著為層析術及鹽酸鹽之結晶。熔點247-248°C (曱醇/乙醚) ,MS: m/e=288 (M+H+)。 實例156 _1技_-咪唑’ 丄3 -溴-4-氟茉某V1H-哞岫-4-某1甲基1-2_乙 基-,鹽酸鹽(1:2) 遵照實例10所述概略程序’標題化合物呈白色結晶性物質 其獲得方式係經由首先使用[1-(3-漠-4-氟-苯基)-1H-味吐-4-基]-曱醇與亞磺醯氣反應’然後與2-乙基咪唑及氫化鈉反應 ,接著為層析術及鹽酸鹽之結晶。熔點238-239eC (甲醇/乙 謎),MS: m/e=349 (M+H+)。 • 82. 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 13285841328584 DESCRIPTION OF THE INVENTION Decomposition (sterol/accuracy), MS: m/e = 295 (M+H+). Example 15 4 4-Tat-1-ylmethyl-1-(3-(isopropyl-cage)_ih-p m.p. g. salt (1:2) according to the procedure outlined in Example 10 The compound is obtained as an off-white crystalline material obtained by first reacting with sulfinium gas using isopropyl-phenyl)·1H·imidazol-4-yl]-nonanol and then reacting with imidazole and sodium hydride, followed by For the chromatography and the crystallization of the hydrochloride. Hyun point 2〇〇_2〇6°C (sterol/B puzzle), MS: m/e=267 (M+H+). Example 155 jH-° rice vomit, 2-mercapto-purine-fri-(Mo-2-) sal-4-a-1 methyl 1-, hydrochloride (1:2) according to the procedure outlined in Example 10 'The title compound is obtained as a white crystalline material' obtained by first reacting (1 _茬_2_yl-1H-imidazol-4-yl)-methanol with sulfinium gas and then with 2-methylimidazole And sodium hydride reaction, followed by chromatography and crystallization of the hydrochloride. Mp 247-248 ° C (decyl alcohol / diethyl ether), MS: m / e = 288 (M+H+). Example 156 _1 _ _ imidazole ' 丄 3 - bromo-4-fluoro gamma V1H- 哞岫 -4- 1 methyl 1-2 ethyl, hydrochloride (1: 2) according to Example 10 The rough procedure 'the title compound is a white crystalline material obtained by first using [1-(3-Iso-4-fluoro-phenyl)-1H-miso-4-yl]-nonanol and sulfoximine gas. The reaction 'reaction then reacts with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 238-239eC (methanol / hexane), MS: m/e = 349 (M+H+). • 82. This paper scale applies to the Chinese National Standard (CNS) A4 specification (210X 297 mm) 1328584
實例157 . IH:咪唑,l-JLLi^g-溴-4·氣茉基viH-唑岵-4-芊]甲某]_2_甲 基-,鹽酸鹽n:7丨 遵照η例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[1_(3_溴_4_氟_笨基)_1Η_ 咪哇-4-基]-曱醇與亞磺醯氣反應,然後與2_甲基咪唑及氫 化鈉反應’接著為層析術及鹽酸鹽之結晶。溶點232_233°C( 曱醇/乙醚),MS: m/e=335 (M+H+)。 實例158 iz(3-溴-4-氟-笨某咪唑-i_某甲基·1Η-咄吔轉酩鑲 遵照貝例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[1-(3-溴_4-氟-笨基)-1Η-味唾-4-基]-甲醇與亞磺醯氣反應’然後與咪唑及氫化納反 應’接著為層析術及鹽酸鹽之結晶。炫點229-23(TC (曱醇/ 乙醚),MS: m/e=321 (Μ+Η+)。 實例159Example 157. IH: imidazole, l-JLLi^g-bromo-4·gumyl viH-oxazole-4-芊]methyl]_2_methyl-, hydrochloride n:7丨 according to η example 10 The schematic procedure is as follows. The title compound is obtained as a white crystalline material obtained by first using [1_(3_bromo-4-fluoro-indolyl)_1Η_imivor-4-yl]-sterol and sulfinamide. The reaction is then reacted with 2-methylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 232_233 ° C (nonanol / diethyl ether), MS: m / e = 335 (M + H +). Example 158 iz (3-bromo-4-fluoro-bung imidazole-i-methyl- 1 Η-咄吔 酩 酩 In accordance with the general procedure described in Example 10, the title compound was obtained as a white crystalline material. By first reacting [1-(3-bromo-4-fluoro-styl)-1Η-sodium-4-yl]-methanol with sulfinium gas and then reacting with imidazole and sodium hydride, followed by chromatography Crystallization of hydrochloride and hydrochloride. Hyun spot 229-23 (TC (nonanol / diethyl ether), MS: m / e = 321 (Μ + Η +). Example 159
jjj.-咪唑,1-ΓΓΜ3-乙某笑某VlH-°朵唑-4-其1甲某1_2·甲其_ ,鹽酸鹽(1:2V 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1-(3-乙基-笨基)·1Η· 咪唑-4-基]-甲醇與亞磺醯氣反應,然後與2·甲基咪唑及氫 化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點>2〇(TC分 解(甲醇/乙醚),MS: m/e=267 (M+H+)。 實例160 -83- 本纸張尺度適用中國國家標準(CMS) A4規格(210 X 297公釐) 1328584 A7 _____B7 五、發明説明(8Q~Γ ~ 1H-咪唑,2-乙基-1-丨Π-Γ3·已篡芄某V1H-哚唑·4-篡1甲其卜 ,鹽酸鹽(1:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1-(3-乙基-苯基)·1Η· 咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2_乙基咪唑及氫 化納反應,接著為層析術及鹽酸鹽之結晶。溶點>2〇〇〇c分 解(曱醇/乙醚),MS: m/e=281 (M+H+)。 實例161 1-(3-乙基-笨基)-4-°米啥-l-基甲基-iH-味嗤鹽酿_ 遵照實例10所述概略程序’標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1_(3_乙基-苯基)·1Η_ °米唾-4-基]-甲醇與亞績醒氣反應’然後與味唾及氩化納反 應’接著為層析術及鹽酸鹽之結晶。熔點 > 丨9〇ec分解(曱醇/ 乙醚),MS: m/e=253 (M+H+)。 實例162 JH-咪唑’ 1-ΓΓ1-Ρ-環丙某茉基)_1H-哚碎_4_其]甲早卜0甲 基-,镑酸镑(〗·?—) 遵照實例10所述概略程序,標題化合物呈淺褐色結晶性物 質獲得’其獲得方式係經由首先使用[1_(3·環丙基笨基 1H-咪唑-4-基]-甲醇與亞磺醯氯反應,然後與2_曱基咪唑及 氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點174_175 °C (甲醇/乙醚),MS: m/e=279 (M+H+)。 實例163 ,1-ΓΓ1-Γ3-二氟甲基·4_氟苯基)·1Η_哔味_4·某1甲美 本紙張尺度適財s s家標準(CNS) Α4規格(21GX 297公爱) -84- 1328584 A7Jjj.-Imidazole, 1-ΓΓΜ3-Bie, a certain VlH-°-oxazole-4-a-1, a 1_2, a acetonide, hydrochloride (1:2V according to the schematic procedure described in Example 10, the title compound is grayish white The crystalline material is obtained by first reacting with sulfinium gas using [1-(3-ethyl-phenyl)·1Η·imidazol-4-yl]-methanol, and then with 2·methylimidazole and Sodium hydride reaction 'subsequent to chromatography and crystallization of the hydrochloride salt. Melting point > 2 〇 (TC decomposition (methanol / diethyl ether), MS: m / e = 267 (M + H +). Example 160 - 83 - paper Zhang scale applies Chinese national standard (CMS) A4 specification (210 X 297 mm) 1328584 A7 _____B7 V. Invention description (8Q~Γ ~ 1H-imidazole, 2-ethyl-1-丨Π-Γ3·已篡芄V1H-carbazole, 4-indole, chlorate (1:2) The title compound was obtained as an off-white crystalline material according to the procedure outlined in Example 10, which was obtained by first using [1-(3). -Ethyl-phenyl)·1Η·Imidazol-4-yl]-nonanol is reacted with sulfinium gas, then reacted with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point > 2〇〇〇c decomposition (sterol / Ether), MS: m/e = 281 (M+H+). Example 161 1-(3-ethyl-phenyl)-4-[upsilon]-l-ylmethyl-iH- miso salt brewing _ The schematic procedure described in Example 10, the title compound, was obtained as an off-white crystalline material obtained by first using [1_(3-ethyl-phenyl)·1Η_°m-4-yl]-methanol and awakening. The gas reaction 'then reacts with the saliva and the argon nanon' followed by the chromatography and the crystallization of the hydrochloride. Melting point > 丨9〇ec decomposition (sterol/ether), MS: m/e=253 (M+ H+). Example 162 JH-imidazole '1-ΓΓ1-Ρ-cyclopropanyl-methyl}_1H-mashed _4_其]甲早卜0 methyl-, pound acid pound (〗 〖?) Follow the example 10 The summary procedure, the title compound is obtained as a light brown crystalline material, which is obtained by first reacting [1_(3·cyclopropyl]1H-imidazol-4-yl]-methanol with sulfinium chloride, and then Reaction with 2_mercaptoimidazole and sodium hydride, followed by crystallization of the chromatographic and hydrochloride salt. mp 174 _ 175 ° C (methanol / diethyl ether), MS: m/e = 279 (M+H+). -ΓΓ1-Γ3-difluoromethyl·4_fluorophenyl)·1Η_哔味_4·一一甲美本纸Scale Fits s s home standard (CNS) Α 4 specifications (21GX 297 public) -84- 1328584 A7
1-2-甲基-,鹽醴鞔Π:2| 遵照實例10所述概略程序,標題化合物呈白色結晶性物 獲得,其獲得方式係經由首先使用^气^二氟甲美— 基)-ιηκ4_基]-曱醇與亞續醒氣反應,然後與2·甲 唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點: 223-225 C 分解(甲醇/乙鍵),ms: m/e=306 (Μ+)。 實例164 ’ 1·丨丨 氟笨基咄地 1-2-乙基-,鹽酸轉 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用Η-ρ —二氟甲基_4氟笨 基)-1Η·咪唑-4-基]-甲醇與亞磺醯氯反應,然後與2乙基咪 嗤及鼠化納反應’接著為層析術及鹽酸鹽之結晶。溶點 229-232°C 分解(曱醇/ 乙醚),MS: m/e=320 (Μ + )。 實例165 丄二(3-二氟曱基-4-敗-装基)-4-°采<-1-基甲基1-1 Η-ρ米唾鹽酸肄 n:2) 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[1-(3-二氟曱基-4-氟-苯 基)-1Η-咪唑-4-基]-甲醇與亞磺醯氯反應,然後與咪唑及氫 化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點23 9-24 1 eC 分解(曱醇/乙謎)’ MS: m/e=292 (M+)。 實例166 j_H-咪唑,2-乙基-l-m-n-f甲篡銪、艾基ΜΗ-咪唑-4-基1甲 -85- 本紙張尺度適用中國國豕標準(CNS) A4規格(2i〇x 297公爱)1-2-Methyl-, salt hydrazine: 2| The title compound was obtained as a white crystalline material according to the procedure outlined in Example 10, which was obtained by first using dimethyl fluoromethanone- Ιηκ4_基]-sterol reacts with a suffocating gas, and then reacts with 2.····················· Melting point: 223-225 C Decomposition (methanol/ethyl bond), ms: m/e = 306 (Μ+). Example 164 '1. 丨丨 丨丨 笨 咄 1-2 1-2-ethyl-, hydrochloric acid was transferred according to the general procedure described in Example 10, the title compound was obtained as a white crystalline material obtained by first using Η-ρ. Difluoromethyl _4 fluorophenyl]-1 Η imidazolyl-4-yl]-methanol is reacted with sulfinium chloride and then reacted with 2 ethyl hydrazine and mouse sodium. 'Next to chromatography and hydrochloride Crystallization. Melting point 229-232 ° C decomposition (sterol / ether), MS: m / e = 320 (Μ + ). Example 165 Bis(3-difluoroindolyl-4-fail-loading)-4-°Chosing <-1-ylmethyl1-1 Η-ρm salic acid hydrazine n: 2) According to Example 10 Briefly described, the title compound is obtained as a white crystalline material obtained by first using [1-(3-difluoroindolyl-4-fluoro-phenyl)-1Η-imidazol-4-yl]-methanol with The sulfinium chloride is reacted and then reacted with imidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 23 9-24 1 eC Decomposition (sterol/accuracy) ' MS: m/e = 292 (M+). Example 166 j_H-imidazole, 2-ethyl-lmnf formazan, acetonide-imidazole-4-yl 1 A-85- This paper scale applies to China National Standard (CNS) A4 specification (2i〇x 297 public )
裝 訂Binding
1328584 A7 B7 五、發明説明(82 ) :- 基,鹽酸镑(Ί·7| 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用π_(3_?基硫烧基-苯 基)-m-味唾-4-基]-甲醇與亞續醯氯反應,然後與2·乙基味 唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點 >200 C 分解(曱醇 / 乙醚),ms: m/e=299 (M+H+)。 實例167 迎-哞唑,2-甲基-1-ΙΙ1ι£1^(甲基硫)笨基1-1H-呻以―/)健]甲 基1-,鹽酸鹽Π:2、 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[丨气^曱基硫烷基-苯 基)-1Η-咪唑-4-基]·甲醇與亞磺醯氣反應,然後與2_甲基咪 唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點 >200eC 分解(甲醇/乙醚),MS: m/e=285 (Μ+Η+) » 實例168 今二味。坐-1-基甲基·1_(3_甲基硫烷基-茉基)_1Η•咗a碰研略 (\:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用[1-(3-甲基硫烷基_苯 基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與咪唑及氫 化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>2〇〇 t分 解(曱醇/乙醚),MS: m/e=271 (M+H+)。 實例169 1_H-咪唑’ 2-乙某-1-丨「1-丨3-(三氟甲氣)茉某·)-1Η•呼毗] -86- 本紙張尺度遴用中國國家標準(CNS) Α4規格(210Χ297公釐) 1328584 A7 ___B7 五、發明説明(84 ) 1-,鹽酸肄Π:2〉 遵照實例10所述概略程序’標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用^气弘乙烯基-苯基)1Η_ 畔嗤-4-基]-曱醇與亞磺醯氣反應,然後與2_曱基咪唑及氫 化納反應’接著為層析術及鹽酸鹽之結晶。溶點207—208 分解(甲醇/乙謎),MS: m/e=265 (M+H+)。 實例173 1H-咪唑,1-ΓΓ1-(3-氣笨基)-1Η-咪唑-4-其1甲早飞,曱其, 鹽酸鹽Π:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用[丨气^氣·苯基)_1Η味 唑-4-基]•甲醇與亞磺醯氯反應,然後與2_曱基咪唑及氫化 納反應’接著為層析術及鹽酸鹽之結晶。熔點>2〇〇t:分解( 曱醇/乙醚),MS: m/e=273 (M+H+)。 實例174 米唾’ 1-『『1-(3·氣笨基基1曱義1-2,其 , 鹽酸鹽Π:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1_(3_氣_苯基)_115_咪 嗅-4-基]-曱醇與亞磺酿氯反應,然後與2_乙基咪唑及氫化 納反應,接著為層析術及鹽酸鹽之結晶。溶點>2〇〇^分解( 曱醇/乙醚),MS: m/e=287 (M+H+)。 實例175 1-(3 -氣-笨基)-4-°米峻-1-基甲基-1H-节唾镑酷 -88 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 _____B7 五、發明説明(85~) ~ ' 遵照實例1 〇所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1_(3_氣_苯基)_11€_咪 唑-4-基]-曱醇與亞磺醯氯反應,然後與咪唑及氫化鈉反應 ’接著為層析術及鹽酸鹽之結晶。溶點>2001分解(曱醇/乙 醚),MS: m/e=259 (M+H+)。 實例176 1H-味°坐,1-171-(3-蛾笨基喷唾-4-基1甲某1-2 -甲基-, 鹽酸鹽(1:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用苯基)_11{_咪 唑-4-基]-曱醇與亞續醯氣反應,然後與2_曱基咪嗅及氫化 鈉反應,接著為層析術及鹽酸鹽之結晶。炫點>222 °c分解( 曱醇/乙醚),MS: m/e=365 (M+H+)。 實例177 1H-咪。坐’ 2·乙基-1-丨丨1-『3-氟~5-(三氟甲基)芏篡·|·1Η•咪唑· 4-基1甲基1-,鹽酸鹽(1:2、 遵照實例10所述概略程序’標題化合物呈白色、結晶性物質 獲得’其獲得方式係經由首先使用[^-(3-氟_5·三氟甲基-苯 基)-1Η-咪唑-4-基]-甲醇與亞磺醯氣反應,然後與2_乙基咪 吐及風化納反應’接著為層析術及鹽酸鹽之結晶。溶點. 243-244°C (甲醇/乙醚),MS: m/e=338 (Μ+)。 實例178 1Η-味吐,1-rn-f3-氟-5-(三氩甲基)茉基1-1H-。朵咄-4-華1甲 基1-2-甲基-,续酸鹽π:2) -89- 本紙張尺度適用中國國家標準(CNS> Α4規格(210Χ 297公釐) 1328584 A7 B7 五 發明説明 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使ffl[1_(3·曱氧_5_三氟甲 基·苯基)·1Η-咪唑-4·基]•曱醇與亞磺醯氯反應,然後與2_乙 基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔 點 245-246°C (曱醇/乙越),MS: m/e=350 (Μ+)。1328584 A7 B7 V. INSTRUCTIONS (82) :- Base, Hydrochloric acid Pound (Ί·7| According to the rough procedure described in Example 10, the title compound is obtained as an off-white crystalline material] obtained by first using π_(3_? Sulfur-phenyl-phenyl)-m-sodium-4-yl]-methanol is reacted with chlorinated chlorobenzene and then reacted with 2-ethyl sulphonate and sodium hydride, followed by chromatography and crystallization of the hydrochloride Melting point > 200 C decomposition (sterol / diethyl ether), ms: m / e = 299 (M + H +). Example 167 ox-carbazole, 2-methyl-1-ΙΙ1ι£1^ (methyl sulphur) Stupid base 1-1H-呻 is ―/) 健]methyl 1-, hydrochloride Π: 2, according to the general procedure described in Example 10, the title compound is obtained as an off-white crystalline material, obtained by first use [ Xenon thiol-alkyl-phenyl)-1 Η-imidazol-4-yl]·methanol is reacted with sulfinium gas, then reacted with 2-methylimidazole and sodium hydride, followed by chromatography and hydrochloric acid Crystallization of salt. Melting point > 200eC decomposition (methanol / ether), MS: m / e = 285 (Μ + Η +) » Example 168.坐-1-ylmethyl·1_(3_methylsulfanyl-methyl)_1Η•咗a ( (: 2) Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material. It is obtained by first reacting [1-(3-methylsulfanyl-phenyl)-1Η-imidazol-4-yl]-nonanol with sulfinium gas and then reacting with imidazole and sodium hydride, followed by For the chromatography and the crystallization of the hydrochloride. Melting point > 2 〇〇 t solution (sterol/diethyl ether), MS: m/e = 271 (M+H+). Example 169 1_H-imidazole '2-B--1-丨" 1-丨3-(trifluoromethane) Mo Mo·)-1Η•呼倍] -86- This paper scale adopts Chinese National Standard (CNS) Α4 specifications (210Χ297 mm) 1328584 A7 ___B7 V. Description of the invention (84) 1-, guanidine hydrochloride: 2> According to the general procedure described in Example 10, the title compound was obtained as a white crystalline material, which was obtained by first using ^气弘vinyl-phenyl) 1Η_ 嗤-4-yl]-nonanol reacts with sulfinium gas, and then reacts with 2_mercaptoimidazole and sodium hydride, followed by chromatography and crystallization of hydrochloride Melting point 207-208 decomposition (methanol / sigma), MS: m / e = 265 (M + H +). Example 173 1H-imidazole, 1-indole 1-(3-indolyl)-1Η-imidazole-4 - Its 1A early flight, 曱, HCl salt: 2) Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material. The method was obtained by first using [丨气^气·phenyl) _1 oxazol-4-yl]•methanol is reacted with sulfinium chloride and then reacted with 2_mercaptoimidazole and sodium hydride. Then followed by chromatography of chromatographic and hydrochloride. Melting point > 2〇〇t: decomposition (sterol / Ether), MS: m/e = 273 (M+H+). Example 174 m. s. 1 - 『1 - (3· 笨 基 基 基 基 基 1-2, 1-2, HCl salt: 2) Following the general procedure described in Example 10, the title compound was obtained as an off-white crystalline material obtained by first using [1_(3_qi_phenyl)_115_imol-4-yl]-sterol and sulfinic acid. Chlorine reaction, then reacted with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of hydrochloride. Melting point > 2 〇〇 ^ decomposition (sterol / ether), MS: m / e = 287 (M+H+). Example 175 1-(3- gas-stupyl)-4-°m-kilo-1-ylmethyl-1H-segmented pound-cool -88 - This paper scale applies to Chinese National Standard (CNS) A4 size (210 X 297 mm) 1328584 A7 _____B7 V. Description of invention (85~) ~ 'According to the rough procedure described in Example 1 ,, the title compound was obtained as an off-white crystalline material obtained by first using [1_( 3_Gas_Phenyl)_11€_Imidazol-4-yl]-nonanol is reacted with sulfinium chloride and then reacted with imidazole and sodium hydride' followed by chromatography and crystallization of the hydrochloride salt. Decomposition 2001 (sterol/diethyl ether), MS: m/e = 259 (M+H+). Example 176 1H-flavored sitting, 1-171-(3- moth-salt spit-4-yl 1 methyl 1-2-methyl-, hydrochloride (1:2) Follow the general procedure described in Example 10. The title compound is obtained as an off-white crystalline material obtained by first reacting phenyl)_11{_imidazol-4-yl]-nonanol with a subtropic gas, and then with 2 曱 咪 咪 及 and sodium hydride The reaction is followed by chromatography and crystallization of the hydrochloride salt. Hyun spot > 222 °c decomposition (sterol / ether), MS: m / e = 365 (M + H +). Example 177 1H-Mi. Sit '2·Ethyl-1-丨丨1-“3-fluoro-5-(trifluoromethyl)芏篡·|·1Η•imidazole·4-yl 1methyl 1-, hydrochloride (1: 2. Following the general procedure described in Example 10, the title compound was obtained as a white, crystalline material obtained by first using [^-(3-fluoro-5·trifluoromethyl-phenyl)-1Η-imidazole- 4-Methoxy]-methanol reacts with sulfinium gas and then reacts with 2-ethyloxypropene and weathered ammonia' followed by chromatography and crystallization of the hydrochloride. Melting point. 243-244 ° C (methanol / ether ), MS: m/e = 338 (Μ+). Example 178 1 Η-taste, 1-rn-f3-fluoro-5-(tris-arylmethyl)methyl 1-1H-. 1 methyl 1-2-methyl-, continuous acid π: 2) -89- This paper scale is applicable to Chinese national standards (CNS> Α4 specification (210Χ 297 mm) 1328584 A7 B7 Five invention descriptions as described in Example 10 For the general procedure, the title compound is obtained as an off-white crystalline material obtained by first making ffl [1_(3·曱____trifluoromethylphenyl)·1Η-imidazole-4·yl]• sterol Reacts with sulfinium chloride, then reacts with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride Melting point 245-246 ° C (sterol / ethylene), MS: m / e = 350 (Μ +).
味唑-1-某甲基-1 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用[1-(3-甲氧·5_三氟曱基_ 笨基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣友應,然後與咪唑及 氫化鈉反應,接著為層析術及鹽酸鹽之結晶,熔點244_246 °C 分解(甲醇/乙醚),MS: m/e=322 (Μ+)。 實例183 jji-咪唑’ 第三丁基笨基V1H-唑呤-4-甚1甲早卜?·甲 基;I-,鹽酸镑(1:2) 遵照實例10所述概略程序,標題化合物呈灰白色結晶性物 質獲得’其獲得方式係經由首先使用[1-(3-第三丁基_苯基 1H-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2_甲基味唾及 虱化鈉反應’接著為層析術及鹽酸鹽之結晶。炫點>2〇〇。〇 分解(甲醇/乙謎),MS: m/e=295 (Μ+Η+)。 實例184 1_Η-咪唑,1-『Π-(3-第三丁基茉某V1H-咮岵-zu某1甲某μ2_甲 基1-2-乙某-,鹽酸鹽π:2) -91 - 本紙張尺度適用中圉國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(88 ) 遵照實例10所述概略程序,標題化合物呈淺褐色結晶性物 質獲得’其獲得方式係經由首先使第三丁基_苯基)_ 1H-咪唾·4·基]-曱醇與亞磺醯氣反應,然後與2_乙基咪唑及 氫化納反應’接著為層析術及鹽酸鹽之結晶。炫點2〇5。匚分 解(甲醇/乙驗),MS: m/e=309 (M+H+)。 實例185 1-(3-第三丁某-笑基)-4-咪唑-1·某甲某·1Η•咪唓驄酸鹽π:2、 遵照實例10所述概略程序’標題化合物呈灰白色結晶性物 質獲得,其獲得方式係經由首先使用[1-(3-第三丁基_苯基)_ 1H-咪唑-4-基]-甲醇與亞磺醯氣反應,然後與咪唑及氫化鈉 反應’接者為層析術及鹽酸鹽之結晶。炫點>200*^分解(甲 醇/乙醚)’ MS: m/e=281 (M+H+)。 實例186 j_H-畔.嗤,氣·4·(三裔曱氣)苯基μΐΗ二咪唑_4其1甲 基1-2-甲基-,鹽酸鹽(1:2、 遵照Λ例1 〇所述概略程序’標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用[i-p-氣三氟曱氧·笨 基)-1 Η-D米唾-4-基]-曱醇與亞項醯氣反應,然後與甲基味 唑及氫化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點 221-222°C (甲醇/乙謎),MS: m/e=357 (M+H+) 〇 實例187Isoxazole-1-methyl-1 was obtained according to the general procedure described in Example 10, and the title compound was obtained as a white crystalline material, which was obtained by first using [1-(3-methoxy-5-trifluoromethyl) Stupid)-1Η-imidazol-4-yl]-nonanol and sulfinamide, then react with imidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride, melting point 244_246 °C decomposition (methanol) /ether), MS: m/e = 322 (Μ+). Example 183 jji-imidazole 'T-butyl phenyl group V1H-oxazolyl-4- even 1 Azyl? Methyl group; I-, hydrochloric acid pound (1:2) Following the general procedure described in Example 10, the title compound was The off-white crystalline material is obtained in a manner obtained by first reacting [1-(3-tert-butyl-phenyl 1H-imidazol-4-yl)-nonanol with sulfinium gas, and then with 2-methyl The taste of saliva and sodium sulphate' followed by the crystallization of the chromatographic and hydrochloride. Hyun point > 2 〇〇. 〇 decomposition (methanol / sigma), MS: m / e = 295 (Μ + Η +) Example 184 1_Η-imidazole, 1-"Π-(3-t-butyl-methyl-V1H-咮岵-zu-1, a certain μ2_methyl1-2-ethyl-, hydrochloride π:2) -91 - This paper size is applicable to the Chinese National Standard (CNS) Α4 specification (210 X 297 mm) 1328584 A7 B7 V. Inventive Note (88) According to the general procedure described in Example 10, the title compound is obtained as a light brown crystalline material. 'The method of obtaining is by first reacting the third butyl-phenyl)-1H-imin-4-yl]-sterol with sulfinium gas and then reacting with 2-ethylimidazole and sodium hydride. Chromatography and crystallization of hydrochloride. Hyun point 2〇5.匚 decomposition (methanol/b test), MS: m/e = 309 (M+H+). Example 185 1-(3-Terti-l-yl)-4-imidazole-1·A certain ·1Η•imidic acid π:2, according to the general procedure described in Example 10, the title compound was grayish white crystal Obtaining substances obtained by first reacting with sulfinium gas using [1-(3-t-butyl-phenyl)-1H-imidazol-4-yl]-methanol and then reacting with imidazole and sodium hydride 'The receiver is the crystal of chromatography and hydrochloride. Hyun point > 200*^ decomposition (methanol/diethyl ether)' MS: m/e = 281 (M+H+). Example 186 j_H-side. 嗤, gas · 4 · (Sanzu 曱 )) phenyl ΐΗ ΐΗ diimidazole _ 4 its 1 methyl 1-2-methyl-, hydrochloride (1: 2, in accordance with the example 1 〇 The summary procedure 'the title compound is obtained as a white crystalline material' is obtained by first using [ip-gas trifluoroantimony·stupyl)-1 Η-D m-sial-4-yl]-sterol and sub The helium gas reacts and then reacts with methyl oxazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 221-222°C (methanol/j-mystery), MS: m/e=357 (M+H+) 实例 Example 187
1Η-咪唑,1-Γ 基卜2_乙基·, 遵照實例1 〇所述概略程序,標題化合物呈白色結晶性物質 -92· 1328584 A7 B71Η-imidazole, 1-indoleyl 2_ethyl·, according to the schematic procedure described in Example 1 ,, the title compound is white crystalline material -92· 1328584 A7 B7
獲得,其獲得方式係經由首先使用[1-(3-氣·4-三氟曱氧_苯 基)-1Η-咪唑-4-基]-曱醇與亞磺醯氯反應’然後與2乙基味 唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點 >250°C (曱醇/乙醚),MS: m/e=370 (Μ+)。 實例188 氣-4-三氟甲氣-苯基)-4-咪唑-1-基甲基-1Η-味咬轉酿睡 (1:2) 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[1-(3-氯-4-三氣甲氧_苯 基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與咪唑及氫 化鈉反應’接著為層析術及鹽酸鹽之結晶。炫點2丨2-213( 甲醇/乙鰱),MS: m/e=342 (M+)。 實例189 Ιϋ-咪嗤’ 1-ΓΠ-Γ3-〔二氟曱氣)茉某i_iH-咪唑-4-篡1甲甚1-7-乙基-,鹽酸轉 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用[1-(3-二氟曱氧·苯基)_ 1H-咪嗤-4-基]-曱醇與亞磺醯氣反應,然後與2_乙基咪唑及 氫化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點216_217 °C (甲醇/乙醚),MS: m/e=319 (M+H+)。 實例190 jjj·咪唑,二氣甲氣)袈某i_iH-咪唑-4-其1甲基1-2-王基-,鹽酸鹽Π:2) 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 -93- 本紙張尺度適用巾g g家料(CNS) Α4規格(21Q χ297公爱) 1328584 A7 一 B7 五、發明説明(90 ) 獲得’其獲得方式係經由首先使用[1-(3-二氟曱氧-苯基)_ 1H-咪唑-4_基]·曱醇與亞磺醯氯反應,然後與2_曱基咪唑及 氫化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點22〇·222 °C (甲醇/乙醚),MS: m,e=305 (Μ+Η+)。 實例191 ——根‘曱氣-笨基米嗤-1-基甲基- 吨暖酸鹽 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲件’其獲得方式係經由首先使用[1_(3_二氟甲氧_苯基)_ 1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與咪唑及氫化鈉 反應’接著為層析術及鹽酸鹽之結晶。炫點2〇5_2〇6。〇(曱醇 /乙醚),MS: m/e=291 (Μ+Η+)。 實例192 1_Η-°米。坐,l-rn-(U笨基)-iH-咪唑-4-某1甲Αμ2_甲某_, 鹽酸鹽Π:2) 遵照實例10所述概略程序’標題化合物呈淺褐色結晶性物 質獲得,其獲得方式係經由首先使用[丨气夂溴-苯基)_1Η•咪 唑-4-基]-甲醇與亞磺醯氣反應,然後與2_甲基咪唑及氫化 納反應’接著為層析術及鹽酸鹽之結晶。炫點205-207°C (甲 醇/乙醚),MS: m/e=317 (M+H+)。 實例193 1H-咪t 二氯甲基)苯基μ1Η咄唆_4_基1甲某ί·2_ 乙基-,鹽酸鹽(1:2) 遵照實例1 〇所述概略程序’標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使二氟甲基-苯基)_ -94- 本紙伕尺度適用中國國家標準(CNS) A4規格(210X297公釐) 裝 訂Obtained, obtained by first reacting [1-(3- gas·4-trifluorooxo-phenyl)-1Η-imidazol-4-yl]-nonanol with sulfinium chloride] and then with 2 The reaction of carbazole and sodium hydride is followed by chromatography and crystallization of the hydrochloride. Melting point > 250 ° C (nonanol / diethyl ether), MS: m / e = 370 (Μ +). Example 188 Gaso-4-trifluoromethane-phenyl)-4-imidazol-1-ylmethyl-1 oxime-flavored bite (1:2) Following the procedure outlined in Example 10, the title compound was white crystal. Obtaining substances obtained by first reacting [1-(3-chloro-4-trimethoxymethoxy-phenyl)-1Η-imidazol-4-yl]-nonanol with sulfinium gas, and then The reaction of imidazole and sodium hydride is followed by chromatography and crystallization of the hydrochloride. Hyun 2丨2-213 (methanol/acetamidine), MS: m/e=342 (M+). Example 189 Ιϋ-Mi嗤' 1-ΓΠ-Γ3-[difluoroanthracene) jasmine i_iH-imidazole-4-篡1 methyl 1-7-ethyl-, hydrochloric acid was transferred according to the general procedure described in Example 10, title The compound is obtained as a white crystalline material, which is obtained by first reacting [1-(3-difluoroindoleoxyphenyl)-1H-amido-4-yl]-nonanol with sulfinium gas, and then Reaction with 2_ethylimidazole and sodium hydride' followed by chromatography and crystallization of the hydrochloride. Mp 216-217 ° C (methanol / diethyl ether), MS: m/e = 319 (M+H+). Example 190 jjj·imidazole, dioxane gas) 袈i i_iH-imidazole-4-l 1 methyl 1-2-whenyl-, hydrochloride Π: 2) Following the general procedure described in Example 10, the title compound was white Crystalline substance-93- This paper size is suitable for towel gg home material (CNS) Α4 specification (21Q χ297 public) 1328584 A7-B7 V. Invention description (90) Obtained 'the method of obtaining it by first using [1-(3 -difluorofluorenyl-phenyl)_ 1H-imidazole-4-yl]·nonanol is reacted with sulfinium chloride and then reacted with 2_mercaptoimidazole and sodium hydride' followed by chromatography and hydrochloride crystallization. Mp 22 〇 222 ° C (methanol / diethyl ether), MS: m, e = 305 (Μ + Η +). Example 191 - Root 'helium-stupyl-mercapto-l-yl-methyl- ton-salt salt according to the general procedure described in Example 10, the title compound was obtained as a white crystalline material's method of obtaining it by first use [ 1_(3_Difluoromethoxy-phenyl)_ 1Η-imidazol-4-yl]-nonanol is reacted with sulfinium gas and then reacted with imidazole and sodium hydride' followed by chromatography and crystallization of hydrochloride . Hyun points 2〇5_2〇6. 〇 (sterol / diethyl ether), MS: m / e = 291 (Μ + Η +). Example 192 1_Η-° meters. Sit, l-rn-(U stupyl)-iH-imidazole-4-one 1 formazan μ2_甲某_, hydrochloride Π: 2) According to the general procedure described in Example 10, the title compound is a light brown crystalline material. Obtained, obtained by first reacting with sulfinium gas by [丨丨夂 bromo-phenyl)_1Η•imidazol-4-yl]-methanol, and then reacting with 2-methylimidazole and sodium hydride. Analysis and crystallization of hydrochloride. Hyun point 205-207 ° C (methanol / diethyl ether), MS: m / e = 317 (M + H +). Example 193 1H-Mi-t-dichloromethyl)phenyl μ1Η咄唆_4_yl 1 A ··2_ethyl-, hydrochloride (1:2) Following the procedure outlined in Example 1 ' Obtained as a white crystalline material obtained by first applying the Difluoromethyl-phenyl)-94-sheet size to the Chinese National Standard (CNS) A4 specification (210X297 mm).
k 1328584 A7 ____B7_ 五、發明説明(91 ~) · ^ 1H·咪唑-4-基]-曱醇與亞磺醯氯反應,然後與咪唑及氫化鈉 反應,接著為層析術及鹽酸鹽之結晶。熔點2l9_22〇=c (甲醇 /乙醚)’ MS: m/e=303 (M+H+)。 實例194 ,l-『fi-『3-(二氟甲基)笨基i-iH-啤唑_4_某1甲其卜上 曱基,鹽酸鹱 遵照貝例10所述概略程序,標題化合物呈白色結晶性物質 獲得’其獲得方式係經由首先使用[1_(3-二氟曱基·苯基)_ 1H-咪唑-4-基]-曱醇與亞磺醢氣反應,然後與2_曱基咪唑及 氫化納反應’接著為層析術及鹽酸鹽之結晶。溶點195_196 °C (曱醇/乙趟),MS: m/e=289 (M+H+) » 實例195 1-(3-二氟甲某-苯基)-4-咪唑-1-基甲基哚唑鹽酸鹽(1:2、 遵照實例10所述概略程序,標題化合物呈白色結晶性物質 獲得,其獲得方式係經由首先使用[丨—^ —二氟曱基-笨基)_ 1H-"米唾-4-基]-曱醇與亞確醒氣反應,然後與咪唑及氫化鈉 反應,接著為層析術及鹽酸鹽之結晶❶熔點216-217。(:(曱醇 / 乙謎),MS: m/e=275 (M+H+)。 實例196 ί 1-Γ1-(3,4-二氣-笨基V1H-咄吔-4-某·甲其1-1H-咪唑-2-某} 曱基-胺,鹽酸H Π 卜[1-(3,4-二氣-苯基)-iH-咪唑-4-基-曱基]-1H-咪唑-2-基}-胺 (〇·7克,2.3毫莫耳)於原曱酸三乙酯(1()毫升)之懸浮液回流 授拌2小時。反應混合物蒸發至乾,溶解於乙醇(10毫升)及 __ -95- 本纸張尺度適用中g g家標準(CNS)如規格(21QX挪公爱) 1328584 A7 ____B7 五、發明説明(92~) ' 於冰浴冷卻。加入硼氫化鈉(0 09 i克,2 4毫莫耳),讓混合 物缓慢達到2 0 C。經18小時後加入乙酸乙酯及鹽水,有機 相經分離,脫水(硫酸鈉)及濃縮。於層析術[矽膠,使用梯 度二氣甲烷至ioo〇/〇(二氯甲烷/甲醇/水性氫氧化銨=9〇:1〇:1) 洗提]後獲得標題化合物之自由態鹼。呈灰白色鹽酸鹽結晶 (0.25克,16〇/〇)。熔點>25(rc (甲醇/乙醚),Ms:爪卜如 (M+H+)。 實例197 [3-_(j.,4-二氣-苯基)-5-(2-甲基胺某_咪唑-丨_早甲篡 唑-4-基1-甲醇鹽醢镑Π ·” {1-[1-(3,4-二氣-苯基)_1Η-咪唑-4-基-曱基]-1Η_咪唑_2_基}· 甲基-胺(0.60克,1.7毫莫耳)於乙酸(7毫升)及水性曱醛(2毫 升37%溶液)於20 C搜拌96小時《反應混合物經蒸發至乾, 層析[矽膠’以梯度二氣曱烷至5〇%(二氣曱烷/曱醇/水性氫 氧化銨-90_ 10· 1)洗提]獲得標題化合物之自由態驗。結晶呈 灰白色鹽酸鹽(0.030克,5%)。熔點>180»c分解(甲醇/乙醚) ,MS: m/e=352 (M+H + )。 實例198 1H-味 __i__-演-5 -氟策基味吨-4-基1 甲基1-2-甲 基-,鹽酸鹽Π:2) 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得,獲得方式係經由[1-(3-溴-5-氟-苯基)-m-咪唑_ 4-基]-曱醇首先與亞磺醯氣反應,然後與2_曱基咪唑及氫化 鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>2〇〇π分解( -96- 本紙張尺度適用中國圉家標準(CMS) Α4規格(210X 297公釐) 1328584 A7 B7 五 發明説明( 93 甲醇/乙謎),MS: m/e=335 (M+H+)。. 實例199 1H-咪唑,1-Γ「1-(3-溴-5-氟茉某V1H-咪唑-4-某1甲某 基-,鹽酸鹽Π:2) 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得’其獲得方式係經由首先使用[1·(3_漠·5_氟_苯 基)-1Η-°米嗤-4-基]-甲醇與亞確醯氣反應,然後與2_乙基味 喷及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。溶點 >200°C 分解(甲醇/乙謎),MS: m/e=349 (Μ+Η+)。 實例200 裝 訂 臭-5 -氣-本基)-4-味唾-1-基甲某_ΐΗ-ρ米唾镑酸験 遵照實例10所述概略方法’獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用π_(3_溴·5氟苯 基)-1Η-咪唑-4-基]-甲醇與亞磺醯氣反應,然後與咪唑及氫 化納反應,接著為層析術及鹽酸鹽之結晶。熔點>2〇〇。匸分 解(曱醇/乙越),MS: m/e=321 (Μ+Η+)。 實例201 線 丰唑,1-丨Γ1-(2.2-二氟-1.3-芏并,声伤 嗤-4-基1甲基1-2-乙基-,鹽酸鹽π:2) 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得,其獲得方式係經由首先使用^·^^-二氟苯并 Π,3]二氧伍園-5·基)·1Η·«Ή·4·基]•曱醇與亞⑽氣反應, 然後與2·甲基Μ及氫化納反應,接著為層析術及鹽酸鹽 之結Wt分解(甲醇/乙越),MS: m/e=333 •97· 1328584 A7 _ 丨1 - B7 五、發明說明(94 ) (M+H+) 〇 實例202 唾’ 二氧·ι_3-茉并二氣伍囿-5-基)-1Η·咪 兔-4-基1甲皋1·2-甲某-,弯酸锂(1:2) 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得’其獲得方式係經由首先使用^-(2 2-二氟-苯并 Π,3]二氧伍園-5-基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應, 然後與2-甲基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽 之結晶。熔點>250。(:(曱醇/乙醚),MS: m/e=319 (M+H+)。 實例203 1二(.?_,2·二氟-苯并【1,31二氯任圊-5-某V4-咪唑-1-基甲基-1H-咪唑鹽酸肄Π 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得’其獲得方式係經由首先使用1^-(2,2-二氟-苯并 [1,3]二氡伍圜-5-基)·1Η-咪唑-4-基]-甲醇與亞績醯氣反應, 然後與味嗅及氫化鈉反應,接著為層析術及鹽酸鹽之結晶 。炫點 245-246°C (曱醇/ 乙趟),MS: m/e=3 19 (Μ+Η+)。 實例204 ?-f4-(2-甲基-味吐-1-基甲某球吨_ι·某μ,杏说 遵照實例10所述概略程方法,獲得標題化合物呈灰白色結 晶性物質獲得,其獲得方式係經由首先使用(奎琳_2_基_ 1H-味嗤-4-基)-甲醇與亞績酿氣反應’然後與2_甲基啼喷及 氫化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點16〇 K 乙酸乙酯/己烷),MS: m/e=290 (M+H+)。 -98- 本紙俵尺度適用中國國家標準(CNS) A4規格(210X297公萤) 1328584 A7 B7__ 五、發明説明^ ) — ~—:- 實例205 U4-〇乙棊某甲某V咪唑·1·基1·^^汰 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得’其獲得方式係經由首先使用(1_喳啉_2_*_1η_ 味咕-4-基)-甲醇與亞磺醯氯反應,然後與2_乙基咪唑及氫 化納反應’接著為層析術及鹽酸鹽之結晶。熔點>8〇β(:分解 (乙酸乙酯/己烷),MS: m/e=304 (M+H+) » 實例206 h(4-咪唑-1-基甲盖-球啥·;1_基)^杏喊 遵照實例10所述概略方法’獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用(1-喳啉_2_基-1H_ 味喷-4-基)-甲醇與亞磺醯氯反應,然後與咪唑及氫化鈉反 應’接著為層析術及鹽酸鹽之結晶。炫點>15〇。(:分解(乙酸 乙酯/己烷),MS: m/e=276 (M+H+)。 實例207 1ϋ-缔唾’ 1-丨氣-4-(三氟甲某筘)笨基卜1H-咪唑-4-基1-甲基1-2-乙某-,骧酸鹽Π:21 遵照實例10所述概略方法’獲得標題化合物呈白色結晶性 物質獲得’其獲得方式係經由首先使用[1-(3-氣-4-三氟曱基 硫烷基-苯基)-1Η-咪唑-4-基]-甲醇與亞磺醯氯反應,然後與 2-乙基咪唑及氫化鈉反應’接著為層析術及鹽酸鹽之結晶 。熔點 214-215°C (甲醇/乙醚),MS: m/e=387 (M+H+)。 實例208 1H-咪唑,1-ΓΓ1-Ρ-氣-4-(三氟甲某銪)苯篡μΐΗ-咪唑·4·某1- .99 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(96~~) 甲基1-2-甲某-,锂酸鹽(1:2) 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得,其獲得方式係經由首先使用[1-(3-氣-4-三氟甲基 硫烷基-苯基)-1Η-咪唑-4-基]•曱醇與亞磺醯氯反應,然後與 2- 甲基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶 。熔點 195-198°C (曱醇/乙醚),MS: m/e=373 (M+H+)。 實例209 1-Π-氩-4-三氟曱基硫烷基-笨基V4-°来唑-1-基甲基-1H-咪唑 鹽酸鹽Π:2) 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得,其獲得方式係經由首先使用[1 -(3-氣-4-三氟曱基 硫烧基-苯基)-1Η-°米嗤-4-基]-甲醇與亞確酿氣反應,然後與 咪唑及氫化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點 244-245°C (曱醇/乙醚),MS: m/e=359 (Μ+Η+) » 實例210 3- H-(2-乙基-咪唑-1·某甲某V咪唑-1-基1-+进 遵照實例10所述概略方法’獲得標題化合物呈灰白色結晶 性物質獲得’其獲得方式係經由首先使用(1_喳啉_3•基·1H_ 咪唑-4-基)-曱醇與亞績醯氣反應,然後與2_乙基味唑及氣 化鈉反應’接著為層析術及鹽酸鹽之結晶。熔點132_丨361 ( 乙酸乙酯 / 己烧)’ MS: m/e=304 (M+H+)。 實例211 3-『4-(2 -甲基-哺吃-1-基甲基喻峰-1_基杏说 遵照實例10所述概略程序’獲得標題化合物呈灰白色結晶 -100-k 1328584 A7 ____B7_ V. Description of the invention (91 ~) · ^ 1H·imidazol-4-yl]-nonanol reacted with sulfinium chloride, then reacted with imidazole and sodium hydride, followed by chromatography and hydrochloride crystallization. Melting point 2l9_22〇=c (methanol / diethyl ether)' MS: m/e = 303 (M+H+). Example 194, l-"fi-"3-(difluoromethyl) phenyl i-iH- oxazole _4_ 11 甲 曱 曱 ,, HCl HCl according to the general procedure described in Shell 10, the title compound Obtained as a white crystalline material's obtained by first reacting [1_(3-difluoroindolyl)phenyl-1H-imidazol-4-yl]-nonanol with sulfinium gas, and then with 2_ The mercapto imidazole and the sodium hydride reaction are followed by chromatography and crystallization of the hydrochloride. Melting point 195_196 °C (sterol/acetamidine), MS: m/e = 289 (M+H+) » Example 195 1-(3-difluoromethyl-phenyl)-4-imidazol-1-yl The carbazole hydrochloride salt (1:2, according to the general procedure described in Example 10, the title compound was obtained as a white crystalline material obtained by first using [丨-^-difluoroindolyl-stupyl)_ 1H -"M.sup.4-yl]-nonanol reacts with Qiqi and then reacts with imidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride salt, mp 216-217. (: (sterol / riddle), MS: m/e = 275 (M+H+). Example 196 ί 1-Γ1-(3,4-two-gas-stupid V1H-咄吔-4- a·A 1-1H-imidazole-2-yl} fluorenyl-amine, H Π [ [1-(3,4-di-phenyl)-iH-imidazol-4-yl-indenyl-1H-imidazole -2-yl}-amine (〇·7 g, 2.3 mmol) was refluxed for 2 hours in a suspension of triethyl orthophthalate (1 ml). The reaction mixture was evaporated to dryness and dissolved in ethanol ( 10 ml) and __ -95- This paper size applies to the gg standard (CNS) such as specifications (21QX Ngong Gong Ai) 1328584 A7 ____B7 V. Invention description (92~) ' Cooling in ice bath. Add sodium borohydride (0 09 i g, 2 4 mmol), the mixture was allowed to slowly reach 20 C. After 18 hours, ethyl acetate and brine were added and the organic phase was separated, dried (sodium sulfate) and concentrated. The ruthenium gel was obtained by using a gradient of methane methane to ioo 〇 / 〇 (dichloromethane / methanol / aqueous ammonium hydroxide = 9 〇: 1 〇: 1) eluted to give the title compound as a free base. (0.25 g, 16 〇 / 〇). Melting point > 25 (rc (methanol / diethyl ether), Ms: claws such as (M + H +). Example 197 [3-_( j., 4-diqi-phenyl)-5-(2-methylamine _imidazole-indole_early carbazole-4-yl-1-methanol 醢 Π Π ·" {1-[1-( 3,4-dioxa-phenyl)_1Η-imidazol-4-yl-indenyl]-1Η-imidazole-2-yl}·methyl-amine (0.60 g, 1.7 mmol) in acetic acid (7 mL) And aqueous furfural (2 ml 37% solution) was mixed at 20 C for 96 hours. The reaction mixture was evaporated to dryness and chromatographed [矽胶' with a gradient of dioxane to 5 % (dioxane / methanol). Aqueous Ammonium Hydroxide-90_10·1) Elution] The free title of the title compound was obtained. The crystals were obtained as pale white salt (0.030 g, 5%). Melting point > 180»c decomposition (methanol / diethyl ether), MS: m/e = 352 (M+H + ). Example 198 1H-flavor __i__-act-5-fluorocarbyl ton-4-yl 1 methyl 1-2-methyl-, hydrochloride Π: 2 The title compound was obtained as an off-white crystalline material according to the procedure outlined in Example 10, obtained by [1-(3-bromo-5-fluoro-phenyl)-m-imidazole-4-yl]-sterol First reacted with sulfinium gas, then with 2_mercaptoimidazole and sodium hydride, followed by chromatography and crystallization of hydrochloride. Melting point > 2〇〇π decomposition (-96- paper Degree of Chinese yuzhen of Standards (CMS) Α4 Specification (210X 297 mm) 1328584 A7 B7 invention described five (93 methanol / ethyl mystery), MS: m / e = 335 (M + H +). Example 199 1H-imidazole, 1-indole "1-(3-bromo-5-fluoromethane V1H-imidazole-4-yl-1methyl-hydrochloride hydrazine: 2) Follow the general method described in Example 10. Obtaining the title compound as an off-white crystalline material obtained by the method of first using [1·(3_漠·5_fluoro-phenyl)-1Η-°m嗤-4-yl]-methanol and Gas reaction, then reacted with 2_ethyl spray and sodium hydride, followed by chromatography and crystallization of hydrochloride. Melting point > 200 ° C decomposition (methanol / sigma), MS: m / e = 349 (Μ+Η+). Example 200 Binding odor-5-gas-bens)-4-flavin-1-yl-methyl _ΐΗ-ρ米素磅酸験According to the general method described in Example 10, the title compound was obtained. Obtained as an off-white crystalline material obtained by first reacting with sulfinium gas using π_(3_bromo-5fluorophenyl)-1Η-imidazol-4-yl]-methanol, followed by reaction with imidazole and sodium hydride , followed by chromatography and crystallization of the hydrochloride. Melting point > 2 〇〇. 匸 decomposition (sterol / ethyl acetonide), MS: m / e = 321 (Μ + Η +). Example 201 line abazole, 1-丨Γ1-(2.2-Difluoro-1.3-indole, acoustic 嗤-4-yl 1 methyl 1-2-ethyl-, salt Acid salt π: 2) Obtained the title compound as a white crystalline material according to the procedure of Example 10, obtained by first using ^·^^-difluorobenzopyrene, 3]dioxol-5 ··················································································乙越), MS: m/e=333 •97· 1328584 A7 _ 丨1 - B7 V. Description of the invention (94) (M+H+) 〇Example 202 Salivation 'diox·ι_3-mosa and two gases- 5-Base)-1Η·Mimray-4-yl 1A hydrazine 1·2-A--, lithium benthoic acid (1:2) According to the general method described in Example 10, the title compound was obtained as a white crystalline material. It is obtained by first reacting with sulfinium gas using ^-(2-difluoro-benzopyrene, 3]dioxoin-5-yl)-1Η-imidazol-4-yl]-nonanol. Then, it is reacted with 2-methylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride salt. Melting point > 250. (: (sterol/diethyl ether), MS: m/e = 319 (M+H+) Example 203 1 bis (.?_,2·difluoro-benzo[1,31 dichloro-inden-5--V4-imidazole-1-yl-methyl) -1H-imidazolium hydrochloride was obtained according to the general procedure described in Example 10 to obtain the title compound as a white crystalline material. The obtained method was obtained by first using 1^-(2,2-difluoro-benzo[1,3]. Dioxan-5-yl)·1Η-imidazol-4-yl]-methanol reacts with the sub-gas, and then reacts with the taste and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Hyun point 245-246 ° C (sterol / acetamidine), MS: m / e = 3 19 (Μ + Η +). Example 204 ?-f4-(2-Methyl---------------------------------------------------------------------------------------------------------------------------------- The method of obtaining is by first reacting with [Qi Lin_2_yl-1H-Miso-4-yl)-methanol and then reacting with the submerged flue gas and then reacting with 2_methylhydrazine and sodium hydride] followed by chromatography And crystallization of the hydrochloride salt, m.p. -98- The paper size is applicable to China National Standard (CNS) A4 specification (210X297 public firefly) 1328584 A7 B7__ V. Invention description ^ ) — ~—:- Example 205 U4-〇乙棊一甲V imidazole·1· base 1. According to the general method described in Example 10, the title compound was obtained as an off-white crystalline material. The obtained method was obtained by first using (1_porphyrin-2_*_1η_miso-4-yl)-methanol and sub- The sulfonium chloride is reacted and then reacted with 2-ethylimidazole and sodium hydride, followed by chromatography of the chromatographic and hydrochloride. Melting point >8〇β(:decomposition (ethyl acetate/hexane), MS: m/e=304 (M+H+) » Example 206 h (4-imidazole-1-yl-methyl-capsule·1; _ base) ^ apricot shouting according to the general method described in Example 10 'obtained the title compound obtained as an off-white crystalline material obtained by first using (1-porphyrin-2-yl-1H-propan-4-yl)- Methanol reacts with sulfinium chloride and then with imidazole and sodium hydride' followed by chromatography and crystallization of the hydrochloride. Hyun> > 15 〇. (: Decomposition (ethyl acetate / hexane), MS: m /e=276 (M+H+). Example 207 1ϋ------丨-丨-4-(trifluoromethyl) 笨 基 1H-imidazol-4-yl 1-methyl 1-2-B -,, 骧 Π Π: 21 Obtained the title compound as a white crystalline material according to the general method described in Example 10, which was obtained by first using [1-(3- gas-4-trifluoromethylsulfanane). Benzyl-phenyl)-1Η-imidazol-4-yl]-methanol is reacted with sulfinium chloride and then reacted with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride salt. 215 ° C (methanol / diethyl ether), MS: m / e = 387 (M + H +). Example 208 1H-imidazole, 1-ΓΓ1- Ρ-Gas-4-(Trifluoromethyl) Benzene 篡μΐΗ-Imidazole·4·一1-.99 This paper scale applies to Chinese National Standard (CNS) Α4 Specification (210 X 297 mm) 1328584 A7 B7 Five , invention description (96~~) methyl 1-2-methyl-, lithinate (1:2) According to the general method described in Example 10, the title compound was obtained as a white crystalline material, which was obtained by first Reaction with [1-(3- gas-4-trifluoromethylsulfanyl-phenyl)-1Η-imidazol-4-yl]• sterol with sulfinium chloride, followed by 2-methylimidazole and hydrogenation Sodium reaction, followed by chromatography and crystallization of the hydrochloride salt mp 195-198 ° C (methanol / diethyl ether), MS: m / e = 373 (M+H+). -Trifluorodecylsulfanyl-styl V4-°oxazol-1-ylmethyl-1H-imidazole hydrochloride Π: 2) Obtained the title compound as a white crystalline material according to the procedure outlined in Example 10 , obtained by first reacting with [1 -(3- gas-4-trifluoromethylsulfanyl-phenyl)-1Η-[methane-4-yl]-methanol, and then reacting with the arsenic gas, and then Reaction with imidazole and sodium hydride' followed by chromatography and crystallization of the hydrochloride. Melting point 244-245 ° C (sterol/diethyl ether), MS: m/e = 359 (Μ+Η+) » Example 210 3- H-(2-ethyl-imidazole-1·A certain V imidazole-1-yl-1-+ The title compound was obtained as an off-white crystalline material according to the general method described in Example 10, which was obtained by first using (1_porphyrin-3-3·1H_imidazol-4-yl)-nonanol and yttrium. The reaction is then reacted with 2-ethyl oxazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 132_丨361 (ethyl acetate / hexane). MS: m/e = 304 (M+H+). Example 211 3-"4-(2-methyl-feed--1-ylmethyl-peak-1-based apricot said following the procedure outlined in Example 10) to obtain the title compound as an off-white crystal -100-
13285841328584
性物質獲得,其獲得方式係經由首先使用(1_喳啉_3·*_1Η· 味唾-4-基)-曱醇與亞磺醯氯反應,然後與2·曱基咪唑及氫 化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點168_172β(:( 乙酸乙酯 / 己烧),MS: m/e=290 (Μ+Η+)。 實例212 / 1:氣-2·『4-(2-曱基来吨-1-基甲某球峻·ι·基1·地哈 遵照實例10所述概略程序,獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用[1_(5_氣_吡啶·2_ 基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2_曱基咪 啥及氫化鈉反應’接著為層析術及鹽酸鹽之結晶。溶點 192-196°C (乙酸乙酯 /己炫),MS: m/e=274 (Μ+Η+)。 實例213 1:氯-2-丨4-(2-乙基-°米啥-1-基甲某米唾基 遵照實例10所述概略程序’獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用氣吡啶·2_ 基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2·乙基咪 嗅及氫化鈉反應’接著為層析術及鹽酸鹽之結晶。炫點 182-185°C (乙酸乙酯 / 己烧),MS: m/e=288 (Μ+Η+)。 實例214Obtaining substances obtained by first reacting (1_porphyrin_3·*_1Η·salt-4-yl)-sterol with sulfinium chloride and then reacting with 2·nonylimidazole and sodium hydride , followed by chromatography and crystallization of the hydrochloride. Melting point 168_172β (: (ethyl acetate / hexane), MS: m / e = 290 (Μ + Η +). Example 212 / 1: gas - 2 · "4-(2-mercapto-ton-1-yl) A. Ball ···················································································· 1Η-imidazol-4-yl]-nonanol is reacted with sulfinium gas and then reacted with 2_mercaptopurine and sodium hydride' followed by chromatography and crystallization of the hydrochloride. Melting point 192-196 °C (ethyl acetate / hexarene), MS: m / e = 274 (Μ + Η +). Example 213 1: chloro-2-indole 4-(2-ethyl-°m啥-1-yl-methyl The saliva group was obtained according to the schematic procedure described in Example 10 to obtain the title compound as an off-white crystalline material obtained by first using a gas pyridine·2-yl)-1 Η-imidazol-4-yl]-nonanol and sulfoximine gas. The reaction is then reacted with 2·ethyl oxime and sodium hydride. The chromatographic and hydrochloride crystals are then clarified. 182-185 ° C (ethyl acetate / hexane), MS: m/e = 288 (Μ+Η+). Example 214
Ui-(2·曱基-咪_嗓-1_基曱基朵唑-1-基1-異崦呲镑醅声p 遵照實例10所述概略程序,獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用(丨_異喳啉_3基_ 1H-咪唑-4-基)-甲醇與亞磺醯氣反應,然後與2_曱基味啥及 氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>25〇<t( • 101 - 本纸乐尺度適用中國國家標準(CNS) A4規格(210X 297公爱) 1328584 A7Ui-(2·曱基-咪_嗓-1_ mercapto-oxazol-1-yl-isoindole-pound pp was obtained according to the schematic procedure described in Example 10, and the title compound was obtained as an off-white crystalline material. The method of obtaining is carried out by first reacting (丨_isoporphyrin-3-yl-1H-imidazol-4-yl)-methanol with sulfinium gas, and then reacting with 2-mercapto miso and sodium hydride, followed by layer Crystallization and crystallization of hydrochloride. Melting point >25〇<t( • 101 - The paper scale applies to China National Standard (CNS) A4 specification (210X 297 public) 1328584 A7
曱醇/乙醚),MS: m/e=290 (M+H+)。 實例215 1^-°丰吐’2-乙基-1-丨丨1-丨4-(三氣甲氣)笨基1_;[只_峡〇<|?-4-芊1_ 曱基1-,鹽酸镑(Ί:2、 遵照實例10所述概略程序’獲得標題化合物呈白色結晶性 物質獲得’其獲得方式係經由首先使用[1-(4-三敗曱氧-笨 基)-1Η-咪吐-4-基]-曱醇與亞續酿氣反應,然後與2_乙基味 唾及氫化鈉反應’接著為層析術及鹽酸鹽之結晶。炫點 216-218°C (曱醇/乙醚),MS: m/e=337 (M+H+)。 實例216 HU嗅,2-曱基-1-ΓΓ1-Γ4-(三氟甲氣)茉某Ι-m-咪唑冰早^ 曱基1,鹽酸鹽Π:2) 遵照實例10所述概略程序,獲得標題化合物呈白色結晶性 物質獲得,其獲得方式係經由首先使用[1-(4-三氟曱氧 -苯基)-1Η-°米。垒-4-基]-曱醇與亞續醢氣反應,然後與2-曱基 咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點 23 1-233°C (曱醇/乙醚),MS: m/e=323 (M+H+)。 實例217 1H-咪唑,1-『Γ1-Π-聯茉-3-某V1H-咪唑-4-基1甲某1-2-甲其_ ,鹽酸鹽(1:2) 1H-咪唑,1-[[1-(3-碘苯基)-iH-咪唑-4-基]-曱基]-2·曱基· (0.20克’ 0.55毫莫耳)於曱苯(1〇毫升)之懸浮液使用肆(三苯 基膦)鈀(0.023克,0.02毫莫耳)處理(於氬氣氣氛下)。30分 鐘後加入苯基二羥硼酸(0.080克,0.66毫莫耳)及2M碳酸卸 -102· 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公爱) 1328584Sterol/diethyl ether), MS: m/e = 290 (M+H+). Example 215 1 ^-°Feng Tu '2-ethyl-1-丨丨1-丨4-(three gas gas) stupid base 1_; [only _ 〇 〇 <|?-4-芊1_ 曱基1 -, pounds of hydrochloric acid (Ί: 2, according to the general procedure described in Example 10, 'obtained the title compound as a white crystalline material obtained' obtained by first using [1-(4-tris-oxy-phenyl)-1Η] - Met-4-yl]-sterol reacts with the subsequent gas, and then reacts with 2-ethyl sulphate and sodium hydride' followed by chromatography and hydrochloride crystallization. Hyun point 216-218 ° C (sterol/diethyl ether), MS: m/e = 337 (M+H+). Example 216 HU sniffer, 2-mercapto-1-in1-in 4-(trifluoromethane) jasmine-m-imidazole ice早^ 曱1, hydrochloride Π: 2) Obtained the title compound as a white crystalline material according to the procedure outlined in Example 10, obtained by first using [1-(4-trifluoroantimony-benzene) Base) -1 Η - ° m. The benzyl-4-yl]-nonanol reacts with the helium gas and is then reacted with 2-mercaptoimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride salt. Melting point 23 1-233 ° C (decyl alcohol / diethyl ether), MS: m / e = 323 (M+H+). Example 217 1H-imidazole, 1-"Γ1-Π-Lianza-3-V1H-imidazol-4-yl 1 A certain 1-2-methyl _, hydrochloride (1:2) 1H-imidazole, 1 -[[1-(3-Iodophenyl)-iH-imidazol-4-yl]-indenyl]-2.indolyl (0.20 g '0.55 mmol) in suspension of toluene (1 mL) The solution was treated with hydrazine (triphenylphosphine) palladium (0.023 g, 0.02 mmol) (under argon). After 30 minutes, add phenyl diboric acid (0.080 g, 0.66 mmol) and 2M carbonic acid unloading -102. This paper scale applies to China National Standard (CNS) A4 specification (210X297 public) 1328584
水/谷液(2·0毫升)。反應混合物回流2小時然後以乙酸乙酯及 水萃取。有機相經脫水(硫酸鈉),濃缩及層析[矽膠,以梯 度二氣f烷至30%(二氣甲烷/甲醇/水性氫氧化銨=9〇:1〇:1) 洗提]。獲得標題化合物之自由態鹼呈無色油(〇 13克,75%) 。呈白色鹽酸鹽結晶。熔點241_243»c (甲醇/乙醚),MS: m/e=315 (M+H+)。 實例218 JJj-咪唑,2-乙基-1-丨丨1·『4·(三氩甲硫)苯某唑Μ早1 甲基1-,鹽酸鹽(1:2) 遵照實例10所述概略方法,獲得標題化合物呈淺黃色結晶 性物質獲得,其獲得方式係經由首先使用[i_(4_三氟甲基硫 烷基-苯基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2_ 乙基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。 炫點 183-185°C (曱醇/ 乙越),MS: m/e=352 (M+)。 實例219 ia:°米嗤,2-曱基-1-『以-『4_(三n甲硫)茉某呻兔_4_某1 曱基1-,鹽酸鹽(1:2) 遵照實例10所述概略方法,獲得標題化合物呈白色結晶性 物質獲得’其獲得方式係經由首先使用[1_(4·三氟曱基琉烧 基-笨基)-1Η-咪唑-4-基]-曱醇與亞磺醯氣反應,然後與2_曱 基咪唑及氫化鈉反應,接著為層析術及鹽酸鹽之結晶。熔 點249-250 C (曱醇 / 乙驗),MS: m/e=3 3 9 (M+H+)。 實例220 6-『4-(2-甲基-咪唑-1-基甲篡)·咪唑_卜基[峰淋 -103- '本纸張尺度適用中國國家標準(CNS) A4規格(21〇 X 297公爱) --- 1328584Water / gluten (2 · 0 ml). The reaction mixture was refluxed for 2 hr then extracted with ethyl acetate and water. The organic phase is dehydrated (sodium sulfate), concentrated and chromatographed [j. The free base of the title compound was obtained as a colorless oil ( 13 g, 75%). It is white hydrochloride crystals. Melting point 241_243»c (methanol / diethyl ether), MS: m/e = 315 (M+H+). Example 218 JJj-imidazole, 2-ethyl-1-indole 1 · "4 · (tri-argonylthio) benzoxazole 1 1 methyl 1-, hydrochloride (1:2) according to Example 10 By way of summary, the title compound is obtained as a pale yellow crystalline material obtained by first using [i_(4-trifluoromethylsulfanyl-phenyl)-1Η-imidazol-4-yl]-sterol with The sulfinium is reacted with helium and then reacted with 2_ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Happiness 183-185 ° C (sterol / B-over), MS: m / e = 352 (M +). Example 219 ia: ° rice bran, 2-mercapto-1-"--"4_(three n-methylthio) moxa rabbit _4_ a 1 thiol 1-, hydrochloride (1:2) according to the example 10, the general method, obtaining the title compound as a white crystalline material, obtained by first using [1_(4·trifluoromethylsulfonyl-phenyl)-1Η-imidazol-4-yl]-oxime The alcohol is reacted with sulfinium gas and then reacted with 2_mercaptoimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Melting point 249-250 C (sterol/B test), MS: m/e = 3 3 9 (M+H+). Example 220 6-"4-(2-Methyl-imidazol-1-ylformamidine)-imidazole_Buji [Fenglin-103- 'This paper scale applies Chinese National Standard (CNS) A4 specification (21〇X 297 public) --- 1328584
遵照實例ίο所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用(卜喹啉心基丨士 咪唑-4-基)-曱醇與亞磺醯氣反應,然後與2·乙基咪唑及氫 化鈉反應,接著為層析術及鹽酸鹽之結晶。熔點>i25t:分 解(乙酸乙酯/己烧),MS: m/e=290 (M+H+)。 實例221 乙基-咪唑-ΐ·基甲盖)·哚唑·美1<;秦进 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用(1_喳啉_6_基·1H_ 咪唑_4_基)-甲醇與亞磺醯氣反應,然後與2_乙基咪唑及氫 化納反應,接著為層析術及鹽酸鹽之結晶。炫點> 7 9 〇c分解 (乙酸乙酯/己烧),MS: m/e=304 (M+H+) » 實例222 g_^f4-(2-曱基米吐-1-基甲基咕嗅某~|g杳’说 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得’其獲得方式係經由首先使用喳啉_8_基·1Η· 咪唑-4·基)-甲醇與亞磺醯氣反應,然後與2·乙基咪唑及氫 化納反應’接著為層析術及鹽酸鹽之結晶。炼點15〇_154〇C( 乙酸乙酯 / 己烷),MS: m/e=290 (M+H+)。 實例223 ?-Γ4-(2-乙基-咪唑-1-基甲基咪唑-1-某1崦毗 遵照實例10所述概略方法,獲得標題化合物呈灰白色結晶 性物質獲得,其獲得方式係經由首先使用(1_„奎啦_8_基-1Η_ 咪唑-4-基)-甲醇與亞磺醯氯反應,然後與2_乙基咪唑及氢 •104- 本泜張尺度通用中國國家標準(CNS) Α4規格(210Χ 297公釐) 1328584Obtaining the title compound as an off-white crystalline material according to the general method described in the example ίο, obtained by first reacting (buquinoline-based sulfoximin-4-yl)-sterol with sulfinium gas, and then Reaction with 2·ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride. Melting point > i25t: cleavage (ethyl acetate/hexane), MS: m/e = 290 (M+H+). Example 221 Ethyl-imidazolium-hydrazide-capped carbazate··carbazole·Meal 1<; Qin Jin Obtained the title compound as an off-white crystalline material according to the general method described in Example 10, which was obtained by first use (1) _Porphyrin_6_yl·1H_imidazole_4_yl)-methanol is reacted with sulfinium gas, and then reacted with 2-ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Hyun point > 7 9 〇c decomposition (ethyl acetate / hexane), MS: m / e = 304 (M + H +) » Example 222 g_^f4-(2-mercapto- -1-ylmethyl咕 sniffing a certain ~|g杳' said that the title compound was obtained as an off-white crystalline material according to the general method described in Example 10, which was obtained by first using porphyrin _8_yl·1Η·imidazole-4·yl)- Methanol is reacted with sulfinium gas and then reacted with 2·ethylimidazole and sodium hydride, followed by chromatography and crystallization of the hydrochloride. Refining point 15〇_154〇C (ethyl acetate / hexane), MS: m/e = 290 (M+H+). Example 223 ?-Γ4-(2-ethyl-imidazol-1-ylmethylimidazole-1-yl 1 崦 崦 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵 遵First use (1_„奎啦_8_基-1Η_imidazol-4-yl)-methanol to react with sulfinium chloride, then with 2_ethylimidazole and hydrogen•104- this 尺度-scale common Chinese national standard (CNS ) Α 4 specifications (210Χ 297 mm) 1328584
化鈉反應’接著為層析術及鹽酸鹽之結晶,炫點78_8丨。匸(乙 酸乙酯 / 己烧)’ MS: m/e=3 04 (M+H+)。 實例224 L-(l-苯并Π,31二氳伍圖-;5-基·出-唑唑-4-某甲其、」H叶岫_ 2-基胺鹽酸镑Π:2) 遵照實例104所述概略方法,1Η-咪唑,ΐ_[[ι·(13_苯并二氧 伍園-5-基)-1Η-咪唑_4_基]甲基]-2-硝基-與鐵於乙醆反應。 過濾、蒸發及層析後,分離標題化合物自由態鹼。自由態 鹼被轉成其淺黃色鹽酸鹽《熔點>245°C分解(曱醇/乙醚), MS: m/e=284 (M+H+)。 實例225 二氟甲棊_4·氟-苯基)-5-(2·甲篡-咪唑·1·基甲甚毗设 標題化合物係根據實例129(DMF替代二喝烷,4小時,1〇〇 °C)呈淺褐色固體(73〇/〇),其製備係經由2_(3_二氟甲基_4_氟_ 苯基)-4,4,5,5-四甲基-[1,3,2]二氧雜二硼伍圜與3_溴_5_(2-曱 基-0米唾-1-基曱基)-!;比咬反應製備。MS: m/e=318.3 (M+H+) 實例226 二氟-乙基)-苯基1-5-(2·曱某-q卡地]·某甲基^比哈 標題化合物係根據實例129(DMF替代二$烧,4小時,1〇〇 C)呈歲褐色固體(70%),其製備係經由[2_(3_(1,1_二氟乙基 )-表基]-4,4,5,5-四甲基-[1,3,2]二氧雜二蝴伍園與3溴·5_(2_ 甲基·味唾-卜基曱基)·,比咬反應製備。MS· m/e=3l4 3 (M+H+)。 -105- 本纸張尺度適用中國國家標準(CNS) A4規格(210X 297公釐)The sodium reaction is followed by chromatography and crystallization of the hydrochloride salt, with a bright spot of 78_8 丨.匸 (ethyl acetate / hexane) ' MS: m/e = 3 04 (M+H+). Example 224 L-(l-benzopyrene, 31 氲 氲 ; -5-yl-exo-oxazol-4-one methyl, "H-leaf _ 2-ylamine hydrochloride pound Π: 2) Follow the example 104. The general method, 1Η-imidazole, ΐ_[[ι·(13_benzodioxan-5-yl)-1Η-imidazole-4-yl]methyl]-2-nitro- and iron Acetylene reaction. After filtration, evaporation and chromatography, the title compound free base was isolated. The free base was converted to its pale yellow hydrochloride "melting point > 245 ° C decomposition (decyl alcohol / diethyl ether), MS: m / e = 284 (M + H +). Example 225 Difluoromethyl hydrazine _4·fluoro-phenyl)-5-(2·methyl hydrazine-imidazole·1·yl carbazide was given the title compound according to Example 129 (DMF instead of dioxane, 4 hours, 1 〇 〇 ° C) is a light brown solid (73 〇 / 〇), which is prepared via 2_(3_difluoromethyl_4_fluoro-phenyl)-4,4,5,5-tetramethyl-[1 , 3,2]dioxadiborazine and 3_bromo-5-(2-indolyl- 0-sal-1-ylindenyl)-!; prepared by a bite reaction. MS: m/e = 318.3 ( M+H+) Example 226 Difluoro-ethyl)-phenyl1-5-(2·曱某-q卡地]·Methyl^Biha title compound according to Example 129 (DMF replaces two-burn, 4 H, 1〇〇C) is an aged brown solid (70%) prepared by [2_(3_(1,1-difluoroethyl)-epi]-4,4,5,5-tetramethyl -[1,3,2]dioxathiamidine and 3bromo-5_(2_methyl·sodium sulphate) were prepared by a bite reaction. MS· m/e=3l4 3 (M +H+). -105- This paper size applies to Chinese National Standard (CNS) A4 specification (210X 297 mm)
k 1328584 A7 B7 五 發明説明(1〇2、· 實例227 . 3-(3-氣-5-三氣甲基-苯基)-5-(2-甲基-味岭-i-基甲基比咬 標題化合物係根據實例129(DMF替k二号烧,4小時,100 C)呈淺褐色固想(67%) ’其製備係經由2-(3-氟-5-三氟曱基· 本基)-4,4,5,5-四曱基-[1,3,2]二氧雜二蝴伍園與3_漠_5_(2_甲 基米嗤-1·基甲基)_Ρ比咬反應製備eMS: m/e=336.3 (M+H+) ο 實例228 1:L3-(1,1-二氟-乙基)-4-氟-笨某1-5-C2-甲基-味衅-U基甲基)- 吡啶 化合物係根據實例129(0^117替代二$炫,4小時,ι〇〇β〇)呈 淺褐色固體(73〇/〇) ’其製備係經由2-[3-(1,1·二氟乙基)_4_氟_ 苯基]·4,4,5,5-四甲基-[1,3,2]二氧雜二硼伍園與3_漠_5_(2_曱 基-咪唾-1-基曱基)-ιτ比.咬反應製備。MS: m/e=332·3 (Μ+Η+) ο 實例229 lUi咪唑,2-環丙基-1-Γ『1-(3,4-二氣笑爷1甲 基1' 遵照實例1所述概略方法’標題化合物之獲得方式係經由4_ 氣甲基-1-(3,4-二氯-苯基)-1Η-咪唾與2-環丙基·ιη-«>米咬及氫 化納反應接著層析術獲得標題化合物呈黃色油。MS: m/e=334 (M+H+)。 實例23’0 5-(4-氟-3 -甲基-笨基)-1-甲基-2-(2-甲某-喷οφ-ΐ冬甲基μ H- -106- 本紙張尺度適用中國國家標準(CNS>八4规+格(210乂297公釐)· 1328584 A7 B7 五、發明説明(103 ) 咪唑鹽酸鹽Π : η 5-溴-1-曱基-2-(2-曱基-咪唑-^基甲基)·1Η_咪唑(01克, 0.3 92毫莫耳)溶解於曱苯(4毫升)及甲醇(〇8毫升),以水性 2Ν碳酸鈉(0.2毫升)、4-氟-3-曱基苯基二羥硼酸(0.078克, 0.510毫莫耳)及肆(三苯基膦)鈀(〇 〇23克,〇 〇2〇毫莫耳)處理 。反應混合物於氬下回流12小時,然後冷卻至室溫及以硫 酸鈉脫水。過濾及蒸發去除溶劑後,殘餘物經層析(矽膠, 以二氣曱烷/曱醇=95:5洗提)。產物溶解於甲醇,冷卻至〇°c 及以鹽酸/醚處理《蒸發去除溶劑及於高度真空下脫水獲得 標題化合物(0.11克,88%)呈淺黃色固體。MS: m/e=285.2 (M+H+) 〇 實例23 1 氟-3-三氟甲基-笨基Μ -甲某_2·(2·甲基_咪唑a•基甲某 )-1Η-咪唑鹽醅鲤p :1) 5-溴-1-曱基-2-(2-曱基-咪唑-i_基曱基)_1H-咪唑(01克, 0.392毫莫耳)溶解於DMF(1.5毫升),以碳酸鉀(〇 1克,〇 784 毫莫耳)、2-(4-氟-3-三氟曱基-苯基)·4,4,5,5-四曱基-[1,3,2] 二氧雜伍園硼烷(0.148克,0.510毫莫耳)以及肆(三苯基膦) 纪(0.047克,〇_〇40毫莫耳)處理《反應混合物m10〇〇c於氬 下加熱12小時’然後冷卻至室溫及以硫酸鈉脫水。過濾及 蒸發去除溶劑後,殘餘物經層析(矽膠,以二氣曱烷/曱醇 =95:5洗提)。產物溶解於曱醇,冷卻至〇。〇及以鹽酸/醚處理 。蒸發去除溶劑及於高度真空下脫水獲得標題化合物(〇 〇89 克 ’ 88%)呈淺褐色固體。MS: m/e=339.2 (M+H+)。k 1328584 A7 B7 Five inventions description (1〇2, · Example 227. 3-(3-Ga-5-trismethyl-phenyl)-5-(2-methyl-weiling-i-ylmethyl The title compound was light brown (67%) according to Example 129 (DMF for k 2, 4 hours, 100 C). The preparation was via 2-(3-fluoro-5-trifluoromethyl). Benzo)-4,4,5,5-tetradecyl-[1,3,2]dioxanthene and 3_-___________methyl-methane-1 -ylmethyl) _Ρ ratio bite reaction to prepare eMS: m/e=336.3 (M+H+) ο Example 228 1: L3-(1,1-difluoro-ethyl)-4-fluoro-stupid 1-5-C2-methyl -Miso-U-methyl)-pyridine compound was light brown solid (73 〇 / 〇) according to Example 129 (0 117 instead of two s, 4 hours, ι〇〇β〇) -[3-(1,1·difluoroethyl)_4_fluoro_phenyl]·4,4,5,5-tetramethyl-[1,3,2]dioxadiboron and 3 _ _ _ 5 _ ( 2 曱 - 咪 咪 咪 -1- 曱 曱 曱 ) - - - ι ι ι 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 229 229 229 229 229 229 229 U U U U Cyclopropyl-1-indole "1-(3,4-dioxime 1 methyl 1' according to the general method described in Example 1 'The title compound was obtained via 4_ gas methyl-1-(3,4 -Dichloro- The title compound was obtained as a yellow oil. MS: m/e = </RTI> (M+H+) </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; Example 23'0 5-(4-Fluoro-3-methyl-phenyl)-1-methyl-2-(2-methyl------------------------------------ Chinese National Standard (CNS> 八四规+格(210乂297 mm)· 1328584 A7 B7 V. Description of Invention (103) Imidazole hydrochloride Π : η 5-bromo-1-indenyl-2-(2- Mercapto-imidazole-methyl-methyl)·1Η-imidazole (01 g, 0.392 mmol) was dissolved in terpene (4 ml) and methanol (8 ml), aqueous 2 Ν sodium carbonate (0.2 mL), 4-Fluoro-3-mercaptophenyl dihydroxyboric acid (0.078 g, 0.510 mmol) and hydrazine (triphenylphosphine) palladium (23 g, 〇〇 2 〇 millimolar). It was refluxed under argon for 12 hours, then cooled to room temperature and dried over sodium sulfate. After the solvent was removed by filtration and evaporation, the residue was chromatographed, eluted with dioxane / decyl alcohol = 95:5. In methanol, cooled to 〇 ° c and treated with hydrochloric acid / ether "evaporation to remove solvent and at a high degree The title compound (0.11 g, 88%) as a pale yellow solid dehydrated. MS: m/e = 285.2 (M+H+) 〇 Example 23 1 fluoro-3-trifluoromethyl- succinyl hydrazine -methyl _2·(2·methyl-imidazole a•基甲)-1Η- Imidazole salt 醅鲤p : 1) 5-bromo-1-indenyl-2-(2-indolyl-imidazolium-i-ylindenyl)_1H-imidazole (01 g, 0.392 mmol) dissolved in DMF (1.5 ML), with potassium carbonate (〇1 g, 〇784 mM), 2-(4-fluoro-3-trifluoromethyl-phenyl)·4,4,5,5-tetradecyl-[1 ,3,2] Dioxazolidine borane (0.148 g, 0.510 mmol) and hydrazine (triphenylphosphine) (0.047 g, 〇_〇 40 mmol) treatment of the reaction mixture m10〇〇c Heated under argon for 12 hours' then cooled to room temperature and dehydrated with sodium sulfate. After removal of the solvent by filtration and evaporation, the residue was purified (jjjjjd The product was dissolved in decyl alcohol and cooled to hydrazine. It is treated with hydrochloric acid/ether. The solvent was removed by evaporation <RTI ID=0.0></RTI> to <RTI ID=0.0> MS: m/e = 339.2 (M + H +).
1328584 A7 B71328584 A7 B7
實例232 . 芝二(4-氣-3-二氣甲基-表基)-1-曱基-2-(2 -甲基-味嗅[•基甲某 )-1Η-咪唑鹽酸镑Π:Π 遵照κ例2 3 1所述之概略方法,化合物係由演_1_甲基_ 2 _ (2-甲基咪唑-1-基甲基)-1Η-咪唑以及2-(4-氣-3-曱基-苯基)· 4,4,5,5-四曱基-[1,3,2]-二氧雜伍園蝴烧獲得。ms: m/e=300.1 (M+)。 實例233 甲_基-咪唑-1-基曱基)-吡啶-3-基1-L2.3 4-四氣-旦崎 。沐鹽酸鹽(1:2) 本化合物係根據如下參考文獻所述概略程序製備: S. Wagaw; S. L. Buchwald;有機化學期刊 1996,61,7240- 7241 3-溴-5-(2-甲基米唾-1-基甲基)·Ρ比咬(〇.1克,0.397毫莫耳) 溶解於曱苯(1毫升),連續使用1,2,3,4-四氫異喳啉(61微升 ,0.476毫莫耳)’第三丁氧化鈉(53毫克,0.556毫莫耳), Pd2(dba)3氣仿錯合物(8.2毫克,0.0079毫莫耳)及R(+)-BINAP (10毫克,0.0159毫莫耳)處理。反應混合物於70。〇於 氬下加熱6小時,冷卻至室溫及以水淬隐。水層以乙酸乙酯 萃取3次。合併萃取物以疏酸鈉脫水,過濾及真空去除溶劑 。殘餘物經層析(矽膠’以二氣曱烷/曱醇=95:05洗提)。產 物溶解於甲醇,冷卻至0°C及以鹽酸/醚處理。蒸發去除溶 劑及於高度真空下脫水獲得標題化合物(〇.〇9克,60%)呈黃 色發泡趙。MS: m/e=305.3 (M+H+)。 -108- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐)Example 232. Zhi Er (4-gas-3-dimethyl-methyl)-1-mercapto-2-(2-methyl-flavored [•基甲)-1Η-imidazole hydrochloride pound Π:遵 According to the general method described in κ, Example 2 3 1 , the compound is derived from 1-methyl-2- 2 (2-methylimidazol-1-ylmethyl)-1 Η-imidazole and 2-(4-gas- 3-Mercapto-phenyl)· 4,4,5,5-tetradecyl-[1,3,2]-dioxene was obtained. Ms: m/e=300.1 (M+). Example 233 M-Methyl-imidazol-1-ylindenyl)-pyridin-3-yl 1-L2.3 4-tetrahydro-dano. Hydrochloride (1:2) This compound was prepared according to the schematic procedure described in the following references: S. Wagaw; SL Buchwald; Journal of Organic Chemistry 1996, 61, 7240-7241 3-bromo-5-(2-methyl Methyl-1-methyl-methyl)·Ρ比 bite (〇.1 g, 0.397 mmol) dissolved in toluene (1 ml), continuous use of 1,2,3,4-tetrahydroisoindoline (61 Microliter, 0.476 mmol; 'Third sodium butoxide (53 mg, 0.556 mmol), Pd2(dba)3 gas-like complex (8.2 mg, 0.0079 mmol) and R(+)-BINAP (10 mg, 0.0159 mmol) treated. The reaction mixture was at 70. The crucible was heated under argon for 6 hours, cooled to room temperature and quenched with water. The aqueous layer was extracted three times with ethyl acetate. The combined extracts were dehydrated with sodium silicate, filtered and the solvent removed in vacuo. The residue was chromatographed (gelatin) eluted with dioxane / methanol = 95:05. The product was dissolved in methanol, cooled to 0 ° C and treated with hydrochloric acid / ether. The solvent was removed by evaporation and dehydrated under high vacuum to give the title compound (yield: 9 g, 60%) as yellow foam. MS: m/e = 305.3 (M+H+). -108- This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm)
裝 訂Binding
1328584 A7 B7 五、發明説明(105 ) 製備中間物之方法 實例234 1^(3,4-二氛·茉某ym-咪唑-4-雜酸 3,4-二氣笨胺(24.3克,150毫莫耳),原甲酸三乙酯(24.0克 ,162毫莫耳),硝基乙酸乙酯(2〇_〇克,150毫莫耳)及乙酸 乙酯(1毫升)之混合物回流1小時。加入額外量原曱酸三乙醋 (300毫升,1.8莫耳),鐵粉^义丨克,450毫莫耳)及乙酸(3〇〇 毫升,5.2莫耳)後,混合物回流5小時。於此段期間,分成3 份加入額外量鐵粉(25.1克,450毫莫耳)。混合物冷卻至6〇 eC及加入乙酸乙酯(1升)。回流1 〇分鐘後,沉澱經過濾出, 及濾液經濃縮。殘餘乙酸經由與甲苯(500毫升)共同蒸發而 共沸蒸餾去除》結晶性殘餘物溶解於二喝烷(3 00毫升),加 入2N氫氧化鈉溶液(300毫升)及木炭(約10克)^混合物回流2 小時,過濾及冷卻至5 °C。加入鹽酸溶液(3 7%)至沉澱完成 。過濾及乾燥獲得標題化合物(25.8克,67%)呈淺褐色結晶 物質。熔點>235°C 分解(水),MS: m/e=255 [(M-Η)·]。 實例235至262係根據實例2:34所述概略程序製備。 實例235 W4-氩-3-甲基-笨基V1H-咪唑-4-钕酸 標題化合物MS: m/e=236 (M+),溶點231-236°C(水/二》号燒) 係呈灰白色結晶物質獲得,其獲得方式係經由4 -氣-3-甲基 苯胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 使用原曱酸三乙酯 '鐵及乙酸處理以及隨後進行絵·性水解。 實例236 -109- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 五 A7 _____ B7 發明説明(1Q6 ) 1-四鱼.辟-5-某-lH-piH斗·4-雜酸 標題化合物 MS: m/e=227 [(M-Η)·],熔點 243·25Γ(:(水 / 二喝 烧)係呈灰白色結晶物質獲得,其獲得方式係經由5_胺基四 氫印與原甲酸二乙醋、硝’基乙酸乙酯 '及乙酸反應,接著 使用原曱酸二乙酯、鐵及乙酸處理及隨後進行驗性水解。 實例237 丄二(3,4 - 一甲基-本基)-1Η - p朵吐-4 -翔酸 標題化合物MS: m/e=216 (M+),熔點>250。(:(水/二呤烷)係 呈灰白色結晶物質獲得’其獲得方式係經由3,4_二曱基苯胺 與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使用 原曱酸三乙酯、鐵及乙酸處理以及隨後進行驗性水解。 實例23 8 1-對曱茉某-1H-咪唑-4-钕酿 標題化合物MS: m/e=2〇2 (M+),熔點>25〇°C(DMF)係呈薔薇 色結晶物質獲得,其獲得方式係經由對甲苯胺與原曱酸三 乙酯、硝基乙酸乙酯、及乙酸反應,接著使用原甲酸三乙 酯、鐵及乙酸處理及隨後進行鹼性水解。 實例239 _1·(4-氟-3-甲基·茉基)-1Η-哚唑-4-#酸 標題化合物MS: m/e=219 [(M-Η)-),溶點 192-198Χ:(水/ 二号 烷)係呈灰白色結晶物質獲得,其獲得方式係經由4·氟_3_曱 基笨胺與原曱酸三乙酯、硝基乙酸乙酯 '及乙酸反應,接 著使用原曱酸三乙酯、鐵及乙酸處理及隨後進行驗性水解β 實例240 •110- 本紙張尺度適用中国圉家標準(CNS) Α4规格(210X297公釐)1328584 A7 B7 V. INSTRUCTIONS (105) Example of a method for preparing an intermediate 234 1^(3,4-di-environment·mum ym-imidazole-4-oxo acid 3,4-dimethanolamine (24.3 g, 150 Milligram), a mixture of triethyl orthoformate (24.0 g, 162 mmol), ethyl nitroacetate (2 〇 〇 ,, 150 mmol) and ethyl acetate (1 mL) was refluxed for 1 hour. After adding an additional amount of ruthenium citrate (300 ml, 1.8 m), iron powder (450 ml), and acetic acid (3 ml, 5.2 m), the mixture was refluxed for 5 hours. During this period, an additional amount of iron powder (25.1 g, 450 mmol) was added in 3 portions. The mixture was cooled to 6 〇 eC and ethyl acetate (1 liter) was added. After refluxing for 1 min, the precipitate was filtered and the filtrate was concentrated. The residual acetic acid was removed by azeotropic distillation with co-evaporation with toluene (500 ml). The crystalline residue was dissolved in dioxane (300 ml), 2N sodium hydroxide solution (300 ml) and charcoal (about 10 g) were added. The mixture was refluxed for 2 hours, filtered and cooled to 5 °C. A hydrochloric acid solution (3 7%) was added until the precipitation was completed. Filtration and drying gave the title compound (25.8 g, 67%). Melting point > 235 ° C Decomposition (water), MS: m/e = 255 [(M-Η)·]. Examples 235 to 262 were prepared according to the general procedure described in Example 2:34. Example 235 W4-argon-3-methyl-phenyl-V1H-imidazole-4-furoic acid title compound MS: m/e = 236 (M+), melting point 231-236 ° C (water / bis) Obtained as an off-white crystalline material obtained by reacting 4-ox-3-methylaniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthoacetate 'iron and acetic acid And subsequent hydrolytic hydrolysis. Example 236 -109- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 Five A7 _____ B7 Invention Description (1Q6) 1-四鱼. 辟-5-某-lH-piH斗· 4-heteroic acid title compound MS: m/e = 227 [(M-Η)·], melting point 243·25 Γ (: (water / ban) is obtained as an off-white crystalline material obtained by 5-amine The tetrahydrogen imprint is reacted with the original formic acid diethyl acetonate, the nitric acid ethyl acetate and the acetic acid, followed by treatment with diethyl ortho ruthenate, iron and acetic acid and subsequent aqueous hydrolysis. Example 237 丄二(3,4 - monomethyl-bens)-1Η-p-tox-4-cyanic acid title compound MS: m/e = 216 (M+), melting point > 250. (: (water/dioxane) is grayish white crystal Substance acquisition is obtained by reacting 3,4-diphenylaniline with triethyl orthosilicate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid, and subsequent Analytical hydrolysis. Example 23 8 1-P. quinone-1H-imidazole-4-brewed title compound MS: m/e=2〇2 (M+), melting point >25〇°C (DMF) is a rose color Acquired crystalline material The mode is carried out by reacting p-toluidine with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid, followed by alkaline hydrolysis. Example 239 _1·(4- Fluoro-3-methyl·melly)-1Η-carbazole-4-# acid title compound MS: m/e=219 [(M-Η)-), melting point 192-198 Χ: (water / dioxane Is obtained as an off-white crystalline material obtained by reacting 4·fluoro-3-indolylamine with triethyl orthoformate, ethyl nitroacetate and acetic acid, followed by triethyl orthosilicate, Iron and acetic acid treatment followed by prophylactic hydrolysis β Example 240 • 110- This paper scale applies to China National Standard (CNS) Α 4 size (210X297 mm)
裝 訂Binding
13285841328584
1-(4-曱基硫烧基-笨某up米唾_4-雜酸 標題化合物 MS: m/e=233 [(M-H)·],熔點 233-245。(:(水/二咩 撰:)係呈红色結晶物質獲得,其獲得方式係經由4_(曱基硫) 苯胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 使用原曱酸二乙酯'鐵及乙酸處理以及隨後進行驗性水解。 實例241 1-(3-三氟甲基笨基咣唾-4-羧酿 標題化合物MS: m/e=256 M+,熔點233-245°C(水/二呤烷)係 呈淺燈色結晶物質獲得,其獲得方式係經由3_(三氟曱基)苯 胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使 用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例242 1-(4-氟-3-三氟甲基-笑某)-1Η·球嗅-4-翔g妾 標題化合物MS: m/e=274 M+,熔點188-193。(:(水/二哼烷)係 呈灰白色結晶物質獲得,其獲得方式係經由4-氟-3-(三氟甲 基)苯胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接 著使用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水 解》 實例243 1-(3-氟-4-三氟甲某-茉基)-1Η-咪唑-4-羧酸 標題化合物MS: m/e=274 M+,熔點>25(TC(水/二哼烷)係呈 灰白色結晶物質獲得,其獲得方式係經由3-氟-4-(三氟甲基 )苯胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 使用原甲酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 •111 · 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)1-(4-Mercaptothiopyranyl-stupyl-upm-salt-4-heteroic acid title compound MS: m/e=233 [(MH)·], melting point 233-245. (:(水/二咩作:) is obtained as a red crystalline material obtained by reacting 4_(mercaptothio)aniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by diethyl proruthenate 'iron and acetic acid Treatment and subsequent pro-hydrolysis. Example 241 1-(3-Trifluoromethyl phenyl sulfonium-4-carboxylate title compound MS: m/e = 256 M+, m.p. 233-245. The alkane is obtained as a light-colored crystalline material obtained by reacting 3-(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by triethyl orthosilicate , iron and acetic acid treatment and subsequent alkaline hydrolysis. Example 242 1-(4-Fluoro-3-trifluoromethyl-miao)-1Η·Bole ol-4-xiang g妾 title compound MS: m/e= 274 M+, melting point 188-193. (: (water/dioxane) is obtained as an off-white crystalline material obtained by 4-fluoro-3-(trifluoromethyl)aniline and triethyl orthophthalate, Ethyl nitroacetate and acetic acid are reacted Treatment with triethyl orthoacetate, iron and acetic acid followed by alkaline hydrolysis. Example 243 1-(3-Fluoro-4-trifluoromethyl-methyl)-1Η-imidazole-4-carboxylic acid title compound MS: m/e = 274 M+, melting point > 25 (TC (water/dioxane) is obtained as an off-white crystalline material obtained by 3-fluoro-4-(trifluoromethyl)aniline and the original hydrazine. Triethyl ethoxide, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. • 111 · This paper scale applies to the Chinese National Standard (CNS) A4 specification ( 210 X 297 mm)
裝 訂Binding
1328584 A7 B7 五、發明説明(108 ) 實例244 . λ·ΐ(4-_甲基-3-三氟甲基-苯某ίη-球啥-4-薄龄 標題化合物MS: m/e=269 [(M-Η)·),熔點>233。(:分解(水/二 呤烷)係呈灰白色結晶物質獲得,其獲得方式係經由4_曱基_ 3-(二氟甲基)苯胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸 反應,接著使用原曱酸三乙酯、鐵及乙酸處理以及隨後進 行驗性水解。 實例245 1-(4-氣-3-曱氣-茉某V1H-唑衅-4-跆醅 標題化合物MS: m/e=252 (M+),熔點231-236。〇(水/二嘮烷) 係呈淺紅色結晶物質獲得’其獲得方式係經由氣_3-甲氧 笨胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 使用原甲酸三乙酯、鐵及乙酸處理以及隨後進行驗性水解。 實例246 h(4-氟_3-甲氳-茉基)-1Η-咣唑-4-钕醅 標題化合物MS: m/e=236 (M+),熔點>182。(:分解(水/二呤烷 )係呈淺褐色結晶物質獲得,其獲得方式係經由4_氟_3_曱氧 苯胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 使用原曱酸三乙酯、鐵及乙酸處理及隨後進行鹼性水解。 實例247 氯-3-甲基-茉某)-1Η-咪唑-4-潋醅 標題化合物MS: m/e=222 (M+),熔點>250*t(水/二》号院)係 呈蕃微色結晶物質獲得’其獲得方式係經由4-氣苯胺與原 曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使用原曱1328584 A7 B7 V. INSTRUCTIONS (108) EXAMPLE 244. λ·ΐ(4-_Methyl-3-trifluoromethyl-benzomh-yttrium-4-thin title compound MS: m/e=269 [(M-Η)·), melting point > 233. (: decomposition (water/dioxane) is obtained as an off-white crystalline material obtained by 4_mercapto-3-(difluoromethyl)aniline with triethyl orthoacetate, ethyl nitroacetate, And acetic acid reaction, followed by treatment with triethyl orthoacetate, iron and acetic acid followed by prophylactic hydrolysis. Example 245 1-(4-gas-3-helium-mosa V1H-oxazol-4-跆醅 heading Compound MS: m/e = 252 (M+), m.p. 231-236. 〇 (water/dioxane) is obtained as a light red crystalline material. The obtained method is obtained by gas 3-methoxyantamine and orthoformic acid. Ethyl ester, ethyl nitroacetate, and acetic acid are reacted, followed by treatment with triethyl orthoformate, iron and acetic acid followed by an exemplary hydrolysis. Example 246 h (4-Fluoro-3-trimethyl-methyl)-1Η - oxazole-4-oxime title compound MS: m/e = 236 (M+), melting point > 182. (: Decomposition (water/dioxane) is obtained as a light brown crystalline material obtained by way of 4 _ Fluorine_3_nonoxyaniline is reacted with triethyl orthosilicate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid followed by alkaline hydrolysis. Chloro-3-methyl-mum)-1Η-imidazole-4-indole title compound MS: m/e=222 (M+), melting point >250*t(水/二》院) The color crystalline material is obtained by the reaction of 4-aniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by the use of the original hydrazine.
裝 訂Binding
-112--112-
1328584 A7 ____B7 五、發明説明(109 ) 酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例248 JL-笨并丨1.31-二氫伍囿-5-某-1H-咪唑-4-游醅 標題化合物MS: m/e=232 (M+),熔點>250。(:(水/二哼烷)係 呈灰色結晶物質獲得,其獲得方式係經由3,4-亞曱基二氧苯 胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使 用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例249 1-(3-氣-4-甲篡-芏基)-1Η-哇唑-4-羧醅 標題化合物MS: m/e=220 (M+),溶點>250eC (水/二1^号院)係 呈灰白色結晶物質獲得,其獲得方式係經由3-氟-4-曱基苯 胺與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使 用原曱酸三乙酯、鐵及乙酸處理以及隨後進行驗性水解。 實例250 1-(3-氩-4-甲笑基)-1Η-哚唑-4-羧酸 標題化合物 MS: m/e=252 (M + )’ 溶點 224-226°C(水/二1^院) 係呈白色結晶物質獲得,其獲得方式係經由3_氣_4_甲氧苯 胺與原甲酸三乙酯' 硝基乙酸乙酯、及乙酸反應,接著使 用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例251 1-(4-氣-2-氣-笨基)-1Η-味嗅-4-翔酸 標題化合物MS: m/e=239 [(M-H)-],熔點234-2381^1^/:4 烷)係呈淺黃色結晶物質獲得,其獲得方式係經由4-氯-2-氟 苯胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著 -113- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 _ B7 五、發明説明(110 ) 使用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解》 實例252 1-(4-溴-芏某米唑-4-羧酸 標題化合物MS: m/e=266 (M+),熔點>250°C(水/二喝烷)係 呈淺黃色結晶物質獲得,其獲得方式係經由4-溴苯胺與原 曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使用原曱 酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例253 二氟甲氣-茉基V1H-咪唑·4·钕酸 標題化合物MS: m/e=253 [(Μ-Η)-],熔點218-225。〇 (水/二巧 烷)係呈白色結晶物質獲得,其獲得方式係經由4-二氟甲氧 笨胺與原曱酸三乙S旨、肖基乙酸乙輯、及乙酸反應,接著 使用原甲酸三乙酯、鐵及乙酸處理以及隨後進行驗性水解。 實例254 】-(4 -下基氣-本基)-1Η -11来嗤-4 -翔酸 標題化合物MS: m/e=293 [(Μ-Η)·],熔點238-243Τ:分解(水/ 二号院)係呈灰白色結晶物質獲得,其獲得方式係經由4_苄 基氧笨胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應, 接著使用原甲酸三乙酯、鐵及乙酸處理以及隨後進行鹼性 水解。 實例255 1ΐ(3 -甲氧-4-曱基-笨基)·ιη-味喷-4-翔酸 標題化合物MS: m/e=232 (Μ+),熔點226-230。(:(水/二呤烷) 係呈薔薇色結晶物質獲得,其獲得方式係經由3_曱氧_4_曱1328584 A7 ____B7 V. INSTRUCTIONS (109) Treatment with triethyl acid, iron and acetic acid followed by alkaline hydrolysis. Example 248 JL-Bist and hydrazine 1.31-dihydro-indole-5-an-1H-imidazole-4-free oxime title compound MS: m/e = 232 (M+), mp. (: (water/dioxane) is obtained as a gray crystalline material obtained by reacting 3,4-decylenedioxyaniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by use Treatment with triethyl orthoacetate, iron and acetic acid followed by alkaline hydrolysis. Example 249 1-(3-Ga-4-methylindole-indenyl)-1Η-wazole-4-carboxyindole The title compound MS: m /e=220 (M+), melting point >250eC (water/di 1^ yard) is obtained as an off-white crystalline material obtained by 3-fluoro-4-mercaptoaniline and triethyl orthosilicate Ethyl nitroacetate, and acetic acid are reacted, followed by treatment with triethyl orthoacetate, iron and acetic acid followed by an assay of hydrolysis. Example 250 1-(3- Argon-4-methylr-yl)-1Η-哚The title compound of the azole-4-carboxylic acid MS: m/e = 252 (M + )' The melting point of 224-226 ° C (water / ii 1 ^ 院) is obtained as a white crystalline material, which is obtained by means of 3-gas _4_methoxyaniline is reacted with triethyl orthoformate 'acetic acid ethyl acetate, and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. Example 251 1-(4- Gas-2-gas-stupid) -1 Η-味 sn sn-4-cyanic acid title compound MS: m / e = 239 [(MH)-], melting point 234-2381^1^/: 4 alkane) is obtained as a pale yellow crystalline material, obtained by Reaction with 4-chloro-2-fluoroaniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by -113- This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 _ B7 V. INSTRUCTION DESCRIPTION (110) Treatment with triethyl orthosilicate, iron and acetic acid followed by alkaline hydrolysis Example 252 1-(4-Bromo-indole azole-4-carboxylic acid title compound MS : m/e = 266 (M+), melting point > 250 ° C (water / dioxane) is obtained as a pale yellow crystalline material obtained by 4-bromoaniline and triethyl orthosilicate, nitro Ethyl acetate, and acetic acid are reacted, followed by treatment with triethyl orthoacetate, iron and acetic acid followed by basic hydrolysis. Example 253 Difluoromethane-methyl V1H-imidazole·4·decanoic acid title compound MS: m /e=253 [(Μ-Η)-], m.p. 218-225. 〇(water/dihydroalkane) is obtained as a white crystalline material obtained by 4-difluoromethoxylamine and ortho-decanoic acid. Sanyi S, Xiao The acetic acid, and acetic acid are reacted, followed by treatment with triethyl orthoformate, iron and acetic acid followed by an experimental hydrolysis. Example 254] - (4 - lower base gas - presently based) - 1 Η -11 to 嗤 - 4 The title compound MS: m/e = 293 [(Μ-Η)·], melting point 238-243 Τ: decomposition (water / No. 2) is obtained as an off-white crystalline material obtained by 4-benzyloxy The stilbene is reacted with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. Example 255 1 ΐ(3-methoxy-4-indolyl-styl)·ιη-味喷-4-Acidic acid The title compound MS: m/e = 232 (Μ+), mp 226-230. (: (water/dioxane) is obtained as a rose-colored crystalline material, which is obtained by means of 3_曱氧_4_曱
裝 訂Binding
114114
1328584 A7 ________B7 _._ 五、發明説明(111 ) 基笨胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接 著使用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水 解。 實例256 _1-(4-三氟甲基-苯某来唾-4-翔酸 標題化合物MS: m/e=256 (M+),溶點>250°C(水/二1^院)係 呈淺黃色結晶物質獲得,其獲得方式係經由4-(三氟曱基)苯 胺與原甲酸三乙酯、硝基乙酸乙酯 '及乙酸反應,接著使 用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例257 1-(1,3-二氣·異笨#咕喃-5-某V1H-"朵-4-羧酸 標題化合物 MS: m/e=230 (Μ+)’ 熔點 245-247°C(DMF/水)係 呈淺褐色結晶物質獲得,其獲得方式係經由3·二氫_5•異 苯并吱喃胺(根據T.Y. Shen等人,醫藥化學期刊,1987,7JL 965製備)與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應, 接著使用原曱酸三乙酯、鐵及乙酸處理以及隨後進行鹼性 水解。 實例258 1-(4-氟-3-曱氣茉某V1H-哚唑-4-鞀S参 標題化合物MS: m/e=236 (M+),熔點>182°C分解(水/二吟烷 )係呈淺褐色結晶物質獲得,其獲得方式係經由4_氟_3甲氧 本胺與原曱酸二乙S旨、硝基乙酸乙醋、及乙酸反應,接著 使用為甲酸二乙醋、鐵及乙酸處理以及隨後進行檢性水解。 實例259 -115- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 _ B7 五、發明説明(112 ) 卜苯基-1H-哚吔-4-羧酸 標題化合物 MS: m/e=188 (M+)’ 熔點 220-221°C(DMF/水)係 呈白色結晶物質獲得,其獲得方式係經由苯胺與原甲酸三 乙酯、硝基乙酸乙酯、及乙酸反應,接著使用原曱酸三乙 酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例260 1-(4·甲氩-策某V1H-咪唑-4-羧酸 標題化合物MS: m/e=218 (M+),熔點>240°C(水/二呵烷)係 呈淺褐色結晶物質獲得,其獲得方式係經由對茴香苯胺與 原甲酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使用原 甲酸三乙酯、鐵及乙酸處理以及隨後進行鹼性水解。 實例261 1-(3-甲氳-茉某)-1Η-咪唑-4-羧酸 標題化合物MS: m/e=218 (M+),熔點196-201°C(水/二°号烷) 係呈淺紅色結晶物質獲得,其獲得方式係經由間茴香苯胺 與原曱酸三乙酯、硝基乙酸乙酯、及乙酸反應,接著使用 原甲酸三乙酯、鐵及乙酸處理以及隨後進行檢性水解。 實例262 1-(4-曱氧-3-三氟甲某-笨基)-1Η-咪唑-4-钕酴 標題化合物MS: m/e=286 (M+),熔點>141。(:分解(水/二哼烷 )係呈淺褐色結晶物質獲得,其獲得方式係經由4_甲氧·3-( 三氟曱基)笨胺與原甲酸三乙酯、硝基乙酸乙酯、及乙酸反 應’接著使用原曱酸三乙酯、鐵及乙酸處理以及隨後進行 鹼性水解。 -116- 本紙俵尺度適用中國囷家標準(CNS) A4規格(210X 297公爱)1328584 A7 ________B7 _._ V. Description of the invention (111) The reaction of a phenylamine with triethyl orthoformate, ethyl nitroacetate, and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid followed by alkali Sexual hydrolysis. Example 256 _1-(4-Trifluoromethyl-Benzene-Saliva-4-cyanate title compound MS: m/e = 256 (M+), melting point > 250 ° C (water / two 1 ^ hospital) Obtained as a pale yellow crystalline material obtained by reacting 4-(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate' and acetic acid, followed by triethyl orthoacetate, iron and acetic acid Treatment and subsequent alkaline hydrolysis. Example 257 1-(1,3-digas·iso-stuppy#-5-V1H-"--4-carboxylic acid title compound MS: m/e=230 (Μ +)' Melting point 245-247 ° C (DMF / water) is obtained as a light brown crystalline material obtained by means of 3 · dihydro 5 5 isophthalonitrile (according to TY Shen et al., Journal of Medicinal Chemistry) , 1987, 7JL 965 preparation) is reacted with triethyl orthosilicate, ethyl nitroacetate, and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid followed by alkaline hydrolysis. Example 258 1-( 4-Fluoro-3-indolyl sulphate V1H-carbazole-4-indole S. The title compound MS: m/e = 236 (M+), melting point > 182 ° C decomposition (water / dioxane) is shallow Obtained as a brown crystalline material obtained by 4_fluoro_3 The amine is reacted with dibasic acid diacetate, nitroacetic acid ethyl acetate, and acetic acid, followed by treatment with formic acid diethyl acetonate, iron and acetic acid, followed by prophylactic hydrolysis. Example 259 -115- This paper scale applies to China National Standard (CNS) A4 Specification (210X 297 mm) 1328584 A7 _ B7 V. Description of Invention (112) Phenyl-1H-indole-4-carboxylic acid title compound MS: m/e=188 (M+)' The melting point of 220-221 ° C (DMF / water) is obtained as a white crystalline material obtained by reacting aniline with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by triethyl orthosilicate, Iron and acetic acid treatment and subsequent alkaline hydrolysis. Example 260 1-(4·A-argon-Cym-V1H-imidazole-4-carboxylic acid title compound MS: m/e = 218 (M+), melting point > 240 ° C (water/dioxane) is obtained as a light brown crystalline material obtained by reacting p-anisidine with triethyl orthoformate, ethyl nitroacetate, and acetic acid, followed by triethyl orthoformate, iron and Acetic acid treatment followed by alkaline hydrolysis. Example 261 1-(3-Methylhydrazine-Momot)-1Η-Imidazole-4-carboxylic acid title complex MS: m/e = 218 (M+), melting point 196-201 ° C (water / hexane) obtained as a light red crystalline material obtained by the intermediate anisidine and triethyl orthophthalate, Ethyl nitroacetate and acetic acid are reacted, followed by treatment with triethyl orthoformate, iron and acetic acid followed by a prophylactic hydrolysis. Example 262 1-(4-Oxyl-3-trifluoromethyl-phenyl)-1 oxime-imidazole-4-indole The title compound MS: m/e = 286 (M+), mp. (: Decomposition (water/dioxane) is obtained as a light brown crystalline material obtained by 4-methoxy-3-(trifluoromethyl) phenylamine and triethyl orthoformate, ethyl nitroacetate. And acetic acid reaction' followed by treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. -116- This paper scale applies to China National Standard (CNS) A4 specification (210X 297 public)
裝 訂Binding
13285841328584
實例263 . 1二(3,4·二氧苯棊)-5·甲羞二出咪唑_4_羧酸乙酯以及 二乳-苯基)-5-甲基-3H-°朵吨-4-始酸乙酯 3,4-二氣苯基二羥硼酸(8 22克,43」毫莫耳),4_曱基咪 唑羧酸乙酯(6.64克,43.1毫莫耳)及乙酸銅(11)(7 83克,43」 毫莫耳)於二氣曱烷(86毫升)之懸浮液於2〇ec攪拌48小時。 過濾去除全部固體,有機相以乙酸乙酯(500毫升)稀釋及與 飽和瑟納特(Seignette)鹽水溶液共同攪拌。經過濾及蒸發後 ’殘餘物經層析(矽膠,以梯度己烷至乙酸乙酯洗提)獲得 2.8克(22%) 3-(3,4-二氣-苯基)_5_甲基_3H·^唑冰叛酸乙醋[ 惊點135-136°C (乙酸乙酯/己烷)’ MS: m/e=298 (M+)]以及 10克(8%) 1-(3,4-二氣-笨基)_5 -曱基·ΐΗ-°米唾-4-缓酸乙酷[ 炫點 163-164°C (乙酸乙酯/己院),MS: m/e=298 (Μ+)]。 實例264 1-(3,4-二氣-茉某V1H-咪吔-4-基1-甲薛 ^(3,4-二氯苯基)-1Η-咪唑-4-羧酸(20_0克,77.8毫莫耳)使用 1Μ BH3 THF錯合物(100毫升)處理及回流2小時。混合物冷 卻至5°C及缓慢加入曱醇(20毫升)。蒸發去除全部揮發分後 ,殘餘物攝取於2N鹽酸溶液(1〇〇毫升)及回流2小時。過遽 後熱水相缓慢使用2N氫氧化鈉溶液處理至pH 1〇。冷卻時標 題化合物結晶呈白色物質(12.2克,65%)。熔點146_147〇c ( 水),MS: m/e=242 (M+)。 實例265至292係根據實例264所述概略程序製備。 實例265 -117 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) A7 B7 五、發明説明(114 ) U二(4-氧-3-t^苯基)_1H-咪唑薛 標題化 σ 物,MS: m/e=222 (Μ+),炫點 126_i33eC (水)係呈 淺褐色結晶物質獲得,其獲得方式係經由1(4_氣_3_甲基_苯 基)·1Η-咪唑·4_羧酸與BA THF錯合物反應接著進行水解後 續處理。 實例266 II-四氫茚·5-基-1H-咪唑·4·甚甲辞— 標題化合物,MS: m/e=214 (Μ+),熔點128-133。(:(水)係呈 淺褐色結晶物質獲得,其獲得方式係經由卜四氫茚_5_基· 1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續處 實例267 二甲基-茉某)-1Η-哚唑_4_某1·甲气 標題化合物,MS: m/e=202 (M+),熔點11〇_116。〇(水)係呈 灰白色結晶物質獲得,其獲得方式係經由1 _(3,4_二曱基_苯 基)-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例268 對甲茉基-1H-咣唑-4-基甲醇 標題化合物,MS: m/e=188 (M+),熔點i〇l-l〇2°C (水)係呈 灰白色結晶物質獲得’其獲得方式係經由1-對曱笨基一士味 啥-4-羧酸與BH3 THF錯合物反應接著進行水解後續處理。 實例269Example 263.2 bis(3,4·dioxybenzoquinone)-5·methazine diimidazole imidazole _4_carboxylic acid ethyl ester and di-milk-phenyl)-5-methyl-3H-°dox-4 - ethyl orthoacetate 3,4-diphenylphenyldihydroxyboronic acid (8 22 g, 43" mmol), ethyl 4-mercaptoimidazolecarboxylate (6.64 g, 43.1 mmol) and copper acetate ( 11) (7 83 g, 43 mM) in a suspension of dioxane (86 mL) was stirred at 2 EtOAc for 48 hours. The whole solid was removed by filtration, and the organic phase was diluted with ethyl acetate (500 ml) and stirred with a sat. After filtration and evaporation, the residue was purified by chromatography (EtOAc eluting eluting elut 3H·^azole ice resorcinating ethyl vinegar [spot 135-136 ° C (ethyl acetate / hexane) 'MS: m / e = 298 (M +)] and 10 g (8%) 1- (3, 4 - 二气-笨基)_5 -曱基·ΐΗ-°米唾-4-缓酸乙酷 [ Hyun Point 163-164°C (ethyl acetate/hexel), MS: m/e=298 (Μ +)]. Example 264 1-(3,4-digas-jamma V1H-imidol-4-yl 1-methylxene^(3,4-dichlorophenyl)-1Η-imidazole-4-carboxylic acid (20_0 g, 77.8 mmol; treated with 1 Μ BH3 THF complex (100 mL) and reflux for 2 hr. The mixture was cooled to 5 ° C and decyl alcohol (20 mL) was slowly added. After evaporation of all volatiles, the residue was taken up in 2N. Hydrochloric acid solution (1 ml) and reflux for 2 hours. After hot water, the hot water phase was slowly treated with 2N sodium hydroxide solution to pH 1. The title compound crystals as white (12.2 g, 65%). 〇c (water), MS: m/e = 242 (M+). Examples 265 to 292 were prepared according to the general procedure described in Example 264. Examples 265 -117 This paper scale applies to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) A7 B7 V. Inventive Note (114) U bis(4-oxo-3-t^phenyl)_1H-imidazole Xue title σ, MS: m/e=222 (Μ+), Hyun Point 126_i33eC (water) is obtained as a light brown crystalline material obtained by reacting 1(4_gas_3_methyl-phenyl)·1Η-imidazole·4-carboxylic acid with BA THF complex followed by Subsequent hydrolysis treatment. 266 II-Tetrahydroindole·5-yl-1H-imidazole·4·Reaching — title compound, MS: m/e = 214 (Μ+), melting point 128-133. (: (water) is light brown Obtained as a crystalline material obtained by reacting tetrahydrofuran-5-yl-1H-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis followed by example 267 dimethyl-mum)-1Η- Carbazole _4_1·1 gas title compound, MS: m/e = 202 (M+), melting point 11 〇 _116. 〇 (water) is obtained as an off-white crystalline material obtained by 1 _(3 , 4_Dimercapto-phenyl)-1H-imidazole-4-carboxylic acid is reacted with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 268 p-Methylyl-1H-indazol-4-ylmethanol title compound , MS: m/e = 188 (M+), melting point i〇ll 〇 2 ° C (water) is obtained as an off-white crystalline material, which is obtained by 1-pair 曱 基 一 一 啥 啥 啥 4-carboxylic acid The reaction with BH3 THF complex followed by hydrolysis followed up. Example 269
Ubii-氟-3-甲某-笑某V1H-咪唑-4-某1-甲醢 •118· 1328584 A7 B7 五、發明説明(115 ) 標題化合物,MS: m/e=206 (M+),.熔點13 8-144°C (水)係呈 灰白色結晶物質獲得,其獲得方式係經由1-(4-氟-3-甲基-苯 基)-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例270 「1-(4-甲基硫烷基-笨基V1H-咪唑-4-基1-甲醇 標題化合物,MS: m/e=220 (M + ),熔點108-114°C (水)係呈 淺褐色結晶物質獲得,其獲得方式係經由1-(4-甲基硫烷基-苯基)-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解 後續處理。 實例271 Γΐ-(3-三氟甲基-苯基V1H-咪唑-4-基1-甲醇 標題化合物,MS_ m/e=242 (Μ+),熔點96-100°C (水)係呈白 色結晶物質獲得,其獲得方式係經由1-(3-三氟曱基-苯基)- 1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續處 理。 實例272 Γ 1-(4-氟-3-三氟曱基-笨基)-1Η-咪唑-4-基卜甲醇 標題化合物,MS: m/e = 260 (M + ),熔點142-146°C (水)係呈 白色結晶物質獲得,其獲得方式係經由1-(4-氟-3-三氟曱基-苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解 後續處理。 實例273 『1-(3-氟-4-三氟甲基-茉某V1H-咪唑-4-基1-曱醇 -119- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 裝 訂Ubii-Fluor-3-A-Laughter V1H-Imidazole-4-Mercapto-118. 1328584 A7 B7 V. Description of Invention (115) Title Compound, MS: m/e=206 (M+),. The melting point of 13 8-144 ° C (water) is obtained as an off-white crystalline material obtained by the method of 1-(4-fluoro-3-methyl-phenyl)-1H-imidazole-4-carboxylic acid and BH3 THF. The compound reaction is followed by hydrolysis followed up. Example 270 "1-(4-Methylsulfanyl-styl-V1H-imidazol-4-yl-methanol-title compound, MS: m/e = 220 (M + ), m.p. It is obtained as a light brown crystalline material obtained by reacting 1-(4-methylsulfanyl-phenyl)-1H-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis for subsequent treatment. 271 Γΐ-(3-Trifluoromethyl-phenyl V1H-imidazol-4-yl 1-methanol title compound, MS_m/e=242 ( Μ+), melting point 96-100 ° C (water) as white crystal Substance obtained obtained by reacting 1-(3-trifluorodecyl-phenyl)-1H-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 272 Γ 1-(4 -Fluoro-3-trifluoromethyl-p-styl)-1 -imidazolyl-4-ylpropanol title compound, MS: m/e = 260 (M + ), mp 142-146 ° C (water) The crystalline material is obtained in a manner that is obtained by reacting 1-(4-fluoro-3-trifluoromethyl-phenyl)-1 -imidazole-4-carboxylic acid with a BH3 THF complex followed by hydrolysis for subsequent treatment. 『1-(3-Fluoro-4-trifluoromethyl-jamma V1H-imidazol-4-yl 1-nonanol-119- This paper scale applies to China Standard (CNS) A4 size (210X 297 mm) stapling
13285841328584
標題化合物’ MS: m/e=260 (M+)熔點142-144。(:(水)係呈 白色結晶物質獲得,其獲得方式係經由1-(3-氟-4-三氟甲基_ 苯基)-1Η-咪唑·4_羧酸與BH3 THF錯合物反應接著進行水 後續處理。 實例274 Γ.1:(4-_£·基曱某笑某V1H•哚唑-4·^Ί•甲醢 標題化合物,MS: m/e=257 (Μ+Η+),熔點 116-119¾ (水)係 呈白色結晶物質獲得’其獲得方式係經由1-(4-曱基-3-三氣 曱基·苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行 水解後續處理。 實例275 Π-(4-氧.:3-曱氣-茉某)·1Η-哚唑-4-基1·甲醢 標題化合物’ MS: m/e=23 8 (Μ+) ’熔點116-119t (水)係至 白色結晶物質獲得,其獲得方式係經由1-(4-氣-3-曱氧-苯基 )-1H-咪唑-4-羧酸與BHs THF錯合物反應接著進行水解後續 處理。 實例276 Π-(4-氟-3-甲氩-装某V1H-咄吨-4-某1-甲薛 標題化合物,MS: m/e=222 (Μ+),熔點174-177°C (水)係呈 灰白色結晶物質獲得,其獲得方式係經由1-(4-氟-3-曱氧-苯 基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例277 Γ1-(4-氣-笨某V1H-咪唑-4-基1-甲醇_ 120- 本纸張尺度適用中國國家標準(CNS) A4规格(210X297公釐)The title compound 'MS: m/e = 260 (M+) m. (: (water) is obtained as a white crystalline material obtained by reacting 1-(3-fluoro-4-trifluoromethyl-phenyl)-1Η-imidazole-4-carboxylic acid with BH3 THF complex. Subsequent water subsequent treatment. Example 274 Γ.1:(4-_£·基曱某笑V1H•carbazole-4·^Ί•甲醢 Title compound, MS: m/e=257 (Μ+Η+ ), melting point 116-1193⁄4 (water) is obtained as a white crystalline material's obtained by 1-(4-mercapto-3-trimethylsulfonylphenyl)-1Η-imidazole-4-carboxylic acid and BH3 The THF complex reaction followed by hydrolysis followed up. Example 275 Π-(4-oxo.: 3-oxime-mum)·1Η-indazol-4-yl-1·carbazide title compound 'MS: m/e =23 8 (Μ+) 'Melting point 116-119t (water) obtained from white crystalline material obtained by 1-(4-carb-3-oxo-phenyl)-1H-imidazole-4-carboxylate The acid is reacted with the BHs THF complex followed by hydrolysis for subsequent treatment. Example 276 Π-(4-Fluoro-3-methyl argon-loaded with a V1H-xanthene-4-one-methyl-title compound, MS: m/e = 222 (Μ+), melting point 174-177 ° C (water) obtained as an off-white crystalline material obtained by 1-(4-fluoro-3-indolyl-phenyl)-1 - Imidazole-4-carboxylic acid is reacted with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 277 Γ1-(4-Gas-Bud V1H-Imidazol-4-yl 1-methanol _ 120- This paper scale applies to China Standard (CNS) A4 specification (210X297 mm)
訂Order
1328584 A7 B71328584 A7 B7
標題化合物’ MS: m/e=i〇8 (M+),溶點115-116。〇(乙酸乙酽 )係呈白色結晶物質獲得,其獲得方式係經由1_(4-氣_笨基 1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續處 理。 實例278 '本并Γ1.31二氮伍園-5 -基-1Η-°来唾-4-基甲醇 標題化合物,MS: m/e=218 (M+),嫁點150-157°C (水)係呈 白色結晶物質獲得,其獲得方式係經由苯并二氧伍 園-5-基-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水 解後續處理。 實例279 [1-(3-氟-4-甲某-茉某V1H-咪唑-4-基1-甲薛 標題化合物,MS: m/e=206 (M+),熔點115-122。(:(水)係呈 淺黃色結晶物質獲得,其獲得方式係經由i-p —氟_4_曱基-苯 基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例280 [1-(3-氣-4-甲氣-装基)-1Η-哚唑-4-基1-甲醢 標題化合物,MS: m/e=238 (M+),熔點133-138X:(水)係呈 灰白色結晶物質獲得,其獲得方式係經由1_(3-氣-4-曱氧-苯 基)-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例281 Γ1-(4-氣-2-氣-茉基)-1Η-咪唑-4-早甲_ -121 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公著)The title compound 'MS: m/e = i 〇 8 (M+), melting point 115-116. The hydrazine (acetonitrile acetate) is obtained as a white crystalline material obtained by the reaction of 1-(4- gas-phenyl 1H-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis followed. Example 278 ' The title compound is MS3 m/e=218 (M+), and the grafting point is 150-157°C (water). The white crystalline material was obtained by the reaction of benzodioxolan-5-yl-1H-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis followed up. Example 279 [1-(3- Fluor-4-methyl-M-V1H-imidazol-4-yl-l-methyl-title compound, MS: m/e=206 (M+), m.p. 115-122. (: (water) is a pale yellow crystalline material. Obtained, obtained by reacting ip-fluoro-4-indolyl-phenyl)-1Η-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 280 [1-(3- gas -4-Methane-supported)-1Η-oxazol-4-yl 1-methylindole title compound, MS: m/e = 238 (M+), mp 133-138X: (water) obtained as an off-white crystalline material Obtained by 1_(3-Ga-4-oxo-phenyl)-1H-imidazole-4-carboxylic acid with BH3 THF The complex reaction followed by hydrolysis followed up. Example 281 Γ 1-(4-Ga-2-Gas-Methyl)-1Η-imidazole-4-early A_ -121 - This paper scale applies to Chinese National Standard (CNS) A4 Specifications (210 X 297 public)
裝 訂Binding
線 1328584 A7 B7 五、發明説明(118 ) 標題化合物,MS: m/e=226 (M+),.熔點120-130°C (水)係呈 灰白色結晶物質獲得,其獲得方式係經由1-(4-氣-2-氟-苯基 )-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續 處理。 實例282 [1-(4-溴-苯基)-111-咪唑-4-基1-甲醇 標題化合物,MS: m/e=252 (M+),熔點132-139°C (水)係呈 淺黃色結晶物質獲得,其獲得方式係經由1-(4-溴-苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續處理。 實例283 Γ1-Μ-二氣甲茉某V1H-咪唑-4-基1-甲薛 標題化合物,MS: m/e=240 (M+),熔點66-72°C (水)係呈淺 褐色結晶物質獲得,其獲得方式係經由1-(4-二氟曱氧-苯基 )-1H-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解後續 處理。 實例284 Γ1-(4-芊基氣-茉基)-1Η-咪唑-4-基1-甲醇 標題化合物,MS: m/e=280 (M+),熔點151-152°C (乙酸乙酯 )係呈白色結晶物質獲得,其獲得方式係經由1-(4-芊基氧-苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水解 後續處理。 實例285 Γ1-Π-甲氣-4-甲基-茉基)-1Η-咪唑-4-基1-甲醇 標題化合物,MS: m/e=218 (M+),熔點141-147°C (水)係呈 -122- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 B7 五 發明説明(119 白色結晶物質獲得,其獲得方式係經由i_(3-甲氧-4-曱基-苯 基)-1H-咪唑-4_羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例286 LLI4-三氤甲某-茉基)-ιη·咣基μ甲醢 標題化合物,MS: m/e=242 (Μ+),熔點153-156Χ:(水)係呈 灰白色結晶物質獲得,其獲得方式係經由1_(4_三氟曱基-苯 基)·1Η-咪唑-4-羧酸與BA THF錯合物反應接著進行水解後 續處理。 實例287 [1-(1,3-二氪-異笨并咬嗔-5-某)-1!^-°米唾-4-某1-甲醇 標題化合物’ MS: m/e=216 (Μ+),熔點161-165。(:(乙酸乙醋 )係呈灰白色結晶物質獲得,其獲得方式係經由1_(1,3·二氫_ 異笨并呋喃-5-基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接 著進行水解後續處理。 實例288 LM3-氟-4-甲氣-苯基MH-咄岫_4-基1·甲醇 標題化合物,MS: m/e=222 (M+),熔點112-120°C (二氯曱烧 /二異丙基醚)係呈白色結晶物質獲得,其獲得方式係經由 (4-氟-3-甲氧-苯基)·1Η-咪唑-4-羧酸與BH3 THF錯合物反應 接著進行水解後續處理》 實例289 (1-茉某-1H-咪唑-4-基V甲醢 標題化合物’ MS: m/e=174 (M+),熔點U6-118T:(水)係呈 -123- 本紙朶尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 A7 B7 五、發明説明 白色結晶物質獲得’其獲得方式係經由苯基_1Η·ο米峻_4_ 羧酸與BHbTHF錯合物反應接著進行水解後續處理。 實例290 Γ1-(4-甲氧-茉某朵唾-4-某1-甲薛 標題化合物’ MS: m/e=204 (M+),熔點i〇7-l〇9°C (乙酸乙醋 )係呈白色結晶物質獲得’其獲得方式係經由1_(4_曱氧-苯 基)-1H·。米唾-4-羧酸與BH3 THF錯合物反應接著進行水解後 續處理。 實例291 『1-(3-甲氡-笨某咪唑-4-某1-甲醢 標題化合物’ MS: m/e=204 (M+),熔點80-85T:(乙酸乙酯/ 己炫·)^呈白色結晶物質獲得’其獲得方式係經由1_(3_曱 氧-笨基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應接著進行水 解後續處理。 實例292 Π-(4 -曱氧-3-三氟甲基-笨基米峰-4-某1·甲辞 標題化合物,MS: m/e=272 (M+) ’熔點147-150X:(水)係呈 灰白色結晶物質獲得’其獲得方式係經由1 _(4_甲氧=氣 曱基-苯基)-1Η-味啥-4-羧酸與BH3 THF錯合物反應接著進行 水解後續處理。 實例293 Π-(3·氣-4-甲基-策基)-1 H·畔唾-4·基~|·甲畔 根據實例234’ 3-氯-4-甲基笨胺(21.5克,150毫莫耳)與原甲 酸三乙酯、硝基乙酸乙酯及乙酸反應,接著使用原曱酸三 -124-Line 1328584 A7 B7 V. Description of the Invention (118) The title compound, MS: m/e = 226 (M+), mp 120-130 ° C (water) obtained as an off-white crystalline material obtained by 1-( 4-Vethyl-2-fluoro-phenyl)-1H-imidazole-4-carboxylic acid is reacted with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 282 [1-(4-Bromo-phenyl)-111-imidazol-4-yl 1-methanol title compound, m.p. The yellow crystalline material is obtained by the reaction of 1-(4-bromo-phenyl)-1Η-imidazole-4-carboxylic acid with a BH3 THF complex followed by hydrolysis for subsequent treatment. Example 283 Γ1-Μ-二气甲莫V1H-imidazol-4-yl 1-methylxyl title compound, MS: m/e=240 (M+), mp 66-72 ° C (water) as light brown crystal The material is obtained in a manner that is obtained by reacting 1-(4-difluoroindolyl-phenyl)-1H-imidazole-4-carboxylic acid with a BH3 THF complex followed by hydrolysis for subsequent treatment. Example 284 Γ 1-(4-Mercapto-m-yl)-1 oxime-imidazol-4-yl-methanol mp mp m m m m m It is obtained as a white crystalline material obtained by reacting 1-(4-mercaptooxy-phenyl)-1Η-imidazole-4-carboxylic acid with a BH3 THF complex followed by hydrolysis for subsequent treatment. Example 285 Γ1-Π-Methane-4-methyl-methyl)-1Η-imidazol-4-yl 1-methanol title compound, m.p. ) is -122- This paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm) 1328584 A7 B7 Five inventions description (119 white crystalline material obtained, obtained by i_(3-methoxy-4) - mercapto-phenyl)-1H-imidazole-4_carboxylic acid is reacted with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 286 LLI4-trimethyl-methyl-methyl)-ιη·咣基μ甲醢Compound, MS: m/e = 242 (Μ +), melting point 153-156 Χ: (water) obtained as an off-white crystalline material obtained by 1-(4-trifluoromethyl-phenyl)·1Η-imidazole The 4-carboxylic acid is reacted with a BA THF complex followed by a subsequent treatment with hydrolysis. Example 287 [1-(1,3-dioxin-iso-and-bito-5-m)-1!^-°m-sodium-4-one-methanol title compound 'MS: m/e=216 (Μ +), melting point 161-165. (: (ethyl acetate) is obtained as an off-white crystalline material obtained by the method of 1_(1,3·dihydro-isobenzofuran-5-yl)-1Η-imidazole-4-carboxylic acid and BH3 THF. The </ br> </ br> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; 120 ° C (dichlorohydrazine / diisopropyl ether) is obtained as a white crystalline material obtained by (4-fluoro-3-methoxy-phenyl)·1Η-imidazole-4-carboxylic acid and BH3 THF complex reaction followed by hydrolysis for subsequent treatment. Example 289 (1-Methyl-1H-imidazol-4-yl V-carboxamide title compound 'MS: m/e = 174 (M+), mp. Water) is -123- This paper is suitable for Chinese National Standard (CNS) A4 specification (210X297 mm) 1328584 A7 B7 V. Invention Description White crystalline material obtained 'its obtained by phenyl_1Η·ο米峻_ 4_ Carboxylic acid is reacted with BHbTHF complex followed by hydrolysis for subsequent treatment. Example 290 Γ1-(4-methoxy-jamma sal-4-a 1-methylxyl title compound 'MS: m/e=204 (M+) , melting point i〇7-l〇9°C (ethyl acetate) The white crystalline material was obtained as 'obtained by the reaction of 1_(4_曱-oxy-phenyl)-1H·. m.sup.4-carboxylic acid and BH3 THF complex followed by hydrolysis followed up. Example 291 『1- (3-methylhydrazine-stupidyl imidazole-4-one 1-methylindole title compound 'MS: m/e=204 (M+), mp 80-85T: (ethyl acetate / hex···) The obtained method was obtained by reacting 1_(3_oxa-phenyl)-1Η-imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolysis for subsequent treatment. Example 292 Π-(4-oxo-3 -Trifluoromethyl-stupyl-mythracene-4-one-1. The title compound, MS: m/e = 272 (M+) 'melting point 147-150X: (water) is obtained as an off-white crystalline material. The reaction is carried out by reacting 1 _(4_methoxy = gas thiol-phenyl)-1 Η-miso-4-carboxylic acid with BH3 THF complex followed by hydrolysis. Example 293 Π-(3·gas-4 -Methyl-Zipyl)-1 H·Saliva-4·yl~|·A-side according to Example 234' 3-Chloro-4-methyl-p-amine (21.5 g, 150 mmol) with triethyl orthoformate Ester, ethyl nitroacetate and acetic acid are reacted, followed by the use of the original ruthenium tris-124-
裝 訂Binding
k 本纸張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1328584 A7 ___ B7 五、發明説明(121 ) ' " 乙酯、鐵及乙酸處理以及隨後進行.驗性水解。分離得之酸 (10.0克)根據實例264經由與BH3 THF錯合物反應而直接還 原,接著進行水解後續處理’獲得標題化合物呈白色結晶 固體(5.2克’ 16%)。熔點126-133 °C (乙酸乙酯/己烧),MS: m/e=222 (M+)。 實例294至297係根據實例293所述概略程序製備。 實例294 Π-(4-氣-3-三氟甲基-笨某)-1只-°米嗅-4-某~|-甲薛· 3-三氟甲基-4-氣苯胺與原甲酸三乙酯 '硝基乙酸乙酯及乙 酸反應,接著使用原甲酸三乙酯、鐵及乙酸處理,以及隨 後接受鹼性水解。分離之酸直接使用BH3 THF錯合物還原 ’接著進行水解後續處理,獲得標題化合物,熔點148-153 °C (乙酸乙酯/二異丙基醚),MS: m/e=276 (M+),呈白色結 晶固體。 實例295k This paper size applies to the Chinese National Standard (CNS) A4 specification (210X 297 mm) 1328584 A7 ___ B7 V. Description of invention (121) ' " Ethyl, iron and acetic acid treatment and subsequent. Hydrophilic hydrolysis. The isolated acid (10.0 g) was purified directly from EtOAc EtOAc (EtOAc) Melting point 126-133 ° C (ethyl acetate / hexane), MS: m / e = 222 (M+). Examples 294 through 297 were prepared according to the general procedure described in Example 293. Example 294 Π-(4-Ga-3-trifluoromethyl-stupid)-1 -°米 sn sn-4-a~|-methylxyl-3-trifluoromethyl-4-aniline and orthoformic acid The triethyl ester 'nitroacetate and acetic acid are reacted, followed by treatment with triethyl orthoformate, iron and acetic acid, and then basic hydrolysis. The isolated acid is directly purified using BH3 THF </RTI> </ RTI> </ RTI> </ RTI> followed by hydrolysis to give the title compound, m.p. 148-153 <RTIgt; , a white crystalline solid. Example 295
Ll-(3-氯-4-氟-茉某1Η-_吨-4-基1·甲醇 3- 氣-4-氣苯胺與原甲酸三乙酯、硝基乙酸乙酯及乙酸反應 ’接著使用原曱酸三乙酯、鐵及乙酸處理,以及隨後接受 驗性水解。分離之酸直接使用BH3 THF錯合物還原,接著 進行水解後續處理,獲得標題化合物,熔點(水) ,MS: m/e=226 (M+),呈灰白色結晶固體。 實例296 (_1-聯装-4·-基-華甲醇 4- 苯基苯胺與原曱酸三乙酯、硝基乙酸乙酯及乙酸反應, -125- 本紙張&度ia_ g目家標準(CNS) M規格(嫩297公爱)Ll-(3-chloro-4-fluoro-jam-1Η-_吨-4-yl-1·methanol 3-aluminum-4-aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid' Treatment with triethyl orthoacetate, iron and acetic acid, and subsequent acceptance of the analytical hydrolysis. The isolated acid is directly reduced with BH3 THF complex followed by hydrolysis to give the title compound, m.p. e = 226 (M+), as an off-white crystalline solid. Example 296 (_1-Co-B-4--M-Methanol 4-phenylphenylamine was reacted with triethyl orthanoate, ethyl nitroacetate and acetic acid, - 125- Paper & degree ia_ g target standard (CNS) M specification ( tender 297 public)
裝 訂Binding
k- 1328584 A7 ------- B7 五、發明説明(122 ) 接著使用原甲酸三乙酯、鐵及乙酸處理,以及隨後接受鹼 性水解。分離之酸直接使用BH3 THF錯合物還原,接著進 行水解後續處理,獲得標題化合物,熔點173-177。(:(二氣甲 烧/二異丙基醚),MS: m/e=250 (M+),呈黃色結晶固體。 實例297 異丙暮-3-甲基-茉某V1H-咪唑-4-基1-甲薛 4-異丙基-3-甲基-苯胺與原曱酸三乙酯 '硝基乙酸乙酯及乙 酸反應’接著使用原曱酸三乙酯、鐵及乙酸處理,以及隨 後接受鹼性水解❶分離之酸直接使用BH3 THF錯合物還原 ’接著進行水解後續處理,獲得標題化合物,熔點98-1〇2 C (一乳曱烧/二異丙基謎),MS: m/e=230 (M+),呈黃色結 晶固體。 實例298K-1328584 A7 ------- B7 V. INSTRUCTION DESCRIPTION (122) Subsequent treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. The isolated acid was directly purified using a BH3 THF complex, followed by hydrolysis to give the title compound, m.p. (: (dioxane/diisopropyl ether), MS: m/e = 250 (M+), as a yellow crystalline solid. Example 297 isopropyl hydrazol-3-methyl-m. 1-methylxyl-4-isopropyl-3-methyl-phenylamine is reacted with triethyl orthoacetate 'nitroacetic acid and acetic acid' followed by treatment with triethyl orthosilicate, iron and acetic acid, and subsequently The acid which was subjected to basic hydrolysis and hydrazine separation was directly purified using BH3 THF complex' followed by hydrolysis to give the title compound, m.p. 98-1 〇 2 C (yield/diisopropyl), MS: m /e=230 (M+), as a yellow crystalline solid. Example 298
Li-(3,4-二氳-菜其)-5-甲某-1H-咪唑-4-某1-甲醢 於1-(3,4-二氣-苯基)·5-曱基-iH-°米。坐-4-叛酸乙酯(0.82克, 2.7毫莫耳)於THF (27毫升)之溶液内,逐份加入紹氫化鐘 (0.21克’ 5.4毫莫耳)維持溫度小於1〇它。混合物於冰浴授 拌2小時’然後緩慢加入1毫升飽和瑟納特鹽水溶液。以乙 酸乙酯100毫升稀釋後,混合物經過濾,濃缩及層析[矽膠 ’以梯度二氣甲烷至80%(二氯甲烷/甲醇=9:1)洗提]。獲得 標題化合物呈白色結晶固體(0.46克,6 6%)。炫點174-17 5 °C (二氣曱烷/二異丙基醚),MS: m/e=256 (M+)。 實例299 4-氣曱基-1-(3.4·二氩-笑篡V1H-咪唑 •126- 本紙張尺度適用中g g家科(CMS) A4規格(21Q X 297公爱) 1328584 A7 B7 五、發明説明(123 ) 於冰浴緩慢添加亞磺醯氣(39.5毫升,過量4-二氯-苯基)-111-°米咬-4-基]-甲醇(9,6克,39.5毫莫耳)。所得混合 物攪拌24小時。蒸發後’油狀殘餘物以醚濕磨,獲得1〇 克(86%)標題化合物鹽酸鹽呈灰白色固體。為了獲得自由態 驗,鹽小心使用水性氫氧化鈉(2N)中和及以乙酸乙酯萃取 。有機相經脫水(硫酸鈉)及濃縮獲得8.43克(95%)標題化合 物呈灰白色固體。炫點146-147 °C分解(乙酸乙酯/己统), MS: m/e=260 (M+)。 實例3 0 0 m-咪唑,1-ΓΓ1-(3,4-二氣苯基)-iH-唑唑-4-某1甲甚卜9-崎 基- 4-氣甲基-1-(3,4-二氯苯基)-lH-咪唑(2.0克,7.5毫莫耳)溶解 於DMF (25毫升)’加入2-硝基咪唑(1〇克,8.8毫莫耳)及碳 酸铯(1.43克,4.4毫莫耳),結果所得混合物於7〇°c攪拌3小 時。蒸發去除溶劑後,殘餘物溶解於乙酸乙酯及以水洗滌 。有機相經脫水(硫酸鈉),濃縮及層析[矽膠,以梯度二氣 曱烷至50%(二氣甲烷/甲醇=9:1)洗提]獲得2 48克(98%)標題 化合物呈灰白色固體。熔點130_131。〇(二氣甲烷/二異丙基 醚),MS: m/e=291 [(M-N〇2)+]。 實例301 11^-°十、啥’ 氣_3·甲某苯基)_1H-咪唑_4_篡1甲其 硝基- 根據實例299 [1-(4-氯-3-甲基-笨基)_1H•咪唑_4_基卜甲醇與 亞磺醯氣反應,所得4-氣曱基-丨气肛氣_3·甲基_笨基)·1Η_咪Li-(3,4-diindole-Vinyl)-5-methyl-1H-imidazole-4-some 1-methylindole in 1-(3,4-dioxa-phenyl)·5-fluorenyl- iH-° meters. A solution of 4-deoxyethyl ester (0.82 g, 2.7 mmol) in THF (27 mL) was added portionwise to EtOAc (0.21 g <RTIgt; The mixture was stirred in an ice bath for 2 hours' then slowly added 1 ml of a saturated sodium salt solution. After diluting with 100 ml of ethyl acetate, the mixture was filtered, concentrated and chromatographed eluted with EtOAc EtOAc (EtOAc:EtOAc The title compound was obtained as a white crystalline solid (0.46 g, 6%). Hyun point 174-17 5 ° C (dioxane / diisopropyl ether), MS: m / e = 256 (M +). Example 299 4-gas fluorenyl-1-(3.4·di-argon-smiling V1H-imidazole•126- This paper scale applies to gg family (CMS) A4 specification (21Q X 297 public) 1328584 A7 B7 V. Invention Description (123) Slowly add sulfinamide (39.5 ml, excess 4-dichloro-phenyl)-111-° m--4-yl]-methanol (9,6 g, 39.5 mmol) in an ice bath. The resulting mixture was stirred for 24 hours. After evaporation, the oily residue was triturated with ether to give 1 g (yield: 86%) of the title compound hydrochloride as an off white solid. The mixture was neutralized with EtOAc. , MS: m/e = 260 (M+). Example 3 0 0 m-imidazole, 1-indole 1-(3,4-diphenyl)-iH-oxazol-4-one 1 Azza 9-Saki 4- 4-methylmethyl-1-(3,4-dichlorophenyl)-lH-imidazole (2.0 g, 7.5 mmol) dissolved in DMF (25 mL) - 2-nitroimidazole (1 加入) Grams, 8.8 millimoles) and barium carbonate (1.43 grams, 4.4 millimoles), the result The mixture was stirred at 7 ° C for 3 hours. After evaporation of the solvent, the residue was crystallised eluted eluted eluted eluted Obtained to 50% (di-methane/methanol = 9:1) eluted to yield 2 48 g (98%) of the title compound as pale white solid. mp. /e=291 [(MN〇2)+]. Example 301 11^-°10, 啥' gas _3·methyl phenyl)_1H-imidazole _4_篡1 nitro group - according to example 299 [1 -(4-Chloro-3-methyl-phenyl)_1H•imidazole_4_ylbupropanol is reacted with sulfinium gas to obtain 4-gas sulfhydryl-helium anal gas_3·methyl_stupyl) ·1Η_咪
1328584 A7 ________B7 _ 五、發明説明(124 ) 嗤進一步呈其鹽酸鹽直接反應。如此如實例300所述’ 4-氣 曱基-1-(4-氣-3-甲基-苯基)·1Η-咪唑鹽酸鹽與2-硝基咪唑 (1.2當量)及碳酸鉋(1.2當量)反應,於蒸發及萃取後續處理 後’結果導致獲得粗產物,粗產物藉層析術純化。熔點 147-148°C (二氣曱烷/己烷),MS: m/e=271 [(Μ-Ν〇2)Ί。 實例302及303係根據實例301所述概略程序製備。 實例302 1只-咪唑’1-『丨1-(4-甲基茉某)-1只-咪唑-4-其1曱其1-2-硇基-(1-對甲苯基-1Η-咪唑-4-基)-甲醇首先使用亞磺醯氣然後使 用2-硝基咪唑及碳酸铯處理。於蒸發、萃取後續處理及層 析術後’獲得標題化合物呈白色固體。炫點147- 148°C (二氣 甲烧/二異丙基醚),MS: m/e=23 7 [(M-N〇2)+] » 實例303 1H-咪唑,2-硝基-1-K1-茉基-1H-哚唑-4-基)甲某1-(卜苯基-1H-咪唑-4-基)-曱醇首先使用亞磺醯氣然後使用2-硝基咪唑及碳酸鉋處理。於蒸發、萃取後續處理及層析術 後’獲得標題化合物呈白色固體。熔點126-127。(:(二氣曱烷 /二異丙基醚),MS: m/e=223 [(M-N02)+]。 實例3 04 1-(3,4-二氣-笨基)-1 Η-味啥-4-势酸酿脖 羰基二咪唑(0.49克’ 3毫莫耳)添加至ι_(3,4-二氣·苯基)-ΐΗ-咪唑-4-羧酸(0.64克’ 2.5毫莫耳)於DMF (10毫升)之經授拌 之懸浮液。於60°C經1小時後’反應混合物冷卻至室溫,加 入水性氨(25%,20毫升)及持續攪拌12小時。然後加水(100 -128- 本纸張尺度適用中國國家標準(CNS) A4规格(210X297公釐) B7 五、發明説明(125 毫升)’過濾出沉澱產物。由乙醇再結晶獲得標題化合物呈 灰白色晶體。熔點244-245°C (乙醇),MS: m/e=255 (M+)。 實例305 二氣-笨基ViH-咪唑-4-甲某脖反丁烯二酸鹽π:1\ 1-(3,4-二氣-苯基)-ΐΗ-咪唑-4-缓酸醯胺(4.32克,16_9毫莫耳 )使用1Μ BH3 THF錯合物(100毫升)處理及回流6小時。現合 物冷卻至5°C及緩慢加入曱醇(50毫升)。蒸發去除全部揮發 分後,殘餘物攝取於6N鹽酸溶液(30毫升)及回流15分鐘。 反應混合物經過’緩慢以6N氫氧化鈉(3 0毫升)處理及以乙 酸乙醋(3 X 200毫升)萃取。有機相經脫水(硫酸鈉),濃縮, 所得粗產物經層析[矽膠,使用(二氣甲烷/曱醇/水性氫氧化 氨=90:10:1)洗提]獲得標題化合物自由態鹼,呈淺褐色半固 體物質(2.62克’ 64%)。使用等.莫耳量反丁烯二酸處理後, 標題化合物經分離呈白色結晶物質。熔點176-177eC (曱醇/ 乙_),MS: m/e=241 (M+)。 實例306 N-『l-(3,4-二氣-笨基)-1Η-咪唑-4-某-甲基1-乙醯胺 於1-(3,4-二氣·苯基)-1Η-咪唑-4-曱胺(0.20克,0_83毫莫耳) 於THF (30毫升)之溶液内加入三乙基胺(0 079克,0.78毫莫 耳)及乙醯氣(0.082毫克’ 1.0毫莫耳反應混合物於室溫攪 拌12小時。蒸發去除溶劑後,殘餘物溶解於乙酸乙酯及以 水洗滌。有機相經脫水(硫酸鈉),濃縮,結果所得粗產物經 層析ί矽膠,以梯度二氯曱烷至100%(二氣曱烷/甲醇=9:1)洗 提]。獲得標題化合物呈灰白色結晶物質(〇. 17克,74%) »熔 -129· 本紙乐尺度適用中國@家標準(CNS) A4規格(210X297公釐〉 1328584 A7 ___ B7 i、發明説明(126 ) ~ 點 177-180°C (甲醇/二氯曱院),MS: m/e=284 (M+H+)。 實例3071328584 A7 ________B7 _ V. Description of the invention (124) 嗤 Further direct reaction with its hydrochloride. Thus as described in Example 300, '4-azepine-1-(4-a-3-methyl-phenyl).1Η-imidazole hydrochloride with 2-nitroimidazole (1.2 equivalents) and carbonic acid planer (1.2) Equivalent) reaction, after evaporation and subsequent purification of the extract, results in the crude product obtained, which is purified by chromatography. Melting point 147-148 ° C (dioxane / hexane), MS: m / e = 271 [(Μ - Ν〇 2) Ί. Examples 302 and 303 were prepared according to the general procedure described in Example 301. Example 302 1 -Imidazole '1-"丨1-(4-Methyl-Mo)-1 -Imidazole-4-, 1 曱1-2-indolyl-(1-p-tolyl-1Η-imidazole The -4-yl)-methanol was first treated with sulfinium and then with 2-nitroimidazole and cesium carbonate. The title compound was obtained as a white solid after evaporation, workup, and chromatography. Hyun point 147-148 ° C (dioxane / diisopropyl ether), MS: m / e = 23 7 [(MN 〇 2) +] » Example 303 1H-imidazole, 2-nitro-1- K1-methyl-1H-carbazol-4-yl)methyl 1-(Phenyl-1H-imidazol-4-yl)-nonanol was firstly sulfinated with sulfinium and then 2-nitroimidazole and carbonic acid planer deal with. The title compound was obtained as a white solid after evaporation, EtOAc. Melting point 126-127. (:(dioxane/diisopropyl ether), MS: m/e = 223 [(M-N02)+]. Example 3 04 1-(3,4-di-p-phenyl)-1 Η -Miso-4-pot acid nectar carbonyl diimidazole (0.49 g '3 mmol) added to ι_(3,4-dioxaphenyl)-indole-imidazole-4-carboxylic acid (0.64 g '2.5 The mixture was stirred in DMF (10 mL). After 1 hour at 60 ° C, the reaction mixture was cooled to room temperature, aqueous ammonia (25%, 20 mL) was added and stirring was continued for 12 hours. Then add water (100 -128- This paper size applies to Chinese National Standard (CNS) A4 size (210X297 mm) B7 V. Invention instructions (125 ml) 'Filter out the precipitated product. Recrystallize from ethanol to give the title compound as off-white crystal Melting point 244-245 ° C (ethanol), MS: m/e = 255 (M+). Example 305 Dioxane-studyl ViH-imidazole-4-methyl-n-methyl fumarate π:1\ 1- (3,4-Di-O-phenyl)-indole-imidazole-4-acidic decylamine (4.32 g, 16-9 mmol) was treated with 1 Μ BH3 THF (100 mL) and reflux for 6 hours. Cool to 5 ° C and slowly add decyl alcohol (50 ml). After evaporation to remove all volatiles, The residue was taken up in 6N aqueous HCl (30 mL) and refluxed for 15 min. The reaction mixture was subjected to <RTI ID=0.0>&&&&&&&&&&&&& Sodium sulphate), concentrated, and the obtained crude product was purified by chromatography (dichloromethane / hexane / hydr. Substance (2.62 g '64%). The title compound was isolated as a white crystalline material after EtOAc (m.p.). 241 (M+). Example 306 N-"l-(3,4-digas-phenyl)-1Η-imidazole-4-yl-methyl-1-acetamide in 1-(3,4-dioxane Phenyl)-1Η-imidazole-4-decylamine (0.20 g, 0-83 mmol). To a solution of THF (30 mL), triethylamine (0 079 g, 0.78 mmol) and acetonitrile ( The residue was dissolved in ethyl acetate and washed with water. The crude product was chromatographed eluting with EtOAc EtOAc (EtOAc:EtOAc) »熔-129· The paper scale applies to China@家标准(CNS) A4 specification (210X297 mm) 1328584 A7 ___ B7 i, invention description (126) ~ point 177-180 °C (methanol / dichlorinated sputum), MS: m/e = 284 (M+H+). Example 307
Nd:l-(3,4-二氧-苯基)-1Η-咪唑-甲某]-銪Λ醢胗 於N-[l-(3,4-二氣-苯基)-1Η-咪唑-4·基-甲基_乙醯胺Q]克, 3.7毫莫耳)於l,2-二甲氧乙烷(11毫升)之懸浮液内加入勞森 試劑(Lawesson’s reagent)(0.82克,2.0毫莫耳)及混合物回流 90分鐘。加入飽和碳酸氫鈉溶液(50毫升)及以二氣曱烷(3 χ 100毫升)萃取後,合併有機相經脫水(硫酸鈉),濃縮,結果 所得粗產物經層析[矽膠’以梯度二氣曱烷至1〇〇0/〇(二氣甲 烷/曱醇=9:1)洗提]«獲得標題化合物呈褐色結晶物質(〇 75 克,68%)。熔點 166-17(TC (甲醇/二氣曱烷),MS: m/e=299 (M+)。 實例308 1τΠ-(3,4-二氧-苯基)_iH-咪。坐-4-某-曱早hh-h来峻-2-甲裕 4-氯曱基-l-(3,4-二氯-苯基)-1Η-咪唑(1 31克’ 5.0毫莫耳)溶 解於DMF (10毫升),加入2·咪唑羧醛(〇 48克,5 〇毫莫耳) 及碳酸鉋(0.82克,2.5毫莫耳),結果所得混合物於^«^攪 拌12小時。蒸發去除溶劑後,殘餘物溶解於乙酸乙酯及以 水洗滌。有機相經脫水(硫酸鈉),濃縮及層析[矽膠,以梯 度一氣曱烷至100%(二氣曱烷/甲醇=9:1)洗提]獲得〇98克 (61%)標題化合物呈灰白色固體。熔點13〇131。匸(二氣甲烷/ 一異丙基鍵=9:1),MS: m/e=320 (M+)。 實例309 一直二Jr基)-3-甲基-1H-吡唑以及〗·π.4-二氩-芏D-5-Nd:l-(3,4-dioxo-phenyl)-1Η-imidazole-methyl]-indole N-[l-(3,4-di-phenyl)-1Η-imidazole- 4·Base-methyl-acetamide Q] g, 3.7 mmoles, added Lawesson's reagent (0.82 g, 2.0) in a suspension of 1,2-dimethoxyethane (11 ml). Millions) and the mixture was refluxed for 90 minutes. After adding saturated sodium hydrogencarbonate solution (50 ml) and extracting with dioxane (3 χ 100 ml), the combined organic phases were dried (sodium sulfate) and concentrated, and the obtained crude product was chromatographed Gas decane to 1 〇〇 0 / 〇 (diqi methane / decyl alcohol = 9: 1) elution] «The title compound was obtained as a brown crystalline material ( 〇 75 g, 68%). Melting point 166-17 (TC (methanol / dioxane), MS: m / e = 299 (M +). Example 308 1 Π Π - (3, 4- dioxo-phenyl) _iH - imi. - 曱 early hh-h to jun-2-jiayu 4-chloroindolyl-l-(3,4-dichloro-phenyl)-1 Η-imidazole (1 31 g '5.0 mmol) dissolved in DMF ( 10 ml), 2·imidazole carboxaldehyde (〇48 g, 5 〇 mmol) and carbonic acid planer (0.82 g, 2.5 mmol) were added, and the resulting mixture was stirred for 12 hours under evaporation. The residue is dissolved in ethyl acetate and washed with water. The organic phase is dried (sodium sulfate), concentrated and chromatographed eluted eluted eluted elut The title compound was obtained as an off-white solid, m.p. 13 </ s </ s </ s </ </ </ </ > </ </ </ > </ </ > </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; Always two Jr-based)-3-methyl-1H-pyrazole and 〗 π.4-Di-argon-芏D-5-
1328584 A7 B7 五、發明説明(127 ) 曱基-1H-毗唑 3,4-二氯苯基肼(4.27克,20.0毫莫耳)於乙醇(5〇毫升)及水 (50毫升)之溶液使用3-氧基丁醛二曱基縮醛(2.64克,20.0毫 莫耳)處理及回流1小時。真空去除醇,水性殘餘物以乙酸 乙酯(2 X 150毫升)萃取。有機相經脫水(硫酸鈉),過濾及蒸 發β剩餘油經層析[矽膠’以梯度己烷至1〇〇/0(己烷/乙酸乙 酯=1:1)洗提]獲得3.01克(66%) 1-(3,4-二氣-笨基)-3 -甲基-1H-吡唑[熔點57-58°C (乙酸乙酯/己烷),MS: m/e=226 (M+)] 呈灰白色晶體以及1.32克(29%) 1-(3,4-二氣-苯基)-5-甲基-1H-吡唑[熔點46-47°C (己烷)’MS: m/e=226 (M+)]呈白色晶 體。 實例310 氯甲某-l-〔3,4-二氣-笨基)-1Η-吡吔 1-(3,4-二氣-笨基)-1Η-吡唑-4-羧酸(3.0克,12毫莫耳)(US 5064851)以1M BH3 THF錯合物(50毫升)處理及回流90分鐘 。混合物冷卻至5 °C,緩慢加入甲醇(5 0毫升)。蒸發去除全 部揮發物後,殘餘物攝取於25%鹽酸溶液(50毫升)及回流15 分鐘。過濾後水相於冰浴冷卻及以28%氫氡化鈉溶液(50毫 升)緩慢處理。標題化合物呈淺黃色物質結晶(2.6克,86%) 。熔點 66-67°C (水),MS: m/e=260 (M+)。 實例3 11 1-(3.4-二氱-茉基)-1Η-吡唑-4·甲醛 [1-(3,4-二氣-苯基)-1Η-咪唑-4-基]-曱醇(10.8克,44.3毫莫 耳)於THF (270毫升)及水(30毫升)混合物之溶液使用氧化錳 • 131 - 本纸張尺度適用中g g家標準(CNS) A4規格(21Q χ 297公爱)1328584 A7 B7 V. INSTRUCTIONS (127) A solution of mercapto-1H-pyrazole 3,4-dichlorophenylhydrazine (4.27 g, 20.0 mmol) in ethanol (5 mL) and water (50 mL) Treatment with 3-oxybutyraldehyde didecyl acetal (2.64 g, 20.0 mmol) and reflux for 1 hour. The alcohol was removed in vacuo and the aqueous residue was taken ethyl acetate (2 X 150 mL). The organic phase was dehydrated (sodium sulfate), filtered and evaporated. The residual oil was purified by chromatography [[J], eluting with gradient hexane to 1 〇〇 /0 (hexane / ethyl acetate = 1:1) to obtain 3.01 g ( 66%) 1-(3,4-dioxa-phenyl)-3-methyl-1H-pyrazole [melting point 57-58 ° C (ethyl acetate / hexane), MS: m / e = 226 ( M+)] is off-white crystals and 1.32 g (29%) of 1-(3,4-di-phenyl)-5-methyl-1H-pyrazole [melting point 46-47 ° C (hexanes) 'MS: m/e = 226 (M+)] is a white crystal. Example 310 Chloromethyl-l-[3,4-dioxa-phenyl]-1Η-pyridinium 1-(3,4-dioxa-phenyl)-1Η-pyrazole-4-carboxylic acid (3.0 g , 12 mmol (US 5064851) was treated with 1 M BH3 THF (50 mL) and refluxed for 90 min. The mixture was cooled to 5 ° C and methanol (50 mL) was slowly added. After evaporation of all volatiles, the residue was taken up in 25% hydrochloric acid (50 mL) and reflux for 15 min. After filtration, the aqueous phase was cooled in an ice bath and slowly treated with a 28% aqueous solution of sodium hydride (50 mL). The title compound was obtained as a pale yellow material (2.6 g, 86%). Melting point 66-67 ° C (water), MS: m/e = 260 (M+). Example 3 11 1-(3.4-Bis-Methyl)-1Η-pyrazole-4·carbaldehyde [1-(3,4-di-phenyl)-1Η-imidazol-4-yl]-nonanol ( 10.8 g, 44.3 mmol) solution of a mixture of THF (270 ml) and water (30 ml) using manganese oxide • 131 - This paper scale applies to the gg standard (CNS) A4 specification (21Q 297 297 public)
裝 訂Binding
k 1328584 A7 B7 五、發明説明(128 ) -- (IV)(5克’ 57.5毫莫耳)處理,混合物回流4小時。加入第二 份氧化猛(IV)( 1.5克)’持續回流1.5小時。混合物經西萊特 (Celite)過濾,殘餘物以甲醇洗蘇。添加甲苯至滤液,共濟 蒸餾去除水。褐色殘餘物攝取於二氣甲烧,放置時形成白 色晶體。過遽獲得1-(3,4-二氣-苯基)-1>{-°米啥-4-曱酿(2.5克 ,25%),MS: m/e=240.0 (M+) 〇 實例312 1- Π- (3,4-二氣-笨基V1H-味嗤-4-基1-乙醇 於甲基碘化鎂於醚之溶液(3 Μ,13 _7毫升,41.1毫莫耳)及 醚(40毫升)之溶液内分成數份加入1-(3,4-二氣-苯基)·1Η-咪 唑-4-甲醛(2.58克,10.7毫莫耳)。然後緩慢加入THF (50毫 升),於回流下持續攪拌1小時》加入水性氣化銨(飽和,3〇 毫升)後,混合物以乙酸乙酯萃取。有機相經脫水(硫酸鈉) 及蒸發獲得1-(3,4·二氣-苯基)-1Η-咪唑-4-基]-乙醇(2.56克, 93%)呈淺褐色固體。MS: m/e=257.0 (Μ+Η+)。 實例313 1-(3,4-二氣-笑其)-iH-咪唑-4-游醢甲酯 1-(3,4-二氣-苯基)_1H-咪唑-4-羧酸(7.0克,27毫莫耳),曱 醇(150毫升)及濃硫酸(25毫升)之混合物回流3小時。然後溶 液濃縮至約80毫升,加入碳酸鈉(60克)於水於〇°C之溶液 (500毫升)。以二氣甲烷萃取,將有機相脫水以及蒸發去除 溶劑獲得褐色殘餘物,殘餘物以醚濕磨獲得標題化合物(6.0 克,81%)呈淺褐色固體。MS: m/e=269.9 (M+)。 實例314 _____ ·132· 本纸乐尺度適用巾s g家科(CNS) Α4規格⑼㈣97公爱) 1328584 A7 ___ B7 五、發明説明(129 ) 2-『1-(3,4-二氣-苯某)_1^-嵘崦-4-某1-芮-2-醇 以類似實例312之方式,i_(3,4-二氣-苯基)-1Η-咪唑_4·羧酸 曱酯(1.5克,5·53毫莫耳)使用過量曱基碘化鎂處理。萃取 後續處理後獲得標題化合物(1.3克,86%) β MS: m/e=270.1 (M+)。 實例315 1H-咪唑,2-Γ(2-甲篡-1H-咪唑-1-某)甲基1-4-丨3-(三意甲某) 苯基1-1-丨丨2-(三曱基矽烷某)乙氣1甲基1_ 1Η-咪唑’ 4-碘-2-[(2-曱基-1Η-咪唑-1-基)曱基>1-[[2-(三曱 基矽烷基)乙氧]甲基-(0.080克,0.191毫莫耳)溶解於甲苯(4 毫升)及曱醇(0.8毫升),以2Ν碳酸鈉(0.2毫升),3-(三氟曱 基)苯基二羥硼酸(0.049克’ 0.248毫莫耳)及肆(三笨基膦)鈀 (0.0114克,0.0095毫莫耳)處理。反應混合物於氬下回流 150小時’然後於室溫冷卻及脫水(硫酸鈉)。過濾及蒸發去 除溶劑後,殘餘物經層析(石夕膠,以二氣曱烧/曱醇=95 ·5洗 提)獲得標題化合物(0.036克,43%)呈褐色油^ ms. m/e=437.4 (M+H+)。 實例3 16至3 19係根據實例3 15所述概略程序製備。 實例316 jjl二咪唾,4-(4-氟-3-曱基苯基)-2-Γ(2-甲篡咪唑·】_芊)甲 基Μ-ΓΓ2-(三甲某矽烷基)乙氩1甲甚卜 標題化合物’ MS·· m/e=400.2 (Μ+)係由1Η_咪唑,4·碘·2· [(2-甲基-1Η-咪唑-1-基)曱基]-1-[[2-(三曱基矽烷基)乙氧]曱 基-及4-氟-3-曱基苯基二羥硼酸製備。 •133.k 1328584 A7 B7 V. INSTRUCTIONS (128) -- (IV) (5 g '57.5 mmol) treatment, the mixture was refluxed for 4 hours. A second portion of oxidized (IV) (1.5 g) was added and reflux was continued for 1.5 hours. The mixture was filtered through Celite and the residue was washed with methanol. Toluene was added to the filtrate, and the water was removed by distillation. The brown residue was taken up in the second gas, and white crystals were formed upon standing. 1-(3,4-di-phenyl-phenyl)-1>{-° miloxime-4-brewing (2.5 g, 25%), MS: m/e = 240.0 (M+) 〇 Example 312 1- Π- (3,4-diqi-stupyl V1H-miso-4-yl 1-ethanol in methyl iodide in ether (3 Μ, 13 _7 ml, 41.1 mmol) and ether (40 ml) was added in portions to 1-(3,4-di-phenyl-phenyl)-indolyl-4-imidazole-4-carbaldehyde (2.58 g, 10.7 mmol). Then slowly added THF (50 mL) Stirring under reflux for 1 hour. After adding aqueous ammonium hydride (saturated, 3 mL), the mixture was extracted with ethyl acetate. The organic phase was dried (sodium sulfate) and evaporated to give 1-(3,4·2 gas -Phenyl)-1Η-imidazol-4-yl]-ethanol (2.56 g, 93%) as a light brown solid. MS: m/e=257.0 (Μ+Η+). Example 313 1-(3,4- Diqi-laughing)-iH-imidazole-4-free methyl ester 1-(3,4-di-phenyl)_1H-imidazole-4-carboxylic acid (7.0 g, 27 mmol), sterol A mixture of (150 ml) and concentrated sulfuric acid (25 ml) was refluxed for 3 hours. Then the solution was concentrated to about 80 ml, and sodium carbonate (60 g) was added to a solution of water (500 ml). The title compound (6.0 g, 81%) was obtained as a pale brown solid. MS: m/e=269.9 (M+). 314 _____ ·132· This paper is suitable for towel sg family (CNS) Α4 specifications (9) (four) 97 public love) 1328584 A7 ___ B7 V. Invention description (129) 2-『1-(3,4-二气-苯某) _1^-嵘崦-4- a 1-indol-2-ol in the same manner as in Example 312, i_(3,4-di-phenyl)-1Η-imidazole-4,carboxylate (1.5 g, 5.53 millimolar) treated with excess mercapto magnesium iodide. The title compound (1.3 g, 86%). m. Example 315 1H-imidazole, 2-anthracene (2-methylindole-1H-imidazole-1-yl)methyl1-4-anthracene 3-(single) phenyl1-1-anthracene 2-(trimium) Ethylene acetophenone 1-methyl 1_ 1 Η-imidazole ' 4-iodo-2-[(2-mercapto-1 Η-imidazol-1-yl) fluorenyl] 1-[[2-(tridecyldecane) Ethyl]methyl-(0.080 g, 0.191 mmol) dissolved in toluene (4 ml) and methanol (0.8 ml) with 2 Ν sodium carbonate (0.2 ml), 3-(trifluoromethyl)benzene Treatment with bishydroxyboronic acid (0.049 g '0.248 mmol) and hydrazine (triphenylphosphine) palladium (0.0114 g, 0.0095 mmol). The reaction mixture was refluxed under argon for 150 hours' then cooled and dried (sodium sulfate) at room temperature. After the solvent was removed by filtration and evaporated, m~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ e=437.4 (M+H+). Examples 3 16 to 3 19 were prepared according to the general procedure described in Example 3 15. Example 316 jjl dimethicin, 4-(4-fluoro-3-indolylphenyl)-2-indole (2-methylimidazole), methyl hydrazine-hydrazine 2-(trimethyl decyl) ethyl argon 1A, the title compound 'MS·· m/e=400.2 (Μ+) is from 1Η-imidazole, 4·iodine·2·[(2-methyl-1Η-imidazol-1-yl)indenyl]- Preparation of 1-[[2-(tridecylidenealkyl)ethoxy]indolyl- and 4-fluoro-3-indolylphenyldihydroxyboronic acid. •133.
1328584 A7 __ ____B7 五、發明説明(13Q~) — -- 實例3 17 . 1H-1嗔’ 4-(3,4-二.氟-苯棊甲基_1H_咪唑]某)甲某 VI-丨丨2-(三甲基矽烷基)乙氣甲芊^ 標題化合物,MS: m/e=404.2 (M+)係由1H-咪唑,4-碘-2- [(2-甲基-1H-咪唑-1-基)曱基]三曱基矽烷基)乙氧]曱 基-及3,4-二氣甲基苯基二經蝴酸製備。 實例3 18 1.技-电嗅2-|~(2-甲啥二卜基)甲某Μ-Γ4]甲某益、笑 基1-1-172-(三甲基石夕烧基)乙氧其1_ 標題化合物,MS·· m/e=414_2 (Μ+)係由1Η-咪唑,4-碘-2- [(2-甲基-1H-咪唑-1-基)甲基]三甲基矽烷基)乙氧]曱 基-及4-甲基硫苯基二羥硼酸製備。 實例3 19 1Η-座4-(4-氟-3-甲某苯基)_2_Γ1Η_咪唑基甲某V1_ Γ[2-(三甲基矽烷基)己急甲其> 標題化合物’ MS: m/e=387.3 (Μ+Η+)係由 1Η-咪唑,2-(1Η-味吐-1-基曱基)-4-碘-ΐ-[[2·(三甲基矽烷基)乙氧]甲基]•及4· 氟-3-曱基苯基二羥硼酸製備。 實例320 1Η-味峻,4-蛾-2-Γ(2-甲某-1Η-咪唑-1-基)甲基1-1-「Γ2-(笔甲 基矽烷基)乙氡1甲某1- [4·碘-1-(2-(三曱基矽烷基-乙氧曱基)_1Η_咪唑·2·基]甲醇 (1.0克’ 2_8毫莫耳)及四溴曱烷(1 3克,4 〇毫莫耳)溶解於 THF (10.0毫升)及冷卻至〇〇c。以3〇分鐘時間逐份加入三笨 -134- 本纸張尺度適用中國固家標準_纷A4规格(21〇X297公爱) 1328584 A7 _ B7 五、發明説明(131 ) 基膦(1.07克,3.95毫莫耳)。反應混合物於0°C攪拌1小時獲 得白色懸浮液。於第二燒瓶内,氫化鈉(0.615克,14.1毫莫 耳,55%於礦油)懸浮於DMF (20毫升)及冷卻至〇。〇 ^逐份加 入2-甲基啼唾(1.16克,14.1毫莫耳)。反應混合物於6〇。〇授 拌30分鐘,冷卻至0°C及以前述懸浮液處理。於室溫授拌2 小時後,反應混合物以飽和碳酸氫鈉(50毫升)淬熄.水層以 乙酸乙酯萃取三次。合併萃取物以硫酸鈉脫水,過渡及真 空去除溶劑。殘餘物經層析(矽膠,以二氯曱烷/曱醇=97:3 洗提)獲得標題化合物(0.835克,71%)呈褐色油。MS: m/e=419.0 (M+H+)。 實例321係根據實例320所述概略程序製備》 實例321 1H-咪唑,2-ΠΗ-咪唑-1-基甲基)-4-蛾-1-ΓΓ2-Γ三甲篡石夕烷某) 乙氡1甲某1- 標題化合物,MS: m/e=405.3 (M+H+)係由4-破-1-(2-三曱基 矽烷基-乙氧曱基)-1Η-咪唑-2-基]-曱醇及咪唑製備。 實例322 [1-碘1-(2-三甲基矽烷基-乙氯甲基)-iH-咪唑-2-某1-甲醢 4-碘-1-(2-三甲基矽烷基-乙氧曱基)-iH-咪唑-2-甲醛(4.6克 ’ 13.1毫莫耳)於氬下溶解於乙醇(5〇毫升)。加入硼氫化鈉 (0.514克’13.1毫莫耳),混合物於室溫攪拌45分鐘。加水 (200毫升)。水層以乙酸乙酯萃取3次。合併萃取物以硫酸鈉 脫水’過濾及真空去‘溶劑β粗製殘餘物攝取於己烷及於 室溫攪拌》過濾獲得[4-碘1-(2-三甲基矽烷基-乙氧甲基)- I_______ -135- 本纸張尺度適财準(CNS) A4規格(21〇><297公爱)- 1328584 A7 - _ B7 五、發明説明(132 ) 1H-咪唑_2_基]_曱醇(4.〇克,87%)呈白色固體。MS: m/e = 354.〇 (M+)。 實例323 七l峨-M2-三甲某矽烷基-乙氧甲基涉唑_2_甲越 4.5- 二碘-1-(2-三曱基矽烷基-乙氧甲基)·1Η_咪唑(8 86克, 19.68毫莫耳)於無水THF (110毫升)之溶液於氬下冷卻至_78 °<3’使用正丁基鋰(13.5毫升’21.65毫莫耳,161^於己烷) 逐滴處理》於-78°C攪拌10分鐘及於-45。(:攪拌30分鐘後,反 應混合物冷卻至-78°C及使用DMF (1 〇毫升)處理一次。讓混 合物溫熱至室溫及加入飽和氣化銨(1 50毫升)。水層以乙酸 乙酯萃取2次。合併萃取物以硫酸鈉脫水,過遽及真空去除 溶劑。殘餘物經層析(石夕膠’以己烧/乙酸乙酯=98:2洗提)獲 得標題化合物(5·18克,75%)呈淺黃色油》MS: m/e=352.1 (M+)。 實例324 4.5- 二碘-1-(2-三甲基矽烷某-乙氣甲基)-1Η-哄岫 4.5- 二碘-咪唑(根據 D_S. Carver, S.D. Lindell 及 E.A. Saville-Stones,四面體,1997,ϋ,42,14481-14496)製備(10·1 克, 31.6毫莫耳)逐份添加至氫化鈉(1.38克,31·6毫莫耳,55% 於礦油)於無水DMF (45毫升)之懸浮液。反尨混合物於室溫 攪拌90分鐘,然後冷卻至〇°C及以2-(三曱基矽烷基)-乙氧甲 基氣(6.81毫升,34.7毫莫耳)於DMF (10毫莫耳)之溶液缓慢 處理。於0°C攪拌2小時後,反應混合物倒入水(200毫升)及 乙酸乙酯(50毫升)之混合物》混合物經過濾,母液以乙酸乙 -136- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 裝 訂1328584 A7 __ ____B7 V. Description of Invention (13Q~) — -- Example 3 17 .1H-1嗔' 4-(3,4-Di.fluoro-benzoquinonemethyl_1H-imidazole] a) A VI-丨丨2-(Trimethyldecyl)ethane ethane oxime ^ Title compound, MS: m/e = 404.2 (M+) from 1H-imidazole, 4-iodo-2-[(2-methyl-1H- Imidazolyl-1-yl)indolyl]trimethylsulfonylalkyl)ethoxy]indolyl- and 3,4-dimethylmethyldicarboxylate are prepared by the acid. Example 3 18 1. Technique-Electric scent 2-|~(2-甲啥二卜基)甲Μ-Γ4]甲某益,笑基1-1-172-(三methyl石夕烧基)ethoxy 1_ The title compound, MS·· m/e = 414_2 (Μ+) is from 1Η-imidazole, 4-iodo-2-[(2-methyl-1H-imidazol-1-yl)methyl]trimethylnonane Preparation of ethoxy] fluorenyl- and 4-methylthiophenyldihydroxyboronic acid. Example 3 19 1 Η-座 4-(4-Fluoro-3-methylphenyl)_2_Γ1Η_imidazolylmethyl V1_ Γ[2-(trimethyldecyl)hexidine]> title compound 'MS: m /e=387.3 (Μ+Η+) is from 1Η-imidazole, 2-(1Η-味吐-1-ylindenyl)-4-iodo-indole-[[2·(trimethyldecyl)ethoxy] Preparation of methyl]• and 4·fluoro-3-mercaptophenyldihydroxyboronic acid. Example 320 1Η-味峻, 4-Moth-2-Γ(2-甲一-1Η-imidazol-1-yl)methyl1-1-"Γ2-(Pentylmethylalkyl)Ethyl 1A 1 - [4. Iodine-1-(2-(tridecylsulfenyl-ethoxycarbonyl)_1Η-imidazole·2·yl]methanol (1.0 g '2_8 mmol) and tetrabromodecane (13 g) , 4 〇 millimol) dissolved in THF (10.0 ml) and cooled to 〇〇c. Add 3 stupid-134 in 3 minutes. This paper scale applies to China's solid standard _ A4 specifications (21 〇 X297 公) 1328584 A7 _ B7 V. Description of the invention (131) phosphine (1.07 g, 3.95 mmol). The reaction mixture was stirred at 0 ° C for 1 hour to obtain a white suspension. In the second flask, sodium hydride ( 0.615 g, 14.1 mmol, 55% in mineral oil) suspended in DMF (20 mL) and cooled to 〇. 〇^ Partially added 2-methyl hydrazine (1.16 g, 14.1 mmol). 6 〇 〇 〇 〇 〇 〇 〇 〇 〇 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 Extract three times. The combined extracts are dehydrated with sodium sulfate. The solvent was removed in vacuo <RTI ID=0.0></RTI></RTI></RTI> <RTI ID=0.0></RTI> (M+H+) Example 321 was prepared according to the procedure outlined in Example 320. Example 321 1H-imidazole, 2-indole-imidazol-1-ylmethyl)-4-Moth-1-ΓΓ2-Γ三甲篡石夕A certain compound, MS: m/e = 405.3 (M+H+) is 4-bromo-1-(2-trimethylsulfanyl-ethoxycarbonyl)-1Η- Preparation of imidazol-2-yl]-nonanol and imidazole. Example 322 [1-Iodo-1-(2-trimethyldecyl-ethylchloromethyl)-iH-imidazole-2-some 1-methylindole 4-iodine 1-(2-trimethyldecyl-ethoxy)-iH-imidazole-2-carboxaldehyde (4.6 g ' 13.1 mmol) was dissolved in ethanol (5 mL) under argon. Sodium borohydride was added. (0.514 g '13.1 mmol), the mixture was stirred at room temperature for 45 min. Water (200 ml) was added and the aqueous layer was extracted with ethyl acetate three times. The combined extracts were dehydrated with sodium sulfate 'filtered and vacuumed' solvent The residue was taken up in hexane and stirred at room temperature to obtain [4-iodo 1-(2-trimethyldecyl-ethoxy) )- I_______ -135- This paper size is suitable for the standard (CNS) A4 specification (21〇><297 public)- 1328584 A7 - _ B7 V. Invention description (132) 1H-imidazole_2_based] _ sterol (4. gram, 87%) was a white solid. MS: m/e = 354. 〇 (M+). Example 323 峨l峨-M2-trimethyl decyl-ethoxymethyl oxazolidine-2_methyl-5-diiodo-1-(2-tridecylfluorenyl-ethoxymethyl)·1Η-imidazole 8 86 g, 19.68 mmol) in anhydrous THF (110 mL) cooled to _78 ° <3> using n-butyllithium (13.5 mL '21.65 mM, 161 hexanes) The dropwise treatment was stirred at -78 ° C for 10 minutes and at -45. (After stirring for 30 minutes, the reaction mixture was cooled to -78 ° C and treated once with DMF (1 mL). The mixture was warmed to room temperature and saturated ammonium sulfate (1 50 mL) was added. The ester was extracted twice. The combined extracts were dried over sodium sulfate, and the solvent was evaporated, evaporated, mjjjjjjjj 18 g, 75%) light yellow oil "MS: m/e = 352.1 (M+). Example 324 4.5-diiodo-1-(2-trimethyldecane-ethyl-methyl)-1Η-哄岫4.5-Diiodo-imidazole (according to D_S. Carver, SD Lindell and EA Saville-Stones, tetrahedron, 1997, ϋ, 42, 14481-14496) Preparation (10·1 g, 31.6 mmol) was added portionwise to hydrogenation A suspension of sodium (1.38 g, 31.6 mmol, 55% in mineral oil) in anhydrous DMF (45 mL). The mixture was stirred at room temperature for 90 min then cooled to 〇 ° C and 2- Trimethylsulfonyl)-ethoxymethyl gas (6.81 ml, 34.7 mmol) was slowly treated in DMF (10 mmol). After stirring at 0 °C for 2 hours, the reaction mixture was poured. (200 mL) and ethyl acetate (50 ml) mixture "mixture was filtered, mother liquor present paper -136- acetate scale applies China National Standard (CNS) A4 size (210X297 mm) bookbinding
1328584 A7 B7 五、發明説明(133 酯萃取3次。合併萃取物以硫酸鈉脫水,過濾及真空去除溶 劑。殘餘物經層析(矽膠’以己烷/乙酸乙酯=9:1洗提)獲得 標題化合物(9_44克’ 66.4%)呈淡黃色油。MS: m/e=450.0 (M+)。 實例325 3- 氯甲基-5-(3,4-二氣-笨基吡啶鹽酸鹽 [5-(3,4-二氣-苯基)*^比咬-3-基]-甲醇(4 70毫克,1.9毫莫耳) 與亞磺醯氯(4.9毫升)之溶液於20°C攪拌15小時。蒸發去除 亞磺醯氯及於50°C於高度真空下脫水2小時獲得標題化合物 (558毫克,98%)淺黃色固體。MS: m/e=271.〇 (m+)。 實例326-328係根據實例325所述概略程序製備。 實例326 2- 氮甲基-3-Π,4-二氣-笨基吡啶鹽酸鹽 標題化合物,MS: m/e=271.0 (M+)係經由[4-(3 4-二氣-苯其 )-吡啶-2-基]-甲醇與亞磺醯氯於20°C反應15小時獲得,呈淺 褐色發泡體(99%產率)。 實例327 4- 氣甲基-2-Π,4-二氯-茉基吡啶鹽酸鹽 標題化合物’ MS: m/e=271.0 (M+)係經由[2-(3,4-二氣-苯其 )-口比咬-4 -基]-曱醇與亞績酿亂於2〇C反應1小時獲得,呈淺 褐色發泡體(1 〇〇%產率)。 實例328 3- 氯曱基-5-(3,4-二氣-茉某V吡啶鹽酸鹽(1:1^ 標題化合物,MS: m/e=245.1 (M+)係經由[5-(3 4-二氣-苯其 -137- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公爱·) 1328584 A7 _ B7 五、發明説明(134 ) )_2_甲基-吡啶-3-基]-甲醇與亞磺醯氯於20°C反應1小時然後 回流2小時獲得,呈黃色固體(98%產率)。 實例329 Γ5-Γ3.4-二氯-茉基吡啶-3-某1-甲醇 於鋁氫化鋰(161毫克,4.2毫莫耳)於THF (20毫升)之懸浮液 内,於0°C逐滴加入5-(3,4-二氣-苯基)-菸鹼酸曱酯(2.0克, 7.0毫莫耳)於THF (20毫升),又於此溫度攪拌2小時。反應 藉小心加入THF/水(9:1)淬熄,然後直接以硫酸鈉脫水,過 濾及蒸發去除溶劑。殘餘物經層析[矽膠,以二氣曱烷/(2M 氨,曱醇)=97:3洗提]獲得標題化合物(480毫克,27%)呈橙 色固體。MS: m/e=254.0 (M+H+)。 實例330-332係根據實例329所述概略程序製備。 實例330 Γ2-(3,4-二氣-笨基吡啶-4-基1-甲醇 標題化合物,MS: m/e=252.0 ([Μ-ΗΓ)係呈淺黃色固體獲得 (53%產率),其獲得方式係經由2-(3,4-二氣-苯基)-異菸鹼酸 曱酯與鋁氫化鋰於THF於20°C反應1小時,接著層析[矽膠, 以二氯曱烷/(2M氨曱醇)=19:1洗提]。 實例331 Γ4-Γ3.4-二氯-茉基吡啶-2-基1-甲醇 標題化合物,MS: m/e=252.0 ([M-Η]·)係呈淺褐色油(94%產 率)獲得,其獲得方式係經由4-(3,4-二氣·苯基)-吡啶-2-羧酸 曱酯與1M鋁氫化鋰/THF溶液於THF於20°C反應1小時,接著 進行層析純化。 ___- 138- 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(135 實例332 ^^^~1^-笨某)-2-甲其-毗琮-3-基1^甲醇鹽酸镑门.22 標題化合物,]^3:111/6=227.2 (1^+)係呈嗶嘰色固體(5 8%產率 )獲待’其獲得方式係經由5_(3,4-二甲基-苯基)-2-曱基-終驗 酸乙酯與硼氫化鈉(5當量)於乙醇(5毫升)反應,於2〇t搜拌 23小時,接著進行層析純化。 實例333 一亂·苯基)-於驗酸曱醋 於5-溴吡啶_3-羧酸曱酯(2克,9.3毫莫耳)於曱笨(50毫升)之 溶液内加入肆-(三苯基膦)_鈀(〇)(32〇毫克’ 0.28毫莫耳)接著 加入氯化鋰(785毫克,18.5毫莫耳),混合物於20。(:攪拌30 分鐘。然後加入3,4-二氯苯基二羥硼酸(50重量%於THF/水 9:1)(3.7克,3.3毫升,9_7毫莫耳)及2N水性碳酸鉀(11.3毫升 ’ 2.5當量)’經攪拌之混合物於氬氣氛下於i〇〇〇c加熱23小 時。冷卻後’加水(25毫升),水相經分離及以乙酸乙酯萃取 。合併有機萃取物以飽和氯化鈉溶液洗滌,以硫酸鈉脫水 ’過濾及蒸發去除溶劑,產物於501於高度真空脫水2小時 獲得標題化合物(2.48克,95%)呈嗶嘰色固體^ Ms: m/e=281 ‘0 (M+H.)。 實例334-336係根據實例333所述概略程序製_。 實例334 4-(3,_4-二氣-茉基V吡啶-2-羚酸甲酯 標題化合物,MS: m/e=281.0 (M + )係經由4-溴比咬-2-敌酸 曱酯與3,4-二氣笨基二羥硼酸反應獲得,呈淺黃色固體 -139- 本紙張尺度適用中國國家揉準(CNS) A4規格(210X297公釐) 13285841328584 A7 B7 V. Description of the invention (133 ester extraction 3 times. The combined extracts are dehydrated with sodium sulfate, filtered and the solvent is removed in vacuo. The residue is purified by chromatography eluting with hexane/ethyl acetate = 9:1 The title compound (9-44 g, 66.4%) was obtained as pale yellow oil. MS: m/e=450.0 (M+). Example 325 3- chloromethyl-5-(3,4-dis a solution of [5-(3,4-di-phenyl)*^ butyl-3-yl]-methanol (4 70 mg, 1.9 mmol) and sulfinium chloride (4.9 ml) at 20 ° C After stirring for 15 hours, the sulfinium chloride was removed by evaporation and the title compound (558 mg, 98%) was obtained as a pale yellow solid. 326-328 was prepared according to the procedure outlined in Example 325. </RTI> </RTI> </RTI> <RTI ID=0.0></RTI> </RTI> </RTI> <RTIgt; Obtained by reacting [4-(3 4-dioxa-benzoic)-pyridin-2-yl]-methanol with sulfinium chloride at 20 ° C for 15 hours, as a light brown foam (99% yield). Example 327 4-Methylmethyl-2-indole, 4-dichloro-molylpyridine hydrochloride title compound 'MS: m/ e=271.0 (M+) was obtained by reacting [2-(3,4-digas-benzoquinone)-mouth-battery-4-yl]-sterol with a subtle yield of 2〇C for 1 hour. Brown foam (1% yield). Example 328 3-Chloromethyl-5-(3,4-digas-jammidine hydrochloride (1:1^ title compound, MS: m/ e=245.1 (M+) is via [5-(3 4-diox-benzo-137-) paper scale applicable to China National Standard (CNS) A4 specification (210X297 public love) 1328584 A7 _ B7 V. Description of invention (134)) _2-Methyl-pyridin-3-yl]-methanol was reacted with sulfinium chloride at 20 ° C for 1 hour and then refluxed for 2 hours to give a yellow solid (98% yield). Example 329 Γ5-Γ3 .4-Dichloro-molylpyridine-3-mer 1-methanol in a suspension of lithium aluminum hydride (161 mg, 4.2 mmol) in THF (20 mL). 3,4-Di-O-phenyl)- nicotinic acid decyl ester (2.0 g, 7.0 mmol) in THF (20 mL), and then stirred at room temperature for 2 hr. 1) Quenching, then dehydrating directly with sodium sulfate, filtering and evaporating to remove the solvent. The residue is chromatographed [ruthenium, dioxane / (2M ammonia, decyl alcohol) = 97:3 Mention] to obtain the title compound (480 mg, 27%) as a orange solid. MS: m/e = 254.0 (M+H+). Examples 330-332 were prepared according to the general procedure described in Example 329. Example 330 Γ2-(3,4-di-p-pyridylpyridin-4-yl 1-methanol title compound, MS: m/e=252.0 ([ Μ-ΗΓ) was obtained as pale yellow solid (53% yield) It is obtained by reacting 2-(3,4-di-phenyl)-isonicotinic acid decyl ester with lithium aluminum hydride in THF at 20 ° C for 1 hour, followed by chromatography [gelatin, with dichloroguanidine Alkane/(2M-aminosterol)=19:1 elution]. Example 331 Γ4-Γ3.4-Dichloro-methylpyridin-2-yl 1-methanol title compound, MS: m/e=252.0 ([M -Η]·) is obtained as a light brown oil (94% yield) obtained by decyl 4-(3,4-di-phenyl)-pyridine-2-carboxylate and 1M aluminum hydride /THF solution was reacted in THF at 20 ° C for 1 hour, followed by chromatographic purification. ___- 138- This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 B7 V. Description of invention (135 Example 332 ^^^~1^-stupid)-2-methyl-pyridin-3-yl 1^methanol hydrochloride pound gate.22 title compound,]^3:111/6=227.2 (1^+ ) is a ochre solid (5 8% yield) to be obtained by way of 5-(3,4-dimethyl-phenyl)-2-indenyl-ethyl acetate and sodium borohydride ( 5 equivalents) Ethanol (5 ml) was reacted and mixed for 2 hours at 2 Torr, followed by chromatographic purification. Example 333: chaotic phenyl) - acid oxime vinegar in 5-bromopyridine-3-carboxylate (2克, 9.3 mmol; 肆-(triphenylphosphine)-palladium (〇) (32 〇 mg '0.28 mmol) was added to a solution of hydrazine (50 ml) followed by lithium chloride (785 mg, 18.5 millimoles), the mixture is at 20. (: Stir for 30 minutes. Then add 3,4-dichlorophenyldihydroxyboronic acid (50% by weight in THF/water 9:1) (3.7 g, 3.3 ml, 9-7 mmol) and 2N aqueous potassium carbonate (11.3) </ RTI> </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; The title compound (2.48 g, 95%) was obtained as a pale solid. Ms: m/e = 281 </ </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> (M+H.) Examples 334-336 are according to the procedure outlined in Example 333. Example 334 4-(3, _4-di-methane-methyl-pyridin-2-carboxylate methyl ester title compound, MS: m/e=281.0 (M + ) is obtained by reacting 4-bromo-butan-2-carbazate with 3,4-dioxalyldihydroxyboronic acid, which is light yellow solid-139- This paper scale is applicable to China. National Standard (CNS) A4 specification (210X297 mm) 1328584
(10%產率)。 實例335 二氩二^基私異菸鹼醅甲酷 標題化合物,MS: m/e=281.0 (Μ+)係經由2-碘-異菸鹼酸曱 δ旨與3,4-二氣苯基二羥硼酸反應獲得’呈淺褐色固體(59〇/〇 產率)。 實例336 ^ιί3,4-二氧二基比啶-2-游酸甲酯 標題化合物,、MS: m/e=282.0 (M+)係經由6-溴-吡啶-2-羧酸 甲酯與3’4-二氣-苯基二羥硼酸反應獲得,呈淺黃色固體(7% 產率)。 實例337 2_-蛾-異终絵·酿甲西气 2-氣-峨咬-4-羧酸(5克,31.7毫莫耳)於丁-2-酮(150毫升)之 溶液於回流下與蛾化鈉共同加熱6小時,經萃取水性後續處 理後獲得2·碘-異菸鹼酸(7.3克,92.4%產率)。此物料溶解 於THF (50毫升),使用新鮮醚系重氮甲烷溶液(44毫升, 0.55莫耳/升)g旨化。蒸發去除溶劑及經矽膠襯墊過濾[以二 氣曱烷/(2M氨甲醇)=19:1洗提]後,獲得標題化合物(2.3克, 44%)呈深黃色油。MS: m/e=263.0 (M+)。 實例338 U臭-5-(2-曱基-咪唑·ι_基甲某毗啶 於氫化鈉(0.54克’ 12·3毫莫耳)於THF (40毫升)於20°C經攪 拌之懸浮液内以45分鐘時間分成數份加入2-曱基咪唑。然 • 140·(10% yield). Example 335 diar arsenyl nicotinic nicotinamide title compound, MS: m/e = 281.0 (Μ+) via 2-iodo-isonicotinic acid 曱δ with 3,4-diphenyl The diboronic acid reaction gave 'light brown solid (59 〇 / 〇 yield). Example 336 ^ιί3,4-dioxadiylpyridin-2-carbamic acid methyl ester title compound, MS: m/e=282.0 (M+) via 6-bromo-pyridine-2-carboxylic acid methyl ester and 3 The reaction was carried out by the reaction of '4-di-phenyl-dihydroxyboronic acid as a pale yellow solid (7% yield). Example 337 2_-Moth-Different 絵···································· The sodium was heated together for 6 hours, and after extraction and aqueous subsequent treatment, 2·iodo-isonicotinic acid (7.3 g, 92.4% yield) was obtained. This material was dissolved in THF (50 mL) using EtOAc (EtOAc: EtOAc) The solvent was evaporated to dryness eluted EtOAcqqqqqqqqq MS: m/e = 263.0 (M+). Example 338 U odor-5-(2-mercapto-imidazole·ι_yl-methyl-pyridinium in sodium hydride (0.54 g '12·3 mmol) in THF (40 mL) at 20 ° C with stirring Add 2-mercaptoimidazole in several portions over 45 minutes in the liquid.
裝Loading
本紙張尺度適用中國國家標準(CNS) A*規格(21〇χ 297公釐) 1328584 五、發明説明(137 ) 後加入3-漠-5-(氣曱基)·ρ比咬(1克,4..I毫莫耳)於乙醇(8毫升 ),混合物於氬氣氣氛下回流加熱1小時。冷卻及蒸發去除 溶劑後,殘餘物懸浮於曱醇,過濾及吸附至矽膠。以二氣 甲烷/(2M氨甲醇)=98:2層析洗提獲得標題化合物(0 56克, 53%)呈黃色油。MS: m/e=251.0 (M+)。 實例339 3-溴-5-(氣甲基吡啶 於亞磺醯氯(41毫升,344毫莫耳)之冷溶液内於〇。〇小心(高 度放熱)逐份加入(5 ->臭-σ比咬-3-基)-曱醇(1〇克,44.5毫莫耳) 。添加完成後’混合物加熱至回流歷1小時而完成反應。冷 卻後加入趟(50毫升)’混合物冷卻至4°c »沉殿固體經過渡 出’以冷醚洗條然後於50°C真空脫水2小時獲得標題化合物 (9.1 克,84%)呈淺黃色固體。MS: m/e=206.9 (M+)。 實例340 (j-溴-吡啶-3-某甲醇鹽醴镑η:】) 5·溴菸鹼酸乙酯(25克’ 108毫莫耳)溶解於乙醇(500毫升), 於20 °C以30分鐘時間逐份添加新鮮硼氫化鈉(25克,660毫 莫耳)處理。於氬氣氣氛下連續搜拌隔夜。其後緩慢(經2〇分 鐘時間)加入1N鹽酸(50毫升),接著加入2N氫氧化鈉(25毫 升)及水(75毫升),混合物於周圍溫度攪拌2小時。蒸發去除 醇後,水相以二氣甲烷(4x 150毫升)萃取,合併萃取物以鹽 水洗滌然後以硫酸鈉脫水’過濾及蒸發。所得黃色油溶解 於小量乙醇,於4°C以1小時時間使用0.93 Μ鹽酸/乙醇(62毫 升’ 1.2當量)處理’於去除溶劑及於5〇°c下高度真空脫水16 1328584 A7 B7 r 五、發明説明(138 小時後,獲得標題化合物(1〇 9克,44%)呈淺黃色固體。 MS: m/e=186.9 (M+) 〇 實例341 1- i3,4-二曱基-茉基)_2•甲篡·蘇鹼酸乙酯 得自[3-二曱基胺基_2_(3,4·二曱基_苯基)烯丙啶]·二甲基·四 氟硼酸銨(1:1),後者又係由3,4_二曱基_苯基乙酸(根據a j Liepa ;澳洲化學期刊,198H(12),2647_55製備)製備。 實例342 2_-ί4-氣-3-三氟甲基-苯基>)_4,4,5,5·四甲某_π 3 21二 園硼烷 本化合物係以參考文獻已知方法(γ. Masuda, Μ. Murata,S. Watanabe,有機化學期刊,1997,ϋ 6458-9)之修改方法製 備。含有乙酸鉀(3.4克’ 34.7毫莫耳),PdCl2(PPh3)2 (234毫 克’ 0.34毫莫耳)及系ι(皮納可酸根(pinac〇iato))二蝴(3 2克, 12‘7毫莫耳)之燒瓶内加入5-溴-2-氣-笨并三氟(3克,11.5毫 莫耳)於二哼烷溶液。混合物於氬氣氣氛下加入至10〇〇c歷3 小時。冷卻後加入乙酸乙酯,然後有機混合物以飽和氣化 鈉溶液洗滌’然後以硫酸鈉脫水及蒸發去除溶劑。殘餘物 經層析(矽膠,以己烷/乙酸乙酯=9:1洗提)獲得標題化合物 (2.35克,66%)呈淺褐色固體。MS: m/e=306.1 (M+)。 實例343-347係根據實例342所述概略程序製備。 實例343 2- (3,4-氣-4-甲基-笑某)-4.4,5,5-四曱基-Γ1.3.21二氩雜伍園硼 -142- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297兮爱)This paper scale applies to China National Standard (CNS) A* specification (21〇χ 297 mm) 1328584 V. Invention description (137) After adding 3-Mo-5-(gas 曱 base)·ρ ratio bite (1 g, 4. Immol) in ethanol (8 mL), the mixture was heated under reflux for 1 hour under argon. After the solvent was removed by cooling and evaporation, the residue was suspended in methanol, filtered and then applied to silica gel. The title compound (0 56 g, 53%) was obtained as a yellow oil. MS: m/e = 251.0 (M+). Example 339 3-Bromo-5- (a gas methylpyridine in sulfinium chloride (41 mL, 344 mmol) in a cold solution in hydrazine. 〇 Care (highly exothermic) was added in portions (5 -> σ 咬 -3- ) ) 曱 曱 曱 曱 曱 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 The title compound (9.1 g, 84%) was obtained as a pale-yellow solid. mp. m/e = 206.9 (M+). Example 340 (j-bromo-pyridine-3-methanolate 醴p::) 5·Bromonicotinic acid ethyl ester (25 g of '108 mmol) dissolved in ethanol (500 ml) at 20 °C The fresh sodium borohydride (25 g, 660 mmol) was added portionwise over 30 minutes. The mixture was continuously stirred overnight under an argon atmosphere. Thereafter, 1N hydrochloric acid (50 mL) was added slowly (after 2 min). 2N sodium hydroxide (25 ml) and water (75 ml) were added, and the mixture was stirred at ambient temperature for 2 hours. After evaporation to remove the alcohol, the aqueous phase was di-methane (4 x 150 ml) After extraction, the combined extracts were washed with brine and then dehydrated with sodium sulfate 'filtered and evaporated. The obtained yellow oil was dissolved in a small amount of ethanol and treated with 0.93 hydrazine hydrochloride/ethanol (62 ml of '1.2 equivalents) at 4 ° C for 1 hour. Removal of solvent and high vacuum dehydration at 5 ° C. 16 1328584 A7 B7 r V. Description of the invention (138 hours later, the title compound (1 〇 9 g, 44%) was obtained as pale yellow solid. MS: m/e = 186.9 (M+) 〇Example 341 1- i3,4-Dimercapto-mosyl)_2• formazan sulphonic acid ethyl ester was obtained from [3-didecylamino 2_2 (3,4·didecyl) _Phenyl)allylidine]-dimethyl-ammonium tetrafluoroborate (1:1), which is further composed of 3,4-didecyl-phenylacetic acid (according to aj Liepa; Australian Chemical Journal, 198H (12) ), prepared by 2647_55). Example 342 2_-ί4-gas-3-trifluoromethyl-phenyl>)_4,4,5,5·tetramethyl _π 3 21 diborane borane Reference is made to a known method (γ. Masuda, Μ. Murata, S. Watanabe, Journal of Organic Chemistry, 1997, ϋ 6458-9). Contains potassium acetate (3.4 g '34.7 mmol), PdCl2 (PPh3) 2 (234 mg '0.34 mmol) and ι (pinac〇iato) two butterflies (32 g, 12' A 7 mM flask was charged with 5-bromo-2-a-p- and trifluoro (3 g, 11.5 mmol) in dioxane. The mixture was added to 10 ° C for 3 hours under an argon atmosphere. After cooling, ethyl acetate was added, and then the organic mixture was washed with a saturated sodium carbonate solution. The residue was purified by EtOAcjjjjjjjjj MS: m/e = 306.1 (M+). Examples 343-347 were prepared according to the general procedure described in Example 342. Example 343 2-(3,4-Ga-4-methyl-lamo)-4.4,5,5-tetradecyl-Γ1.3.21 Diargon-boron Boron-142- This paper scale applies to Chinese national standards ( CNS) A4 specification (210 X 297 兮 love)
裝 訂Binding
U28584 A7U28584 A7
標題化合物,MS: m/e=252.1 (M+)係使用2-氣_4_蛾_甲苯作 為起始物料獲得,呈淺黃色半固體(30%產率 實例344 hi4·氧_3·甲基-苯基)-4,4,5,5·四甲棊氣雜值圊,拉 標題化合物,MS: m/e=252.1 (M+)係使用5_漠_2_氯_甲笨獲 得,呈無色固韹(16%產率)。 實例345 5-(4,4,5,5-四甲基-Γ1,3,21-二氧雜伍圜硼烷·2_其、-9,3-二急 笨并呋喃 標題化合物,MS: m/e=246.1 (Μ+)係使用2,3-二氫-5-硬苯并 [b]呋喃獲得,呈淺黃色油(5 1%產率)。 實例346 2·四氫茚-5-基-4,4,5,5-四甲基-丨1,3,21-二氳鞞伍圄硼忮 標題化合物,MS: m/e=244.1 (M+)係使用三氟-曱烷磺酸四 氫印-5-基酯獲得,呈淺黃色油(96%產率),三氟-曱炫續酸 四氩茚-5-基酯又係得自四氫茚-5-醇,係經由使用三氟-曱 烷磺酐,DMAP及三乙基胺於二氯甲烷於-70°C至20°C處理 獲得。 實例347 2-(4-氟-3-三氟甲基-笨基)-4,4,5,5-四甲某-『1,3,21二氣雜伍 圜硼烷 標題化合物,MS: m/e=290.1 (M+)係使用5-溴-2-氟-苯并三 氟獲得,呈無色油(76%產率)。 實例348 -143- 本纸張尺度適用中國国家標準(CNS) A4規格(210X 297公釐) 1328584 五、發明説明(14〇 ) Π-(3-三氧曱基硫统基-笨基)·ιη_ρ米p坐-·4-基1-甲醇 遵照實例293所述概略方法,3_(三氟曱基硫)笨胺與原曱酸 二乙酯’硝基乙酸乙酯及乙酸反應’接著使用原曱酸三乙 醋,鐵及乙酸處理’隨後進行鹼性水解。分離得之酸直接 根據實例264還原,還原方法係經由與BH3 THF錯合物反應 接著水解後續處理’獲得標題化合物呈淺褐色結晶固體。 炫點 73-75°C (水),MS: m/e=274 (M+)。 實例349 二氟-乙基)-苯某 °•坐-4-基}-甲醇 遵ft?、貫例293所述概略方法,3-(1,卜二默-乙基)_苯胺[R,〇. Neri, J.G. Topliss, Ger. Offen. (1972), DE 2130452 19721221 CAN 78:124310]與原甲酸三乙酯,硝基乙酸乙酯及乙酸反 應’接著使用原甲酸三乙酯,鐵及乙酸處理,隨後進行驗 性水解。分離得之酸直接根據實例264還原,還原方法係經 由與BH3 THF錯合物反應接著水解後續處理,獲得標題化 合物呈白色結晶固體。熔點1〇4-1〇8。〇(水),MS: m/e=238 (M+)。 實例350 {1-「3-(1,1- 一乳-乙基)-苯基1-4-氟-1Η-°米°坐-4 -基甲醇 遵照實例293所述概略方法,3-(1,1_二氟-乙墓)_4_氟_笨胺與 原甲酸二乙酯’硝基乙酸乙酯及乙酸反應,接著使用原曱 酸三乙酯’鐵及乙酸處理’隨後進行鹼性水解β分離得之 酸直接根據實例264還原,還原方法係經由與Βη3 THF錯合 物反應接著水解後續處理,獲得標題化合物呈白色結晶固 •144- 本紙張尺度適用中國S家標準(CNS) A4規格(210X 297公爱) 1328584 A7 _____ B7 _ 五、發明説明(⑷ ) 體。MS: m/e=257 (M + H+)。 實例3 5 1 3-Π,1-二氟-乙甚V4-氯-茉胺 於2-(1,1-二氟-乙基卜丨-氟-斗-硝基苯(10.4克,50.6毫莫耳)於 甲醇(200毫升)之溶液加入鈀/碳(10%,4克),結果所得混合 物於20°C氫化2小時。過濾去除催化劑後,溶劑經蒸發獲得 標題化合物呈#色半固體物質(8.5克,96%)。MS: m/e=l 75 (M+) » 實例352 2-( 1,1-二氟-乙某氟_4 —硝某-茉 1-(2-氟-5-硝基-苯基)_乙酮(ι〇·8克,59.0毫莫耳)於二乙基胺 基三氟化硫(15.5毫升,118毫莫耳)之溶液於50。(:攪拌6小時 。混合物於冰浴冷卻,緩慢添加至冰冷水性2Ν氫氧化鈉溶 液(100毫升)。以二氣曱烷萃取後,有機相經脫水(硫酸鈉) 及濃縮。層析(矽膠,以乙酸乙酯/己烷=;1:4洗提)後,獲得 標題化合物呈暗褐色油(9.8克,81%)。MS: m/e=205 (Μ+)。 實例353 1-(3-異丙基-笨基来唾-4-錄酸 遵照實例234所述概略方法,3-異丙基苯胺與原曱酸三乙酯 ’硝基乙酸乙S旨及乙酸反應’接著使用原申酸三乙g旨,鐵 及乙酸處理’隨後接著鹼性水解《獲得標題化合物呈淺褐 色結晶固體。熔點>122°C分解(水/二噚烷)。MS: m/e=231 (M + H+)。 實例354 -145- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 裝 訂The title compound, MS: m/e = 252.1 (M+), was obtained as the starting material using 2- gas _4_ moth-toluene as a light yellow semi-solid (30% yield 344 hi4·oxy_3·methyl -phenyl)-4,4,5,5·tetramethyl hydrazine gas, 标题, the title compound, MS: m/e=252.1 (M+) obtained using 5_ desert_2_chloro_methyl stupid Colorless solid (16% yield). Example 345 5-(4,4,5,5-Tetramethyl-indole 1,3,21-dioxaindole borane·2_,-9,3-di- succinylfuran title compound, MS: m/e = 246.1 (Μ+) was obtained using 2,3-dihydro-5-bromobenzo[b]furan as a pale yellow oil (5 1% yield). Example 346 2·tetrahydroindole-5 -4,4,5,5-tetramethyl-indole 1,3,21-diindole, borax, the title compound, MS: m/e = 244.1 (M+) using trifluoro-decane Obtained as a light yellow oil (96% yield), and trifluoro-indene acid tetrahydroindole-5-yl ester is obtained from tetrahydroindol-5-ol. It was obtained by treatment with trifluoro-decanesulfonic anhydride, DMAP and triethylamine in dichloromethane at -70 ° C to 20 ° C. Example 347 2-(4-fluoro-3-trifluoromethyl-phenyl -4,4,5,5-tetramethyl-"1,3,21 dioxane borane title compound, MS: m/e = 290.1 (M+) using 5-bromo-2-fluoro- Obtained as benzotrifluoride as a colorless oil (76% yield). Example 348 -143- This paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm) 1328584 V. Description of invention (14〇) Π -(3-trioxothiol-styl)·ιη_ρ米p sit-·4-base 1-methanol The general procedure of Example 293, 3 - (trifluoromethylsulfonyl) phenanthrene was reacted with diethyl decanoate 'nitroacetic acid and acetic acid' followed by treatment with triacetic acid, iron and acetic acid. Alkaline hydrolysis. The isolated acid was directly reduced according to Example 264. The reduction method was obtained by reacting with BH3 THF complex followed by hydrolysis and subsequent treatment to give the title compound as a light brown crystalline solid. H.s. 73-75 ° C (water). MS: m/e = 274 (M+). Example 349: difluoro-ethyl)-benzene. Dimer-ethyl)-aniline [R, 〇. Neri, JG Topliss, Ger. Offen. (1972), DE 2130452 19721221 CAN 78:124310] Reaction with triethyl orthoformate, ethyl nitroacetate and acetic acid' Subsequent treatment with triethyl orthoformate, iron and acetic acid followed by an analytical hydrolysis. The isolated acid was directly reduced according to Example 264. The title compound was obtained as a white crystalline solid. Melting point 1〇4-1〇8. 〇 (water), MS: m/e = 238 (M+). Example 350 {1-"3-(1,1-mono-ethyl-phenyl)-phenyl1-4-fluoro-1?-?m??-4-ylethanol followed the general procedure described in Example 293, 3-( 1,1_Difluoro-B tomb)_4_Fluorine-stupylamine is reacted with diethyl orthoformate 'nitroacetate and acetic acid, followed by treatment with triethyl orthoacetate 'iron and acetic acid' followed by alkaline The acid obtained by hydrolysis of β is directly reduced according to the example 264, and the reduction method is carried out by reacting with the Βη3 THF complex followed by hydrolysis to obtain the title compound as a white crystalline solid. 144- This paper scale is applicable to the Chinese S standard (CNS) A4. Specifications (210X 297 public) 1328584 A7 _____ B7 _ V. Description of invention ((4) ) Body: MS: m/e=257 (M + H+). Example 3 5 1 3-Π, 1-Difluoro-BV V4 -Chloro-mosamine added palladium on carbon in a solution of 2-(1,1-difluoro-ethyl-p-fluoro-fluoro-bu-nitrobenzene (10.4 g, 50.6 mmol) in methanol (200 mL) 10%, 4 g), the resulting mixture was hydrogenated at 20 ° C for 2 hours. After removal of the catalyst by filtration, the solvent was evaporated to give the title compound as a semi-solid substance (8.5 g, 96%). MS: m/e=l 75 (M+) » Example 352 2-( 1,1-two - B-Fluorine_4 - Nitrogen-Methyl 1-(2-fluoro-5-nitro-phenyl)-ethanone (ι〇·8 g, 59.0 mmol) in diethylaminotrifluoride A solution of sulfur (15.5 ml, 118 mmol) was added to 50. (: stirring for 6 hours. The mixture was cooled in an ice-bath, and slowly added to ice-cold aqueous 2? sodium hydroxide solution (100 ml). After extraction with dioxane, The title compound was obtained as a dark brown oil (yield: EtOAc, EtOAc) m/e = 205 (Μ +). Example 353 1-(3-Isopropyl-p-styl- saliva-4-acid as described in Example 234, 3-isopropyl aniline and triethyl orthanoate The ester 'nitroacetic acid B is intended to be reacted with acetic acid' followed by the use of the original acid triethylene glycol, iron and acetic acid treatment followed by alkaline hydrolysis to obtain the title compound as a light brown crystalline solid. Melting point > 122 ° C decomposition ( Water/dioxane. MS: m/e=231 (M + H+). Example 354 -145- This paper scale applies to Chinese National Standard (CNS) A4 size (210X297 mm) Binding
1328584 五、發明説明(142 ) Π-(3-異丙基·苯基V1H-咮唑-4-基 遵照實例264所述概略方法,1-(3-異丙基_笨基唑_4_ 叛酸與BH3 THF錯合物反應’接著接受水解後續處理。獲 得標題化合物呈淺褐色結晶固體。熔點76-77 eC (水)。MS: m/e=216 (M+)。 實例355 1 -奈-2-基-1H-^唾-4·藉酸曱西旨 2-茶基二經领酸(1·4克,8毫莫耳),1H-咪唾_4_羧酸曱醋 (1.0克,8毫莫耳)及乙酸銅(I·4克,8毫莫耳)於二氣甲烷(20 毫升)之懸浮液於20°C授拌24小時。加入乙酸乙酯(1〇〇毫升) 及飽和水性瑟納特鹽溶液(50毫升),所得混合物又攪拌2小 時。分離後’有機相經脫水(硫酸鈉),濃縮及層析(矽膠, 以二氣曱炫>/曱醇=99:1洗提)獲得標題化合物(0.49克,24%) ,呈白色結晶物質。熔點143-144 °C (乙酸乙酯)。MS·· m/e=252 (M+)。 實例356 (1-奈-2-基-1Η-°朵嗅-4 -基甲醇 遵照實例298所述概略方法,ι_莕·2_基-1H-咪唑-4-羧酸曱酯 與銘氫化鐘反應,接著接受水解後續處理及層析術,獲得 標題化合物呈淺褐色膠狀物^ MS: m/e=225 (Μ+) » 實例357 Π-(3-漠-4-氟-苯基妹吐_4·基·]-甲薛 遵照實例293所述概略方法,3_溴_4·氟-笨胺(K s γ· Lau等 人,有機化學期刊,1981,46, 2280-6)與原曱酸三乙酯,硝 本纸張尺度適財g g家標準(CNS) M規格(加χ撕公爱) 裝 訂 • 146- 1328584 A7 _____B7 五、發明説明(143 ) 基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及乙 酸處理,隨後進行鹼性水解。分離得之酸直接根據實例264 還原’還原方法係經由與BH3 THF錯合物反應接著水解後 續處理’獲得標題化合物呈白色結晶固體。熔點15 1-152°C ( 水),MS: m/e=270 (M+)。 實例358 1-(3->臭-笨基V1H-味吐-4-翔酸 遵照實例234所述概略方法,3-溴苯胺與原曱酸三乙酯,硝 基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及乙 酸處理,隨後接受鹼性水解。獲得標題化合物呈淺褐色結 晶固體。熔點 205-207°C (水/二呤烷)。MS: m/e=267 (M-Η·)。 實例359 Π-(3-溴-装某V1H-咪唑-4-基1-甲醇 遵照實例264所述概略方法,1-(3-溴·苯基)-1Η-咪唑-4-羧酸 與BH3 THF錯合物反應,接著接受水解後續處理。獲得標 題化合物呈灰白色固體。MS: m/e=253 (Μ+Η+)。 實例360 Γΐ-(3-乙烯篡-笑篡)-iH-咪唑-4-基1-甲醇 於氬氣氣氛下,[1-(3-溴-苯基)-1Η-咪唑-4-基]-曱醇(3.0克, 12毫莫耳)於DMF (90毫升)之溶液依續使用PdCh(PPh3)2 (〇_87克,0.1毫莫耳)及乙烯基三丁基錫烷(4.1克,13毫莫耳 )處理。結果所得混合物加熱至60°C歷8小時。蒸發去除溶 劑後,殘餘物使用乙酸乙酯(60毫升)及水性10%氟化鉀溶液 攪拌30分鐘。有機相經分離,水相以乙酸乙酯萃取3次》合 1___ _147- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A71328584 V. INSTRUCTIONS (142) Π-(3-Isopropyl-phenyl V1H-carbazole-4-yl group follows the general procedure described in Example 264, 1-(3-isopropyl-stupidylazole_4_ rebellion The acid was reacted with a BH3 THF complex. The title compound was obtained as a light brown crystalline solid. m.p. s. s. 2-Base-1H-^Salt-4·Acid acid 曱西2- 2-茶基二经领酸 (1·4 g, 8 mmol), 1H-Mimi _4_carboxylic acid vinegar (1.0 g , 8 mM) and a suspension of copper acetate (1.4 g, 8 mmol) in di-methane (20 mL) at 20 ° C for 24 hours. Add ethyl acetate (1 mL) And saturated aqueous sodium salt solution (50 ml), the mixture was stirred for another 2 hours. After separation, the organic phase was dehydrated (sodium sulfate), concentrated and chromatographed (yellow gel, dioxin > / sterol = The title compound (0.49 g, 24%) was obtained as white crystals. m.p. 143- 144 s (ethyl acetate). MS·· m/e=252 (M+). Example 356 (1) -Ny-2-yl-1 Η-° odor-4-yl methanol according to the schematic method described in Example 298 Ι_荇·2_yl-1H-imidazole-4-carboxylic acid oxime ester is reacted with a hydrogenation clock, followed by hydrolysis followed up and chromatography to give the title compound as a light brown gum. MS: m/e = 225 (Μ+) » Example 357 Π-(3-Iso-4-fluoro-phenyl-stimulus _4·yl·]-methyl-elast according to the general procedure described in Example 293, 3_bromo-4·fluoro-moleamine (K s γ· Lau et al., Journal of Organic Chemistry, 1981, 46, 2280-6) and triethyl orthoformate, nitric acid scale gg standard (CNS) M specification (plus twisting public love) Binding • 146- 1328584 A7 _____B7 V. Description of the invention (143) The reaction of ethyl acetate and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid, followed by alkaline hydrolysis. The isolated acid is directly according to Example 264. The reduction 'reduction method is obtained by reacting with BH3 THF </ br> </ br> </ br> </ br> 1-(3->Smell-Stupid V1H-Smell-4-Acidic Acid Following the general procedure described in Example 234, 3-bromoaniline was reacted with triethyl orthanoate, ethyl nitroacetate and acetic acid, followed by Treated with triethyl orthoformate, iron and acetic acid, followed by basic hydrolysis to give the title compound as a light brown crystalline solid. m.p. 205-207 ° C (water / dioxane) MS: m/e = 267 (M -Η·). Example 359 Π-(3-bromo-prepared to a V1H-imidazol-4-yl 1-methanol according to the procedure outlined in Example 264, 1-(3-bromo-phenyl)-1 Η-imidazole-4-carboxylic acid and BH3 The THF complex was reacted, followed by hydrolysis for subsequent workup. The title compound was obtained as an off-white solid. MS: m/e = 253 ( Μ + Η + ). Example 360 Γΐ-(3-vinyl oxime- 篡 篡)-iH-imidazole 4-yl 1-methanol under argon atmosphere, [1-(3-bromo-phenyl)-1Η-imidazol-4-yl]-nonanol (3.0 g, 12 mmol) in DMF (90 mL) The solution was treated with PdCh(PPh3)2 (〇_87 g, 0.1 mmol) and vinyltributylstannane (4.1 g, 13 mmol). The resulting mixture was heated to 60 ° C for 8 hours. After evaporating to remove the solvent, the residue was stirred with ethyl acetate (60 mL) and aqueous 10% potassium chloride solution for 30 min. The organic phase was separated and the aqueous phase was extracted three times with ethyl acetate. 1____147- Applicable to China National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7
併機相經脫水(硫酸鈉)’濃縮及層析[矽膠,以梯度二氣甲 烷至40%(二氣曱烷/曱醇=9:1)洗提]獲得標題化合物呈無色 油(1.2克,51%)。MS: m/e=201 (M+H+)。 實例361 [1-(3-環丙基-茉基咪唑-4-基1-甲薛 於氬氣氣氛下,[1-(3-乙烯基-苯基)-1Η-咪唑-4-基卜甲醇 (〇.1〇克,0.5毫莫耳)於曱苯(2〇毫升)之混合物依續使用二乙 基辞(3.8毫升1.1 Μ於己烷溶液,4.2毫莫耳)及二碘曱烷(6 6 克’ 25毫莫耳)處理。結果所得混j合物於2〇攪拌12小時。 過濾出沉澱及與乙酸乙酯及飽和水性氣化銨溶液共同授掉 30分鐘。分離有機相’脫水(硫酸鈉)及濃縮獲得標題化合物 呈黃色油(0.10克,93%) » MS: m/e=215 (M+H+)。 實例362 2· —氣甲基-石肖基-苯 2-氟-5-硝基笨曱醛(1.7克’ 1〇毫莫耳)於二氣曱烧(5〇毫升) 之溶液使用二乙基胺基三氣化硫(1·8毫升’ 14毫莫耳)處理 及於20 C搜拌72小時。然後加入飽和碳酸氫鈉水溶液(2〇〇 毫升),混合物攪拌1小時。有機相經分離,脫水(硫酸鈉)及 層析[矽膠,以梯度己烷至1〇〇〇/0(己烷/乙酸乙酯=3:1)洗提] 獲得標題化合物呈無色油(1.4克,74%)。MS: m/e=191 (Μ+)。 實例363 3_-二氟甲基-4-氟-装胺鹽酸鹽(ι:π 於粉狀體(88.0克,1·58莫耳)於乙酸(500毫升)之混合物内於 120°C缓慢加入2-二氟甲基-1-氟-4-硝基苯(25.0克,131毫莫 -148- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 A7The combined phase was dehydrated (sodium sulphate) and concentrated and chromatographed eluted with EtOAc (EtOAc: EtOAc (EtOAc) , 51%). MS: m/e = 201 (M+H+). Example 361 [1-(3-cyclopropyl-methylpyrazole-4-yl-1-methylxene under argon atmosphere, [1-(3-vinyl-phenyl)-1Η-imidazole-4-yl) A mixture of methanol (〇.1 g, 0.5 mmol) in toluene (2 ml) continued to use diethyl (3.8 ml of 1.1 hexane in hexane, 4.2 mmol) and diiododecane. (6 6 g '25 mmol). The resulting mixture was stirred for 12 hours at 2 Torr. The precipitate was filtered off and combined with ethyl acetate and a saturated aqueous ammonium hydride solution for 30 minutes. Dehydrated (sodium sulphate) and EtOAc (EtOAc m. A solution of 5-nitroindole aldehyde (1.7 g '1 〇 millimolar) in dioxane (5 〇 ml) using diethylaminotrisulfide (1·8 ml '14 mmol) The mixture was stirred for 20 hours at 20 C. Then a saturated aqueous solution of sodium hydrogencarbonate (2 mL) was added and the mixture was stirred for 1 hour. The organic phase was separated, dried (sodium sulfate) and chromat. 1〇〇〇/0 (hexane/ Ethyl acetate = 3:1) eluted to give the title compound as a colorless oil (1. 4 g, 74%). MS: m/e = 191 ( Μ+). Example 363 3 - difluoromethyl-4-fluoro- Add 2-difluoromethyl-1-fluoro-4 slowly at 120 ° C in a mixture of amine hydrochloride (ι: π in powder (88.0 g, 1.58 mol) in acetic acid (500 ml) at 120 °C -Nitrobenzene (25.0 g, 131 mmol-148- This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1328584 A7
耳)。完成添加後持續攪拌15分鐘,.反應混合物冷卻至20*t ,過濾及蒸發。殘餘物與乙酸乙酯(1升)共同攪拌,過濾, 蒸發及層析[矽膠,以梯度己烷至100%(己烷/乙酸乙酯=2:1) 洗提]獲得標題化合物自由態鹼呈深褐色油(15.11克,72%) 。分析樣本使用鹽酸處理及呈白色鹽酸鹽結晶。熔點>240 °C 分解(曱醇/乙醚),MS: m/e=161 (M+)。 實例364 1-(3-二氟甲基-4-氣-苯基MH-咪唑-4-羧酸 遵照實例234所述概略方法,3-二氟甲基-4-氟苯胺與原甲酸 二乙酯’硝基乙酸乙酯及乙酸反應’接著使用原曱酸三乙 酯,鐵及乙酸處理’隨後接受驗性水解。獲得標題化合物 呈淺褐色結晶固體。熔點>247。(:分解(水/二哼院)。MS: m/e=255 (M-Η-)。 實例365 Γΐ-(3-二氟甲基-4-1-苯基)-1Η-咪唑-4-某1-甲g| 遵照實例264所述概略方法,1-(3-二氟甲基-4-氟-苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應,接著接受水解後續處 理。獲得標題化合物呈灰白色固體。炫點133-134 °C (水)。 MS: m/e=242 (M+) ° 實例366 1-(3-甲基硫烷基-笨基V1H-咪唑-4-羧酸 遵照實例234所述概略方法,3-(甲基硫)笨胺與原甲酸三乙 酯’硝基乙酸乙酯及乙酸反應,接著使用原曱酸三乙g旨, 鐵及乙酸處理’隨後接受驗性水解》獲得標題化合物呈灰 -149- 本纸張尺度適用中國國家標準(CNS) A4規格(21〇 X 297公爱) 1328584 A7 __B7_ 五、發明説明(146^~ ' 色結晶固體。熔點190-192°C (水/二呤烷)。MS: m/e=234 (Μ-Η·)。 實例367 Γ1-Π-甲基硫烷基-笨基V1H-咄崦-4-基」-甲醇 遵照實例264所述概略方法,1-(3-甲基硫烷基-苯基)-1Η-咪 唑-4-羧酸與BH3 THF錯合物反應,接著接受水解後續處理 。獲得標題化合物呈灰白色結晶固體。熔點> 120°C水解(水) 。MS: m/e=221 (M+H+)。 實例368 Γ1-Π-三氟甲氡-笨基)-1Η-哇唑-4-羧酸 遵照實例234所述概略方法,1-(3·三氟甲氧)苯胺與原曱酸 三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原曱酸三乙 酯,鐵及乙酸處理’隨後接著鹼性水解》獲得標題化合物 呈灰色結晶固體。熔點173-175 °C (水/二呤烷)。MS: m/e=273 (M+H+)。 實例369 Γ1-Π-三氟甲氣-笨基)-1Η-咪唑-4-某1-甲_ 遵照實例264所述概略方法,1-(3-三氟曱氧-苯基)-iH-咪唑-4-羧酸與BH3 THF錯合物反應,接著接受水解後續處理。獲 得標題化合物呈灰白色結晶固體。MS: m/e=258 (M+)。 實例370 Γ1-Π-氯-笨某V1H-咪唑-4-基1-甲 遵照實例293所述概略方法,3-氣苯胺與原曱酸三乙酯,硝 基乙酸乙醋及乙酸反應’接著使用原曱酸三乙醋,鐵及乙 -150- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 A7 B7 五、發明説明(147 ) 酸處理,隨後進行驗性水解。分離得之酸直接根據實例264 還原,還原方法係經由與BH3 THF錯合物反應接著水解後 續處理,獲得標題化合物呈灰白色結晶固體。熔點78-79°c ( 水)’.MS: m/e=209 (M+)。 實例371 1-Γ3-碘-茉基)-1Η-咪唑-4-羧酸 遵照實例234所述概略方法,3-碘苯胺與原甲酸三乙酯’硝 基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及乙 酸處理,隨後接受鹼性水解。獲得標題化合物呈灰白色結 晶固體。熔點 229-230°C (水/二哼烷)。MS: m/e=313 (M-Η·)。 實例372 Π-Π-碘-茉基)-1Η-咪唑-4-基1-甲醇 遵照實例264所述概略方法,1-(3-碘-苯基)-1Η-咪唑-4-羧酸 與BH3 THF錯合物反應,接著接受水解後續處理。獲得標 題化合物呈黃色油。MS: m/e=301 (M+H+)。 實例373 1-门-氣-5-三氟甲基-苯基V1H-咪唑-4-羧酸 遵照實例234所述概略方法,3-氟-5-三氟甲基苯胺與原曱酸 三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原曱酸三乙 酯,鐵及乙酸處理,隨後接受鹼性水解。獲得標題化合物 呈白色結晶固體。熔點>250°C (水/二哼烷)。MS: m/e=273 (M-Η·)。 實例374 Γ1-(3-氟-5-三氟甲基-苯基ΜΗ-咪唑-4-基1-曱醇 -151 - 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(148 ) 遵照實例264所述概略方法’ 1-(3-氟-5-三氟甲基-苯基)-1Η-咪唑-4-羧酸與BH3 THF錯合物反應,接著接受水解後續處 理。獲得標題化合物呈白色結晶固體。熔點144_145°C (水) 。MS: m/e=261 (M+H+)。 實例375 Γ1-(3-甲氣-5-三氟甲基-笨基V1H-咪唑-4-基1-甲醇 遵照實例293所述概略方法,3-甲氧-5-三氟甲基苯胺與原甲 酸三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原甲酸三 乙酯,鐵及乙酸處理,隨後進行鹼性水解。分離得之酸直 接根據實例264還原’還原方法係經由與BH3 THF錯合物反 應接著水解後續處理,獲得標題化合物呈淺褐色結晶固體 。熔點 133-134°C (水),MS: m/e=272 (Μ+)。 實例376 Π-Π-第三丁基-笨基V1H-咪唑-4-基1-甲醇 遵照實例293所述概略方法,3-第三丁基苯胺與原甲酸三乙 酯,硝基乙酸乙酯及乙酸反應,接著使用原曱酸三乙酯, 鐵及乙酸處理,隨後進行鹼性水解。分離得之酸直接根據 實例264還原,還原方法係經由與BH3 THF錯合物反應接著 水解後續處理,獲得標題化合物呈無色油。MS: m/e=230 (M+)。 實例377 1-(3-1-4-三氤甲氣-策基V1H-咪唑-4-羧酸 遵照實例234所述概略方法,3-氯-5-(三氟甲氧)苯胺與原甲 酸三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原曱酸三 -152- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐)ear). Stirring was continued for 15 minutes after completion of the addition. The reaction mixture was cooled to 20*t, filtered and evaporated. The residue was stirred with ethyl acetate (1 liter), filtered, evaporated, EtOAcjjjjjjjjjjj Dark brown oil (15.11 g, 72%). The analytical samples were treated with hydrochloric acid and crystallized as white hydrochloride. Melting point > 240 ° C decomposition (sterol / diethyl ether), MS: m / e = 161 (M +). Example 364 1-(3-Difluoromethyl-4-gas-phenyl MH-imidazole-4-carboxylic acid according to the procedure outlined in Example 234, 3-difluoromethyl-4-fluoroaniline and diethyl orthoformate The ester 'nitroacetic acid and acetic acid were reacted' followed by treatment with triethyl orthophthalate, iron and acetic acid. Subsequent hydrolysis was carried out to give the title compound as a light brown crystalline solid. mp. 247. /二哼院).MS: m/e=255 (M-Η-). Example 365 Γΐ-(3-Difluoromethyl-4-1-phenyl)-1Η-imidazole-4-some 1-A g| Following the general procedure described in Example 264, 1-(3-difluoromethyl-4-fluoro-phenyl)-1 oxime-imidazole-4-carboxylic acid was reacted with BH3 THF. The title compound was obtained as an off-white solid. 133-134 ° C (water). MS: m/e=242 (M+) ° Example 366 1-(3-methylsulfanyl-phenyl-V1H-imidazole-4- The carboxylic acid was reacted according to the general procedure described in Example 234, 3-(methylsulfanyl)amine and triethyl orthoformate's ethyl nitroacetate and acetic acid, followed by triethyl phthalic acid, iron and acetic acid. Subsequent Acceptance of Hydrolysis" to obtain the title compound in gray-149- paper size Applicable to China National Standard (CNS) A4 specification (21〇X 297 public) 1328584 A7 __B7_ V. Description of invention (146^~ 'Color crystalline solid. Melting point 190-192°C (water/dioxane). MS: m /e = 234 (Μ-Η·). Example 367 Γ1-Π-methylsulfanyl-stupyl V1H-indol-4-yl"-methanol as outlined in Example 264, 1-(3-A Reaction of the sulfhydryl-phenyl)-1 oxime-imidazole-4-carboxylic acid with a BH3 THF complex followed by hydrolysis to give the title compound as an off-white crystalline solid. mp. MS: m/e = 221 (M+H+). </RTI> </RTI> </RTI> </RTI> <RTI ID=0.0></RTI> </RTI> <RTIgt; </RTI> <RTIgt; Trifluoromethoxy)aniline is reacted with triethyl orthophthalate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid followed by alkaline hydrolysis to give the title compound as a gray crystalline solid. Melting point 173-175 ° C (water / dioxane). MS: m / e = 273 (M + H +). Example 369 Γ 1-Π - trifluoromethane - stupid) -1 - imidazole - 4 1-A_ Following the general procedure described in Example 264, 1-(3-trifluorooxo-benzene ) -IH- imidazole-4-carboxylic acid complexes are reacted with BH3 THF, followed by hydrolysis to accept the subsequent processing of the title compound is obtained an off-white crystalline solid .MS:. M / e = 258 (M +). Example 370 Γ1-Π-Chloro-Stupid V1H-Imidazol-4-yl 1-A. Following the general procedure described in Example 293, 3-aniline was reacted with triethyl orthophthalate, nitroacetic acid and acetic acid. Use original tannic acid triethyl vinegar, iron and B-150- This paper scale is applicable to China National Standard (CNS) A4 specification (210X297 mm) 1328584 A7 B7 V. Invention description (147) Acid treatment, followed by analytical hydrolysis . The isolated acid was directly reduced according to Example 264. The title compound was obtained as a pale white crystalline solid. Melting point 78-79 ° C (water)'. MS: m/e = 209 (M+). Example 371 1-Indole 3-iodo-momenyl-1 oxime-imidazole-4-carboxylic acid Following the general procedure described in Example 234, 3-iodoaniline was reacted with triethyl orthoformate 'nitroacetate and acetic acid, followed by Treatment with triethyl orthoformate, iron and acetic acid followed by alkaline hydrolysis. The title compound was obtained as an off-white crystalline solid. Melting point 229-230 ° C (water / dioxane). MS: m/e = 313 (M-Η·). Example 372: Π-Π-iodo-mosyl)-1 Η-imidazol-4-yl 1-methanol The general procedure described in Example 264, 1-(3-iodo-phenyl)-1 oxime-imidazole-4-carboxylic acid and The BH3 THF complex is reacted followed by a subsequent treatment with hydrolysis. The title compound was obtained as a yellow oil. MS: m/e = 301 (M+H+). Example 373 1-Gentium-Gas-5-trifluoromethyl-phenyl V1H-imidazole-4-carboxylic acid Following the general procedure described in Example 234, 3-fluoro-5-trifluoromethylaniline and triethyl orthanoate The ester, ethyl nitroacetate and acetic acid are reacted, followed by treatment with triethyl orthosilicate, iron and acetic acid followed by alkaline hydrolysis. The title compound was obtained as a white crystalline solid. Melting point > 250 ° C (water / dioxane). MS: m/e = 273 (M-Η·). Example 374 Γ 1-(3-Fluoro-5-trifluoromethyl-phenylindole-imidazol-4-yl 1-nonanol-151 - This paper scale applies to Chinese National Standard (CNS) Α4 specification (210 X 297 PCT) 1328584 A7 B7 V. INSTRUCTIONS (148) Following the general procedure described in Example 264 '1-(3-Fluoro-5-trifluoromethyl-phenyl)-1Η-imidazole-4-carboxylic acid with BH3 THF The compound was reacted, followed by hydrolysis, to give the title compound as a white crystalline solid. mp 144 </ </ </RTI> <RTIgt; </RTI> <RTIgt; </RTI> (water). MS: m/e = 261 (M+H+). Example 375 Γ 1-(3-methyl-5 -Trifluoromethyl-styl V1H-imidazol-4-yl 1-methanol according to the general procedure described in Example 293, 3-methoxy-5-trifluoromethylaniline and triethyl orthoformate, ethyl nitroacetate And acetic acid reaction, followed by treatment with triethyl orthoformate, iron and acetic acid, followed by alkaline hydrolysis. The isolated acid was directly reduced according to Example 264. The reduction method was carried out by reacting with BH3 THF complex followed by hydrolysis followed by hydrolysis. The title compound was obtained as a light brown crystalline solid. m.p. s.: 134 - 134 C (water), MS: m / e = 272 ( Μ + ). Example 376 Π Π Π 第三 第三 第三 第三 笨 笨 笨 笨 笨 笨 基1-methanol compliance The general procedure of Example 293, 3-tert-butylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid followed by basic hydrolysis. The isolated acid was directly reduced according to Example 264. The title compound was obtained as a colorless oil, m.p. -1-4-trimethylamine-tactic V1H-imidazole-4-carboxylic acid according to the general procedure described in Example 234, 3-chloro-5-(trifluoromethoxy)aniline and triethyl orthoformate, nitro Ethyl acetate and acetic acid are reacted, followed by the use of the original tannic acid tri-152- This paper scale applies to the Chinese National Standard (CNS) A4 specification (210X297 mm)
裝 訂Binding
13285841328584
乙酯,鐵及乙酸處理’隨後接受鹼性水解。獲得標題化合 物呈淺褐色結晶固體。熔點230-23 TC (水/二哼烷)。MS: m/e=305 (M-Η-)。 實例378 『1-(3-氣4-三氟曱氣-笨基米唾-4-基1-甲醇 遵照實例264所述概略方法,i_(3_氣_4-三氟甲氧-苯基)_1H_ 咪唑-4-羧酸與BH3 THF錯合物反應,接著接受水解後續處 理。獲得標題化合物呈白色結晶固體。溶點115-116°C (水) 。MS: m/e=292 (M+)。 實例379 1·(3-二氟曱氡-苯基V1H-咪唑-4-#g拿 遵照實例234所述概略方法,3-(二氟甲氧)苯胺與原曱酸三 乙酯’硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯 ,鐵及乙酸處理’隨後接受鹼性水解。獲得標題化合物呈 淺褐色結晶固體。熔點190-191°C分解(水/二呤烷)。MS: m/e=253 。 實例380 Γ1-(3-二氟甲氣-笨基)-1Η-咪唑-4-基1-甲醢 遵照實例264所述概略方法,1-(3-二氟曱氧-苯基卜丨士咪唑· 4·羧酸與BH3 THF錯合物反應’接著接受水解後續處理。獲 得標題化合物呈白色結晶固體。MS: m/e=240 (M+)。 實例381 『1-(3-二氟甲基-笨基V1H-咪唑-4-某1·甲 遵照實例293所述概略方法,3-二氟曱基苯胺(g.E. Wdght等 -153- 本紙張尺度適用中國國家標準(CMS) A4規格(210X 297公釐) 1328584 A7 B7 五、發明説明(15Q ) 人,醫藥化學期刊’ 1995,ϋ 49-57)與原甲酸三乙酯’硝 基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯’鐵及乙 酸處理,隨後進行鹼性水解。分離得之酸直接根據實例264 還原,還原方法係經由與BH3 THF錯合物反應接著水解後 續處理,獲得標題化合物呈淺褐色固體。MS: m/e=225 (M+H+)。 實例382 Γ1-Γ3-溴-5-氟-茉基)-1Η-咪唑-4-基1-甲醇 遵照實例293所述概略方法’ 3-溴-5-氟苯胺(K. Yoshiizumi 等人,生物有機醫藥化學函件,1998,皂3397-3402)與原曱 酸三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原甲酸三 乙酯,鐵及乙酸處理,隨後進行鹼性水解。分離得之酸直 接根據實例264還原,還原方法係經由與BH3 THF錯合物反 應接著水解後續處理,獲得標題化合物呈淺褐色固體。熔 點 134-13 8°C (乙酸乙酯 /己烷),MS: m/e=271 (M+H+)。 實例383 Π-(2.2-二氟-茉#[1,31二氣伍園-5-基)-1Η-咪唑-4-基1-曱醇 遵照實例293所述概略方法,2,2-二氟-苯并[1,3]二氧伍圜-5-基胺與原曱酸三乙酯,硝基乙酸乙酯及乙酸反應,接著使 用原曱酸三乙酯,鐵及乙酸處理,隨後進行鹼性水解。分 離得之酸直接根據實例264還原,還原方法係經由與BH3 THF錯合物反應接著水解後續處理,獲得標題化合物呈淺 褐色固體。熔點 163-164°C (水),MS: m/e=254 (M+)。 實例384 -154- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 ------^____._ 五、發明説明(151 ) 1- ;»奎g林-2-基-1H-P米唾-4-翔酸乙酷 2- 胺基喳啉(10.0克’ 69毫莫耳),原甲酸三乙酯(14〇毫升, 過量),硝基乙酸乙酯(9.2克,69毫莫耳)及乙酸(1毫升)之混 合物回流3小時。加入乙酸(14〇毫升)及鐵粉(11 6克,208毫 莫耳)’混合物回流5小時。此期間又加入3份鐵粉(各丨i 6克 ,208毫莫耳)》混合物冷卻至60°c及加入乙酸乙酯(5〇〇毫升 )。回流10分鐘後,過濾出沉澱及濾液經濃縮。殘餘乙酸與 曱苯(500毫升)共同蒸發共沸蒸館去除。於層析術(矽膠,以 梯度己烷至乙酸乙酯洗提)後,獲得標題化合物呈灰白色結 晶物質(12.2克,66%)。熔點129-130。(:(乙酸乙酯/己烷), MS: m/e=268 (M+H+)。 實例385 (1-岭4-2-基-114-°米°^-4-某)-甲薛 遵照實例298所述概略方法,1-,奎琳·2-基_ih-°米吐-4-叛酸曱 S旨與銘氫化链反應,接著接受水解後續處理及層析術β獲 得標題化合物呈灰白色結晶物質。熔點136- 137。〇(乙醇), MS: m/e=225 (M+)。 實例386 [1-(3-氩-4-三氤甲基硫烷基-笨基V1H-咄唑-4-篡卜甲西|_ 遵照實例293所述概略方法’ 3-氯-4-(三氟曱基硫)苯胺與原 曱酸三乙酯,硝基乙酸乙酯及乙酸反應,接著使用原甲酸 三乙酯’鐵及乙酸處理,隨後進行鹼性水解。分離得之酸 直接根據實例264還原,還原方法係經由與BH3 THF錯合物 反應接著水解後續處理,獲付標題化合物呈淺褐色结晶固 -155- 1328584 A7 _____?!_ 五、發明説明(152 ) -- 體。熔點 105-106°C (水),MS: m/e=308 (M+)。 實例387 Ι-p奎琳-3-基-1H-蛛吨-4-翔酸乙醋 遵照實例384所述概略方法,2-胺基喳啉與原甲酸三乙醋, 硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及 乙酸處理。經後續處理及層析術後,獲得標題化合物,呈 喝嘰色結晶固體。熔點170-171°C (乙酸乙酯/己烷),MS: m/e=267 (M+) ° 實例388 Π-4琳-3-某-1Η-°来啼-4-某V甲醇 1-奎啉-3-基-1H-咪唑-4-羧酸乙酯(5_0克,18.7毫莫耳)於曱 苯(1〇〇毫升)之懸浮液冷卻至-78。(:。逐滴加入二異丁基氫化 鋁(19毫升1M於THF溶液,19毫莫耳)同時維持溫度低於_7〇 °C。混合物於此溫度攪拌2小時,然後讓反應混合物缓慢到 達〇°C。加入飽和水性瑟納特鹽溶液(1〇毫升)後連續攪拌卜】、 時。混合物以乙酸乙酯(100毫升)稀釋,過濾,濃縮及層析[ 矽膠,以梯度二氣甲烷至80%(二氣曱烷/曱醇/水性氫氧化銨 =90:10:1)洗提]。獲得標題化合物呈淺褐色結晶固體(12〇克 ’ 28%)。熔點 142-145。(:(乙酸乙酯),MS: m/e=226 (M+H+)。 實例389 ·蚱b免-2_基1H-珠啥·4-竣酸乙酷 遵照實例384所述概略方法,2·胺基_5_氣吡啶與原甲酸三乙 酯,硝基乙酸乙酯及乙酸反應,接著使用原曱酸三乙酯, 鐵及乙酸處理。經後續處理及層析術後,獲得標題化合物 本纸張尺度適用中国國豕標準(CNS) Α4規格(210X297公爱〇 -156- 1328584 A7Ethyl, iron and acetic acid treatments were subsequently subjected to alkaline hydrolysis. The title compound was obtained as a light brown crystalline solid. Melting point 230-23 TC (water / dioxane). MS: m/e = 305 (M-Η-). Example 378 "1-(3-gas 4-trifluoroanthracene-stupyl-methanol-4-yl 1-methanol according to the general procedure described in Example 264, i_(3_ gas_4-trifluoromethoxy-phenyl) </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; Example 379 1·(3-Difluoroindole-phenyl V1H-imidazole-4-#g was taken according to the general procedure described in Example 234, 3-(difluoromethoxy)aniline and triethyl orthophthalate' Ethyl nitroacetate and acetic acid are reacted, followed by treatment with triethyl orthoformate, iron and acetic acid 'subsequently subjected to basic hydrolysis. The title compound is obtained as a light brown crystalline solid. mp 190-191 ° C. MS: m/e = 253. Example 380 Γ 1-(3-difluoromethane-stupyl)-1 Η-imidazol-4-yl 1-carboxamidine according to the general procedure described in Example 264, 1-(3- The reaction of the difluorooxime-phenyl bastazide 4·carboxylic acid with the BH3 THF complex was followed by the subsequent work up to afford the title compound as a white crystalline solid. MS: m/e = 240 (M+). 381 『1-(3-Difluoromethyl-styl V1H-imidazole- 4- Some 1A According to the general method described in Example 293, 3-difluorodecylaniline (gE Wdght et al. -153- This paper scale applies to Chinese National Standard (CMS) A4 specification (210X 297 mm) 1328584 A7 B7 , invention description (15Q), the Journal of Medicinal Chemistry '1995, ϋ 49-57) reacted with triethyl orthoformate 'nitroacetate and acetic acid, followed by treatment with triethyl orthoformate 'iron and acetic acid, followed by Alkaline hydrolysis. The isolated acid was directly purified according to Example 264. The title compound was obtained as a light brown solid, m.p. Example 382 Γ1-Γ3-bromo-5-fluoro-jamo)-1 Η-imidazol-4-yl 1-methanol The procedure outlined in Example 293 '3-bromo-5-fluoroaniline (K. Yoshiizumi et al., Bioorganic medicinal chemical letter, 1998, soap 3397-3402) is reacted with triethyl orthosilicate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid, followed by alkaline hydrolysis. The acid obtained was directly reduced according to Example 264, and the reduction method was via a complex with BH3 THF. The title compound was obtained as a light brown solid. m.p. 134 - 13 <RTI ID=0.0></RTI> </RTI> <RTIgt; Difluoro-methane #[1,31二气伍园-5-yl)-1Η-imidazol-4-yl 1-nonanol followed the general procedure described in Example 293, 2,2-difluoro-benzo[1, 3] Dioxol-5-ylamine is reacted with triethyl orthophthalate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid, followed by alkaline hydrolysis. The isolated acid was directly reduced according to Example 264. The title compound was obtained as a light brown solid. Melting point 163-164 ° C (water), MS: m/e = 254 (M+). Example 384 -154- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 ------^____._ V. Invention description (151) 1-;»奎格林-2-yl-1H-P m-sodium-4-cyanate ethyl 2-amino porphyrin (10.0 g '69 mmol), triethyl orthoformate (14 〇 ml, excess), nitroacetic acid A mixture of ester (9.2 g, 69 mmol) and acetic acid (1 mL) was refluxed for 3 h. A mixture of acetic acid (14 ml) and iron powder (11 g, 208 mmol) was added and refluxed for 5 hours. During this time, 3 additional iron powders (6 g each, 208 mmol) were added and the mixture was cooled to 60 ° C and ethyl acetate (5 mL) was added. After refluxing for 10 minutes, the precipitate was filtered off and the filtrate was concentrated. The residual acetic acid and toluene (500 ml) were co-evaporated and removed by co-boiling. The title compound was obtained as an off-white crystalline material (12.2 g, 66%). Melting point 129-130. (: (ethyl acetate / hexane), MS: m / e = 268 (M + H +). Example 385 (1-ling 4-2-yl-114-°m °^-4-) - A Xue Following the general procedure described in Example 298, 1-, quinolin-2-yl-ih-[deg.]-4-oxo-indole 曱S was reacted with the hydrogenation chain followed by hydrolysis followed up and chromatography to obtain the title compound. Grayish white crystalline material. Melting point 136-137. 〇 (ethanol), MS: m/e = 225 (M+). Example 386 [1-(3- </ RTI> </ RTI> </ RTI> </ RTI>咄 篡 篡 篡 | | _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Treatment with triethyl orthoformate 'iron and acetic acid followed by basic hydrolysis. The isolated acid was directly reduced according to Example 264. The reduction was carried out by reacting with BH3 THF complex followed by hydrolysis and subsequent treatment. Brown crystal solid-155- 1328584 A7 _____?!_ V. Description of invention (152) - Body. Melting point 105-106 ° C (water), MS: m/e = 308 (M+). Example 387 Ι-p Kui Lin-3-yl-1H-spirt ton-4-cyanate ethyl vinegar according to the example 384 Briefly, the 2-amino porphyrin is reacted with triethylacetic acid formic acid, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid. After subsequent treatment and chromatography, the title compound is obtained. </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; </ RTI> <RTIgt; -4- a solution of V-methyl 1- quinolin-3-yl-1H-imidazole-4-carboxylate (5_0 g, 18.7 mmol) in a suspension of toluene (1 mL) to -78 (: Add diisobutylaluminum hydride (19 ml of 1 M in THF, 19 mmol) while maintaining the temperature below _7 ° C. The mixture is stirred at this temperature for 2 hours, then the reaction mixture is allowed to slowly Arrive at 〇 ° C. Add saturated aqueous sodium salt solution (1 ml) and stir continuously. The mixture is diluted with ethyl acetate (100 ml), filtered, concentrated and chromatographed. Methane to 80% (dioxane / decyl alcohol / aqueous ammonium hydroxide = 90:10:1) eluted. The title compound was obtained as a light brown crystalline solid (12 gram ' 28%). 145. (: (ethyl acetate), MS: m/e = 226 (M+H+). Example 389 · 蚱b from -2 - yl 1H-bead 啥 竣 竣 竣 竣 遵 遵 遵 遵 遵The method, 2, amine _5_gas pyridine is reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthosilicate, iron and acetic acid. After the subsequent treatment and chromatography, the title compound was obtained. The paper size is applicable to the Chinese National Standard (CNS) Α4 specification (210X297 公爱〇 -156-1328584 A7)
’呈畢嘴色結晶固體。炫點163-164°C (乙酸乙酯),MS: m/e=252 (M+H+)。 實例390 Π-(5-氣-吡啶-2-某V1H·咪唑-4·基1-甲醇 遵照實例388所述概略方法,ι_(5_氯比咬_2_基)-ιη-11 米嗤-4_ 叛酸乙醋與二異丁基氫化鋁反應。水解後續處理及層析術 後’獲得標題化合物,呈淺褐色結晶固體。熔點82_87°c (乙 酸乙酯 / 乙醚),MS: m/e=210 (M+H+)。 實例391 1-異峻琳-3-基-1H-味峻-4-叛酸乙酯 遵照實例3 84所述概略方法,3 -胺基p奎啦與原甲酸三乙§旨, 石肖基乙酸乙醋及乙酸反應’接著使用原甲酸三乙g旨,鐵及 乙酸處理。經後續處理及層析術後,獲得標題化合物,呈 嗶嘰色結晶固體。熔點161-162°C (乙酸乙酯),MS·· m/e=268 (M+H+)。 實例392 Π-異喹啉-3-某-1H-唑唑-4-基甲醇 遵照實例298所述概略方法,1-異喹啉-3-基-1H-咪唑-4-叛酸 甲酯與鋁氫化鋰反應,接著接受水解後續處理及層析術。 獲得標題化合物呈灰白色蠟狀固體。MS: m/e=226 (M+H+) 實例393 Π-(4-三氟甲氣-茉某V1H-嗉唑-4-基1-甲醇 遵照實例293所述概略方法,4-(三氟曱氧)苯胺與原曱酸三 -157- 本纸張尺度適用中固國家標準(CNS) Α4規格(210 X 297公釐)'by the mouth of a crystalline solid. Hyun point 163-164 ° C (ethyl acetate), MS: m/e = 252 (M+H+). Example 390 Π-(5-Gas-pyridine-2-mer V1H.imidazole-4.yl 1-methanol according to the general procedure described in Example 388, ι ((5- chloro s </ br> -4_ Resin-ethyl acetoacetate is reacted with diisobutylaluminum hydride. After the hydrolysis treatment and chromatography, the title compound is obtained as a light brown crystalline solid. m.p. 82-87 ° C (ethyl acetate / ether), MS: m/ e=210 (M+H+). Example 391 1-Iso-Jin-3-yl-1H-Miso-Tetra-Tetraic Acid Ethyl Ethyl Ethyl Ethylacetate The reaction of triethyl sulphate, succinyl acetate and acetic acid was followed by treatment with triethyl ethane formic acid, iron and acetic acid. After subsequent workup and chromatography, the title compound was obtained as a crystalline solid. 162 ° C (ethyl acetate), MS·· m/e = 268 (M+H+). </RTI> </RTI> </RTI> </RTI> <RTI ID=0.0></RTI> </RTI> <RTIgt; Method, 1-isoquinolin-3-yl-1H-imidazole-4-methylate methyl ester is reacted with lithium aluminum hydride, followed by hydrolysis followed up and chromatography. The title compound is obtained as a pale white waxy solid. MS: m /e=226 (M+H+) Example 393 Π-(4-Trifluoro Methane-Mu V1H-carbazol-4-yl 1-methanol according to the general method described in Example 293, 4-(trifluoroanthracene)aniline and protoporic acid tri-157- This paper scale applies to the national standard of solid state (CNS) Α4 size (210 X 297 mm)
裝 訂Binding
k- 五、發明説明(154 ) 乙酯,硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙醋 ,鐵及乙酸處理,隨後進行鹼性水解。分離得之酸直接根 據實例264還原,還原方法係經由與BH3 THF錯合物反應接 著水解後續處理,獲得標題化合物呈白色結晶物質。溶.點 105-106°C (乙醚),MS: m/e=258 (M+) » 實例394 1-(4-三氣甲基硫烷基-笨基)-1Η-哚唑·4-敎醅 遵照實例234所述概略方法’ 4_(三氟甲基硫)_苯胺與原曱酸 三乙酯’硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙 酯,鐵及乙酸處理’隨後接受驗性水解。獲得標題化合物 呈淺褐色結晶固體。熔點247-248。(:(水/二。号烧)》MS: m/e=288 (M+) » 實例395 Π-(4-三氟曱基疏烷-笨基)-1Η-唑唑-4-某1-甲醇 遵照實例264所述概略方法,1-(4-三氟甲基硫烷基-苯基)· 1H-咪唑-4-缓酸與BH3 THF錯合物反應,接著接受水解後續 處理。獲得標題化合物呈灰白色結晶固體。熔點145-147。(:( 水)。MS: m/e=275 (M+H+)。 實例396 1-p奎g林-6-基-1H-味吐-4-叛酸乙醋 遵照實例384所述概略方法,6-胺基唛u林與原曱酸三乙酯, 硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及 乙酸處理。經後續處理及層析術後,獲得標題化合物,呈 褐色結晶固體。熔點90-94 °C (乙酸乙酯/己烷),MS: -158- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 1328584 五、發明説明(155 m/e=268 (M+H+) 實例397 + (l-^»奎p林-6-基-lH-球嗅·4-甚V甲醇 遵照實例388所述概略方法,1·喳啉-6-基-1H-咪唑-4-羧酸乙 酯與二異丁基氫化鋁反應。水解後續處理及層析術後,獲 得標題化合物,呈淺褐色結晶固體。熔點183-187°C (乙酸乙 酯/己烷)’ MS: m/e=226 (M+H+)。 實例398 l-tr奎啦-8·基-1H·咪唾-4-翔酸乙酯 遵照實例384所述概略方法,8-胺基哇啉與原曱酸三乙酯, 硝基乙酸乙酯及乙酸反應,接著使用原甲酸三乙酯,鐵及 乙酸處理。經後續處理及層析術後,獲得標題化合物,呈 淺褐色結晶固體。熔點>92。(:分解(乙酸乙酯/己烷),MS: m/e=267 (M+H+)。 實例399 (1 - ;r奎g林基·1Η-Ρ米唾-4-基甲醇 遵照實例388所述概略方法,1—奎琳-8-基-1Η-咪唑-4-羧酸乙 酯與二異丁基氫化铭反應。水解後續處理及層析術後,獲 得標題化合物,呈淺褐色結晶固體。溶點168-170°C (乙醚) ,MS: m/e=225 (M+)。 實例400 1H-蛛峻’ 笨开二氣伍圓-5-基米峻-4-某1甲- 基1 - 2 石為- 遵照實例301所述概略方法’(1-笨并[L3]二氧伍園_5_基_K- V. Description of the Invention (154) The ethyl ester, ethyl nitroacetate and acetic acid are reacted, followed by treatment with triethylacetic acid formic acid, iron and acetic acid, followed by alkaline hydrolysis. The isolated acid was directly reduced according to Example 264, and the reduction was carried out by reaction with a BH3 THF complex followed by hydrolysis to give the title compound as a white crystalline material. Solvent point 105-106 ° C (diethyl ether), MS: m / e = 258 (M +) » Example 394 1-(4-tris-methylsulfanyl-phenyl)-1 Η-carbazole概略According to the general procedure described in Example 234, '4-(trifluoromethylsulfanyl)-phenylamine was reacted with triethyl orthoacetate 'nitroacetate and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid' Acceptive hydrolysis. The title compound was obtained as a light brown crystalline solid. Melting point 247-248. (:(水/二。号烧)》MS: m/e=288 (M+) » Example 395 Π-(4-Trifluorodecyl-alkane-stupyl)-1Η-oxazol-4-one 1- Methanol Following the general procedure described in Example 264, 1-(4-trifluoromethylsulfanyl-phenyl)·1H-imidazole-4-hypoacid was reacted with BH3 THF complex, followed by hydrolysis followed up. The compound is an off-white crystalline solid. M.p. 145-147. (: (water). MS: m/e = 275 (M+H+). Example 396 1-p---------- The acid-reducing vinegar was reacted according to the general procedure described in Example 384, and the 6-amino sulfonium was reacted with triethyl orthosilicate, ethyl nitroacetate and acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid. After the subsequent treatment and chromatography, the title compound was obtained as a brown crystalline solid. m.p.: 90-94 ° C (ethyl acetate/hexane), MS: -158- The paper size is applicable to the Chinese National Standard (CNS) A4 specification. (210X297 mm) 1328584 V. Description of invention (155 m/e=268 (M+H+) Example 397 + (l-^»Quin p-L-6-yl-lH-ball sniffing 4-V-Methanol compliance example The general method of 388, 1 · porphyrin-6-yl-1H-imidazole-4-carboxylic acid ethyl ester and diisobutyl hydrogen The title compound was obtained as a light brown crystalline solid. m.p. 183-187 ° C (ethyl acetate /hexane). MS: m/e=226 (M+H+) Example 398 l-tr-quile-8-yl-1H-imida-4-propionic acid ethyl ester according to the general procedure described in Example 384, 8-amino morpholine and triethyl orthosilicate, nitroacetic acid The ester is reacted with acetic acid, followed by treatment with triethyl orthoformate, iron and acetic acid. The title compound is obtained as a light brown crystalline solid. Hexane), MS: m/e = 267 (M+H +). Example 399 (1 - ; r y y y y y y y y y y Ethyl-8-yl-1 oxime-imidazole-4-carboxylate was reacted with diisobutylhydrogenation. After hydrolysis and subsequent chromatography, the title compound was obtained as a light brown crystalline solid. C (Ethyl ether), MS: m/e = 225 (M+). Example 400 1H-Spider' Stupid two-gas Wuyuan-5-Kimijun-4-One 1A-Base 1 - 2 Stone is - Follow Example 301 of the schematic method '(1-Baohe [L3] Dioxin Garden _5_基_
裝 訂Binding
-159·-159·
13285841328584
1H-咪唑-4-基)-甲醇首先使用亞磺醯氣處理,然後使用2_确 基咪唑及碳酸铯處理。於蒸發、萃取後續處理及層析術後 ’獲得標題化合物呈淺褐色固體。熔點>156°C分解(二氣曱 院 / 二異丙基越),MS: m/e=3 14 (M+H+)。 實例401 . h(3-二氟甲某-4-氟-茉某V4.4.5.5-四甲某-Γ1.3.21二氣雜伍囿 標題化合物係根據實例342獲得,呈無色油(54%產率),使 用4-溴-2-二氟曱基-1-氟-苯及貳(皮納可酸根)二硼作為起始 物料。MS: m/e=272 (M+)。 實例402 2-『3-(1,1-二氟-乙基)-茉某1-4.4.5.5-四甲基-[1,3.21二氮雜你 園 標題化合物係根據實例342獲得,呈無色油(60%產率),使 用1-漠- 3-(1,1-二氟-乙基)-苯及戴(皮納可酸根)二爛作為起 始物料。MS: m/e=268 (M+)。 實例403 2-Π-氣-5-三氟甲基-苯某V4.4.5.5-四甲基_-Γΐ,3,21二氮雜杯 m_ 標題化合物係根據實例342獲得,呈無色油(48%產率),使 用3-溴-5-氟笨并三氟及貳(皮納可酸根)二硼作為起始物料 ° MS: m/e=290 (M+) 〇 實例404 7-Ρ-Π.卜二氟-乙基V4-氣-芄某1-4,4,5,5-四曱基-Π.3.21二氳 雜伍圜 -160- 度適用中目国冢標準(CNS) A4規格(210X297公釐)The 1H-imidazol-4-yl)-methanol was first treated with sulfinium gas and then treated with 2 - imidazole and cesium carbonate. The title compound was obtained as a light brown solid after evaporation, extraction, and chromatography. Melting point > 156 ° C decomposition (dioxane / diisopropyl), MS: m / e = 3 14 (M + H +). Example 401. h(3-Difluoromethyl-4-fluoro-jam V4.4.5.5-tetramethyl-anthracene 1.3.21 dioxanthene title compound was obtained according to Example 342 as a colorless oil (54%) Yield: 4-bromo-2-difluorodecyl-1-fluoro-benzene and hydrazine (pinaconate) diboron were used as starting materials. MS: m/e = 272 (M+). - "3-(1,1-Difluoro-ethyl)-Moth 1-4.4.5.5-Tetramethyl-[1,3.21 Diazepine title compound was obtained according to Example 342 as a colorless oil (60 % yield), using 1-oxa-3-(1,1-difluoro-ethyl)-benzene and Dai (Pinalacate) as the starting material. MS: m/e=268 (M+) Example 403 2-Π-Gas-5-trifluoromethyl-Benzene V4.4.5.5-Tetramethyl--anthracene, 3,21 Diazepine m_ The title compound was obtained according to Example 342 as a colorless oil. (48% yield) using 3-bromo-5-fluoro benzotrifluoro and hydrazine (pinaconate) diboron as starting material. MS: m/e = 290 (M+) 〇 Example 404 7-Ρ - Π. Difluoro-ethyl V4-gas-芄 1-4,4,5,5-tetradecyl-Π.3.21 二氲杂圜-160- degree Applicable to China National Standard (CNS) A4 size (210X297 mm)
裝 訂Binding
1328584 A7 __B7 五、發明説明(157 ) 標題化合物係根據實例342獲得’呈橙色油(28%產率)’使 用4-溴-2-(1,1-二氟-乙基)-1-氟-苯及貳(皮納可酸根)二硼作 為起始物料。MS: m/e=286.2 (M+)。 實例405 4- 溴-2-二氤甲基-1-氟-笨 5- 溴-2-氟笨甲醛(2克,9.85毫莫耳)溶解於二氣曱烷(50毫升 )。反應混合物置於氬氣氣氛下及冷卻至0 °C。逐滴加入二 乙基胺基三氟化硫(2.04毫升’ 14.78毫莫耳)。讓混合物溫 熱至室溫及攪拌隔夜。然後以飽和碳酸氫鈉水溶液淬熄。 分離各層,水層以二氣甲烷萃取。合併有機相以硫酸鈉脫 水及蒸發去除溶劑。褐色油經層析(矽膠’己烷/乙酸乙酯洗 提)獲得標題化合物(1.55克,70%)呈無色油。MS·· m/e=226.0 (M+H+) ° 實例406 I-〉臭-3-( 1,1-二氣乙基本. 標題化合物係根據實例405(淨二乙基胺基三氟化硫)’使用 3-溴-苯乙酮作為起始物料獲得,呈無色油(15%產率)。MS: m/e=220.0 (M+)。 實例407 1-Γ2-氣-5-硝基-苯基乙酮 標題化合物係遵照參考文獻方法M.Q. Zhang,A. Haemers, D. Vanden Berghe,S.R. Pattyn,W. Bollaert,雜環化學期刊 ,1991, 28, 673-683使用,2’-氟苯乙酮作為起始物料製備。 反應獲得淺黃色固體(85%產率)。MS: m/e=205_0 (M+)。 •161 · 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(158 ) 實例408 . 4-溴-2-Π,1-二氟乙基)-1-氟-苯 標題化合物係遵照參考文獻方法(八.丁&1^1^511丨,7'· Agatsuma, M. Matsuda, T. Ohta, Τ. Nunozawa, Τ. Endo · S. Nozoe,化學製藥公報,1992,迎j 3185-3188)使用 3-(1,1-二 氟-乙基)·4-氟-苯基胺作為起始物料製備。反應獲得深紅色 液體(產率 46%)。h-NMR (400 MHz) <5 =1.99 (t, J=11.75 Hz, 3H), 7.02 (t, J=6.0 Hz, 1H), 7.50-7.55 (m, 1H), 7.65-7.69 (m, 1H). 實例409 2-環丙基-1H-咪唑 於環丙烷羧醯亞胺酸乙酯(3 2.9克,291毫莫耳)於曱醇(40毫 升)之溶液内加入胺基乙醛二甲基縮醛(34.5毫升,320毫莫 耳),反應混合物攪拌2日。反應混合物經濃縮,加入濃鹽 酸及水,混合物再度濃縮。殘餘物溶解於水,藉加入碳酸 鈉將pH調整至8及濃縮混合物。褐色殘餘物懸浮於乙醇及過 濾。濾液經濃縮獲得30.6克(283毫莫耳,97%)標題化合物 。MS: m/e=107.1 (M-Η)。 實例410 環丙烷羧醯亞胺酸乙酯鹽酸鹽 氣化氫氣體穩定流緩慢流經環丙烷甲腈(25克,373毫莫耳) 於乙醇(17.2毫升)溶液。15小時後反應混合物冷卻至0°C及 逐滴加入乙醚。過濾出沉澱標題化合物,呈無色結晶物質 (32.9克,220毫莫耳,59%)。MS: m/e=l 12.2 (M-Η)。 •162· 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐)1328584 A7 __B7 V. INSTRUCTION DESCRIPTION (157) The title compound was obtained according to Example 342 as 'yellow oil (28% yield)' using 4-bromo-2-(1,1-difluoro-ethyl)-1-fluoro -Benzene and hydrazine (Pinaconate) diboron as starting materials. MS: m/e = 286.2 (M+). Example 405 4-Bromo-2-diindolemethyl-1-fluoro-stuppy 5-bromo-2-fluorobenzaldehyde (2 g, 9.85 mmol) was dissolved in dioxane (50 mL). The reaction mixture was placed under an argon atmosphere and cooled to 0 °C. Diethylaminosulfur trifluoride (2.04 ml '14.78 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight. It was then quenched with saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with di-methane. The combined organic phases were dehydrated with sodium sulfate and evaporated to remove solvent. The title compound (1.55 g, 70%) MS·· m/e=226.0 (M+H+) ° Example 406 I->Smelly-3-(1,1-di-ethylethyl). The title compound is based on Example 405 (Net diethylaminosulfur trifluoride) '''''''''''' The title compound of phenyl ethyl ketone is in accordance with the reference method MQ Zhang, A. Haemers, D. Vanden Berghe, SR Pattyn, W. Bollaert, Journal of Heterocyclic Chemistry, 1991, 28, 673-683, 2'-fluorophenyl The ketone was prepared as a starting material. The reaction gave a pale-yellow solid (yield: 85%). MS: m/e = 205 s (M+). • 161 · The paper size applies to the Chinese National Standard (CNS) A4 specification (210 X 297) PCT 1328584 A7 B7 V. INSTRUCTIONS (158) EXAMPLE 408. 4-Bromo-2-indole, 1-difluoroethyl)-1-fluoro-benzene The title compound is in accordance with the reference method (8. Ding & 1^1^511丨, 7'· Agatsuma, M. Matsuda, T. Ohta, Τ. Nunozawa, Τ. Endo · S. Nozoe, Chemical and Pharmaceutical Bulletin, 1992, Ying j 3185-3188) Using 3-(1, 1-Difluoro-ethyl)·4-fluoro-phenylamine was prepared as a starting material. The reaction gave a dark red liquid (yield 46%). </ RTI> <RTIgt; 1H). Example 409 2-Cyclopropyl-1H-imidazole in a solution of ethyl cyclopropanecarboxylate imidate (3 2.9 g, 291 mmol) in decyl alcohol (40 mL) Methyl acetal (34.5 mL, 320 mmol) and the reaction mixture was stirred for 2 days. The reaction mixture was concentrated, concentrated hydrochloric acid and water were added and the mixture was concentrated again. The residue was dissolved in water and the pH was adjusted to 8 and concentrated mixture by sodium carbonate. The brown residue was suspended in ethanol and filtered. The filtrate was concentrated to give 30.6 g (yel. MS: m/e = 107.1 (M - Η). Example 410 Cyclopropane Carboxylidene Ethyl Ester Hydrochloride A steady stream of gaseous hydrogen gas was slowly passed through a solution of cyclopropanecarbonitrile (25 g, 373 mmol) in ethanol (17.2 mL). After 15 hours, the reaction mixture was cooled to 0 ° C and diethyl ether was added dropwise. The title compound was precipitated as a colourless crystalline material (32.9 g, 220 m. MS: m/e = l 12.2 (M - Η). •162. This paper scale applies to the Chinese National Standard (CNS) Α4 specification (210 X 297 mm)
裝 ηη
1328584 A7 B7 五、發明説明(159 實例411 V溴-1-甲某·2_(2-甲基-咪吔-1·華甲華Λ-1Η-咪唑 (5-溴-1-甲基-1Η-咪唑-2-基)-甲醇(1.0克,5.24毫莫耳)及四 溴曱烷(2.48 ’ 7.33毫莫耳)溶解於THF (1〇·〇毫升)及冷卻至0 °C。以30分鐘時間逐份加入三苯基膦(1.98克,7.33毫莫耳) 。反應混合物於〇°C攪拌1小時獲得白色沉澱。第二燒瓶内 ,氫化鈉(1.05克,26.18毫莫耳,60%於礦油)懸浮於DMF (20毫升)及冷卻至〇°C。逐份加入2_甲基咪唑(2.15克,26.2 毫莫耳)。反應混合物於60°C攪拌30分鐘,冷卻至〇°C且以 前述懸浮液處理。於室溫攪拌2小時後,反應混合物以水性 飽和碳酸氫鈉溶液(50毫升)淬熄。水層以乙酸乙酯萃取三次 。合併萃取物以硫酸鈉脫水,過濾,真空去除溶劑。殘餘 物經層析(矽膠,以二氯甲烷/曱醇=95:5洗提)獲得標題化合 物(0.7克,52%)呈褐色固體。MS: m/e=255_0 (M+)。 實例412 (5-溴-1-甲基-1H-咪唑-2-基V甲醢 卜曱基咪唑-2-曱醇(3.15克,28毫莫耳)(尺丄81111仳61§;?.乂· Nguyen;醫藥化學研究7,2,1997, 123-136)於-20°C懸浮於 THF(75毫升)及緩慢以N-溴丁二醯亞胺(4.9克,27毫莫耳)處 理(30分鐘内處理)。讓反應混合物缓慢溫熱至室溫及以飽和 水性碳酸氫鈉溶液(50毫升)淬熄。水層以乙酸乙酯萃取3次 。合併萃取物以飽和碳酸氫鈉水溶液洗滌,以硫酸鈉脫水 ,過濾及真空去除溶劑。殘餘物經層析(矽膠,首先以乙酸 乙酯/己烷= 1:1洗提然後以二氣曱烷/曱醇=95:05洗提)獲得 -163- 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 裝 訂1328584 A7 B7 V. INSTRUCTIONS INSTRUCTIONS (159 EXAMPLES 411 VBrom-1-A-2·(2-Methyl-Mimi-1·华甲华Λ-1Η-Imidazole (5-Bromo-1-methyl-1Η) -Imidazolyl-2-yl)-methanol (1.0 g, 5.24 mmol) and tetrabromodecane (2.48 ' 7.33 mmol) dissolved in THF (1 mL·ml) and cooled to 0 ° C. Triphenylphosphine (1.98 g, 7.33 mmol) was added portionwise over a minute. The reaction mixture was stirred at EtOAc for 1 hour to give a white precipitate. In the second flask, sodium hydride (1.05 g, 26.18 mmol, 60%) Suspension in DMF (20 ml) and cooling to 〇 ° C. 2 -Methylimidazole (2.15 g, 26.2 mmol) was added portionwise. The reaction mixture was stirred at 60 ° C for 30 minutes and cooled to 〇 ° After the mixture was stirred for 2 hours at room temperature, the mixture was quenched with aqueous saturated sodium hydrogen carbonate (50 mL). The solvent was removed in vacuo <RTI ID=0.0> m/e = 255_0 (M+). Example 412 (5-bromo-1-methyl-1H-imidazol-2-yl-V-indole-imidazole-2-indole (3.15 g, 28 mmol). 81111仳61§;?.乂·Nguyen; Medicinal Chemistry Research 7, 2, 1997, 123-136) suspended in THF (75 ml) at -20 ° C and slowly with N-bromosuccinimide (4.9 g) The reaction mixture was slowly warmed to room temperature and quenched with saturated aqueous sodium hydrogen carbonate (50 mL). Washed with saturated aqueous sodium hydrogencarbonate solution, dried over sodium sulfate, filtered and evaporated in vacuo. The residue was purified by chromatography (yield eluted with ethyl acetate / hexane = 1:1 then dioxane / oxime Alcohol = 95:05 elution) Obtained -163- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) Binding
k- 1328584 A7 B7 五、發明説明(160 ) 錠剞配方(濕造粒) 標題化合物(2.11克,67%)呈白色固體。MS: m/e=191_2 (M+)。K- 1328584 A7 B7 V. INSTRUCTIONS (160) Ingot formulation (wet granulation) The title compound (2.11 g, 67%) was obtained as white solid. MS: m/e = 191_2 (M+).
實例A 項目 成分 毫克/錠 5毫克 25毫克 100毫克 500毫克 1. 式1化合物 5 25 100 500 2. 乳糖無水DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. 微晶纖維素 30 30 30 150 5. 硬脂酸鎂 1 1 1 1 總量 167 167 167 831 製造程序 1. 混合項目1、2、3及4且使用純水造粒。 2. 於50°C乾燥顆粒。 3. 讓顆粒通過適當研磨設備。 4. 添加第5項且混合三分鐘;於適當壓機加壓。 實例B 膠囊劑配方 項目成分 毫克/錠 5毫克 25毫克 100毫克 500毫克 1. 式1化合物 5 25 100 500 -164- 本纸張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1328584 A7 B7 五、發明説明(161 ) 2. 含水乳糖 159 123 148 — 3. 玉米殿粉 25 35 40 70 4. 滑石 10 15 10 25 5. 硬脂酸鎂 1 2 2 5 總量 200 200 300 600 製造程序 1. 於適當混合機混合項目1、2及3項30分鐘。 2. 加入4及5項且混合3分鐘。 3. 填裝入適當膠囊内。 4. 加入第5項及混合三分鐘;於適當壓機上壓縮。 • 165- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐)Example A Item Ingredient mg/ingot 5 mg 25 mg 100 mg 500 mg 1. Formula 1 Compound 5 25 100 500 2. Lactose anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. Microcrystalline cellulose 30 30 30 150 5. Magnesium stearate 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure 1. Mix items 1, 2, 3 and 4 and granulate with pure water. 2. Dry the granules at 50 °C. 3. Allow the particles to pass through the appropriate grinding equipment. 4. Add item 5 and mix for three minutes; pressurize with a suitable press. Example B Capsule Formulation Item Ingredients mg/ingot 5 mg 25 mg 100 mg 500 mg 1. Formula 1 Compound 5 25 100 500 -164- This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1328584 A7 B7 V. INSTRUCTIONS (161) 2. Aqueous lactose 159 123 148 — 3. Corn house powder 25 35 40 70 4. Talc 10 15 10 25 5. Magnesium stearate 1 2 2 5 Total 200 200 300 600 Manufacturing Procedure 1. Mix items 1, 2 and 3 for 30 minutes with a suitable mixer. 2. Add 4 and 5 items and mix for 3 minutes. 3. Fill in the appropriate capsules. 4. Add item 5 and mix for three minutes; compress on a suitable press. • 165- This paper size applies to the Chinese National Standard (CNS) A4 specification (210X 297 mm)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW91101137A TWI328584B (en) | 2002-01-24 | 2002-01-24 | Imidazole derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW91101137A TWI328584B (en) | 2002-01-24 | 2002-01-24 | Imidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI328584B true TWI328584B (en) | 2010-08-11 |
Family
ID=45074427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW91101137A TWI328584B (en) | 2002-01-24 | 2002-01-24 | Imidazole derivatives |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI328584B (en) |
-
2002
- 2002-01-24 TW TW91101137A patent/TWI328584B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1489580B (en) | Imidazole derivatives | |
| TW546297B (en) | Heterocyclic compounds as antiinflammatory agents and their making process, pharmaceutical composition containing the same and their uses | |
| KR101287713B1 (en) | Imidazole carboxamides | |
| US5332831A (en) | Benzofuran derivatives | |
| HU202843B (en) | Process for producing tolunitriles substituted by heterocyclic group in alpha-position and pharmaceutical compositions comprising such compounds as active ingredient | |
| HUP0004412A2 (en) | Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders | |
| NO170080B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE (SUBSTITUTED ARALKYL) HETEROCYCLIC COMPOUNDS | |
| WO1998031227A1 (en) | Novel cannabinoid receptor modulators | |
| JP2001516361A (en) | New cannabinoid receptor agonist | |
| IE61823B1 (en) | (1h-azol-1-ylmethyl) substituted benzotriazole derivatives | |
| JP2003520273A (en) | Indazole compounds, pharmaceutical compositions and methods for inducing or inhibiting cell proliferation | |
| TW201016671A (en) | Novel imidazolidine compounds as androgen receptor modulators | |
| AU2009279137A1 (en) | Pyrazolo [5,1-b] oxazole derivatives as CRF1 antagonists | |
| CN104817508B (en) | A kind of trinitrogenazole alcohol analog derivative and its preparation method and application | |
| DK162842B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 1-PERFLUORALKYL-2- (1,2,4-TRIAZOL-1-YL) ETHANOL COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS THEREOF | |
| RO113985B1 (en) | DERIVATIVES OF 1 - (ARYL CYCLAMILOAMICYL) - IMIDAZOL, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS | |
| TWI328584B (en) | Imidazole derivatives | |
| JPWO2010090200A1 (en) | Phenylimidazole compound | |
| TWI297683B (en) | Diazole derivatives | |
| AU697346B2 (en) | Indoline and azaindoline derivatives as 5-HT1D alpha receptor agonists | |
| AU2002246043B2 (en) | Imidazole derivatives | |
| HU197729B (en) | Process for producing triazol- and imidazol derivatives and pharmaceutical compositions containing them | |
| AU2002246043A1 (en) | Imidazole derivatives | |
| HK1063794B (en) | Imidazole derivatives | |
| HK1146646B (en) | Imidazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |